Genetic	O	O
mapping	O	O
of	O	O
the	O	O
copper	B-Disease	OMIM:215600
toxicosis	I-Disease	OMIM:215600
locus	O	O
in	O	O
Bedlington	O	O
terriers	O	O
to	O	O
dog	O	O
chromosome	O	O
10	O	O
,	O	O
in	O	O
a	O	O
region	O	O
syntenic	O	O
to	O	O
human	O	O
chromosome	O	O
region	O	O
2p13	O	O
-	O	O
p16	O	O
.	O	O

Abnormal	O	O
hepatic	B-Disease	D008107
copper	I-Disease	D008107
accumulation	I-Disease	D008107
is	O	O
recognized	O	O
as	O	O
an	O	O
inherited	B-Disease	D030342
disorder	I-Disease	D030342
in	O	O
man	O	O
,	O	O
mouse	O	O
,	O	O
rat	O	O
and	O	O
dog	O	O
.	O	O

The	O	O
major	O	O
cause	O	O
of	O	O
hepatic	B-Disease	D008107
copper	I-Disease	D008107
accumulation	I-Disease	D008107
in	O	O
man	O	O
is	O	O
a	O	O
dysfunctional	O	O
ATP7B	O	O
gene	O	O
,	O	O
causing	O	O
Wilson	B-Disease	D006527
disease	I-Disease	D006527
(	O	O
WD	B-Disease	D006527
)	O	O
.	O	O

Mutations	O	O
in	O	O
the	O	O
ATP7B	O	O
genes	O	O
have	O	O
also	O	O
been	O	O
demonstrated	O	O
in	O	O
mouse	O	O
and	O	O
rat	O	O
.	O	O

The	O	O
ATP7B	O	O
gene	O	O
has	O	O
been	O	O
excluded	O	O
in	O	O
the	O	O
much	O	O
rarer	O	O
human	O	O
copper	B-Disease	D008107
overload	I-Disease	D008107
disease	O	O
non	B-Disease	OMIM:215600
-	I-Disease	OMIM:215600
Indian	I-Disease	OMIM:215600
childhood	I-Disease	OMIM:215600
cirrhosis	I-Disease	OMIM:215600
,	O	O
indicating	O	O
genetic	O	O
heterogeneity	O	O
.	O	O

By	O	O
investigating	O	O
the	O	O
common	O	O
autosomal	O	O
recessive	O	O
copper	B-Disease	OMIM:215600
toxicosis	I-Disease	OMIM:215600
(	O	O
CT	B-Disease	OMIM:215600
)	O	O
in	O	O
Bedlington	O	O
terriers	O	O
,	O	O
we	O	O
have	O	O
identified	O	O
a	O	O
new	O	O
locus	O	O
involved	O	O
in	O	O
progressive	O	O
liver	B-Disease	D008107
disease	I-Disease	D008107
.	O	O

We	O	O
examined	O	O
whether	O	O
the	O	O
WD	B-Disease	D006527
gene	O	O
ATP7B	O	O
was	O	O
also	O	O
causative	O	O
for	O	O
CT	B-Disease	OMIM:215600
by	O	O
investigating	O	O
the	O	O
chromosomal	O	O
co	O	O
-	O	O
localization	O	O
of	O	O
ATP7B	O	O
and	O	O
C04107	O	O
,	O	O
using	O	O
fluorescence	O	O
in	O	O
situ	O	O
hybridization	O	O
(	O	O
FISH	O	O
)	O	O
.	O	O

C04107	O	O
is	O	O
an	O	O
anonymous	O	O
microsatellite	O	O
marker	O	O
closely	O	O
linked	O	O
to	O	O
CT	B-Disease	OMIM:215600
.	O	O

However	O	O
,	O	O
BAC	O	O
clones	O	O
containing	O	O
ATP7B	O	O
and	O	O
C04107	O	O
mapped	O	O
to	O	O
the	O	O
canine	O	O
chromosome	O	O
regions	O	O
CFA22q11	O	O
and	O	O
CFA10q26	O	O
,	O	O
respectively	O	O
,	O	O
demonstrating	O	O
that	O	O
WD	B-Disease	D006527
cannot	O	O
be	O	O
homologous	O	O
to	O	O
CT	B-Disease	OMIM:215600
.	O	O

The	O	O
copper	O	O
transport	O	O
genes	O	O
CTR1	O	O
and	O	O
CTR2	O	O
were	O	O
also	O	O
excluded	O	O
as	O	O
candidate	O	O
genes	O	O
for	O	O
CT	B-Disease	OMIM:215600
since	O	O
they	O	O
both	O	O
mapped	O	O
to	O	O
canine	O	O
chromosome	O	O
region	O	O
CFA11q22	O	O
.	O	O

2	O	O
-	O	O
22	O	O
.	O	O

5	O	O
.	O	O

A	O	O
transcribed	O	O
sequence	O	O
identified	O	O
from	O	O
the	O	O
C04107	O	O
-	O	O
containing	O	O
BAC	O	O
was	O	O
found	O	O
to	O	O
be	O	O
homologous	O	O
to	O	O
a	O	O
gene	O	O
expressed	O	O
from	O	O
human	O	O
chromosome	O	O
2p13	O	O
-	O	O
p16	O	O
,	O	O
a	O	O
region	O	O
devoid	O	O
of	O	O
any	O	O
positional	O	O
candidate	O	O
genes	O	O
.	O	O

Molecular	O	O
analysis	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
in	O	O
205	O	O
families	O	O
:	O	O
extended	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
in	O	O
FAP	B-Disease	D011125
and	O	O
evidence	O	O
for	O	O
the	O	O
role	O	O
of	O	O
APC	B-Disease	D011125
amino	O	O
acid	O	O
changes	O	O
in	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
predisposition	O	O
.	O	O

BACKGROUND	O	O
/	O	O
AIMS	O	O
The	O	O
development	O	O
of	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
and	O	O
a	O	O
variable	O	O
range	O	O
of	O	O
extracolonic	O	O
manifestations	O	O
in	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
(	O	O
FAP	B-Disease	D011125
)	O	O
is	O	O
the	O	O
result	O	O
of	O	O
the	O	O
dominant	O	O
inheritance	O	O
of	O	O
adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
(	O	O
APC	B-Disease	D011125
)	O	O
gene	O	O
mutations	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
direct	O	O
mutation	O	O
analysis	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
was	O	O
performed	O	O
to	O	O
determine	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
for	O	O
nine	O	O
extracolonic	O	O
manifestations	O	O
and	O	O
to	O	O
investigate	O	O
the	O	O
incidence	O	O
of	O	O
APC	B-Disease	D011125
mutations	O	O
in	O	O
non	O	O
-	O	O
FAP	B-Disease	D011125
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
.	O	O

METHODS	O	O
The	O	O
APC	B-Disease	D011125
gene	O	O
was	O	O
analysed	O	O
in	O	O
190	O	O
unrelated	O	O
FAP	B-Disease	D011125
and	O	O
15	O	O
non	O	O
-	O	O
FAP	B-Disease	D011125
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
patients	O	O
using	O	O
denaturing	O	O
gradient	O	O
gel	O	O
electrophoresis	O	O
,	O	O
the	O	O
protein	O	O
truncation	O	O
test	O	O
,	O	O
and	O	O
direct	O	O
sequencing	O	O
.	O	O

RESULTS	O	O
Chain	O	O
terminating	O	O
signals	O	O
were	O	O
only	O	O
identified	O	O
in	O	O
patients	O	O
belonging	O	O
to	O	O
the	O	O
FAP	B-Disease	D011125
group	O	O
(	O	O
105	O	O
patients	O	O
)	O	O
.	O	O

Amino	O	O
acid	O	O
changes	O	O
were	O	O
identified	O	O
in	O	O
four	O	O
patients	O	O
,	O	O
three	O	O
of	O	O
whom	O	O
belonged	O	O
to	O	O
the	O	O
non	O	O
-	O	O
FAP	B-Disease	D011125
group	O	O
of	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
patients	O	O
.	O	O

Genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
identified	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
nature	O	O
of	O	O
certain	O	O
extracolonic	O	O
manifestations	O	O
in	O	O
FAP	B-Disease	D011125
patients	O	O
belonging	O	O
to	O	O
three	O	O
mutation	O	O
subgroups	O	O
.	O	O

CONCLUSIONS	O	O
Extended	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
made	O	O
in	O	O
this	O	O
study	O	O
may	O	O
have	O	O
the	O	O
potential	O	O
to	O	O
determine	O	O
the	O	O
most	O	O
appropriate	O	O
surveillance	O	O
and	O	O
prophylactic	O	O
treatment	O	O
regimens	O	O
for	O	O
those	O	O
patients	O	O
with	O	O
mutations	O	O
associated	O	O
with	O	O
life	O	O
threatening	O	O
conditions	O	O
.	O	O

This	O	O
study	O	O
also	O	O
provided	O	O
evidence	O	O
for	O	O
the	O	O
pathological	O	O
nature	O	O
of	O	O
amino	O	O
acid	O	O
changes	O	O
in	O	O
APC	B-Disease	D011125
associated	O	O
with	O	O
both	O	O
FAP	B-Disease	D011125
and	O	O
non	O	O
-	O	O
FAP	B-Disease	D011125
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
patients	O	O
.	O	O

.	O	O

A	O	O
European	O	O
multicenter	O	O
study	O	O
of	O	O
phenylalanine	B-Disease	OMIM:261600
hydroxylase	I-Disease	OMIM:261600
deficiency	I-Disease	OMIM:261600
:	O	O
classification	O	O
of	O	O
105	O	O
mutations	O	O
and	O	O
a	O	O
general	O	O
system	O	O
for	O	O
genotype	O	O
-	O	O
based	O	O
prediction	O	O
of	O	O
metabolic	O	O
phenotype	O	O
.	O	O

Phenylketonuria	B-Disease	D010661
(	O	O
PKU	B-Disease	D010661
)	O	O
and	O	O
mild	B-Disease	D010661
hyperphenylalaninemia	I-Disease	D010661
(	O	O
MHP	B-Disease	D010661
)	O	O
are	O	O
allelic	B-Disease	D030342
disorders	I-Disease	D030342
caused	O	O
by	O	O
mutations	O	O
in	O	O
the	O	O
gene	O	O
encoding	O	O
phenylalanine	O	O
hydroxylase	O	O
(	O	O
PAH	O	O
)	O	O
.	O	O

Previous	O	O
studies	O	O
have	O	O
suggested	O	O
that	O	O
the	O	O
highly	O	O
variable	O	O
metabolic	O	O
phenotypes	O	O
of	O	O
PAH	B-Disease	OMIM:261600
deficiency	I-Disease	OMIM:261600
correlate	O	O
with	O	O
PAH	O	O
genotypes	O	O
.	O	O

We	O	O
identified	O	O
both	O	O
causative	O	O
mutations	O	O
in	O	O
686	O	O
patients	O	O
from	O	O
seven	O	O
European	O	O
centers	O	O
.	O	O

On	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
phenotypic	O	O
characteristics	O	O
of	O	O
297	O	O
functionally	O	O
hemizygous	O	O
patients	O	O
,	O	O
105	O	O
of	O	O
the	O	O
mutations	O	O
were	O	O
assigned	O	O
to	O	O
one	O	O
of	O	O
four	O	O
arbitrary	O	O
phenotype	O	O
categories	O	O
.	O	O

We	O	O
proposed	O	O
and	O	O
tested	O	O
a	O	O
simple	O	O
model	O	O
for	O	O
correlation	O	O
between	O	O
genotype	O	O
and	O	O
phenotypic	O	O
outcome	O	O
.	O	O

The	O	O
observed	O	O
phenotype	O	O
matched	O	O
the	O	O
predicted	O	O
phenotype	O	O
in	O	O
79	O	O
%	O	O
of	O	O
the	O	O
cases	O	O
,	O	O
and	O	O
in	O	O
only	O	O
5	O	O
of	O	O
184	O	O
patients	O	O
was	O	O
the	O	O
observed	O	O
phenotype	O	O
more	O	O
than	O	O
one	O	O
category	O	O
away	O	O
from	O	O
that	O	O
expected	O	O
.	O	O

Among	O	O
the	O	O
seven	O	O
contributing	O	O
centers	O	O
,	O	O
the	O	O
proportion	O	O
of	O	O
patients	O	O
for	O	O
whom	O	O
the	O	O
observed	O	O
phenotype	O	O
did	O	O
not	O	O
match	O	O
the	O	O
predicted	O	O
phenotype	O	O
was	O	O
4	O	O
%	O	O
-	O	O
23	O	O
%	O	O
(	O	O
P	O	O
<	O	O
.	O	O

0001	O	O
)	O	O
,	O	O
suggesting	O	O
that	O	O
differences	O	O
in	O	O
methods	O	O
used	O	O
for	O	O
mutation	O	O
detection	O	O
or	O	O
phenotype	O	O
classification	O	O
may	O	O
account	O	O
for	O	O
a	O	O
considerable	O	O
proportion	O	O
of	O	O
genotype	O	O
-	O	O
phenotype	O	O
inconsistencies	O	O
.	O	O

Our	O	O
data	O	O
indicate	O	O
that	O	O
the	O	O
PAH	O	O
-	O	O
mutation	O	O
genotype	O	O
is	O	O
the	O	O
main	O	O
determinant	O	O
of	O	O
metabolic	O	O
phenotype	O	O
in	O	O
most	O	O
patients	O	O
with	O	O
PAH	B-Disease	OMIM:261600
deficiency	I-Disease	OMIM:261600
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
the	O	O
classification	O	O
of	O	O
105	O	O
PAH	O	O
mutations	O	O
may	O	O
allow	O	O
the	O	O
prediction	O	O
of	O	O
the	O	O
biochemical	O	O
phenotype	O	O
in	O	O
>	O	O
10	O	O
,	O	O
000	O	O
genotypes	O	O
,	O	O
which	O	O
may	O	O
be	O	O
useful	O	O
for	O	O
the	O	O
management	O	O
of	O	O
hyperphenylalaninemia	B-Disease	D010661
in	O	O
newborns	O	O
.	O	O

Disruption	O	O
of	O	O
splicing	O	O
regulated	O	O
by	O	O
a	O	O
CUG	O	O
-	O	O
binding	O	O
protein	O	O
in	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
.	O	O

Myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
is	O	O
caused	O	O
by	O	O
a	O	O
CTG	O	O
expansion	O	O
in	O	O
the	O	O
3	O	O
untranslated	O	O
region	O	O
of	O	O
the	O	O
DM	B-Disease	D009223
gene	O	O
.	O	O

One	O	O
model	O	O
of	O	O
DM	B-Disease	D009223
pathogenesis	O	O
suggests	O	O
that	O	O
RNAs	O	O
from	O	O
the	O	O
expanded	O	O
allele	O	O
create	O	O
a	O	O
gain	O	O
-	O	O
of	O	O
-	O	O
function	O	O
mutation	O	O
by	O	O
the	O	O
inappropriate	O	O
binding	O	O
of	O	O
proteins	O	O
to	O	O
the	O	O
CUG	O	O
repeats	O	O
.	O	O

Data	O	O
presented	O	O
here	O	O
indicate	O	O
that	O	O
the	O	O
conserved	O	O
heterogeneous	O	O
nuclear	O	O
ribonucleoprotein	O	O
,	O	O
CUG	O	O
-	O	O
binding	O	O
protein	O	O
(	O	O
CUG	O	O
-	O	O
BP	O	O
)	O	O
,	O	O
may	O	O
mediate	O	O
the	O	O
trans	O	O
-	O	O
dominant	O	O
effect	O	O
of	O	O
the	O	O
RNA	O	O
.	O	O

CUG	O	O
-	O	O
BP	O	O
was	O	O
found	O	O
to	O	O
bind	O	O
to	O	O
the	O	O
human	O	O
cardiac	O	O
troponin	O	O
T	O	O
(	O	O
cTNT	O	O
)	O	O
pre	O	O
-	O	O
messenger	O	O
RNA	O	O
and	O	O
regulate	O	O
its	O	O
alternative	O	O
splicing	O	O
.	O	O

Splicing	O	O
of	O	O
cTNT	O	O
was	O	O
disrupted	O	O
in	O	O
DM	B-Disease	D009223
striated	O	O
muscle	O	O
and	O	O
in	O	O
normal	O	O
cells	O	O
expressing	O	O
transcripts	O	O
that	O	O
contain	O	O
CUG	O	O
repeats	O	O
.	O	O

Altered	O	O
expression	O	O
of	O	O
genes	O	O
regulated	O	O
posttranscriptionally	O	O
by	O	O
CUG	O	O
-	O	O
BP	O	O
therefore	O	O
may	O	O
contribute	O	O
to	O	O
DM	B-Disease	D009223
pathogenesis	O	O
.	O	O

.	O	O

Maternal	B-Disease	D024182
disomy	I-Disease	D024182
and	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
consistent	O	O
with	O	O
gamete	O	O
complementation	O	O
in	O	O
a	O	O
case	O	O
of	O	O
familial	O	O
translocation	O	O
(	O	O
3	O	O
;	O	O
15	O	O
)	O	O
(	O	O
p25	O	O
;	O	O
q11	O	O
.	O	O

2	O	O
)	O	O
.	O	O

Maternal	B-Disease	C538037
uniparental	I-Disease	C538037
disomy	I-Disease	C538037
(	I-Disease	C538037
UPD	I-Disease	C538037
)	I-Disease	C538037
for	I-Disease	C538037
chromosome	I-Disease	C538037
15	I-Disease	C538037
is	O	O
responsible	O	O
for	O	O
an	O	O
estimated	O	O
30	O	O
%	O	O
of	O	O
cases	O	O
of	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
(	O	O
PWS	B-Disease	D011218
)	O	O
.	O	O

We	O	O
report	O	O
on	O	O
an	O	O
unusual	O	O
case	O	O
of	O	O
maternal	B-Disease	C538037
disomy	I-Disease	C538037
15	I-Disease	C538037
in	O	O
PWS	B-Disease	D011218
that	O	O
is	O	O
most	O	O
consistent	O	O
with	O	O
adjacent	O	O
-	O	O
1	O	O
segregation	O	O
of	O	O
a	O	O
paternal	O	O
t	O	O
(	O	O
3	O	O
;	O	O
15	O	O
)	O	O
(	O	O
p25	O	O
;	O	O
q11	O	O
.	O	O

2	O	O
)	O	O
with	O	O
simultaneous	O	O
maternal	O	O
meiotic	O	O
nondisjunction	O	O
for	O	O
chromosome	O	O
15	O	O
.	O	O

The	O	O
patient	O	O
(	O	O
J	O	O
.	O	O

B	O	O
.	O	O

)	O	O
,	O	O
a	O	O
17	O	O
-	O	O
year	O	O
-	O	O
old	O	O
white	O	O
male	O	O
with	O	O
PWS	B-Disease	D011218
,	O	O
was	O	O
found	O	O
to	O	O
have	O	O
47	O	O
chromosomes	O	O
with	O	O
a	O	O
supernumerary	O	O
,	O	O
paternal	O	O
der	O	O
(	O	O
15	O	O
)	O	O
consisting	O	O
of	O	O
the	O	O
short	O	O
arm	O	O
and	O	O
the	O	O
proximal	O	O
long	O	O
arm	O	O
of	O	O
chromosome	O	O
15	O	O
,	O	O
and	O	O
distal	O	O
chromosome	O	O
arm	O	O
3p	O	O
.	O	O

The	O	O
t	O	O
(	O	O
3	O	O
;	O	O
15	O	O
)	O	O
was	O	O
present	O	O
in	O	O
the	O	O
balanced	O	O
state	O	O
in	O	O
the	O	O
patients	O	O
father	O	O
and	O	O
a	O	O
sister	O	O
.	O	O

Fluorescent	O	O
in	O	O
situ	O	O
hybridization	O	O
analysis	O	O
demonstrated	O	O
that	O	O
the	O	O
PWS	B-Disease	D011218
critical	O	O
region	O	O
resided	O	O
on	O	O
the	O	O
derivative	O	O
chromosome	O	O
3	O	O
and	O	O
that	O	O
there	O	O
was	O	O
no	O	O
deletion	O	O
of	O	O
the	O	O
PWS	B-Disease	D011218
region	O	O
on	O	O
the	O	O
normal	O	O
pair	O	O
of	O	O
15s	O	O
present	O	O
in	O	O
J	O	O
.	O	O

B	O	O
.	O	O

Methylation	O	O
analysis	O	O
at	O	O
exon	O	O
alpha	O	O
of	O	O
the	O	O
small	O	O
nuclear	O	O
ribonucleoprotein	O	O
-	O	O
associated	O	O
polypeptide	O	O
N	O	O
(	O	O
SNRPN	O	O
)	O	O
gene	O	O
showed	O	O
a	O	O
pattern	O	O
characteristic	O	O
of	O	O
only	O	O
the	O	O
maternal	O	O
chromosome	O	O
15	O	O
in	O	O
J	O	O
.	O	O

B	O	O
.	O	O

Maternal	B-Disease	D024182
disomy	I-Disease	D024182
was	O	O
confirmed	O	O
by	O	O
polymerase	O	O
chain	O	O
reaction	O	O
analysis	O	O
of	O	O
microsatellite	O	O
repeats	O	O
at	O	O
the	O	O
gamma	O	O
-	O	O
aminobutyric	O	O
acid	O	O
receptor	O	O
beta3	O	O
subunit	O	O
(	O	O
GABRB3	O	O
)	O	O
locus	O	O
.	O	O

A	O	O
niece	O	O
(	O	O
B	O	O
.	O	O

B	O	O
.	O	O

)	O	O
with	O	O
45	O	O
chromosomes	O	O
and	O	O
the	O	O
derivative	O	O
3	O	O
but	O	O
without	O	O
the	O	O
der	O	O
(	O	O
15	O	O
)	O	O
demonstrated	O	O
a	O	O
phenotype	O	O
consistent	O	O
with	O	O
that	O	O
reported	O	O
for	O	O
haploinsufficiency	O	O
of	O	O
distal	O	O
3	O	O
p	O	O
.	O	O

Uniparental	B-Disease	D024182
disomy	I-Disease	D024182
associated	O	O
with	O	O
unbalanced	O	O
segregation	O	O
of	O	O
non	O	O
-	O	O
Robertsonian	O	O
translocations	O	O
has	O	O
been	O	O
reported	O	O
previously	O	O
but	O	O
has	O	O
not	O	O
,	O	O
to	O	O
our	O	O
knowledge	O	O
,	O	O
been	O	O
observed	O	O
in	O	O
a	O	O
case	O	O
of	O	O
PWS	B-Disease	D011218
.	O	O

Furthermore	O	O
,	O	O
our	O	O
findings	O	O
are	O	O
best	O	O
interpreted	O	O
as	O	O
true	O	O
gamete	O	O
complementation	O	O
resulting	O	O
in	O	O
maternal	B-Disease	C538037
UPD	I-Disease	C538037
15	I-Disease	C538037
and	O	O
PWS	B-Disease	D011218
Segregation	O	O
distortion	O	O
in	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
.	O	O

Myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
is	O	O
an	O	O
autosomal	B-Disease	D030342
dominant	I-Disease	D030342
disease	I-Disease	D030342
which	O	O
,	O	O
in	O	O
the	O	O
typical	O	O
pedigree	O	O
,	O	O
shows	O	O
a	O	O
three	O	O
generation	O	O
anticipation	O	O
cascade	O	O
.	O	O

This	O	O
results	O	O
in	O	O
infertility	B-Disease	D007246
and	O	O
congenital	B-Disease	D009223
myotonic	I-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
CDM	B-Disease	D009223
)	O	O
with	O	O
the	O	O
disappearance	O	O
of	O	O
DM	B-Disease	D009223
in	O	O
that	O	O
pedigree	O	O
.	O	O

The	O	O
concept	O	O
of	O	O
segregation	O	O
distortion	O	O
,	O	O
where	O	O
there	O	O
is	O	O
preferential	O	O
transmission	O	O
of	O	O
the	O	O
larger	O	O
allele	O	O
at	O	O
the	O	O
DM	B-Disease	D009223
locus	O	O
,	O	O
has	O	O
been	O	O
put	O	O
forward	O	O
to	O	O
explain	O	O
partially	O	O
the	O	O
maintenance	O	O
of	O	O
DM	B-Disease	D009223
in	O	O
the	O	O
population	O	O
.	O	O

In	O	O
a	O	O
survey	O	O
of	O	O
DM	B-Disease	D009223
in	O	O
Northern	O	O
Ireland	O	O
,	O	O
59	O	O
pedigrees	O	O
were	O	O
ascertained	O	O
.	O	O

Sibships	O	O
where	O	O
the	O	O
status	O	O
of	O	O
all	O	O
the	O	O
members	O	O
had	O	O
been	O	O
identified	O	O
were	O	O
examined	O	O
to	O	O
determine	O	O
the	O	O
transmission	O	O
of	O	O
the	O	O
DM	B-Disease	D009223
expansion	O	O
from	O	O
affected	O	O
parents	O	O
to	O	O
their	O	O
offspring	O	O
.	O	O

Where	O	O
the	O	O
transmitting	O	O
parent	O	O
was	O	O
male	O	O
,	O	O
58	O	O
.	O	O

3	O	O
%	O	O
of	O	O
the	O	O
offspring	O	O
were	O	O
affected	O	O
,	O	O
and	O	O
in	O	O
the	O	O
case	O	O
of	O	O
a	O	O
female	O	O
transmitting	O	O
parent	O	O
,	O	O
68	O	O
.	O	O

7	O	O
%	O	O
were	O	O
affected	O	O
.	O	O

Studies	O	O
on	O	O
meiotic	O	O
drive	O	O
in	O	O
DM	B-Disease	D009223
have	O	O
shown	O	O
increased	O	O
transmission	O	O
of	O	O
the	O	O
larger	O	O
allele	O	O
at	O	O
the	O	O
DM	B-Disease	D009223
locus	O	O
in	O	O
non	O	O
-	O	O
DM	B-Disease	D009223
heterozygotes	O	O
for	O	O
CTGn	O	O
.	O	O

This	O	O
study	O	O
provides	O	O
further	O	O
evidence	O	O
that	O	O
the	O	O
DM	B-Disease	D009223
expansion	O	O
tends	O	O
to	O	O
be	O	O
transmitted	O	O
preferentially	O	O
.	O	O

Ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
:	O	O
identification	O	O
and	O	O
detection	O	O
of	O	O
founder	O	O
-	O	O
effect	O	O
mutations	O	O
in	O	O
the	O	O
ATM	O	O
gene	O	O
in	O	O
ethnic	O	O
populations	O	O
.	O	O

To	O	O
facilitate	O	O
the	O	O
evaluation	O	O
of	O	O
ATM	O	O
heterozygotes	O	O
for	O	O
susceptibility	O	O
to	O	O
other	O	O
diseases	O	O
,	O	O
such	O	O
as	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
,	O	O
we	O	O
have	O	O
attempted	O	O
to	O	O
define	O	O
the	O	O
most	O	O
common	O	O
mutations	O	O
and	O	O
their	O	O
frequencies	O	O
in	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
(	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
)	O	O
homozygotes	O	O
from	O	O
10	O	O
ethnic	O	O
populations	O	O
.	O	O

Both	O	O
genomic	O	O
mutations	O	O
and	O	O
their	O	O
effects	O	O
on	O	O
cDNA	O	O
were	O	O
characterized	O	O
.	O	O

Protein	O	O
-	O	O
truncation	O	O
testing	O	O
of	O	O
the	O	O
entire	O	O
ATM	O	O
cDNA	O	O
detected	O	O
92	O	O
(	O	O
66	O	O
%	O	O
)	O	O
truncating	O	O
mutations	O	O
in	O	O
140	O	O
mutant	O	O
alleles	O	O
screened	O	O
.	O	O

The	O	O
haplotyping	O	O
of	O	O
patients	O	O
with	O	O
identical	O	O
mutations	O	O
indicates	O	O
that	O	O
almost	O	O
all	O	O
of	O	O
these	O	O
represent	O	O
common	O	O
ancestry	O	O
and	O	O
that	O	O
very	O	O
few	O	O
spontaneously	O	O
recurring	O	O
ATM	O	O
mutations	O	O
exist	O	O
.	O	O

Assays	O	O
requiring	O	O
minimal	O	O
amounts	O	O
of	O	O
genomic	O	O
DNA	O	O
were	O	O
designed	O	O
to	O	O
allow	O	O
rapid	O	O
screening	O	O
for	O	O
common	O	O
ethnic	O	O
mutations	O	O
.	O	O

These	O	O
rapid	O	O
assays	O	O
detected	O	O
mutations	O	O
in	O	O
76	O	O
%	O	O
of	O	O
Costa	O	O
Rican	O	O
patients	O	O
(	O	O
3	O	O
)	O	O
,	O	O
50	O	O
%	O	O
of	O	O
Norwegian	O	O
patients	O	O
(	O	O
1	O	O
)	O	O
,	O	O
25	O	O
%	O	O
of	O	O
Polish	O	O
patients	O	O
(	O	O
4	O	O
)	O	O
,	O	O
and	O	O
14	O	O
%	O	O
of	O	O
Italian	O	O
patients	O	O
(	O	O
1	O	O
)	O	O
,	O	O
as	O	O
well	O	O
as	O	O
in	O	O
patients	O	O
of	O	O
Amish	O	O
/	O	O
Mennonite	O	O
and	O	O
Irish	O	O
English	O	O
backgrounds	O	O
.	O	O

Additional	O	O
mutations	O	O
were	O	O
observed	O	O
in	O	O
Japanese	O	O
,	O	O
Utah	O	O
Mormon	O	O
,	O	O
and	O	O
African	O	O
American	O	O
patients	O	O
.	O	O

These	O	O
assays	O	O
should	O	O
facilitate	O	O
screening	O	O
for	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
heterozygotes	O	O
in	O	O
the	O	O
populations	O	O
studied	O	O
.	O	O

.	O	O

Constitutional	O	O
RB1	O	O
-	O	O
gene	O	O
mutations	O	O
in	O	O
patients	O	O
with	O	O
isolated	O	O
unilateral	B-Disease	D012175
retinoblastoma	I-Disease	D012175
.	O	O

In	O	O
most	O	O
patients	O	O
with	O	O
isolated	O	O
unilateral	B-Disease	D012175
retinoblastoma	I-Disease	D012175
,	O	O
tumor	B-Disease	D009369
development	O	O
is	O	O
initiated	O	O
by	O	O
somatic	O	O
inactivation	O	O
of	O	O
both	O	O
alleles	O	O
of	O	O
the	O	O
RB1	O	O
gene	O	O
.	O	O

However	O	O
,	O	O
some	O	O
of	O	O
these	O	O
patients	O	O
can	O	O
transmit	O	O
retinoblastoma	B-Disease	D012175
predisposition	O	O
to	O	O
their	O	O
offspring	O	O
.	O	O

To	O	O
determine	O	O
the	O	O
frequency	O	O
and	O	O
nature	O	O
of	O	O
constitutional	O	O
RB1	O	O
-	O	O
gene	O	O
mutations	O	O
in	O	O
patients	O	O
with	O	O
isolated	O	O
unilateral	B-Disease	D012175
retinoblastoma	I-Disease	D012175
,	O	O
we	O	O
analyzed	O	O
DNA	O	O
from	O	O
peripheral	O	O
blood	O	O
and	O	O
from	O	O
tumor	B-Disease	D009369
tissue	O	O
.	O	O

The	O	O
analysis	O	O
of	O	O
tumors	B-Disease	D009369
from	O	O
54	O	O
(	O	O
71	O	O
%	O	O
)	O	O
of	O	O
76	O	O
informative	O	O
patients	O	O
showed	O	O
loss	O	O
of	O	O
constitutional	O	O
heterozygosity	O	O
(	O	O
LOH	O	O
)	O	O
at	O	O
intragenic	O	O
loci	O	O
.	O	O

Three	O	O
of	O	O
13	O	O
uninformative	O	O
patients	O	O
had	O	O
constitutional	O	O
deletions	O	O
.	O	O

For	O	O
39	O	O
randomly	O	O
selected	O	O
tumors	B-Disease	D009369
,	O	O
SSCP	O	O
,	O	O
hetero	O	O
-	O	O
duplex	O	O
analysis	O	O
,	O	O
sequencing	O	O
,	O	O
and	O	O
Southern	O	O
blot	O	O
analysis	O	O
were	O	O
used	O	O
to	O	O
identify	O	O
mutations	O	O
.	O	O

Mutations	O	O
were	O	O
detected	O	O
in	O	O
21	O	O
(	O	O
91	O	O
%	O	O
)	O	O
of	O	O
23	O	O
tumors	B-Disease	D009369
with	O	O
LOH	O	O
.	O	O

In	O	O
6	O	O
(	O	O
38	O	O
%	O	O
)	O	O
of	O	O
16	O	O
tumors	B-Disease	D009369
without	O	O
LOH	O	O
,	O	O
one	O	O
mutation	O	O
was	O	O
detected	O	O
,	O	O
and	O	O
in	O	O
9	O	O
(	O	O
56	O	O
%	O	O
)	O	O
of	O	O
the	O	O
tumors	B-Disease	D009369
without	O	O
LOH	O	O
,	O	O
both	O	O
mutations	O	O
were	O	O
found	O	O
.	O	O

Thus	O	O
,	O	O
a	O	O
total	O	O
of	O	O
45	O	O
mutations	O	O
were	O	O
identified	O	O
in	O	O
tumors	B-Disease	D009369
of	O	O
36	O	O
patients	O	O
.	O	O

Thirty	O	O
-	O	O
nine	O	O
of	O	O
the	O	O
mutations	O	O
-	O	O
including	O	O
34	O	O
small	O	O
mutations	O	O
,	O	O
2	O	O
large	O	O
structural	O	O
alterations	O	O
,	O	O
and	O	O
hypermethylation	O	O
in	O	O
3	O	O
tumors	B-Disease	D009369
-	O	O
were	O	O
not	O	O
detected	O	O
in	O	O
the	O	O
corresponding	O	O
peripheral	O	O
blood	O	O
DNA	O	O
.	O	O

In	O	O
6	O	O
(	O	O
17	O	O
%	O	O
)	O	O
of	O	O
the	O	O
36	O	O
patients	O	O
,	O	O
a	O	O
mutation	O	O
was	O	O
detected	O	O
in	O	O
constitutional	O	O
DNA	O	O
,	O	O
and	O	O
1	O	O
of	O	O
these	O	O
mutations	O	O
is	O	O
known	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
reduced	O	O
expressivity	O	O
.	O	O

The	O	O
presence	O	O
of	O	O
a	O	O
constitutional	O	O
mutation	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
an	O	O
early	O	O
age	O	O
at	O	O
treatment	O	O
.	O	O

In	O	O
1	O	O
patient	O	O
,	O	O
somatic	O	O
mosaicism	O	O
was	O	O
demonstrated	O	O
by	O	O
molecular	O	O
analysis	O	O
of	O	O
DNA	O	O
and	O	O
RNA	O	O
from	O	O
peripheral	O	O
blood	O	O
.	O	O

In	O	O
2	O	O
patients	O	O
without	O	O
a	O	O
detectable	O	O
mutation	O	O
in	O	O
peripheral	O	O
blood	O	O
,	O	O
mosaicism	O	O
was	O	O
suggested	O	O
because	O	O
1	O	O
of	O	O
the	O	O
patients	O	O
showed	O	O
multifocal	O	O
tumors	B-Disease	D009369
and	O	O
the	O	O
other	O	O
later	O	O
developed	O	O
bilateral	B-Disease	D012175
retinoblastoma	I-Disease	D012175
.	O	O

In	O	O
conclusion	O	O
,	O	O
our	O	O
results	O	O
emphasize	O	O
that	O	O
the	O	O
manifestation	O	O
and	O	O
transmissibility	O	O
of	O	O
retinoblastoma	B-Disease	D012175
depend	O	O
on	O	O
the	O	O
nature	O	O
of	O	O
the	O	O
first	O	O
mutation	O	O
,	O	O
its	O	O
time	O	O
in	O	O
development	O	O
,	O	O
and	O	O
the	O	O
number	O	O
and	O	O
types	O	O
of	O	O
cells	O	O
that	O	O
are	O	O
affected	O	O
.	O	O

.	O	O

Missense	O	O
mutations	O	O
in	O	O
the	O	O
most	O	O
ancient	O	O
residues	O	O
of	O	O
the	O	O
PAX6	O	O
paired	O	O
domain	O	O
underlie	O	O
a	O	O
spectrum	O	O
of	O	O
human	O	O
congenital	B-Disease	D005124
eye	I-Disease	D005124
malformations	I-Disease	D005124
.	O	O

Mutations	O	O
of	O	O
the	O	O
human	O	O
PAX6	O	O
gene	O	O
underlie	O	O
aniridia	B-Disease	D015783
(	O	O
congenital	B-Disease	D015783
absence	I-Disease	D015783
of	I-Disease	D015783
the	I-Disease	D015783
iris	I-Disease	D015783
)	O	O
,	O	O
a	O	O
rare	O	O
dominant	O	O
malformation	B-Disease	D005124
of	I-Disease	D005124
the	I-Disease	D005124
eye	I-Disease	D005124
.	O	O

The	O	O
spectrum	O	O
of	O	O
PAX6	O	O
mutations	O	O
in	O	O
aniridia	B-Disease	D015783
patients	O	O
is	O	O
highly	O	O
biased	O	O
,	O	O
with	O	O
92	O	O
%	O	O
of	O	O
all	O	O
reported	O	O
mutations	O	O
leading	O	O
to	O	O
premature	O	O
truncation	O	O
of	O	O
the	O	O
protein	O	O
(	O	O
nonsense	O	O
,	O	O
splicing	O	O
,	O	O
insertions	O	O
and	O	O
deletions	O	O
)	O	O
and	O	O
just	O	O
2	O	O
%	O	O
leading	O	O
to	O	O
substitution	O	O
of	O	O
one	O	O
amino	O	O
acid	O	O
by	O	O
another	O	O
(	O	O
missense	O	O
)	O	O
.	O	O

The	O	O
extraordinary	O	O
conservation	O	O
of	O	O
the	O	O
PAX6	O	O
protein	O	O
at	O	O
the	O	O
amino	O	O
acid	O	O
level	O	O
amongst	O	O
vertebrates	O	O
predicts	O	O
that	O	O
pathological	O	O
missense	O	O
mutations	O	O
should	O	O
in	O	O
fact	O	O
be	O	O
common	O	O
even	O	O
though	O	O
they	O	O
are	O	O
hardly	O	O
ever	O	O
seen	O	O
in	O	O
aniridia	B-Disease	D015783
patients	O	O
.	O	O

This	O	O
indicates	O	O
that	O	O
there	O	O
is	O	O
a	O	O
heavy	O	O
ascertainment	O	O
bias	O	O
in	O	O
the	O	O
selection	O	O
of	O	O
patients	O	O
for	O	O
PAX6	O	O
mutation	O	O
analysis	O	O
and	O	O
that	O	O
the	O	O
missing	O	O
PAX6	O	O
missense	O	O
mutations	O	O
frequently	O	O
may	O	O
underlie	O	O
phenotypes	O	O
distinct	O	O
from	O	O
textbook	O	O
aniridia	B-Disease	D015783
.	O	O

Here	O	O
we	O	O
present	O	O
four	O	O
novel	O	O
PAX6	O	O
missense	O	O
mutations	O	O
,	O	O
two	O	O
in	O	O
association	O	O
with	O	O
atypical	O	O
phenotypes	O	O
ectopia	B-Disease	C536185
pupillae	I-Disease	C536185
(	O	O
displaced	B-Disease	C536185
pupils	I-Disease	C536185
)	O	O
and	O	O
congenital	B-Disease	D020417
nystagmus	I-Disease	D020417
(	O	O
searching	B-Disease	D020417
gaze	I-Disease	D020417
)	O	O
,	O	O
and	O	O
two	O	O
in	O	O
association	O	O
with	O	O
more	O	O
recognizable	O	O
aniridia	B-Disease	D015783
phenotypes	O	O
.	O	O

Strikingly	O	O
,	O	O
all	O	O
four	O	O
mutations	O	O
are	O	O
located	O	O
within	O	O
the	O	O
PAX6	O	O
paired	O	O
domain	O	O
and	O	O
affect	O	O
amino	O	O
acids	O	O
which	O	O
are	O	O
highly	O	O
conserved	O	O
in	O	O
all	O	O
known	O	O
paired	O	O
domain	O	O
proteins	O	O
.	O	O

Our	O	O
results	O	O
support	O	O
the	O	O
hypothesis	O	O
that	O	O
the	O	O
under	O	O
-	O	O
representation	O	O
of	O	O
missense	O	O
mutations	O	O
is	O	O
caused	O	O
by	O	O
ascertainment	O	O
bias	O	O
and	O	O
suggest	O	O
that	O	O
a	O	O
substantial	O	O
burden	O	O
of	O	O
PAX6	B-Disease	OMIM:106210
-	I-Disease	OMIM:106210
related	I-Disease	OMIM:106210
disease	I-Disease	OMIM:106210
remains	O	O
to	O	O
be	O	O
uncovered	O	O
.	O	O

.	O	O

Somatic	O	O
instability	O	O
of	O	O
the	O	O
CTG	O	O
repeat	O	O
in	O	O
mice	O	O
transgenic	O	O
for	O	O
the	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
region	O	O
is	O	O
age	O	O
dependent	O	O
but	O	O
not	O	O
correlated	O	O
to	O	O
the	O	O
relative	O	O
intertissue	O	O
transcription	O	O
levels	O	O
and	O	O
proliferative	O	O
capacities	O	O
.	O	O

A	O	O
(	O	O
CTG	O	O
)	O	O
nexpansion	O	O
in	O	O
the	O	O
3	O	O
-	O	O
untranslated	O	O
region	O	O
(	O	O
UTR	O	O
)	O	O
of	O	O
the	O	O
DM	B-Disease	D009223
protein	O	O
kinase	O	O
gene	O	O
(	O	O
DMPK	O	O
)	O	O
is	O	O
responsible	O	O
for	O	O
causing	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
.	O	O

Major	O	O
instability	O	O
,	O	O
with	O	O
very	O	O
large	O	O
expansions	O	O
between	O	O
generations	O	O
and	O	O
high	O	O
levels	O	O
of	O	O
somatic	O	O
mosaicism	O	O
,	O	O
is	O	O
observed	O	O
in	O	O
patients	O	O
.	O	O

There	O	O
is	O	O
a	O	O
good	O	O
correlation	O	O
between	O	O
repeat	O	O
size	O	O
(	O	O
at	O	O
least	O	O
in	O	O
leucocytes	O	O
)	O	O
,	O	O
clinical	O	O
severity	O	O
and	O	O
age	O	O
of	O	O
onset	O	O
.	O	O

The	O	O
trinucleotide	O	O
repeat	O	O
instability	O	O
mechanisms	O	O
involved	O	O
in	O	O
DM	B-Disease	D009223
and	O	O
other	O	O
human	O	O
genetic	B-Disease	D030342
diseases	I-Disease	D030342
are	O	O
unknown	O	O
.	O	O

We	O	O
studied	O	O
somatic	O	O
instability	O	O
by	O	O
measuring	O	O
the	O	O
CTG	O	O
repeat	O	O
length	O	O
at	O	O
several	O	O
ages	O	O
in	O	O
various	O	O
tissues	O	O
of	O	O
transgenic	O	O
mice	O	O
carrying	O	O
a	O	O
(	O	O
CTG	O	O
)	O	O
55expansion	O	O
surrounded	O	O
by	O	O
45	O	O
kb	O	O
of	O	O
the	O	O
human	O	O
DM	B-Disease	D009223
region	O	O
,	O	O
using	O	O
small	O	O
-	O	O
pool	O	O
PCR	O	O
.	O	O

These	O	O
mice	O	O
have	O	O
been	O	O
shown	O	O
to	O	O
reproduce	O	O
the	O	O
intergenerational	O	O
and	O	O
somatic	O	O
instability	O	O
of	O	O
the	O	O
55	O	O
CTG	O	O
repeat	O	O
suggesting	O	O
that	O	O
surrounding	O	O
sequences	O	O
and	O	O
the	O	O
chromatin	O	O
environment	O	O
are	O	O
involved	O	O
in	O	O
instability	O	O
mechanisms	O	O
.	O	O

As	O	O
observed	O	O
in	O	O
some	O	O
of	O	O
the	O	O
tissues	O	O
of	O	O
DM	B-Disease	D009223
patients	O	O
,	O	O
there	O	O
is	O	O
a	O	O
tendency	O	O
for	O	O
repeat	O	O
length	O	O
and	O	O
somatic	O	O
mosaicism	O	O
to	O	O
increase	O	O
with	O	O
the	O	O
age	O	O
of	O	O
the	O	O
mouse	O	O
.	O	O

Furthermore	O	O
,	O	O
we	O	O
observed	O	O
no	O	O
correlation	O	O
between	O	O
the	O	O
somatic	O	O
mutation	O	O
rate	O	O
and	O	O
tissue	O	O
proliferation	O	O
capacity	O	O
.	O	O

The	O	O
somatic	O	O
mutation	O	O
rates	O	O
in	O	O
different	O	O
tissues	O	O
were	O	O
also	O	O
not	O	O
correlated	O	O
to	O	O
the	O	O
relative	O	O
inter	O	O
-	O	O
tissue	O	O
difference	O	O
in	O	O
transcriptional	O	O
levels	O	O
of	O	O
the	O	O
three	O	O
genes	O	O
(	O	O
DMAHP	O	O
,	O	O
DMPK	O	O
and	O	O
59	O	O
)	O	O
surrounding	O	O
the	O	O
repeat	O	O
.	O	O

.	O	O

ATM	O	O
mutations	O	O
and	O	O
phenotypes	O	O
in	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
families	O	O
in	O	O
the	O	O
British	O	O
Isles	O	O
:	O	O
expression	O	O
of	O	O
mutant	O	O
ATM	O	O
and	O	O
the	O	O
risk	O	O
of	O	O
leukemia	B-Disease	D007938
,	O	O
lymphoma	B-Disease	D008223
,	O	O
and	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

We	O	O
report	O	O
the	O	O
spectrum	O	O
of	O	O
59	O	O
ATM	O	O
mutations	O	O
observed	O	O
in	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
(	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
)	O	O
patients	O	O
in	O	O
the	O	O
British	O	O
Isles	O	O
.	O	O

Of	O	O
51	O	O
ATM	O	O
mutations	O	O
identified	O	O
in	O	O
families	O	O
native	O	O
to	O	O
the	O	O
British	O	O
Isles	O	O
,	O	O
11	O	O
were	O	O
founder	O	O
mutations	O	O
,	O	O
and	O	O
2	O	O
of	O	O
these	O	O
11	O	O
conferred	O	O
a	O	O
milder	O	O
clinical	O	O
phenotype	O	O
with	O	O
respect	O	O
to	O	O
both	O	O
cerebellar	B-Disease	D013132
degeneration	I-Disease	D013132
and	O	O
cellular	O	O
features	O	O
.	O	O

We	O	O
report	O	O
,	O	O
in	O	O
two	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
families	O	O
,	O	O
an	O	O
ATM	O	O
mutation	O	O
(	O	O
7271T	O	O
-	O	O
-	O	O
>	O	O
G	O	O
)	O	O
that	O	O
may	O	O
be	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
in	O	O
both	O	O
homozygotes	O	O
and	O	O
heterozygotes	O	O
(	O	O
relative	O	O
risk	O	O
12	O	O
.	O	O

7	O	O
;	O	O
P	O	O
=	O	O
.	O	O

0025	O	O
)	O	O
,	O	O
although	O	O
there	O	O
is	O	O
a	O	O
less	O	O
severe	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
phenotype	O	O
in	O	O
terms	O	O
of	O	O
the	O	O
degree	O	O
of	O	O
cerebellar	B-Disease	D013132
degeneration	I-Disease	D013132
.	O	O

This	O	O
mutation	O	O
(	O	O
7271T	O	O
-	O	O
-	O	O
>	O	O
G	O	O
)	O	O
also	O	O
allows	O	O
expression	O	O
of	O	O
full	O	O
-	O	O
length	O	O
ATM	O	O
protein	O	O
at	O	O
a	O	O
level	O	O
comparable	O	O
with	O	O
that	O	O
in	O	O
unaffected	O	O
individuals	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
have	O	O
studied	O	O
18	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
patients	O	O
,	O	O
in	O	O
15	O	O
families	O	O
,	O	O
who	O	O
developed	O	O
leukemia	B-Disease	D007938
,	O	O
lymphoma	B-Disease	D008223
,	O	O
preleukemic	O	O
T	O	O
-	O	O
cell	O	O
proliferation	O	O
,	O	O
or	O	O
Hodgkin	B-Disease	D006689
lymphoma	I-Disease	D006689
,	O	O
mostly	O	O
in	O	O
childhood	O	O
.	O	O

A	O	O
wide	O	O
variety	O	O
of	O	O
ATM	O	O
mutation	O	O
types	O	O
,	O	O
including	O	O
missense	O	O
mutations	O	O
and	O	O
in	O	O
-	O	O
frame	O	O
deletions	O	O
,	O	O
were	O	O
seen	O	O
in	O	O
these	O	O
patients	O	O
.	O	O

We	O	O
also	O	O
show	O	O
that	O	O
25	O	O
%	O	O
of	O	O
all	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
patients	O	O
carried	O	O
in	O	O
-	O	O
frame	O	O
deletions	O	O
or	O	O
missense	O	O
mutations	O	O
,	O	O
many	O	O
of	O	O
which	O	O
were	O	O
also	O	O
associated	O	O
with	O	O
expression	O	O
of	O	O
mutant	O	O
ATM	O	O
protein	O	O
.	O	O

Low	O	O
frequency	O	O
of	O	O
BRCA1	O	O
germline	O	O
mutations	O	O
in	O	O
45	O	O
German	O	O
breast	B-Disease	D061325
/	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
families	O	O
.	O	O

In	O	O
this	O	O
study	O	O
we	O	O
investigated	O	O
45	O	O
German	O	O
breast	B-Disease	D061325
/	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
families	O	O
for	O	O
germline	O	O
mutations	O	O
in	O	O
the	O	O
BRCA1	O	O
gene	O	O
.	O	O

We	O	O
identified	O	O
four	O	O
germline	O	O
mutations	O	O
in	O	O
three	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
families	O	O
and	O	O
in	O	O
one	O	O
breast	B-Disease	D061325
-	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
family	O	O
.	O	O

among	O	O
these	O	O
were	O	O
one	O	O
frameshift	O	O
mutation	O	O
,	O	O
one	O	O
nonsense	O	O
mutation	O	O
,	O	O
one	O	O
novel	O	O
splice	O	O
site	O	O
mutation	O	O
,	O	O
and	O	O
one	O	O
missense	O	O
mutation	O	O
.	O	O

The	O	O
missense	O	O
mutation	O	O
was	O	O
also	O	O
found	O	O
in	O	O
2	O	O
.	O	O

8	O	O
%	O	O
of	O	O
the	O	O
general	O	O
population	O	O
,	O	O
suggesting	O	O
that	O	O
it	O	O
is	O	O
not	O	O
disease	O	O
associated	O	O
.	O	O

The	O	O
average	O	O
age	O	O
of	O	O
disease	O	O
onset	O	O
in	O	O
those	O	O
families	O	O
harbouring	O	O
causative	O	O
mutations	O	O
was	O	O
between	O	O
32	O	O
.	O	O

3	O	O
and	O	O
37	O	O
.	O	O

4	O	O
years	O	O
,	O	O
whereas	O	O
the	O	O
family	O	O
harbouring	O	O
the	O	O
missense	O	O
mutation	O	O
had	O	O
an	O	O
average	O	O
age	O	O
of	O	O
onset	O	O
of	O	O
51	O	O
.	O	O

2	O	O
years	O	O
.	O	O

These	O	O
findings	O	O
show	O	O
that	O	O
BRCA1	O	O
is	O	O
implicated	O	O
in	O	O
a	O	O
small	O	O
fraction	O	O
of	O	O
breast	B-Disease	D061325
/	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
families	O	O
suggesting	O	O
the	O	O
involvement	O	O
of	O	O
another	O	O
susceptibility	O	O
gene	O	O
(	O	O
s	O	O
)	O	O
Oral	O	O
contraceptives	O	O
and	O	O
the	O	O
risk	O	O
of	O	O
hereditary	B-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
.	O	O

Hereditary	B-Disease	D061325
Ovarian	I-Disease	D061325
Cancer	I-Disease	D061325
Clinical	O	O
Study	O	O
Group	O	O
.	O	O

BACKGROUND	O	O
Women	O	O
with	O	O
mutations	O	O
in	O	O
either	O	O
the	O	O
BRCA1	O	O
or	O	O
the	O	O
BRCA2	O	O
gene	O	O
have	O	O
a	O	O
high	O	O
lifetime	O	O
risk	O	O
of	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
.	O	O

Oral	O	O
contraceptives	O	O
protect	O	O
against	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
in	O	O
general	O	O
,	O	O
but	O	O
it	O	O
is	O	O
not	O	O
known	O	O
whether	O	O
they	O	O
also	O	O
protect	O	O
against	O	O
hereditary	B-Disease	D061325
forms	I-Disease	D061325
of	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
.	O	O

METHODS	O	O
We	O	O
enrolled	O	O
207	O	O
women	O	O
with	O	O
hereditary	B-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
and	O	O
161	O	O
of	O	O
their	O	O
sisters	O	O
as	O	O
controls	O	O
in	O	O
a	O	O
case	O	O
-	O	O
control	O	O
study	O	O
.	O	O

All	O	O
the	O	O
patients	O	O
carried	O	O
a	O	O
pathogenic	O	O
mutation	O	O
in	O	O
either	O	O
BRCA1	O	O
(	O	O
179	O	O
women	O	O
)	O	O
or	O	O
BRCA2	O	O
(	O	O
28	O	O
women	O	O
)	O	O
.	O	O

The	O	O
control	O	O
women	O	O
were	O	O
enrolled	O	O
regardless	O	O
of	O	O
whether	O	O
or	O	O
not	O	O
they	O	O
had	O	O
either	O	O
mutation	O	O
.	O	O

Lifetime	O	O
histories	O	O
of	O	O
oral	O	O
-	O	O
contraceptive	O	O
use	O	O
were	O	O
obtained	O	O
by	O	O
interview	O	O
or	O	O
by	O	O
written	O	O
questionnaire	O	O
and	O	O
were	O	O
compared	O	O
between	O	O
patients	O	O
and	O	O
control	O	O
women	O	O
,	O	O
after	O	O
adjustment	O	O
for	O	O
year	O	O
of	O	O
birth	O	O
and	O	O
parity	O	O
.	O	O

RESULTS	O	O
The	O	O
adjusted	O	O
odds	O	O
ratio	O	O
for	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
associated	O	O
with	O	O
any	O	O
past	O	O
use	O	O
of	O	O
oral	O	O
contraceptives	O	O
was	O	O
0	O	O
.	O	O

5	O	O
(	O	O
95	O	O
percent	O	O
confidence	O	O
interval	O	O
,	O	O
0	O	O
.	O	O

3	O	O
to	O	O
0	O	O
.	O	O

8	O	O
)	O	O
.	O	O

The	O	O
risk	O	O
decreased	O	O
with	O	O
increasing	O	O
duration	O	O
of	O	O
use	O	O
(	O	O
P	O	O
for	O	O
trend	O	O
,	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
;	O	O
use	O	O
for	O	O
six	O	O
or	O	O
more	O	O
years	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
60	O	O
percent	O	O
reduction	O	O
in	O	O
risk	O	O
.	O	O

Oral	O	O
-	O	O
contraceptive	O	O
use	O	O
protected	O	O
against	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
both	O	O
for	O	O
carriers	O	O
of	O	O
the	O	O
BRCA1	O	O
mutation	O	O
(	O	O
odds	O	O
ratio	O	O
,	O	O
0	O	O
.	O	O

5	O	O
;	O	O
95	O	O
percent	O	O
confidence	O	O
interval	O	O
,	O	O
0	O	O
.	O	O

3	O	O
to	O	O
0	O	O
.	O	O

9	O	O
)	O	O
and	O	O
for	O	O
carriers	O	O
of	O	O
the	O	O
BRCA2	O	O
mutation	O	O
(	O	O
odds	O	O
ratio	O	O
,	O	O
0	O	O
.	O	O

4	O	O
;	O	O
95	O	O
percent	O	O
confidence	O	O
interval	O	O
,	O	O
0	O	O
.	O	O

2	O	O
to	O	O
1	O	O
.	O	O

1	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
Oral	O	O
-	O	O
contraceptive	O	O
use	O	O
may	O	O
reduce	O	O
the	O	O
risk	O	O
of	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
in	O	O
women	O	O
with	O	O
pathogenic	O	O
mutations	O	O
in	O	O
the	O	O
BRCA1	O	O
or	O	O
BRCA2	O	O
gene	O	O
Founder	O	O
BRCA1	O	O
and	O	O
BRCA2	O	O
mutations	O	O
in	O	O
French	O	O
Canadian	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
families	O	O
.	O	O

We	O	O
have	O	O
identified	O	O
four	O	O
mutations	O	O
in	O	O
each	O	O
of	O	O
the	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
-	O	O
susceptibility	O	O
genes	O	O
,	O	O
BRCA1	O	O
and	O	O
BRCA2	O	O
,	O	O
in	O	O
French	O	O
Canadian	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
and	O	O
breast	B-Disease	D061325
/	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
families	O	O
from	O	O
Quebec	O	O
.	O	O

To	O	O
identify	O	O
founder	O	O
effects	O	O
,	O	O
we	O	O
examined	O	O
independently	O	O
ascertained	O	O
French	O	O
Canadian	O	O
cancer	B-Disease	D009369
families	O	O
for	O	O
the	O	O
distribution	O	O
of	O	O
these	O	O
eight	O	O
mutations	O	O
.	O	O

Mutations	O	O
were	O	O
found	O	O
in	O	O
41	O	O
of	O	O
97	O	O
families	O	O
.	O	O

Six	O	O
of	O	O
eight	O	O
mutations	O	O
were	O	O
observed	O	O
at	O	O
least	O	O
twice	O	O
.	O	O

The	O	O
BRCA1	O	O
C4446T	O	O
mutation	O	O
was	O	O
the	O	O
most	O	O
common	O	O
mutation	O	O
found	O	O
,	O	O
followed	O	O
by	O	O
the	O	O
BRCA2	O	O
8765delAG	O	O
mutation	O	O
.	O	O

Together	O	O
,	O	O
these	O	O
mutations	O	O
were	O	O
found	O	O
in	O	O
28	O	O
of	O	O
41	O	O
families	O	O
identified	O	O
to	O	O
have	O	O
a	O	O
mutation	O	O
.	O	O

The	O	O
odds	O	O
of	O	O
detection	O	O
of	O	O
any	O	O
of	O	O
the	O	O
four	O	O
BRCA1	O	O
mutations	O	O
was	O	O
18	O	O
.	O	O

7x	O	O
greater	O	O
if	O	O
one	O	O
or	O	O
more	O	O
cases	O	O
of	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
were	O	O
also	O	O
present	O	O
in	O	O
the	O	O
family	O	O
.	O	O

The	O	O
odds	O	O
of	O	O
detection	O	O
of	O	O
any	O	O
of	O	O
the	O	O
four	O	O
BRCA2	O	O
mutations	O	O
was	O	O
5	O	O
.	O	O

3x	O	O
greater	O	O
if	O	O
there	O	O
were	O	O
at	O	O
least	O	O
five	O	O
cases	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
in	O	O
the	O	O
family	O	O
.	O	O

Interestingly	O	O
,	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
case	O	O
<	O	O
36	O	O
years	O	O
of	O	O
age	O	O
was	O	O
strongly	O	O
predictive	O	O
of	O	O
the	O	O
presence	O	O
of	O	O
any	O	O
of	O	O
the	O	O
eight	O	O
mutations	O	O
screened	O	O
.	O	O

Carriers	O	O
of	O	O
the	O	O
same	O	O
mutation	O	O
,	O	O
from	O	O
different	O	O
families	O	O
,	O	O
shared	O	O
similar	O	O
haplotypes	O	O
,	O	O
indicating	O	O
that	O	O
the	O	O
mutant	O	O
alleles	O	O
were	O	O
likely	O	O
to	O	O
be	O	O
identical	O	O
by	O	O
descent	O	O
for	O	O
a	O	O
mutation	O	O
in	O	O
the	O	O
founder	O	O
population	O	O
.	O	O

The	O	O
identification	O	O
of	O	O
common	O	O
BRCA1	O	O
and	O	O
BRCA2	O	O
mutations	O	O
will	O	O
facilitate	O	O
carrier	O	O
detection	O	O
in	O	O
French	O	O
Canadian	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
and	O	O
breast	B-Disease	D061325
/	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
families	O	O
.	O	O

Truncation	O	O
mutations	O	O
in	O	O
the	O	O
transactivation	O	O
region	O	O
of	O	O
PAX6	O	O
result	O	O
in	O	O
dominant	O	O
-	O	O
negative	O	O
mutants	O	O
.	O	O

PAX6	O	O
is	O	O
a	O	O
transcription	O	O
factor	O	O
with	O	O
two	O	O
DNA	O	O
-	O	O
binding	O	O
domains	O	O
(	O	O
paired	O	O
box	O	O
and	O	O
homeobox	O	O
)	O	O
and	O	O
a	O	O
proline	O	O
-	O	O
serine	O	O
-	O	O
threonine	O	O
(	O	O
PST	O	O
)	O	O
-	O	O
rich	O	O
transactivation	O	O
domain	O	O
.	O	O

PAX6	O	O
regulates	O	O
eye	O	O
development	O	O
in	O	O
animals	O	O
ranging	O	O
from	O	O
jellyfish	O	O
to	O	O
Drosophila	O	O
to	O	O
humans	O	O
.	O	O

Heterozygous	O	O
mutations	O	O
in	O	O
the	O	O
human	O	O
PAX6	O	O
gene	O	O
result	O	O
in	O	O
various	O	O
phenotypes	O	O
,	O	O
including	O	O
aniridia	B-Disease	D015783
,	O	O
Peters	B-Disease	C537884
anomaly	I-Disease	C537884
,	O	O
autosomal	B-Disease	C537022
dominant	I-Disease	C537022
keratitis	I-Disease	C537022
,	O	O
and	O	O
familial	B-Disease	OMIM:136520
foveal	I-Disease	OMIM:136520
dysplasia	I-Disease	OMIM:136520
.	O	O

It	O	O
is	O	O
believed	O	O
that	O	O
the	O	O
mutated	O	O
allele	O	O
of	O	O
PAX6	O	O
produces	O	O
an	O	O
inactive	O	O
protein	O	O
and	O	O
aniridia	B-Disease	D015783
is	O	O
caused	O	O
due	O	O
to	O	O
genetic	O	O
haploinsufficiency	O	O
.	O	O

However	O	O
,	O	O
several	O	O
truncation	O	O
mutations	O	O
have	O	O
been	O	O
found	O	O
to	O	O
occur	O	O
in	O	O
the	O	O
C	O	O
-	O	O
terminal	O	O
half	O	O
of	O	O
PAX6	O	O
in	O	O
patients	O	O
with	O	O
Aniridia	B-Disease	D015783
resulting	O	O
in	O	O
mutant	O	O
proteins	O	O
that	O	O
retain	O	O
the	O	O
DNA	O	O
-	O	O
binding	O	O
domains	O	O
but	O	O
have	O	O
lost	O	O
most	O	O
of	O	O
the	O	O
transactivation	O	O
domain	O	O
.	O	O

It	O	O
is	O	O
not	O	O
clear	O	O
whether	O	O
such	O	O
mutants	O	O
really	O	O
behave	O	O
as	O	O
loss	O	O
-	O	O
of	O	O
-	O	O
function	O	O
mutants	O	O
as	O	O
predicted	O	O
by	O	O
haploinsufficiency	O	O
.	O	O

Contrary	O	O
to	O	O
this	O	O
theory	O	O
,	O	O
our	O	O
data	O	O
showed	O	O
that	O	O
these	O	O
mutants	O	O
are	O	O
dominant	O	O
-	O	O
negative	O	O
in	O	O
transient	O	O
transfection	O	O
assays	O	O
when	O	O
they	O	O
are	O	O
coexpressed	O	O
with	O	O
wild	O	O
-	O	O
type	O	O
PAX6	O	O
.	O	O

We	O	O
found	O	O
that	O	O
the	O	O
dominant	O	O
-	O	O
negative	O	O
effects	O	O
result	O	O
from	O	O
the	O	O
enhanced	O	O
DNA	O	O
binding	O	O
ability	O	O
of	O	O
these	O	O
mutants	O	O
.	O	O

Kinetic	O	O
studies	O	O
of	O	O
binding	O	O
and	O	O
dissociation	O	O
revealed	O	O
that	O	O
various	O	O
truncation	O	O
mutants	O	O
have	O	O
3	O	O
-	O	O
5	O	O
-	O	O
fold	O	O
higher	O	O
affinity	O	O
to	O	O
various	O	O
DNA	O	O
-	O	O
binding	O	O
sites	O	O
when	O	O
compared	O	O
with	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
PAX6	O	O
.	O	O

These	O	O
results	O	O
provide	O	O
a	O	O
new	O	O
insight	O	O
into	O	O
the	O	O
role	O	O
of	O	O
mutant	O	O
PAX6	O	O
in	O	O
causing	O	O
aniridia	B-Disease	D015783
.	O	O

.	O	O

Crystal	O	O
structure	O	O
of	O	O
the	O	O
hemochromatosis	B-Disease	D006432
protein	O	O
HFE	O	O
and	O	O
characterization	O	O
of	O	O
its	O	O
interaction	O	O
with	O	O
transferrin	O	O
receptor	O	O
.	O	O

HFE	O	O
is	O	O
an	O	O
MHC	O	O
-	O	O
related	O	O
protein	O	O
that	O	O
is	O	O
mutated	O	O
in	O	O
the	O	O
iron	B-Disease	D019190
-	I-Disease	D019190
overload	I-Disease	D019190
disease	I-Disease	D019190
hereditary	B-Disease	D006432
hemochromatosis	I-Disease	D006432
.	O	O

HFE	O	O
binds	O	O
to	O	O
transferrin	O	O
receptor	O	O
(	O	O
TfR	O	O
)	O	O
and	O	O
reduces	O	O
its	O	O
affinity	O	O
for	O	O
iron	O	O
-	O	O
loaded	O	O
transferrin	O	O
,	O	O
implicating	O	O
HFE	O	O
in	O	O
iron	O	O
metabolism	O	O
.	O	O

The	O	O
2	O	O
.	O	O

6	O	O
A	O	O
crystal	O	O
structure	O	O
of	O	O
HFE	O	O
reveals	O	O
the	O	O
locations	O	O
of	O	O
hemochromatosis	B-Disease	D006432
mutations	O	O
and	O	O
a	O	O
patch	O	O
of	O	O
histidines	O	O
that	O	O
could	O	O
be	O	O
involved	O	O
in	O	O
pH	O	O
-	O	O
dependent	O	O
interactions	O	O
.	O	O

We	O	O
also	O	O
demonstrate	O	O
that	O	O
soluble	O	O
TfR	O	O
and	O	O
HFE	O	O
bind	O	O
tightly	O	O
at	O	O
the	O	O
basic	O	O
pH	O	O
of	O	O
the	O	O
cell	O	O
surface	O	O
,	O	O
but	O	O
not	O	O
at	O	O
the	O	O
acidic	O	O
pH	O	O
of	O	O
intracellular	O	O
vesicles	O	O
.	O	O

TfR	O	O
HFE	O	O
stoichiometry	O	O
(	O	O
2	O	O
1	O	O
)	O	O
differs	O	O
from	O	O
TfR	O	O
transferrin	O	O
stoichiometry	O	O
(	O	O
2	O	O
2	O	O
)	O	O
,	O	O
implying	O	O
a	O	O
different	O	O
mode	O	O
of	O	O
binding	O	O
for	O	O
HFE	O	O
and	O	O
transferrin	O	O
to	O	O
TfR	O	O
,	O	O
consistent	O	O
with	O	O
our	O	O
demonstration	O	O
that	O	O
HFE	O	O
,	O	O
transferrin	O	O
,	O	O
and	O	O
TfR	O	O
form	O	O
a	O	O
ternary	O	O
complex	O	O
.	O	O

Stable	O	O
interaction	O	O
between	O	O
the	O	O
products	O	O
of	O	O
the	O	O
BRCA1	O	O
and	O	O
BRCA2	O	O
tumor	B-Disease	D009369
suppressor	O	O
genes	O	O
in	O	O
mitotic	O	O
and	O	O
meiotic	O	O
cells	O	O
.	O	O

BRCA1	O	O
and	O	O
BRCA2	O	O
account	O	O
for	O	O
most	O	O
cases	O	O
of	O	O
familial	O	O
,	O	O
early	O	O
onset	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
/	I-Disease	D061325
or	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
and	O	O
encode	O	O
products	O	O
that	O	O
each	O	O
interact	O	O
with	O	O
hRAD51	O	O
.	O	O

Results	O	O
presented	O	O
here	O	O
show	O	O
that	O	O
BRCA1	O	O
and	O	O
BRCA2	O	O
coexist	O	O
in	O	O
a	O	O
biochemical	O	O
complex	O	O
and	O	O
colocalize	O	O
in	O	O
subnuclear	O	O
foci	O	O
in	O	O
somatic	O	O
cells	O	O
and	O	O
on	O	O
the	O	O
axial	O	O
elements	O	O
of	O	O
developing	O	O
synaptonemal	O	O
complexes	O	O
.	O	O

Like	O	O
BRCA1	O	O
and	O	O
RAD51	O	O
,	O	O
BRCA2	O	O
relocates	O	O
to	O	O
PCNA	O	O
+	O	O
replication	O	O
sites	O	O
following	O	O
exposure	O	O
of	O	O
S	O	O
phase	O	O
cells	O	O
to	O	O
hydroxyurea	O	O
or	O	O
UV	O	O
irradiation	O	O
.	O	O

Thus	O	O
,	O	O
BRCA1	O	O
and	O	O
BRCA2	O	O
participate	O	O
,	O	O
together	O	O
,	O	O
in	O	O
a	O	O
pathway	O	O
(	O	O
s	O	O
)	O	O
associated	O	O
with	O	O
the	O	O
activation	O	O
of	O	O
double	O	O
-	O	O
strand	O	O
break	O	O
repair	O	O
and	O	O
/	O	O
or	O	O
homologous	O	O
recombination	O	O
.	O	O

Dysfunction	O	O
of	O	O
this	O	O
pathway	O	O
may	O	O
be	O	O
a	O	O
general	O	O
phenomenon	O	O
in	O	O
the	O	O
majority	O	O
of	O	O
cases	O	O
of	O	O
hereditary	B-Disease	D061325
breast	I-Disease	D061325
and	I-Disease	D061325
/	I-Disease	D061325
or	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
.	O	O

.	O	O

A	O	O
novel	O	O
Arg362Ser	O	O
mutation	O	O
in	O	O
the	O	O
sterol	O	O
27	O	O
-	O	O
hydroxylase	O	O
gene	O	O
(	O	O
CYP27	O	O
)	O	O
:	O	O
its	O	O
effects	O	O
on	O	O
pre	O	O
-	O	O
mRNA	O	O
splicing	O	O
and	O	O
enzyme	O	O
activity	O	O
.	O	O

A	O	O
novel	O	O
C	O	O
to	O	O
A	O	O
mutation	O	O
in	O	O
the	O	O
sterol	O	O
27	O	O
-	O	O
hydroxylase	O	O
gene	O	O
(	O	O
CYP27	O	O
)	O	O
was	O	O
identified	O	O
by	O	O
sequencing	O	O
amplified	O	O
CYP27	O	O
gene	O	O
products	O	O
from	O	O
a	O	O
patient	O	O
with	O	O
cerebrotendinous	B-Disease	D019294
xanthomatosis	I-Disease	D019294
(	O	O
CTX	B-Disease	D019294
)	O	O
.	O	O

The	O	O
mutation	O	O
changed	O	O
the	O	O
adrenodoxin	O	O
cofactor	O	O
binding	O	O
residue	O	O
362Arg	O	O
to	O	O
362Ser	O	O
(	O	O
CGT	O	O
362Arg	O	O
to	O	O
AGT	O	O
362Ser	O	O
)	O	O
,	O	O
and	O	O
was	O	O
responsible	O	O
for	O	O
deficiency	B-Disease	D019294
in	I-Disease	D019294
the	I-Disease	D019294
sterol	I-Disease	D019294
27	I-Disease	D019294
-	I-Disease	D019294
hydroxylase	I-Disease	D019294
activity	I-Disease	D019294
,	O	O
as	O	O
confirmed	O	O
by	O	O
expression	O	O
of	O	O
mutant	O	O
cDNA	O	O
into	O	O
COS	O	O
-	O	O
1	O	O
cells	O	O
.	O	O

Quantitative	O	O
analysis	O	O
showed	O	O
that	O	O
the	O	O
expression	O	O
of	O	O
CYP27	O	O
gene	O	O
mRNA	O	O
in	O	O
the	O	O
patient	O	O
represented	O	O
52	O	O
.	O	O

5	O	O
%	O	O
of	O	O
the	O	O
normal	O	O
level	O	O
.	O	O

As	O	O
the	O	O
mutation	O	O
occurred	O	O
at	O	O
the	O	O
penultimate	O	O
nucleotide	O	O
of	O	O
exon	O	O
6	O	O
(	O	O
-	O	O
2	O	O
position	O	O
of	O	O
exon	O	O
6	O	O
-	O	O
intron	O	O
6	O	O
splice	O	O
site	O	O
)	O	O
of	O	O
the	O	O
gene	O	O
,	O	O
we	O	O
hypothesized	O	O
that	O	O
the	O	O
mutation	O	O
may	O	O
partially	O	O
affect	O	O
the	O	O
normal	O	O
splicing	O	O
efficiency	O	O
in	O	O
exon	O	O
6	O	O
and	O	O
cause	O	O
alternative	O	O
splicing	O	O
elsewhere	O	O
,	O	O
which	O	O
resulted	O	O
in	O	O
decreased	O	O
transcript	O	O
in	O	O
the	O	O
patient	O	O
.	O	O

Transfection	O	O
of	O	O
constructed	O	O
minigenes	O	O
,	O	O
with	O	O
or	O	O
without	O	O
the	O	O
mutation	O	O
,	O	O
into	O	O
COS	O	O
-	O	O
1	O	O
cells	O	O
confirmed	O	O
that	O	O
the	O	O
mutant	O	O
minigene	O	O
was	O	O
responsible	O	O
for	O	O
a	O	O
mRNA	O	O
species	O	O
alternatively	O	O
spliced	O	O
at	O	O
an	O	O
activated	O	O
cryptic	O	O
5	O	O
splice	O	O
site	O	O
88	O	O
bp	O	O
upstream	O	O
from	O	O
the	O	O
3	O	O
end	O	O
of	O	O
exon	O	O
6	O	O
.	O	O

Our	O	O
data	O	O
suggest	O	O
that	O	O
the	O	O
C	O	O
to	O	O
A	O	O
mutation	O	O
at	O	O
the	O	O
penultimate	O	O
nucleotide	O	O
of	O	O
exon	O	O
6	O	O
of	O	O
the	O	O
CYP27	O	O
gene	O	O
not	O	O
only	O	O
causes	O	O
the	O	O
deficiency	B-Disease	D019294
in	I-Disease	D019294
the	I-Disease	D019294
sterol	I-Disease	D019294
27	I-Disease	D019294
-	I-Disease	D019294
hydroxylase	I-Disease	D019294
activity	I-Disease	D019294
,	O	O
but	O	O
also	O	O
partially	O	O
leads	O	O
to	O	O
alternative	O	O
pre	O	O
-	O	O
mRNA	O	O
splicing	O	O
of	O	O
the	O	O
gene	O	O
.	O	O

To	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
report	O	O
regarding	O	O
effects	O	O
on	O	O
pre	O	O
-	O	O
mRNA	O	O
splicing	O	O
of	O	O
a	O	O
mutation	O	O
at	O	O
the	O	O
-	O	O
2	O	O
position	O	O
of	O	O
a	O	O
5	O	O
splice	O	O
site	O	O
.	O	O

A	O	O
Japanese	O	O
family	O	O
with	O	O
adrenoleukodystrophy	B-Disease	D000326
with	O	O
a	O	O
codon	O	O
291	O	O
deletion	O	O
:	O	O
a	O	O
clinical	O	O
,	O	O
biochemical	O	O
,	O	O
pathological	O	O
,	O	O
and	O	O
genetic	O	O
report	O	O
.	O	O

We	O	O
report	O	O
a	O	O
Japanese	O	O
family	O	O
with	O	O
adrenoleukodystrophy	B-Disease	D000326
(	O	O
ALD	B-Disease	D000326
)	O	O
with	O	O
a	O	O
three	O	O
base	O	O
pair	O	O
deletion	O	O
(	O	O
delGAG	O	O
291	O	O
)	O	O
in	O	O
the	O	O
ALD	B-Disease	D000326
gene	O	O
.	O	O

A	O	O
variety	O	O
of	O	O
phenotypes	O	O
were	O	O
observed	O	O
within	O	O
this	O	O
family	O	O
.	O	O

While	O	O
the	O	O
proband	O	O
(	O	O
patient	O	O
1	O	O
)	O	O
was	O	O
classified	O	O
as	O	O
having	O	O
a	O	O
rare	O	O
intermediate	O	O
type	O	O
of	O	O
adult	O	O
cerebral	O	O
and	O	O
cerebello	O	O
-	O	O
brain	O	O
stem	O	O
forms	O	O
,	O	O
his	O	O
younger	O	O
brother	O	O
(	O	O
patient	O	O
2	O	O
)	O	O
and	O	O
nephew	O	O
(	O	O
patient	O	O
3	O	O
)	O	O
had	O	O
a	O	O
childhood	O	O
ALD	B-Disease	D000326
type	O	O
.	O	O

Another	O	O
nephew	O	O
(	O	O
patient	O	O
4	O	O
)	O	O
of	O	O
patient	O	O
1	O	O
was	O	O
classified	O	O
as	O	O
having	O	O
an	O	O
adolescent	O	O
form	O	O
.	O	O

The	O	O
tau	O	O
level	O	O
in	O	O
the	O	O
cerebrospinal	O	O
fluid	O	O
(	O	O
CSF	O	O
)	O	O
in	O	O
patient	O	O
1	O	O
was	O	O
as	O	O
high	O	O
as	O	O
that	O	O
of	O	O
patients	O	O
with	O	O
Alzheimers	B-Disease	D000544
disease	I-Disease	D000544
(	O	O
AD	B-Disease	D000544
)	O	O
.	O	O

His	O	O
brain	O	O
magnetic	O	O
resonance	O	O
image	O	O
(	O	O
MRI	O	O
)	O	O
showed	O	O
abnormalities	B-Disease	D002526
in	I-Disease	D002526
the	I-Disease	D002526
bilateral	I-Disease	D002526
cerebellar	I-Disease	D002526
hemispheres	I-Disease	D002526
and	O	O
brain	O	O
stem	O	O
,	O	O
but	O	O
not	O	O
in	O	O
the	O	O
cerebral	O	O
white	O	O
matter	O	O
,	O	O
where	O	O
marked	O	O
reductions	O	O
of	O	O
the	O	O
cerebral	O	O
blood	O	O
flow	O	O
and	O	O
oxygen	O	O
metabolism	O	O
were	O	O
clearly	O	O
demonstrated	O	O
by	O	O
positron	O	O
emission	O	O
tomography	O	O
(	O	O
PET	O	O
)	O	O
.	O	O

In	O	O
patients	O	O
2	O	O
and	O	O
3	O	O
,	O	O
the	O	O
autopsy	O	O
findings	O	O
showed	O	O
massive	O	O
demyelination	B-Disease	D003711
of	I-Disease	D003711
the	I-Disease	D003711
cerebral	I-Disease	D003711
white	I-Disease	D003711
matter	I-Disease	D003711
with	O	O
sparing	O	O
of	O	O
the	O	O
U	O	O
-	O	O
fibers	O	O
,	O	O
compatible	O	O
with	O	O
the	O	O
findings	O	O
of	O	O
childhood	O	O
ALD	B-Disease	D000326
.	O	O

Oleic	O	O
and	O	O
erucic	O	O
acids	O	O
(	O	O
Lorenzos	O	O
Oil	O	O
)	O	O
were	O	O
administered	O	O
to	O	O
patients	O	O
1	O	O
and	O	O
4	O	O
,	O	O
but	O	O
sufficient	O	O
effectiveness	O	O
was	O	O
not	O	O
obtained	O	O
.	O	O

The	O	O
findings	O	O
in	O	O
this	O	O
family	O	O
suggest	O	O
that	O	O
delGAG291	O	O
is	O	O
part	O	O
of	O	O
the	O	O
cause	O	O
of	O	O
Japanese	O	O
ALD	B-Disease	D000326
with	O	O
phenotypic	O	O
variations	O	O
.	O	O

Moreover	O	O
,	O	O
although	O	O
the	O	O
scale	O	O
of	O	O
the	O	O
study	O	O
is	O	O
limited	O	O
,	O	O
there	O	O
is	O	O
a	O	O
possibility	O	O
that	O	O
PET	O	O
can	O	O
detect	O	O
an	O	O
insidious	B-Disease	D004194
lesion	I-Disease	D004194
which	O	O
is	O	O
undetectable	O	O
by	O	O
computed	O	O
tomogram	O	O
(	O	O
CT	O	O
)	O	O
or	O	O
MRI	O	O
analysis	O	O
,	O	O
and	O	O
that	O	O
the	O	O
higher	O	O
level	O	O
of	O	O
tau	O	O
reflects	O	O
the	O	O
process	O	O
of	O	O
neuronal	B-Disease	D009410
degeneration	I-Disease	D009410
in	O	O
ALD	B-Disease	D000326
.	O	O

Lorenzos	O	O
Oil	O	O
should	O	O
be	O	O
given	O	O
in	O	O
the	O	O
early	O	O
stage	O	O
.	O	O

.	O	O

Two	O	O
frequent	O	O
missense	O	O
mutations	O	O
in	O	O
Pendred	B-Disease	C536648
syndrome	I-Disease	C536648
.	O	O

Pendred	B-Disease	C536648
syndrome	I-Disease	C536648
is	O	O
an	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
disorder	I-Disease	D030342
characterized	O	O
by	O	O
early	O	O
childhood	O	O
deafness	B-Disease	D003638
and	O	O
goiter	B-Disease	D006042
.	O	O

A	O	O
century	O	O
after	O	O
its	O	O
recognition	O	O
as	O	O
a	O	O
syndrome	O	O
by	O	O
Vaughan	O	O
Pendred	B-Disease	C536648
,	O	O
the	O	O
disease	O	O
gene	O	O
(	O	O
PDS	B-Disease	C536648
)	O	O
was	O	O
mapped	O	O
to	O	O
chromosome	O	O
7q22	O	O
-	O	O
q31	O	O
.	O	O

1	O	O
and	O	O
,	O	O
recently	O	O
,	O	O
found	O	O
to	O	O
encode	O	O
a	O	O
putative	O	O
sulfate	O	O
transporter	O	O
.	O	O

We	O	O
performed	O	O
mutation	O	O
analysis	O	O
of	O	O
the	O	O
PDS	B-Disease	C536648
gene	O	O
in	O	O
patients	O	O
from	O	O
14	O	O
Pendred	B-Disease	C536648
families	O	O
originating	O	O
from	O	O
seven	O	O
countries	O	O
and	O	O
identified	O	O
all	O	O
mutations	O	O
.	O	O

The	O	O
mutations	O	O
include	O	O
three	O	O
single	O	O
base	O	O
deletions	O	O
,	O	O
one	O	O
splice	O	O
site	O	O
mutation	O	O
and	O	O
10	O	O
missense	O	O
mutations	O	O
.	O	O

One	O	O
missense	O	O
mutation	O	O
(	O	O
L236P	O	O
)	O	O
was	O	O
found	O	O
in	O	O
a	O	O
homozygous	O	O
state	O	O
in	O	O
two	O	O
consanguineous	O	O
families	O	O
and	O	O
in	O	O
a	O	O
heterozygous	O	O
state	O	O
in	O	O
five	O	O
additional	O	O
non	O	O
-	O	O
consanguineous	O	O
families	O	O
.	O	O

Another	O	O
missense	O	O
mutation	O	O
(	O	O
T416P	O	O
)	O	O
was	O	O
found	O	O
in	O	O
a	O	O
homozygous	O	O
state	O	O
in	O	O
one	O	O
family	O	O
and	O	O
in	O	O
a	O	O
heterozygous	O	O
state	O	O
in	O	O
four	O	O
families	O	O
.	O	O

Pendred	B-Disease	C536648
patients	O	O
in	O	O
three	O	O
non	O	O
-	O	O
consanguineous	O	O
families	O	O
were	O	O
shown	O	O
to	O	O
be	O	O
compound	O	O
heterozygotes	O	O
for	O	O
L236P	O	O
and	O	O
T416P	O	O
.	O	O

In	O	O
total	O	O
,	O	O
one	O	O
or	O	O
both	O	O
of	O	O
these	O	O
mutations	O	O
were	O	O
found	O	O
in	O	O
nine	O	O
of	O	O
the	O	O
14	O	O
families	O	O
analyzed	O	O
.	O	O

The	O	O
identification	O	O
of	O	O
two	O	O
frequent	O	O
PDS	B-Disease	C536648
mutations	O	O
will	O	O
facilitate	O	O
the	O	O
molecular	O	O
diagnosis	O	O
of	O	O
Pendred	B-Disease	C536648
syndrome	I-Disease	C536648
.	O	O

Aspartylglucosaminuria	B-Disease	D054880
among	O	O
Palestinian	O	O
Arabs	O	O
.	O	O

Aspartylglucosaminuria	B-Disease	D054880
(	O	O
AGU	B-Disease	D054880
)	O	O
is	O	O
a	O	O
rare	O	O
disorder	B-Disease	D008661
of	I-Disease	D008661
glycoprotein	I-Disease	D008661
metabolism	I-Disease	D008661
caused	O	O
by	O	O
the	O	O
deficiency	B-Disease	D054880
of	I-Disease	D054880
the	I-Disease	D054880
lysosomal	I-Disease	D054880
enzyme	I-Disease	D054880
aspartylglucosaminidase	I-Disease	D054880
(	O	O
AGA	O	O
)	O	O
.	O	O

AGU	B-Disease	D054880
is	O	O
inherited	O	O
as	O	O
an	O	O
autosomal	O	O
recessive	O	O
trait	O	O
and	O	O
occurs	O	O
with	O	O
a	O	O
high	O	O
frequency	O	O
in	O	O
Finland	O	O
because	O	O
of	O	O
a	O	O
founder	O	O
effect	O	O
.	O	O

While	O	O
very	O	O
few	O	O
patients	O	O
with	O	O
AGU	B-Disease	D054880
have	O	O
been	O	O
reported	O	O
from	O	O
non	O	O
-	O	O
Finnish	O	O
origin	O	O
,	O	O
we	O	O
diagnosed	O	O
the	O	O
disorder	O	O
in	O	O
8	O	O
patients	O	O
originating	O	O
from	O	O
3	O	O
unrelated	O	O
families	O	O
,	O	O
all	O	O
Palestinian	O	O
Arabs	O	O
from	O	O
the	O	O
region	O	O
of	O	O
Jerusalem	O	O
.	O	O

The	O	O
clinical	O	O
diagnosis	O	O
of	O	O
AGU	B-Disease	D054880
is	O	O
often	O	O
difficult	O	O
,	O	O
in	O	O
particular	O	O
early	O	O
in	O	O
the	O	O
course	O	O
of	O	O
the	O	O
disease	O	O
,	O	O
and	O	O
most	O	O
of	O	O
the	O	O
patients	O	O
are	O	O
diagnosed	O	O
after	O	O
the	O	O
age	O	O
of	O	O
5	O	O
years	O	O
.	O	O

However	O	O
,	O	O
since	O	O
these	O	O
patients	O	O
excrete	O	O
early	O	O
large	O	O
amounts	O	O
of	O	O
aspartylglucosamine	O	O
in	O	O
urine	O	O
,	O	O
biochemical	O	O
screening	O	O
is	O	O
easy	O	O
by	O	O
urine	O	O
chromatography	O	O
.	O	O

.	O	O

Mutation	O	O
spectrum	O	O
and	O	O
genotype	O	O
-	O	O
phenotype	O	O
analyses	O	O
in	O	O
Cowden	B-Disease	D006223
disease	I-Disease	D006223
and	O	O
Bannayan	B-Disease	D006223
-	I-Disease	D006223
Zonana	I-Disease	D006223
syndrome	I-Disease	D006223
,	O	O
two	O	O
hamartoma	B-Disease	D006223
syndromes	I-Disease	D006223
with	O	O
germline	O	O
PTEN	O	O
mutation	O	O
.	O	O

The	O	O
tumour	B-Disease	D009369
suppressor	O	O
gene	O	O
PTEN	O	O
,	O	O
which	O	O
maps	O	O
to	O	O
10q23	O	O
.	O	O

3	O	O
and	O	O
encodes	O	O
a	O	O
403	O	O
amino	O	O
acid	O	O
dual	O	O
specificity	O	O
phosphatase	O	O
(	O	O
protein	O	O
tyrosine	O	O
phosphatase	O	O
;	O	O
PTPase	O	O
)	O	O
,	O	O
was	O	O
shown	O	O
recently	O	O
to	O	O
play	O	O
a	O	O
broad	O	O
role	O	O
in	O	O
human	O	O
malignancy	B-Disease	D009369
.	O	O

Somatic	O	O
PTEN	O	O
deletions	O	O
and	O	O
mutations	O	O
were	O	O
observed	O	O
in	O	O
sporadic	B-Disease	D001943
breast	I-Disease	D001943
,	I-Disease	D001943
brain	I-Disease	D001943
,	I-Disease	D001943
prostate	I-Disease	D001943
and	I-Disease	D001943
kidney	I-Disease	D001943
cancer	I-Disease	D001943
cell	O	O
lines	O	O
and	O	O
in	O	O
several	O	O
primary	O	O
tumours	B-Disease	D009369
such	O	O
as	O	O
endometrial	B-Disease	D016889
carcinomas	I-Disease	D016889
,	O	O
malignant	B-Disease	D008545
melanoma	I-Disease	D008545
and	O	O
thyroid	B-Disease	D013964
tumours	I-Disease	D013964
.	O	O

In	O	O
addition	O	O
,	O	O
PTEN	O	O
was	O	O
identified	O	O
as	O	O
the	O	O
susceptibility	O	O
gene	O	O
for	O	O
two	O	O
hamartoma	B-Disease	D006223
syndromes	I-Disease	D006223
Cowden	B-Disease	D006223
disease	I-Disease	D006223
(	O	O
CD	B-Disease	D006223
;	O	O
MIM	O	O
158350	O	O
)	O	O
and	O	O
Bannayan	B-Disease	D006223
-	I-Disease	D006223
Zonana	I-Disease	D006223
(	I-Disease	D006223
BZS	I-Disease	D006223
)	I-Disease	D006223
or	I-Disease	D006223
Ruvalcaba	I-Disease	D006223
-	I-Disease	D006223
Riley	I-Disease	D006223
-	I-Disease	D006223
Smith	I-Disease	D006223
syndrome	I-Disease	D006223
(	O	O
MIM	O	O
153480	O	O
)	O	O
.	O	O

Constitutive	O	O
DNA	O	O
from	O	O
37	O	O
CD	B-Disease	D006223
families	O	O
and	O	O
seven	O	O
BZS	B-Disease	D006223
families	O	O
was	O	O
screened	O	O
for	O	O
germline	O	O
PTEN	O	O
mutations	O	O
.	O	O

PTEN	O	O
mutations	O	O
were	O	O
identified	O	O
in	O	O
30	O	O
of	O	O
37	O	O
(	O	O
81	O	O
%	O	O
)	O	O
CD	B-Disease	D006223
families	O	O
,	O	O
including	O	O
missense	O	O
and	O	O
nonsense	O	O
point	O	O
mutations	O	O
,	O	O
deletions	O	O
,	O	O
insertions	O	O
,	O	O
a	O	O
deletion	O	O
/	O	O
insertion	O	O
and	O	O
splice	O	O
site	O	O
mutations	O	O
.	O	O

These	O	O
mutations	O	O
were	O	O
scattered	O	O
over	O	O
the	O	O
entire	O	O
length	O	O
of	O	O
PTEN	O	O
,	O	O
with	O	O
the	O	O
exception	O	O
of	O	O
the	O	O
first	O	O
,	O	O
fourth	O	O
and	O	O
last	O	O
exons	O	O
.	O	O

A	O	O
hot	O	O
spot	O	O
for	O	O
PTEN	O	O
mutation	O	O
in	O	O
CD	B-Disease	D006223
was	O	O
identified	O	O
in	O	O
exon	O	O
5	O	O
that	O	O
contains	O	O
the	O	O
PTPase	O	O
core	O	O
motif	O	O
,	O	O
with	O	O
13	O	O
of	O	O
30	O	O
(	O	O
43	O	O
%	O	O
)	O	O
CD	B-Disease	D006223
mutations	O	O
identified	O	O
in	O	O
this	O	O
exon	O	O
.	O	O

Seven	O	O
of	O	O
30	O	O
(	O	O
23	O	O
%	O	O
)	O	O
were	O	O
within	O	O
the	O	O
core	O	O
motif	O	O
,	O	O
the	O	O
majority	O	O
(	O	O
five	O	O
of	O	O
seven	O	O
)	O	O
of	O	O
which	O	O
were	O	O
missense	O	O
mutations	O	O
,	O	O
possibly	O	O
pointing	O	O
to	O	O
the	O	O
functional	O	O
significance	O	O
of	O	O
this	O	O
region	O	O
.	O	O

Germline	O	O
PTEN	O	O
mutations	O	O
were	O	O
identified	O	O
in	O	O
four	O	O
of	O	O
seven	O	O
(	O	O
57	O	O
%	O	O
)	O	O
BZS	B-Disease	D006223
families	O	O
studied	O	O
.	O	O

Interestingly	O	O
,	O	O
none	O	O
of	O	O
these	O	O
mutations	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
PTPase	O	O
core	O	O
motif	O	O
.	O	O

It	O	O
is	O	O
also	O	O
worthy	O	O
of	O	O
note	O	O
that	O	O
a	O	O
single	O	O
nonsense	O	O
point	O	O
mutation	O	O
,	O	O
R233X	O	O
,	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
germline	O	O
DNA	O	O
from	O	O
two	O	O
unrelated	O	O
CD	B-Disease	D006223
families	O	O
and	O	O
one	O	O
BZS	B-Disease	D006223
family	O	O
.	O	O

Genotype	O	O
-	O	O
phenotype	O	O
studies	O	O
were	O	O
not	O	O
performed	O	O
on	O	O
this	O	O
small	O	O
group	O	O
of	O	O
BZS	B-Disease	D006223
families	O	O
.	O	O

However	O	O
,	O	O
genotype	O	O
-	O	O
phenotype	O	O
analysis	O	O
inthe	O	O
group	O	O
of	O	O
CD	B-Disease	D006223
families	O	O
revealed	O	O
two	O	O
possible	O	O
associations	O	O
worthy	O	O
of	O	O
follow	O	O
-	O	O
up	O	O
in	O	O
independent	O	O
analyses	O	O
.	O	O

The	O	O
first	O	O
was	O	O
an	O	O
association	O	O
noted	O	O
in	O	O
the	O	O
group	O	O
of	O	O
CD	B-Disease	D006223
families	O	O
with	O	O
breast	B-Disease	D001941
disease	I-Disease	D001941
.	O	O

A	O	O
correlation	O	O
was	O	O
observed	O	O
between	O	O
the	O	O
presence	O	O
/	O	O
absence	O	O
of	O	O
a	O	O
PTEN	O	O
mutation	O	O
and	O	O
the	O	O
type	O	O
of	O	O
breast	O	O
involvement	O	O
(	O	O
unaffected	O	O
versus	O	O
benign	O	O
versus	O	O
malignant	O	O
)	O	O
.	O	O

Specifically	O	O
and	O	O
more	O	O
directly	O	O
,	O	O
an	O	O
association	O	O
was	O	O
also	O	O
observed	O	O
between	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
PTEN	O	O
mutation	O	O
and	O	O
malignant	B-Disease	D001941
breast	I-Disease	D001941
disease	I-Disease	D001941
.	O	O

Secondly	O	O
,	O	O
there	O	O
appeared	O	O
to	O	O
be	O	O
an	O	O
interdependent	O	O
association	O	O
between	O	O
mutations	O	O
upstream	O	O
and	O	O
within	O	O
the	O	O
PTPase	O	O
core	O	O
motif	O	O
,	O	O
the	O	O
core	O	O
motif	O	O
containing	O	O
the	O	O
majority	O	O
of	O	O
missense	O	O
mutations	O	O
,	O	O
and	O	O
the	O	O
involvement	O	O
of	O	O
all	O	O
major	O	O
organ	O	O
systems	O	O
(	O	O
central	O	O
nervous	O	O
system	O	O
,	O	O
thyroid	O	O
,	O	O
breast	O	O
,	O	O
skin	O	O
and	O	O
gastrointestinal	O	O
tract	O	O
)	O	O
.	O	O

However	O	O
,	O	O
these	O	O
observations	O	O
would	O	O
need	O	O
to	O	O
be	O	O
confirmed	O	O
by	O	O
studying	O	O
a	O	O
larger	O	O
number	O	O
of	O	O
CD	B-Disease	D006223
families	O	O
.	O	O

I1307K	O	O
APC	O	O
and	O	O
hMLH1	O	O
mutations	O	O
in	O	O
a	O	O
non	O	O
-	O	O
Jewish	O	O
family	O	O
with	O	O
hereditary	B-Disease	D003123
non	I-Disease	D003123
-	I-Disease	D003123
polyposis	I-Disease	D003123
colorectal	I-Disease	D003123
cancer	I-Disease	D003123
.	O	O

We	O	O
describe	O	O
a	O	O
French	O	O
Canadian	O	O
hereditary	B-Disease	D003123
non	I-Disease	D003123
-	I-Disease	D003123
polyposis	I-Disease	D003123
colorectal	I-Disease	D003123
cancer	I-Disease	D003123
(	O	O
HNPCC	B-Disease	D003123
)	O	O
kindred	O	O
which	O	O
carries	O	O
a	O	O
novel	O	O
truncating	O	O
mutation	O	O
in	O	O
hMLH1	O	O
.	O	O

Interestingly	O	O
,	O	O
the	O	O
I1307K	O	O
APC	O	O
polymorphism	O	O
,	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
,	O	O
is	O	O
also	O	O
present	O	O
in	O	O
this	O	O
family	O	O
.	O	O

The	O	O
I1307K	O	O
polymorphism	O	O
has	O	O
previously	O	O
only	O	O
been	O	O
identified	O	O
in	O	O
individuals	O	O
of	O	O
self	O	O
-	O	O
reported	O	O
Ashkenazi	O	O
Jewish	O	O
origins	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
in	O	O
this	O	O
family	O	O
,	O	O
there	O	O
appears	O	O
to	O	O
be	O	O
no	O	O
relationship	O	O
between	O	O
the	O	O
I1307K	O	O
polymorphism	O	O
and	O	O
the	O	O
presence	O	O
or	O	O
absence	O	O
of	O	O
cancer	B-Disease	D009369
.	O	O

.	O	O

Wilms	B-Disease	D009396
'	I-Disease	D009396
tumor	I-Disease	D009396
1	O	O
and	O	O
Dax	O	O
-	O	O
1	O	O
modulate	O	O
the	O	O
orphan	O	O
nuclear	O	O
receptor	O	O
SF	O	O
-	O	O
1	O	O
in	O	O
sex	O	O
-	O	O
specific	O	O
gene	O	O
expression	O	O
.	O	O

Products	O	O
of	O	O
steroidogenic	O	O
factor	O	O
1	O	O
(	O	O
SF	O	O
-	O	O
1	O	O
)	O	O
and	O	O
Wilms	B-Disease	D009396
tumor	I-Disease	D009396
1	O	O
(	O	O
WT1	O	O
)	O	O
genes	O	O
are	O	O
essential	O	O
for	O	O
mammalian	O	O
gonadogenesis	O	O
prior	O	O
to	O	O
sexual	O	O
differentiation	O	O
.	O	O

In	O	O
males	O	O
,	O	O
SF	O	O
-	O	O
1	O	O
participates	O	O
in	O	O
sexual	O	O
development	O	O
by	O	O
regulating	O	O
expression	O	O
of	O	O
the	O	O
polypeptide	O	O
hormone	O	O
Mullerian	O	O
inhibiting	O	O
substance	O	O
(	O	O
MIS	O	O
)	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
show	O	O
that	O	O
WT1	O	O
-	O	O
KTS	O	O
isoforms	O	O
associate	O	O
and	O	O
synergize	O	O
with	O	O
SF	O	O
-	O	O
1	O	O
to	O	O
promote	O	O
MIS	O	O
expression	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
WT1	O	O
missense	O	O
mutations	O	O
,	O	O
associated	O	O
with	O	O
male	B-Disease	D058490
pseudohermaphroditism	I-Disease	D058490
in	O	O
Denys	B-Disease	D030321
-	I-Disease	D030321
Drash	I-Disease	D030321
syndrome	I-Disease	D030321
,	O	O
fail	O	O
to	O	O
synergize	O	O
with	O	O
SF	O	O
-	O	O
1	O	O
.	O	O

Additionally	O	O
,	O	O
the	O	O
X	O	O
-	O	O
linked	O	O
,	O	O
candidate	O	O
dosage	O	O
-	O	O
sensitive	O	O
sex	O	O
-	O	O
reversal	O	O
gene	O	O
,	O	O
Dax	O	O
-	O	O
1	O	O
,	O	O
antagonizes	O	O
synergy	O	O
between	O	O
SF	O	O
-	O	O
1	O	O
and	O	O
WT1	O	O
,	O	O
most	O	O
likely	O	O
through	O	O
a	O	O
direct	O	O
interaction	O	O
with	O	O
SF	O	O
-	O	O
1	O	O
.	O	O

We	O	O
propose	O	O
that	O	O
WT1	O	O
and	O	O
Dax	O	O
-	O	O
1	O	O
functionally	O	O
oppose	O	O
each	O	O
other	O	O
in	O	O
testis	O	O
development	O	O
by	O	O
modulating	O	O
SF	O	O
-	O	O
1	O	O
-	O	O
mediated	O	O
transactivation	O	O
.	O	O

.	O	O

Ethnic	O	O
differences	O	O
in	O	O
the	O	O
HFE	O	O
codon	O	O
282	O	O
(	O	O
Cys	O	O
/	O	O
Tyr	O	O
)	O	O
polymorphism	O	O
.	O	O

Recent	O	O
studies	O	O
have	O	O
shown	O	O
that	O	O
hereditary	B-Disease	D006432
hemochromatosis	I-Disease	D006432
(	O	O
HH	B-Disease	D006432
)	O	O
is	O	O
likely	O	O
to	O	O
be	O	O
caused	O	O
by	O	O
homozygosity	O	O
for	O	O
a	O	O
Cys282Tyr	O	O
mutation	O	O
in	O	O
the	O	O
HFE	O	O
gene	O	O
located	O	O
4	O	O
.	O	O

5	O	O
Mb	O	O
telomeric	O	O
to	O	O
HLA	O	O
-	O	O
A	O	O
.	O	O

Population	O	O
studies	O	O
of	O	O
this	O	O
polymorphism	O	O
are	O	O
facilitated	O	O
by	O	O
the	O	O
fact	O	O
that	O	O
the	O	O
Cys282Tyr	O	O
mutation	O	O
creates	O	O
a	O	O
Rsal	O	O
restriction	O	O
site	O	O
.	O	O

We	O	O
have	O	O
studied	O	O
the	O	O
codon	O	O
282	O	O
(	O	O
Cys	O	O
/	O	O
Tyr	O	O
)	O	O
polymorphism	O	O
in	O	O
different	O	O
ethnic	O	O
groups	O	O
.	O	O

In	O	O
agreement	O	O
with	O	O
previous	O	O
observations	O	O
the	O	O
Tyr	O	O
allele	O	O
appeared	O	O
to	O	O
be	O	O
rare	O	O
or	O	O
absent	O	O
in	O	O
Asiatic	O	O
(	O	O
Indian	O	O
,	O	O
Chinese	O	O
)	O	O
populations	O	O
.	O	O

The	O	O
highest	O	O
allele	O	O
frequency	O	O
(	O	O
7	O	O
.	O	O

5	O	O
%	O	O
)	O	O
was	O	O
found	O	O
in	O	O
Swedes	O	O
.	O	O

Saamis	O	O
(	O	O
2	O	O
%	O	O
)	O	O
and	O	O
Mordvinians	O	O
(	O	O
1	O	O
.	O	O

8	O	O
%	O	O
)	O	O
had	O	O
significantly	O	O
lower	O	O
frequencies	O	O
of	O	O
the	O	O
Tyr	O	O
allele	O	O
.	O	O

Comparisons	O	O
with	O	O
allele	O	O
frequencies	O	O
based	O	O
on	O	O
prevalence	O	O
estimates	O	O
of	O	O
HH	B-Disease	D006432
showed	O	O
some	O	O
disagreements	O	O
with	O	O
the	O	O
RFLP	O	O
data	O	O
,	O	O
particularly	O	O
in	O	O
Finns	O	O
.	O	O

The	O	O
newly	O	O
described	O	O
HFE	O	O
marker	O	O
provides	O	O
a	O	O
new	O	O
approach	O	O
to	O	O
the	O	O
screening	O	O
of	O	O
HH	B-Disease	D006432
as	O	O
well	O	O
as	O	O
studies	O	O
of	O	O
the	O	O
relationship	O	O
between	O	O
the	O	O
HFE	O	O
Tyr	O	O
allele	O	O
and	O	O
different	O	O
disorders	O	O
including	O	O
cancer	B-Disease	D009369
Risk	O	O
reversals	O	O
in	O	O
predictive	O	O
testing	O	O
for	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
.	O	O

The	O	O
first	O	O
predictive	O	O
testing	O	O
for	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
(	O	O
HD	B-Disease	D006816
)	O	O
was	O	O
based	O	O
on	O	O
analysis	O	O
of	O	O
linked	O	O
polymorphic	O	O
DNA	O	O
markers	O	O
to	O	O
estimate	O	O
the	O	O
likelihood	O	O
of	O	O
inheriting	O	O
the	O	O
mutation	O	O
for	O	O
HD	B-Disease	D006816
.	O	O

Limits	O	O
to	O	O
accuracy	O	O
included	O	O
recombination	O	O
between	O	O
the	O	O
DNA	O	O
markers	O	O
and	O	O
the	O	O
mutation	O	O
,	O	O
pedigree	O	O
structure	O	O
,	O	O
and	O	O
whether	O	O
DNA	O	O
samples	O	O
were	O	O
available	O	O
from	O	O
family	O	O
members	O	O
.	O	O

With	O	O
direct	O	O
tests	O	O
for	O	O
the	O	O
HD	B-Disease	D006816
mutation	O	O
,	O	O
we	O	O
have	O	O
assessed	O	O
the	O	O
accuracy	O	O
of	O	O
results	O	O
obtained	O	O
by	O	O
linkage	O	O
approaches	O	O
when	O	O
requested	O	O
to	O	O
do	O	O
so	O	O
by	O	O
the	O	O
test	O	O
individuals	O	O
.	O	O

For	O	O
six	O	O
such	O	O
individuals	O	O
,	O	O
there	O	O
was	O	O
significant	O	O
disparity	O	O
between	O	O
the	O	O
tests	O	O
.	O	O

Three	O	O
went	O	O
from	O	O
a	O	O
decreased	O	O
risk	O	O
to	O	O
an	O	O
increased	O	O
risk	O	O
,	O	O
while	O	O
in	O	O
another	O	O
three	O	O
the	O	O
risk	O	O
was	O	O
decreased	O	O
.	O	O

Knowledge	O	O
of	O	O
the	O	O
potential	O	O
reasons	O	O
for	O	O
these	O	O
changes	O	O
in	O	O
results	O	O
and	O	O
impact	O	O
of	O	O
these	O	O
risk	O	O
reversals	O	O
on	O	O
both	O	O
patients	O	O
and	O	O
the	O	O
counseling	O	O
team	O	O
can	O	O
assist	O	O
in	O	O
the	O	O
development	O	O
of	O	O
strategies	O	O
for	O	O
the	O	O
prevention	O	O
and	O	O
,	O	O
where	O	O
necessary	O	O
,	O	O
management	O	O
of	O	O
a	O	O
risk	O	O
reversal	O	O
in	O	O
any	O	O
predictive	O	O
testing	O	O
program	O	O
.	O	O

.	O	O

Identification	O	O
of	O	O
three	O	O
novel	O	O
mutations	O	O
and	O	O
a	O	O
high	O	O
frequency	O	O
of	O	O
the	O	O
Arg778Leu	O	O
mutation	O	O
in	O	O
Korean	O	O
patients	O	O
with	O	O
Wilson	B-Disease	D006527
disease	I-Disease	D006527
.	O	O

Four	O	O
mutations	O	O
-	O	O
-	O	O
R778L	O	O
,	O	O
A874V	O	O
,	O	O
L1083F	O	O
,	O	O
and	O	O
2304delC	O	O
-	O	O
-	O	O
in	O	O
the	O	O
copper	O	O
-	O	O
transporting	O	O
enzyme	O	O
,	O	O
P	O	O
-	O	O
type	O	O
ATPase	O	O
(	O	O
ATP7B	O	O
)	O	O
,	O	O
were	O	O
identified	O	O
in	O	O
Korean	O	O
Patients	O	O
with	O	O
Wilson	B-Disease	D006527
disease	I-Disease	D006527
.	O	O

Arg778Leu	O	O
,	O	O
the	O	O
most	O	O
frequently	O	O
reported	O	O
mutation	O	O
of	O	O
this	O	O
enzyme	O	O
,	O	O
was	O	O
found	O	O
in	O	O
six	O	O
of	O	O
eight	O	O
unrelated	O	O
patients	O	O
studied	O	O
,	O	O
an	O	O
allele	O	O
frequency	O	O
of	O	O
37	O	O
.	O	O

5	O	O
%	O	O
,	O	O
which	O	O
is	O	O
considerably	O	O
higher	O	O
than	O	O
those	O	O
in	O	O
other	O	O
Asian	O	O
populations	O	O
.	O	O

The	O	O
novel	O	O
single	O	O
nucleotide	O	O
deletion	O	O
,	O	O
2304delC	O	O
,	O	O
was	O	O
found	O	O
in	O	O
one	O	O
patient	O	O
.	O	O

Since	O	O
a	O	O
mutation	O	O
at	O	O
cDNA	O	O
nucleotide	O	O
2302	O	O
(	O	O
2302insC	O	O
)	O	O
had	O	O
been	O	O
previously	O	O
described	O	O
,	O	O
this	O	O
region	O	O
of	O	O
the	O	O
ATP7B	O	O
gene	O	O
may	O	O
be	O	O
susceptible	O	O
to	O	O
gene	O	O
rearrangements	O	O
causing	O	O
Wilson	B-Disease	D006527
disease	I-Disease	D006527
.	O	O

Determination	O	O
of	O	O
the	O	O
genomic	O	O
structure	O	O
of	O	O
the	O	O
COL4A4	O	O
gene	O	O
and	O	O
of	O	O
novel	O	O
mutations	O	O
causing	O	O
autosomal	B-Disease	C536587
recessive	I-Disease	C536587
Alport	I-Disease	C536587
syndrome	I-Disease	C536587
.	O	O

Autosomal	B-Disease	C536587
recessive	I-Disease	C536587
Alport	I-Disease	C536587
syndrome	I-Disease	C536587
is	O	O
a	O	O
progressive	O	O
hematuric	B-Disease	D005921
glomerulonephritis	I-Disease	D005921
characterized	O	O
by	O	O
glomerular	B-Disease	D005921
basement	I-Disease	D005921
membrane	I-Disease	D005921
abnormalities	I-Disease	D005921
and	O	O
associated	O	O
with	O	O
mutations	O	O
in	O	O
either	O	O
the	O	O
COL4A3	O	O
or	O	O
the	O	O
COL4A4	O	O
gene	O	O
,	O	O
which	O	O
encode	O	O
the	O	O
alpha3	O	O
and	O	O
alpha4	O	O
type	O	O
IV	O	O
collagen	O	O
chains	O	O
,	O	O
respectively	O	O
.	O	O

To	O	O
date	O	O
,	O	O
mutation	O	O
screening	O	O
in	O	O
the	O	O
two	O	O
genes	O	O
has	O	O
been	O	O
hampered	O	O
by	O	O
the	O	O
lack	O	O
of	O	O
genomic	O	O
structure	O	O
information	O	O
.	O	O

We	O	O
report	O	O
here	O	O
the	O	O
complete	O	O
characterization	O	O
of	O	O
the	O	O
48	O	O
exons	O	O
of	O	O
the	O	O
COL4A4	O	O
gene	O	O
,	O	O
a	O	O
comprehensive	O	O
gene	O	O
screen	O	O
,	O	O
and	O	O
the	O	O
subsequent	O	O
detection	O	O
of	O	O
10	O	O
novel	O	O
mutations	O	O
in	O	O
eight	O	O
patients	O	O
diagnosed	O	O
with	O	O
autosomal	B-Disease	C536587
recessive	I-Disease	C536587
Alport	I-Disease	C536587
syndrome	I-Disease	C536587
.	O	O

Furthermore	O	O
,	O	O
we	O	O
identified	O	O
a	O	O
glycine	O	O
to	O	O
alanine	O	O
substitution	O	O
in	O	O
the	O	O
collagenous	O	O
domain	O	O
that	O	O
is	O	O
apparently	O	O
silent	O	O
in	O	O
the	O	O
heterozygous	O	O
carriers	O	O
,	O	O
in	O	O
11	O	O
.	O	O

5	O	O
%	O	O
of	O	O
all	O	O
control	O	O
individuals	O	O
,	O	O
and	O	O
in	O	O
one	O	O
control	O	O
individual	O	O
homozygous	O	O
for	O	O
this	O	O
glycine	O	O
substitution	O	O
.	O	O

There	O	O
has	O	O
been	O	O
no	O	O
previous	O	O
finding	O	O
of	O	O
a	O	O
glycine	O	O
substitution	O	O
that	O	O
is	O	O
not	O	O
associated	O	O
with	O	O
any	O	O
obvious	O	O
phenotype	O	O
in	O	O
homozygous	O	O
individuals	O	O
.	O	O

A	O	O
gene	O	O
encoding	O	O
a	O	O
transmembrane	O	O
protein	O	O
is	O	O
mutated	O	O
in	O	O
patients	O	O
with	O	O
diabetes	B-Disease	D003920
mellitus	I-Disease	D003920
and	O	O
optic	B-Disease	D009896
atrophy	I-Disease	D009896
(	O	O
Wolfram	B-Disease	OMIM:222300
syndrome	I-Disease	OMIM:222300
)	O	O
.	O	O

Wolfram	B-Disease	OMIM:222300
syndrome	I-Disease	OMIM:222300
(	O	O
WFS	B-Disease	OMIM:222300
;	O	O
OMIM	O	O
222300	O	O
)	O	O
is	O	O
an	O	O
autosomal	B-Disease	D020271
recessive	I-Disease	D020271
neurodegenerative	I-Disease	D020271
disorder	I-Disease	D020271
defined	O	O
by	O	O
young	O	O
-	O	O
onset	O	O
non	O	O
-	O	O
immune	O	O
insulin	B-Disease	D003922
-	I-Disease	D003922
dependent	I-Disease	D003922
diabetes	I-Disease	D003922
mellitus	I-Disease	D003922
and	O	O
progressive	O	O
optic	B-Disease	D009896
atrophy	I-Disease	D009896
.	O	O

Linkage	O	O
to	O	O
markers	O	O
on	O	O
chromosome	O	O
4p	O	O
was	O	O
confirmed	O	O
in	O	O
five	O	O
families	O	O
.	O	O

On	O	O
the	O	O
basis	O	O
of	O	O
meiotic	O	O
recombinants	O	O
and	O	O
disease	O	O
-	O	O
associated	O	O
haplotypes	O	O
,	O	O
the	O	O
WFS	B-Disease	OMIM:222300
gene	O	O
was	O	O
localized	O	O
to	O	O
a	O	O
BAC	O	O
/	O	O
P1	O	O
contig	O	O
of	O	O
less	O	O
than	O	O
250	O	O
kb	O	O
.	O	O

Mutations	O	O
in	O	O
a	O	O
novel	O	O
gene	O	O
(	O	O
WFS1	O	O
)	O	O
encoding	O	O
a	O	O
putative	O	O
transmembrane	O	O
protein	O	O
were	O	O
found	O	O
in	O	O
all	O	O
affected	O	O
individuals	O	O
in	O	O
six	O	O
WFS	B-Disease	OMIM:222300
families	O	O
,	O	O
and	O	O
these	O	O
mutations	O	O
were	O	O
associated	O	O
with	O	O
the	O	O
disease	O	O
phenotype	O	O
.	O	O

WFS1	O	O
appears	O	O
to	O	O
function	O	O
in	O	O
survival	O	O
of	O	O
islet	O	O
beta	O	O
-	O	O
cells	O	O
and	O	O
neurons	O	O
.	O	O

.	O	O

Molecular	O	O
defects	O	O
leading	O	O
to	O	O
human	O	O
complement	B-Disease	OMIM:612446
component	I-Disease	OMIM:612446
C6	I-Disease	OMIM:612446
deficiency	I-Disease	OMIM:612446
in	O	O
an	O	O
African	O	O
-	O	O
American	O	O
family	O	O
.	O	O

Complement	B-Disease	OMIM:612446
component	I-Disease	OMIM:612446
C6	I-Disease	OMIM:612446
deficiency	I-Disease	OMIM:612446
(	O	O
C6D	B-Disease	OMIM:612446
)	O	O
was	O	O
diagnosed	O	O
in	O	O
a	O	O
16	O	O
-	O	O
year	O	O
-	O	O
old	O	O
African	O	O
-	O	O
American	O	O
male	O	O
with	O	O
meningococcal	B-Disease	D008585
meningitis	I-Disease	D008585
.	O	O

The	O	O
patients	O	O
father	O	O
and	O	O
two	O	O
brothers	O	O
also	O	O
had	O	O
C6D	B-Disease	OMIM:612446
,	O	O
but	O	O
gave	O	O
no	O	O
history	O	O
of	O	O
meningitis	B-Disease	D008581
or	O	O
other	O	O
neisserial	B-Disease	D016870
infection	I-Disease	D016870
.	O	O

By	O	O
using	O	O
exon	O	O
-	O	O
specific	O	O
polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
PCR	O	O
)	O	O
/	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
as	O	O
a	O	O
screening	O	O
step	O	O
and	O	O
nucleotide	O	O
sequencing	O	O
of	O	O
target	O	O
exons	O	O
,	O	O
we	O	O
determined	O	O
that	O	O
the	O	O
proband	O	O
was	O	O
a	O	O
compound	O	O
heterozygote	O	O
for	O	O
two	O	O
C6	O	O
gene	O	O
mutations	O	O
.	O	O

The	O	O
first	O	O
,	O	O
1195delC	O	O
located	O	O
in	O	O
exon	O	O
7	O	O
,	O	O
is	O	O
a	O	O
novel	O	O
mutation	O	O
,	O	O
while	O	O
the	O	O
second	O	O
,	O	O
1936delG	O	O
in	O	O
exon	O	O
12	O	O
,	O	O
has	O	O
been	O	O
described	O	O
before	O	O
to	O	O
cause	O	O
C6D	B-Disease	OMIM:612446
in	O	O
an	O	O
unrelated	O	O
African	O	O
-	O	O
American	O	O
individual	O	O
.	O	O

Both	O	O
mutations	O	O
result	O	O
in	O	O
premature	O	O
termination	O	O
codons	O	O
and	O	O
C6	O	O
null	O	O
alleles	O	O
.	O	O

Allele	O	O
-	O	O
specific	O	O
PCR	O	O
indicated	O	O
that	O	O
the	O	O
probands	O	O
two	O	O
brothers	O	O
also	O	O
inherited	O	O
the	O	O
1195delC	O	O
mutation	O	O
from	O	O
their	O	O
heterozygous	O	O
mother	O	O
and	O	O
the	O	O
1936delG	O	O
mutation	O	O
from	O	O
their	O	O
homozygous	O	O
father	O	O
.	O	O

.	O	O

Sperm	O	O
DNA	O	O
analysis	O	O
in	O	O
a	O	O
Friedreich	B-Disease	D005621
ataxia	I-Disease	D005621
premutation	O	O
carrier	O	O
suggests	O	O
both	O	O
meiotic	O	O
and	O	O
mitotic	O	O
expansion	O	O
in	O	O
the	O	O
FRDA	B-Disease	D005621
gene	O	O
.	O	O

Friedreich	B-Disease	D005621
ataxia	I-Disease	D005621
is	O	O
usually	O	O
caused	O	O
by	O	O
an	O	O
expansion	O	O
of	O	O
a	O	O
GAA	O	O
trinucleotide	O	O
repeat	O	O
in	O	O
intron	O	O
1	O	O
of	O	O
the	O	O
FRDA	B-Disease	D005621
gene	O	O
.	O	O

Occasionally	O	O
,	O	O
a	O	O
fully	O	O
expanded	O	O
allele	O	O
has	O	O
been	O	O
found	O	O
to	O	O
arise	O	O
from	O	O
a	O	O
premutation	O	O
of	O	O
100	O	O
or	O	O
less	O	O
triplet	O	O
repeats	O	O
.	O	O

We	O	O
have	O	O
examined	O	O
the	O	O
sperm	O	O
DNA	O	O
of	O	O
a	O	O
premutation	O	O
carrier	O	O
.	O	O

This	O	O
mans	O	O
leucocyte	O	O
DNA	O	O
showed	O	O
one	O	O
normal	O	O
allele	O	O
and	O	O
one	O	O
allele	O	O
of	O	O
approximately	O	O
100	O	O
repeats	O	O
.	O	O

His	O	O
sperm	O	O
showed	O	O
an	O	O
expanded	O	O
allele	O	O
in	O	O
a	O	O
tight	O	O
range	O	O
centering	O	O
on	O	O
a	O	O
size	O	O
of	O	O
approximately	O	O
320	O	O
trinucleotide	O	O
repeats	O	O
.	O	O

His	O	O
affected	O	O
son	O	O
has	O	O
repeat	O	O
sizes	O	O
of	O	O
1040	O	O
and	O	O
540	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
expansion	O	O
occurs	O	O
in	O	O
two	O	O
stages	O	O
,	O	O
the	O	O
first	O	O
during	O	O
meiosis	O	O
followed	O	O
by	O	O
a	O	O
second	O	O
mitotic	O	O
expansion	O	O
.	O	O

We	O	O
also	O	O
show	O	O
that	O	O
in	O	O
all	O	O
informative	O	O
carrier	O	O
father	O	O
to	O	O
affected	O	O
child	O	O
transmissions	O	O
,	O	O
with	O	O
the	O	O
notable	O	O
exception	O	O
of	O	O
the	O	O
premutation	O	O
carrier	O	O
,	O	O
the	O	O
expansion	O	O
size	O	O
decreases	O	O
.	O	O

.	O	O

Eye	B-Disease	D005124
movement	I-Disease	D005124
abnormalities	I-Disease	D005124
correlate	O	O
with	O	O
genotype	O	O
in	O	O
autosomal	O	O
dominant	O	O
cerebellar	B-Disease	D020754
ataxia	I-Disease	D020754
type	I-Disease	D020754
I	I-Disease	D020754
.	O	O

We	O	O
compared	O	O
horizontal	O	O
eye	O	O
movements	O	O
(	O	O
visually	O	O
guided	O	O
saccades	O	O
,	O	O
antisaccades	O	O
,	O	O
and	O	O
smooth	O	O
pursuit	O	O
)	O	O
in	O	O
control	O	O
subjects	O	O
(	O	O
n	O	O
=	O	O
14	O	O
)	O	O
and	O	O
patients	O	O
with	O	O
three	O	O
forms	O	O
of	O	O
autosomal	O	O
dominant	O	O
cerebellar	B-Disease	D020754
ataxias	I-Disease	D020754
type	I-Disease	D020754
I	I-Disease	D020754
spinocerebellar	B-Disease	OMIM:164400
ataxias	I-Disease	OMIM:164400
1	I-Disease	OMIM:164400
and	I-Disease	OMIM:164400
2	I-Disease	OMIM:164400
(	O	O
SCA1	B-Disease	OMIM:164400
,	O	O
n	O	O
=	O	O
11	O	O
;	O	O
SCA2	B-Disease	OMIM:183090
,	O	O
n	O	O
=	O	O
10	O	O
)	O	O
and	O	O
SCA3	B-Disease	D017827
/	O	O
Machado	B-Disease	D017827
-	I-Disease	D017827
Joseph	I-Disease	D017827
disease	I-Disease	D017827
(	O	O
MJD	B-Disease	D017827
)	O	O
(	O	O
n	O	O
=	O	O
16	O	O
)	O	O
.	O	O

In	O	O
SCA1	B-Disease	OMIM:164400
,	O	O
saccade	O	O
amplitude	O	O
was	O	O
significantly	O	O
increased	O	O
,	O	O
resulting	O	O
in	O	O
hypermetria	B-Disease	D002524
.	O	O

The	O	O
smooth	O	O
pursuit	O	O
gain	O	O
was	O	O
decreased	O	O
.	O	O

In	O	O
SCA2	B-Disease	OMIM:183090
,	O	O
saccade	O	O
velocity	O	O
was	O	O
markedly	O	O
decreased	O	O
.	O	O

The	O	O
percentage	O	O
of	O	O
errors	O	O
in	O	O
antisaccades	O	O
was	O	O
greatly	O	O
increased	O	O
and	O	O
was	O	O
significantly	O	O
correlated	O	O
with	O	O
age	O	O
at	O	O
disease	O	O
onset	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
a	O	O
correlation	O	O
between	O	O
smooth	O	O
pursuit	O	O
gain	O	O
and	O	O
the	O	O
number	O	O
of	O	O
trinucleotide	O	O
repeats	O	O
was	O	O
found	O	O
.	O	O

In	O	O
SCA3	B-Disease	D017827
,	O	O
gaze	B-Disease	D009759
-	I-Disease	D009759
evoked	I-Disease	D009759
nystagmus	I-Disease	D009759
was	O	O
often	O	O
present	O	O
as	O	O
was	O	O
saccade	O	O
hypometria	O	O
and	O	O
smooth	O	O
pursuit	O	O
gain	O	O
was	O	O
markedly	O	O
decreased	O	O
.	O	O

Three	O	O
major	O	O
criteria	O	O
,	O	O
saccade	O	O
amplitude	O	O
,	O	O
saccade	O	O
velocity	O	O
,	O	O
and	O	O
presence	O	O
of	O	O
gaze	B-Disease	D009759
-	I-Disease	D009759
evoked	I-Disease	D009759
nystagmus	I-Disease	D009759
,	O	O
permitted	O	O
the	O	O
correct	O	O
assignment	O	O
of	O	O
90	O	O
%	O	O
of	O	O
the	O	O
SCA1	B-Disease	OMIM:164400
,	O	O
90	O	O
%	O	O
of	O	O
the	O	O
SCA2	B-Disease	OMIM:183090
,	O	O
and	O	O
93	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
with	O	O
SCA3	B-Disease	D017827
to	O	O
their	O	O
genetically	O	O
confirmed	O	O
patient	O	O
group	O	O
and	O	O
,	O	O
therefore	O	O
,	O	O
may	O	O
help	O	O
orient	O	O
diagnoses	O	O
of	O	O
SCA1	B-Disease	OMIM:164400
,	O	O
SCA2	B-Disease	OMIM:183090
,	O	O
and	O	O
SCA3	B-Disease	D017827
at	O	O
early	O	O
clinical	O	O
stages	O	O
of	O	O
the	O	O
diseases	O	O
.	O	O

.	O	O

Clustering	O	O
of	O	O
missense	O	O
mutations	O	O
in	O	O
the	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
gene	O	O
in	O	O
a	O	O
sporadic	B-Disease	D015458
T	I-Disease	D015458
-	I-Disease	D015458
cell	I-Disease	D015458
leukaemia	I-Disease	D015458
.	O	O

Ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
(	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
)	O	O
is	O	O
a	O	O
recessive	B-Disease	D030342
multi	I-Disease	D030342
-	I-Disease	D030342
system	I-Disease	D030342
disorder	I-Disease	D030342
caused	O	O
by	O	O
mutations	O	O
in	O	O
the	O	O
ATM	O	O
gene	O	O
at	O	O
11q22	O	O
-	O	O
q23	O	O
(	O	O
ref	O	O
.	O	O

3	O	O
)	O	O
.	O	O

The	O	O
risk	O	O
of	O	O
cancer	B-Disease	D009369
,	O	O
especially	O	O
lymphoid	B-Disease	D008223
neoplasias	I-Disease	D008223
,	O	O
is	O	O
substantially	O	O
elevated	O	O
in	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
patients	O	O
and	O	O
has	O	O
long	O	O
been	O	O
associated	O	O
with	O	O
chromosomal	O	O
instability	O	O
.	O	O

By	O	O
analysing	O	O
tumour	B-Disease	D009369
DNA	O	O
from	O	O
patients	O	O
with	O	O
sporadic	B-Disease	D015461
T	I-Disease	D015461
-	I-Disease	D015461
cell	I-Disease	D015461
prolymphocytic	I-Disease	D015461
leukaemia	I-Disease	D015461
(	O	O
T	B-Disease	D015461
-	I-Disease	D015461
PLL	I-Disease	D015461
)	O	O
,	O	O
a	O	O
rare	O	O
clonal	B-Disease	 D007945
malignancy	I-Disease	 D007945
with	O	O
similarities	O	O
to	O	O
a	O	O
mature	B-Disease	D015458
T	I-Disease	D015458
-	I-Disease	D015458
cell	I-Disease	D015458
leukaemia	I-Disease	D015458
seen	O	O
in	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
,	O	O
we	O	O
demonstrate	O	O
a	O	O
high	O	O
frequency	O	O
of	O	O
ATM	O	O
mutations	O	O
in	O	O
T	B-Disease	D015461
-	I-Disease	D015461
PLL	I-Disease	D015461
.	O	O

In	O	O
marked	O	O
contrast	O	O
to	O	O
the	O	O
ATM	O	O
mutation	O	O
pattern	O	O
in	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
,	O	O
the	O	O
most	O	O
frequent	O	O
nucleotide	O	O
changes	O	O
in	O	O
this	O	O
leukaemia	B-Disease	D007938
were	O	O
missense	O	O
mutations	O	O
.	O	O

These	O	O
clustered	O	O
in	O	O
the	O	O
region	O	O
corresponding	O	O
to	O	O
the	O	O
kinase	O	O
domain	O	O
,	O	O
which	O	O
is	O	O
highly	O	O
conserved	O	O
in	O	O
ATM	O	O
-	O	O
related	O	O
proteins	O	O
in	O	O
mouse	O	O
,	O	O
yeast	O	O
and	O	O
Drosophila	O	O
.	O	O

The	O	O
resulting	O	O
amino	O	O
-	O	O
acid	O	O
substitutions	O	O
are	O	O
predicted	O	O
to	O	O
interfere	O	O
with	O	O
ATP	O	O
binding	O	O
or	O	O
substrate	O	O
recognition	O	O
.	O	O

Two	O	O
of	O	O
seventeen	O	O
mutated	O	O
T	B-Disease	D015461
-	I-Disease	D015461
PLL	I-Disease	D015461
samples	O	O
had	O	O
a	O	O
previously	O	O
reported	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
allele	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
no	O	O
mutations	O	O
were	O	O
detected	O	O
in	O	O
the	O	O
p53	O	O
gene	O	O
,	O	O
suggesting	O	O
that	O	O
this	O	O
tumour	B-Disease	D009369
suppressor	O	O
is	O	O
not	O	O
frequently	O	O
altered	O	O
in	O	O
this	O	O
leukaemia	B-Disease	D007938
.	O	O

Occasional	O	O
missense	O	O
mutations	O	O
in	O	O
ATM	O	O
were	O	O
also	O	O
found	O	O
in	O	O
tumour	B-Disease	D009369
DNA	O	O
from	O	O
patients	O	O
with	O	O
B	B-Disease	D016393
-	I-Disease	D016393
cell	I-Disease	D016393
non	I-Disease	D016393
-	I-Disease	D016393
Hodgkins	I-Disease	D016393
lymphomas	I-Disease	D016393
(	O	O
B	B-Disease	D016393
-	I-Disease	D016393
NHL	I-Disease	D016393
)	O	O
and	O	O
a	O	O
B	B-Disease	D016393
-	I-Disease	D016393
NHL	I-Disease	D016393
cell	O	O
line	O	O
.	O	O

The	O	O
evidence	O	O
of	O	O
a	O	O
significant	O	O
proportion	O	O
of	O	O
loss	O	O
-	O	O
of	O	O
-	O	O
function	O	O
mutations	O	O
and	O	O
a	O	O
complete	O	O
absence	O	O
of	O	O
the	O	O
normal	O	O
copy	O	O
of	O	O
ATM	O	O
in	O	O
the	O	O
majority	O	O
of	O	O
mutated	O	O
tumours	B-Disease	D009369
establishes	O	O
somatic	O	O
inactivation	O	O
of	O	O
this	O	O
gene	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
sporadic	B-Disease	D015461
T	I-Disease	D015461
-	I-Disease	D015461
PLL	I-Disease	D015461
and	O	O
suggests	O	O
that	O	O
ATM	O	O
acts	O	O
as	O	O
a	O	O
tumour	B-Disease	D009369
suppressor	O	O
.	O	O

As	O	O
constitutional	O	O
DNA	O	O
was	O	O
not	O	O
available	O	O
,	O	O
a	O	O
putative	O	O
hereditary	O	O
predisposition	O	O
to	O	O
T	B-Disease	D015461
-	I-Disease	D015461
PLL	I-Disease	D015461
will	O	O
require	O	O
further	O	O
investigation	O	O
.	O	O

.	O	O

Identification	O	O
of	O	O
a	O	O
novel	O	O
nonsense	O	O
mutation	O	O
and	O	O
a	O	O
missense	O	O
substitution	O	O
in	O	O
the	O	O
vasopressin	O	O
-	O	O
neurophysin	O	O
II	O	O
gene	O	O
in	O	O
two	O	O
Spanish	O	O
kindreds	O	O
with	O	O
familial	B-Disease	OMIM:125700
neurohypophyseal	I-Disease	OMIM:125700
diabetes	I-Disease	OMIM:125700
insipidus	I-Disease	OMIM:125700
.	O	O

Familial	B-Disease	OMIM:125700
neurohypophyseal	I-Disease	OMIM:125700
diabetes	I-Disease	OMIM:125700
insipidus	I-Disease	OMIM:125700
(	O	O
FNDI	B-Disease	OMIM:125700
)	O	O
is	O	O
an	O	O
autosomal	B-Disease	D030342
dominant	I-Disease	D030342
disease	I-Disease	D030342
caused	O	O
by	O	O
deficiency	O	O
in	O	O
the	O	O
antidiuretic	O	O
hormone	O	O
arginine	O	O
vasopressin	O	O
(	O	O
AVP	O	O
)	O	O
encoded	O	O
by	O	O
the	O	O
AVP	O	O
-	O	O
neurophysin	O	O
II	O	O
(	O	O
AVP	O	O
-	O	O
NPII	O	O
)	O	O
gene	O	O
on	O	O
chromosome	O	O
20p13	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
analyzed	O	O
two	O	O
families	O	O
with	O	O
FNDI	B-Disease	OMIM:125700
using	O	O
direct	O	O
automated	O	O
fluorescent	O	O
,	O	O
solid	O	O
phase	O	O
,	O	O
single	O	O
-	O	O
stranded	O	O
DNA	O	O
sequencing	O	O
of	O	O
PCR	O	O
-	O	O
amplified	O	O
AVP	O	O
-	O	O
NPII	O	O
DNA	O	O
.	O	O

In	O	O
one	O	O
of	O	O
the	O	O
families	O	O
,	O	O
affected	O	O
individuals	O	O
presented	O	O
a	O	O
novel	O	O
nonsense	O	O
mutation	O	O
in	O	O
exon	O	O
3	O	O
of	O	O
the	O	O
gene	O	O
,	O	O
consisting	O	O
in	O	O
a	O	O
G	O	O
to	O	O
T	O	O
transition	O	O
at	O	O
nucleotide	O	O
2101	O	O
,	O	O
which	O	O
produces	O	O
a	O	O
stop	O	O
signal	O	O
in	O	O
codon	O	O
82	O	O
(	O	O
Glu	O	O
)	O	O
of	O	O
NPII	O	O
.	O	O

The	O	O
premature	O	O
termination	O	O
eliminates	O	O
part	O	O
of	O	O
the	O	O
C	O	O
-	O	O
terminal	O	O
domain	O	O
of	O	O
NPII	O	O
,	O	O
including	O	O
a	O	O
cysteine	O	O
residue	O	O
in	O	O
position	O	O
85	O	O
,	O	O
which	O	O
could	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
correct	O	O
folding	O	O
of	O	O
the	O	O
prohormone	O	O
.	O	O

In	O	O
the	O	O
second	O	O
family	O	O
,	O	O
a	O	O
G279A	O	O
substitution	O	O
at	O	O
position	O	O
-	O	O
1	O	O
of	O	O
the	O	O
signal	O	O
peptide	O	O
was	O	O
observed	O	O
in	O	O
all	O	O
affected	O	O
individuals	O	O
.	O	O

This	O	O
missense	O	O
mutation	O	O
,	O	O
which	O	O
replaces	O	O
Ala	O	O
with	O	O
Thr	O	O
,	O	O
is	O	O
frequent	O	O
among	O	O
FNDI	B-Disease	OMIM:125700
patients	O	O
and	O	O
is	O	O
thought	O	O
to	O	O
reduce	O	O
the	O	O
efficiency	O	O
of	O	O
cleavage	O	O
by	O	O
signal	O	O
peptidases	O	O
.	O	O

.	O	O

Cloning	O	O
of	O	O
a	O	O
novel	O	O
member	O	O
of	O	O
the	O	O
low	O	O
-	O	O
density	O	O
lipoprotein	O	O
receptor	O	O
family	O	O
.	O	O

A	O	O
gene	O	O
encoding	O	O
a	O	O
novel	O	O
transmembrane	O	O
protein	O	O
was	O	O
identified	O	O
by	O	O
DNA	O	O
sequence	O	O
analysis	O	O
within	O	O
the	O	O
insulin	B-Disease	D003922
-	I-Disease	D003922
dependent	I-Disease	D003922
diabetes	I-Disease	D003922
mellitus	I-Disease	D003922
(	O	O
IDDM	B-Disease	D003922
)	O	O
locus	O	O
IDDM4	O	O
on	O	O
chromosome	O	O
11q13	O	O
.	O	O

Based	O	O
on	O	O
its	O	O
chromosomal	O	O
position	O	O
,	O	O
this	O	O
gene	O	O
is	O	O
a	O	O
candidate	O	O
for	O	O
conferring	O	O
susceptibility	O	O
to	O	O
diabetes	B-Disease	D003920
.	O	O

The	O	O
gene	O	O
,	O	O
termed	O	O
low	O	O
-	O	O
density	O	O
lipoprotein	O	O
receptor	O	O
related	O	O
protein	O	O
5	O	O
(	O	O
LRP5	O	O
)	O	O
,	O	O
encodes	O	O
a	O	O
protein	O	O
of	O	O
1615	O	O
amino	O	O
acids	O	O
that	O	O
contains	O	O
conserved	O	O
modules	O	O
which	O	O
are	O	O
characteristic	O	O
of	O	O
the	O	O
low	O	O
-	O	O
density	O	O
lipoprotein	O	O
(	O	O
LDL	O	O
)	O	O
receptor	O	O
family	O	O
.	O	O

These	O	O
modules	O	O
include	O	O
a	O	O
putative	O	O
signal	O	O
peptide	O	O
for	O	O
protein	O	O
export	O	O
,	O	O
four	O	O
epidermal	O	O
growth	O	O
factor	O	O
(	O	O
EGF	O	O
)	O	O
repeats	O	O
with	O	O
associated	O	O
spacer	O	O
domains	O	O
,	O	O
three	O	O
LDL	O	O
-	O	O
receptor	O	O
(	O	O
LDLR	O	O
)	O	O
repeats	O	O
,	O	O
a	O	O
single	O	O
transmembrane	O	O
spanning	O	O
domain	O	O
,	O	O
and	O	O
a	O	O
cytoplasmic	O	O
domain	O	O
.	O	O

The	O	O
encoded	O	O
protein	O	O
has	O	O
a	O	O
unique	O	O
organization	O	O
of	O	O
EGF	O	O
and	O	O
LDLR	O	O
repeats	O	O
;	O	O
therefore	O	O
,	O	O
LRP5	O	O
likely	O	O
represents	O	O
a	O	O
new	O	O
category	O	O
of	O	O
the	O	O
LDLR	O	O
family	O	O
.	O	O

Both	O	O
human	O	O
and	O	O
mouse	O	O
LRP5	O	O
cDNAs	O	O
have	O	O
been	O	O
isolated	O	O
and	O	O
the	O	O
encoded	O	O
mature	O	O
proteins	O	O
are	O	O
95	O	O
%	O	O
identical	O	O
,	O	O
indicating	O	O
a	O	O
high	O	O
degree	O	O
of	O	O
evolutionary	O	O
conservation	O	O
.	O	O

.	O	O

ATM	O	O
germline	O	O
mutations	O	O
in	O	O
classical	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
patients	O	O
in	O	O
the	O	O
Dutch	O	O
population	O	O
.	O	O

Germline	O	O
mutations	O	O
in	O	O
the	O	O
ATM	O	O
gene	O	O
are	O	O
responsible	O	O
for	O	O
the	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
disorder	I-Disease	D030342
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
(	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
)	O	O
.	O	O

In	O	O
our	O	O
study	O	O
,	O	O
we	O	O
have	O	O
determined	O	O
the	O	O
ATM	O	O
mutation	O	O
spectrum	O	O
in	O	O
19	O	O
classical	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
patients	O	O
,	O	O
including	O	O
some	O	O
immigrant	O	O
populations	O	O
,	O	O
as	O	O
well	O	O
as	O	O
12	O	O
of	O	O
Dutch	O	O
ethnic	O	O
origin	O	O
.	O	O

Both	O	O
the	O	O
protein	O	O
truncation	O	O
test	O	O
(	O	O
PTT	O	O
)	O	O
and	O	O
the	O	O
restriction	O	O
endonuclease	O	O
fingerprinting	O	O
(	O	O
REF	O	O
)	O	O
method	O	O
were	O	O
used	O	O
and	O	O
compared	O	O
for	O	O
their	O	O
detection	O	O
efficiency	O	O
,	O	O
identifying	O	O
76	O	O
%	O	O
and	O	O
60	O	O
%	O	O
of	O	O
the	O	O
mutations	O	O
,	O	O
respectively	O	O
.	O	O

Most	O	O
patients	O	O
were	O	O
found	O	O
to	O	O
be	O	O
compound	O	O
heterozygote	O	O
.	O	O

Seventeen	O	O
mutations	O	O
were	O	O
distinct	O	O
,	O	O
of	O	O
which	O	O
10	O	O
were	O	O
not	O	O
reported	O	O
previously	O	O
.	O	O

Mutations	O	O
are	O	O
small	O	O
deletions	O	O
or	O	O
point	O	O
mutations	O	O
frequently	O	O
affecting	O	O
splice	O	O
sites	O	O
.	O	O

Moreover	O	O
,	O	O
a	O	O
16	O	O
.	O	O

7	O	O
-	O	O
kb	O	O
genomic	O	O
deletion	O	O
of	O	O
the	O	O
3	O	O
end	O	O
of	O	O
the	O	O
gene	O	O
,	O	O
most	O	O
likely	O	O
a	O	O
result	O	O
of	O	O
recombination	O	O
between	O	O
two	O	O
LINE	O	O
elements	O	O
,	O	O
was	O	O
identified	O	O
.	O	O

The	O	O
most	O	O
frequently	O	O
found	O	O
mutation	O	O
,	O	O
identified	O	O
in	O	O
three	O	O
unrelated	O	O
Turkish	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
individuals	O	O
,	O	O
was	O	O
previously	O	O
described	O	O
to	O	O
be	O	O
a	O	O
Turkish	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
founder	O	O
mutation	O	O
.	O	O

The	O	O
presence	O	O
of	O	O
a	O	O
founder	O	O
mutation	O	O
among	O	O
relatively	O	O
small	O	O
ethnic	O	O
population	O	O
groups	O	O
in	O	O
Western	O	O
Europe	O	O
could	O	O
indicate	O	O
a	O	O
high	O	O
carrier	O	O
frequency	O	O
in	O	O
such	O	O
communities	O	O
.	O	O

In	O	O
patients	O	O
of	O	O
Dutch	O	O
ethnic	O	O
origin	O	O
,	O	O
however	O	O
,	O	O
no	O	O
significant	O	O
founder	O	O
effect	O	O
could	O	O
be	O	O
identified	O	O
.	O	O

The	O	O
observed	O	O
genetic	O	O
heterogeneity	O	O
including	O	O
the	O	O
relative	O	O
high	O	O
percentage	O	O
of	O	O
splice	O	O
-	O	O
site	O	O
mutations	O	O
had	O	O
no	O	O
reflection	O	O
on	O	O
the	O	O
phenotype	O	O
.	O	O

All	O	O
patients	O	O
manifested	O	O
classical	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
and	O	O
increased	O	O
cellular	O	O
radioresistant	O	O
DNA	O	O
synthesis	O	O
.	O	O

Diagnosis	O	O
of	O	O
hemochromatosis	B-Disease	D006432
.	O	O

If	O	O
untreated	O	O
,	O	O
hemochromatosis	B-Disease	D006432
can	O	O
cause	O	O
serious	O	O
illness	O	O
and	O	O
early	B-Disease	D003643
death	I-Disease	D003643
,	O	O
but	O	O
the	O	O
disease	O	O
is	O	O
still	O	O
substantially	O	O
under	O	O
-	O	O
diagnosed	O	O
.	O	O

The	O	O
cornerstone	O	O
of	O	O
screening	O	O
and	O	O
case	O	O
detection	O	O
is	O	O
the	O	O
measurement	O	O
of	O	O
serum	O	O
transferrin	O	O
saturation	O	O
and	O	O
the	O	O
serum	O	O
ferritin	O	O
level	O	O
.	O	O

Once	O	O
the	O	O
diagnosis	O	O
is	O	O
suspected	O	O
,	O	O
physicians	O	O
must	O	O
use	O	O
serum	O	O
ferritin	O	O
levels	O	O
and	O	O
hepatic	O	O
iron	O	O
stores	O	O
on	O	O
liver	O	O
biopsy	O	O
specimens	O	O
to	O	O
assess	O	O
patients	O	O
for	O	O
the	O	O
presence	O	O
of	O	O
iron	B-Disease	D019190
overload	I-Disease	D019190
.	O	O

Liver	O	O
biopsy	O	O
is	O	O
also	O	O
used	O	O
to	O	O
establish	O	O
the	O	O
presence	O	O
or	O	O
absence	O	O
of	O	O
cirrhosis	B-Disease	D008103
,	O	O
which	O	O
can	O	O
affect	O	O
prognosis	O	O
and	O	O
management	O	O
.	O	O

A	O	O
DNA	O	O
-	O	O
based	O	O
test	O	O
for	O	O
the	O	O
HFE	O	O
gene	O	O
is	O	O
commercially	O	O
available	O	O
,	O	O
but	O	O
its	O	O
place	O	O
in	O	O
the	O	O
diagnosis	O	O
of	O	O
hemochromatosis	B-Disease	D006432
is	O	O
still	O	O
being	O	O
evaluated	O	O
.	O	O

Currently	O	O
,	O	O
the	O	O
most	O	O
useful	O	O
role	O	O
for	O	O
this	O	O
test	O	O
is	O	O
in	O	O
the	O	O
detection	O	O
of	O	O
hemochromatosis	B-Disease	D006432
in	O	O
the	O	O
family	O	O
members	O	O
of	O	O
patients	O	O
with	O	O
a	O	O
proven	O	O
case	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

It	O	O
is	O	O
crucial	O	O
to	O	O
diagnose	O	O
hemochromatosis	B-Disease	D006432
before	O	O
hepatic	B-Disease	D008103
cirrhosis	I-Disease	D008103
develops	O	O
because	O	O
phlebotomy	O	O
therapy	O	O
can	O	O
avert	O	O
serious	O	O
chronic	O	O
disease	O	O
and	O	O
can	O	O
even	O	O
lead	O	O
to	O	O
normal	O	O
life	O	O
expectancy	O	O
.	O	O

.	O	O

PAX6	O	O
mutations	O	O
reviewed	O	O
.	O	O

Mutations	O	O
in	O	O
PAX6	O	O
are	O	O
responsible	O	O
for	O	O
human	O	O
aniridia	B-Disease	D015783
and	O	O
have	O	O
also	O	O
been	O	O
found	O	O
in	O	O
patients	O	O
with	O	O
Peters	B-Disease	C537884
anomaly	I-Disease	C537884
,	O	O
with	O	O
congenital	B-Disease	D002386
cataracts	I-Disease	D002386
,	O	O
with	O	O
autosomal	B-Disease	C537022
dominant	I-Disease	C537022
keratitis	I-Disease	C537022
,	O	O
and	O	O
with	O	O
isolated	B-Disease	OMIM:136520
foveal	I-Disease	OMIM:136520
hypoplasia	I-Disease	OMIM:136520
.	O	O

No	O	O
locus	O	O
other	O	O
than	O	O
chromosome	O	O
11p13	O	O
has	O	O
been	O	O
implicated	O	O
in	O	O
aniridia	B-Disease	D015783
,	O	O
and	O	O
PAX6	O	O
is	O	O
clearly	O	O
the	O	O
major	O	O
,	O	O
if	O	O
not	O	O
only	O	O
,	O	O
gene	O	O
responsible	O	O
.	O	O

Twenty	O	O
-	O	O
eight	O	O
percent	O	O
of	O	O
identified	O	O
PAX6	O	O
mutations	O	O
are	O	O
C	O	O
-	O	O
T	O	O
changes	O	O
at	O	O
CpG	O	O
dinucleotides	O	O
,	O	O
20	O	O
%	O	O
are	O	O
splicing	O	O
errors	O	O
,	O	O
and	O	O
more	O	O
than	O	O
30	O	O
%	O	O
are	O	O
deletion	O	O
or	O	O
insertion	O	O
events	O	O
.	O	O

There	O	O
is	O	O
a	O	O
noticeably	O	O
elevated	O	O
level	O	O
of	O	O
mutation	O	O
in	O	O
the	O	O
paired	O	O
domain	O	O
compared	O	O
with	O	O
the	O	O
rest	O	O
of	O	O
the	O	O
gene	O	O
.	O	O

Increased	O	O
mutation	O	O
in	O	O
the	O	O
homeodomain	O	O
is	O	O
accounted	O	O
for	O	O
by	O	O
the	O	O
hypermutable	O	O
CpG	O	O
dinucleotide	O	O
in	O	O
codon	O	O
240	O	O
.	O	O

Very	O	O
nearly	O	O
all	O	O
mutations	O	O
appear	O	O
to	O	O
cause	O	O
loss	O	O
of	O	O
function	O	O
of	O	O
the	O	O
mutant	O	O
allele	O	O
,	O	O
and	O	O
more	O	O
than	O	O
80	O	O
%	O	O
of	O	O
exonic	O	O
substitutions	O	O
result	O	O
in	O	O
nonsense	O	O
codons	O	O
.	O	O

In	O	O
a	O	O
gene	O	O
with	O	O
such	O	O
extraordinarily	O	O
high	O	O
sequence	O	O
conservation	O	O
throughout	O	O
evolution	O	O
,	O	O
there	O	O
are	O	O
presumed	O	O
undiscovered	O	O
missense	O	O
mutations	O	O
,	O	O
these	O	O
are	O	O
hypothesized	O	O
to	O	O
exist	O	O
in	O	O
as	O	O
-	O	O
yet	O	O
unidentified	O	O
phenotypes	O	O
.	O	O

.	O	O

Schwartz	B-Disease	C537502
-	I-Disease	C537502
Jampel	I-Disease	C537502
syndrome	I-Disease	C537502
type	I-Disease	C537502
2	I-Disease	C537502
and	O	O
Stuve	B-Disease	C537502
-	I-Disease	C537502
Wiedemann	I-Disease	C537502
syndrome	I-Disease	C537502
:	O	O
a	O	O
case	O	O
for	O	O
"	O	O
lumping	O	O
"	O	O
.	O	O

Recent	O	O
studies	O	O
demonstrated	O	O
the	O	O
existence	O	O
of	O	O
a	O	O
genetically	O	O
distinct	O	O
,	O	O
usually	O	O
lethal	O	O
form	O	O
of	O	O
the	O	O
Schwartz	B-Disease	D010009
-	I-Disease	D010009
Jampel	I-Disease	D010009
syndrome	I-Disease	D010009
(	O	O
SJS	B-Disease	D010009
)	O	O
of	O	O
myotonia	B-Disease	D009222
and	O	O
skeletal	B-Disease	C535662
dysplasia	I-Disease	C535662
,	O	O
which	O	O
we	O	O
called	O	O
SJS	B-Disease	D010009
type	O	O
2	O	O
.	O	O

This	O	O
disorder	O	O
is	O	O
reminiscent	O	O
of	O	O
another	O	O
rare	O	O
condition	O	O
,	O	O
the	O	O
Stuve	B-Disease	C537502
-	I-Disease	C537502
Wiedemann	I-Disease	C537502
syndrome	I-Disease	C537502
(	O	O
SWS	B-Disease	C537502
)	O	O
,	O	O
which	O	O
comprises	O	O
campomelia	B-Disease	C537966
at	O	O
birth	O	O
with	O	O
skeletal	B-Disease	C535662
dysplasia	I-Disease	C535662
,	O	O
contractures	B-Disease	D003286
,	O	O
and	O	O
early	B-Disease	D003643
death	I-Disease	D003643
.	O	O

To	O	O
test	O	O
for	O	O
possible	O	O
nosologic	O	O
identity	O	O
between	O	O
these	O	O
disorders	O	O
,	O	O
we	O	O
reviewed	O	O
the	O	O
literature	O	O
and	O	O
obtained	O	O
a	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
the	O	O
only	O	O
two	O	O
surviving	O	O
patients	O	O
,	O	O
one	O	O
with	O	O
SJS	B-Disease	D010009
type	O	O
2	O	O
at	O	O
age	O	O
10	O	O
years	O	O
and	O	O
another	O	O
with	O	O
SWS	B-Disease	C537502
at	O	O
age	O	O
7	O	O
years	O	O
.	O	O

Patients	O	O
reported	O	O
as	O	O
having	O	O
either	O	O
neonatal	O	O
SJS	B-Disease	D010009
or	O	O
SWS	B-Disease	C537502
presented	O	O
a	O	O
combination	O	O
of	O	O
a	O	O
severe	O	O
,	O	O
prenatal	O	O
-	O	O
onset	O	O
neuromuscular	B-Disease	D009468
disorder	I-Disease	D009468
(	O	O
with	O	O
congenital	B-Disease	D003286
joint	I-Disease	D003286
contractures	I-Disease	D003286
,	O	O
respiratory	O	O
and	O	O
feeding	O	O
difficulties	O	O
,	O	O
tendency	O	O
to	O	O
hyperthermia	B-Disease	D005334
,	O	O
and	O	O
frequent	O	O
death	O	O
in	O	O
infancy	O	O
)	O	O
with	O	O
a	O	O
distinct	O	O
campomelic	B-Disease	D055036
-	I-Disease	D055036
metaphyseal	I-Disease	D055036
skeletal	I-Disease	D055036
dysplasia	I-Disease	D055036
.	O	O

The	O	O
similarity	O	O
of	O	O
the	O	O
clinical	O	O
and	O	O
radiographic	O	O
findings	O	O
is	O	O
so	O	O
extensive	O	O
that	O	O
these	O	O
disorders	O	O
appear	O	O
to	O	O
be	O	O
a	O	O
single	O	O
entity	O	O
.	O	O

The	O	O
follow	O	O
-	O	O
up	O	O
observation	O	O
of	O	O
an	O	O
identical	O	O
and	O	O
unique	O	O
pattern	O	O
of	O	O
progressive	O	O
bone	B-Disease	D001848
dysplasia	I-Disease	D001848
in	O	O
the	O	O
two	O	O
patients	O	O
(	O	O
one	O	O
with	O	O
SJS	B-Disease	D010009
type	O	O
2	O	O
,	O	O
one	O	O
with	O	O
SWS	B-Disease	C537502
)	O	O
surviving	O	O
beyond	O	O
infancy	O	O
adds	O	O
to	O	O
the	O	O
evidence	O	O
in	O	O
favor	O	O
of	O	O
identity	O	O
.	O	O

The	O	O
hypothesis	O	O
that	O	O
SWS	B-Disease	C537502
and	O	O
SJS	B-Disease	D010009
type	O	O
2	O	O
are	O	O
the	O	O
same	O	O
disorder	O	O
should	O	O
be	O	O
testable	O	O
by	O	O
molecular	O	O
methods	O	O
.	O	O

.	O	O

The	O	O
185delAG	O	O
BRCA1	O	O
mutation	O	O
originated	O	O
before	O	O
the	O	O
dispersion	O	O
of	O	O
Jews	O	O
in	O	O
the	O	O
diaspora	O	O
and	O	O
is	O	O
not	O	O
limited	O	O
to	O	O
Ashkenazim	O	O
.	O	O

The	O	O
185delAG	O	O
mutation	O	O
in	O	O
BRCA1	O	O
is	O	O
detected	O	O
in	O	O
Ashkenazi	O	O
Jews	O	O
both	O	O
in	O	O
familial	B-Disease	OMIM:613399
breast	I-Disease	OMIM:613399
and	I-Disease	OMIM:613399
ovarian	I-Disease	OMIM:613399
cancer	I-Disease	OMIM:613399
and	O	O
in	O	O
the	O	O
general	O	O
population	O	O
.	O	O

All	O	O
tested	O	O
Ashkenazi	O	O
mutation	O	O
carriers	O	O
share	O	O
the	O	O
same	O	O
allelic	O	O
pattern	O	O
at	O	O
the	O	O
BRCA1	O	O
locus	O	O
.	O	O

Our	O	O
previous	O	O
study	O	O
showed	O	O
that	O	O
this	O	O
Ashkenazi	O	O
mutation	O	O
also	O	O
occurs	O	O
in	O	O
Iraqi	O	O
Jews	O	O
with	O	O
a	O	O
similar	O	O
allelic	O	O
pattern	O	O
.	O	O

We	O	O
extended	O	O
our	O	O
analysis	O	O
to	O	O
other	O	O
non	O	O
-	O	O
Ashkenazi	O	O
subsets	O	O
354	O	O
of	O	O
Moroccan	O	O
origin	O	O
,	O	O
200	O	O
Yemenites	O	O
and	O	O
150	O	O
Iranian	O	O
Jews	O	O
.	O	O

Heteroduplex	O	O
analysis	O	O
complemented	O	O
by	O	O
direct	O	O
DNA	O	O
sequencing	O	O
of	O	O
abnormally	O	O
migrating	O	O
bands	O	O
were	O	O
employed	O	O
.	O	O

Four	O	O
of	O	O
Moroccan	O	O
origin	O	O
(	O	O
1	O	O
.	O	O

1	O	O
%	O	O
)	O	O
and	O	O
none	O	O
of	O	O
the	O	O
Yemenites	O	O
or	O	O
Iranians	O	O
was	O	O
a	O	O
carrier	O	O
of	O	O
the	O	O
185delAG	O	O
mutation	O	O
.	O	O

BRCA1	O	O
allelic	O	O
patterns	O	O
were	O	O
determined	O	O
for	O	O
four	O	O
of	O	O
these	O	O
individuals	O	O
and	O	O
for	O	O
12	O	O
additional	O	O
non	O	O
-	O	O
Ashkenazi	O	O
185delAG	O	O
mutation	O	O
carriers	O	O
who	O	O
had	O	O
breast	B-Disease	D061325
/	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
.	O	O

Six	O	O
non	O	O
-	O	O
Ashkenazi	O	O
individuals	O	O
shared	O	O
the	O	O
common	O	O
Ashkenazi	O	O
haplotype	O	O
,	O	O
four	O	O
had	O	O
a	O	O
closely	O	O
related	O	O
pattern	O	O
,	O	O
and	O	O
the	O	O
rest	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
displayed	O	O
a	O	O
distinct	O	O
BRCA1	O	O
allelic	O	O
pattern	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
the	O	O
185delAG	O	O
BRCA1	O	O
mutation	O	O
occurs	O	O
in	O	O
some	O	O
non	O	O
-	O	O
Ashkenazi	O	O
populations	O	O
at	O	O
rates	O	O
comparable	O	O
with	O	O
that	O	O
of	O	O
Ashkenazim	O	O
.	O	O

The	O	O
majority	O	O
of	O	O
Jewish	O	O
185delAG	O	O
mutation	O	O
carriers	O	O
have	O	O
a	O	O
common	O	O
allelic	O	O
pattern	O	O
,	O	O
supporting	O	O
the	O	O
founder	O	O
effect	O	O
notion	O	O
,	O	O
but	O	O
dating	O	O
the	O	O
mutations	O	O
origin	O	O
to	O	O
an	O	O
earlier	O	O
date	O	O
than	O	O
currently	O	O
estimated	O	O
.	O	O

However	O	O
,	O	O
the	O	O
different	O	O
allelic	O	O
pattern	O	O
at	O	O
the	O	O
BRCA1	O	O
locus	O	O
even	O	O
in	O	O
some	O	O
Jewish	O	O
mutation	O	O
carriers	O	O
,	O	O
might	O	O
suggest	O	O
that	O	O
the	O	O
mutation	O	O
arose	O	O
independently	O	O
.	O	O

.	O	O

The	O	O
RB1	O	O
gene	O	O
mutation	O	O
in	O	O
a	O	O
child	O	O
with	O	O
ectopic	B-Disease	D012175
intracranial	I-Disease	D012175
retinoblastoma	I-Disease	D012175
.	O	O

The	O	O
RB1	O	O
gene	O	O
mutation	O	O
was	O	O
investigated	O	O
in	O	O
a	O	O
child	O	O
with	O	O
ectopic	B-Disease	D012175
intracranial	I-Disease	D012175
retinoblastoma	I-Disease	D012175
using	O	O
DNA	O	O
obtained	O	O
from	O	O
both	O	O
the	O	O
pineal	B-Disease	D019572
and	I-Disease	D019572
retinal	I-Disease	D019572
tumours	I-Disease	D019572
of	O	O
the	O	O
patient	O	O
.	O	O

A	O	O
nonsense	O	O
mutation	O	O
in	O	O
exon	O	O
17	O	O
(	O	O
codon	O	O
556	O	O
)	O	O
of	O	O
the	O	O
RB1	O	O
gene	O	O
was	O	O
found	O	O
to	O	O
be	O	O
present	O	O
homozygously	O	O
in	O	O
both	O	O
the	O	O
retinal	B-Disease	D019572
and	I-Disease	D019572
the	I-Disease	D019572
pineal	I-Disease	D019572
tumours	I-Disease	D019572
.	O	O

The	O	O
same	O	O
mutation	O	O
was	O	O
present	O	O
heterozygously	O	O
in	O	O
the	O	O
DNA	O	O
from	O	O
the	O	O
constitutional	O	O
cells	O	O
of	O	O
the	O	O
patient	O	O
,	O	O
proving	O	O
it	O	O
to	O	O
be	O	O
of	O	O
germline	O	O
origin	O	O
.	O	O

The	O	O
initial	O	O
mutation	O	O
was	O	O
shown	O	O
to	O	O
have	O	O
occurred	O	O
in	O	O
the	O	O
paternally	O	O
derived	O	O
RB1	O	O
allele	O	O
.	O	O

The	O	O
mutation	O	O
is	O	O
in	O	O
an	O	O
area	O	O
of	O	O
the	O	O
gene	O	O
that	O	O
encodes	O	O
the	O	O
protein	O	O
-	O	O
binding	O	O
region	O	O
known	O	O
as	O	O
the	O	O
pocket	O	O
region	O	O
and	O	O
has	O	O
been	O	O
detected	O	O
in	O	O
other	O	O
cases	O	O
of	O	O
retinoblastoma	B-Disease	D012175
.	O	O

.	O	O

Genomic	O	O
structure	O	O
of	O	O
the	O	O
human	O	O
congenital	B-Disease	C536210
chloride	I-Disease	C536210
diarrhea	I-Disease	C536210
(	O	O
CLD	B-Disease	C536210
)	O	O
gene	O	O
.	O	O

Congenital	B-Disease	C536210
chloride	I-Disease	C536210
diarrhea	I-Disease	C536210
(	O	O
CLD	B-Disease	C536210
)	O	O
is	O	O
caused	O	O
by	O	O
mutations	O	O
in	O	O
a	O	O
gene	O	O
which	O	O
encodes	O	O
an	O	O
intestinal	O	O
anion	O	O
transporter	O	O
.	O	O

We	O	O
report	O	O
here	O	O
the	O	O
complete	O	O
genomic	O	O
organization	O	O
of	O	O
the	O	O
human	O	O
CLD	B-Disease	C536210
gene	O	O
which	O	O
spans	O	O
approximately	O	O
39kb	O	O
,	O	O
and	O	O
comprises	O	O
21	O	O
exons	O	O
.	O	O

All	O	O
exon	O	O
/	O	O
intron	O	O
boundaries	O	O
conform	O	O
to	O	O
the	O	O
GT	O	O
/	O	O
AG	O	O
rule	O	O
.	O	O

An	O	O
analysis	O	O
of	O	O
the	O	O
putative	O	O
promoter	O	O
region	O	O
sequence	O	O
shows	O	O
a	O	O
putative	O	O
TATA	O	O
box	O	O
and	O	O
predicts	O	O
multiple	O	O
transcription	O	O
factor	O	O
binding	O	O
sites	O	O
.	O	O

The	O	O
genomic	O	O
structure	O	O
was	O	O
determined	O	O
using	O	O
DNA	O	O
from	O	O
several	O	O
sources	O	O
including	O	O
multiple	O	O
large	O	O
-	O	O
insert	O	O
libaries	O	O
and	O	O
genomic	O	O
DNA	O	O
from	O	O
Finnish	O	O
CLD	B-Disease	C536210
patients	O	O
and	O	O
controls	O	O
.	O	O

Exon	O	O
-	O	O
specific	O	O
primers	O	O
developed	O	O
in	O	O
this	O	O
study	O	O
will	O	O
facilitate	O	O
mutation	O	O
screening	O	O
studies	O	O
of	O	O
patients	O	O
with	O	O
the	O	O
disease	O	O
.	O	O

Genomic	O	O
sequencing	O	O
of	O	O
a	O	O
BAC	O	O
clone	O	O
H_RG364P16	O	O
revealed	O	O
the	O	O
presence	O	O
of	O	O
another	O	O
,	O	O
highly	O	O
homologous	O	O
gene	O	O
3	O	O
of	O	O
the	O	O
CLD	B-Disease	C536210
gene	O	O
,	O	O
with	O	O
a	O	O
similar	O	O
genomic	O	O
structure	O	O
,	O	O
recently	O	O
identified	O	O
as	O	O
the	O	O
Pendred	B-Disease	C536648
syndrome	I-Disease	C536648
gene	O	O
(	O	O
PDS	B-Disease	C536648
)	O	O
.	O	O

.	O	O

Mutation	O	O
analysis	O	O
of	O	O
UBE3A	O	O
in	O	O
Angelman	B-Disease	D017204
syndrome	I-Disease	D017204
patients	O	O
.	O	O

Angelman	B-Disease	D017204
syndrome	I-Disease	D017204
(	O	O
AS	B-Disease	D017204
)	O	O
is	O	O
caused	O	O
by	O	O
chromosome	O	O
15q11	O	O
-	O	O
q13	O	O
deletions	O	O
of	O	O
maternal	O	O
origin	O	O
,	O	O
by	O	O
paternal	O	O
uniparental	B-Disease	D024182
disomy	I-Disease	D024182
(	O	O
UPD	B-Disease	D024182
)	O	O
15	O	O
,	O	O
by	O	O
imprinting	O	O
defects	O	O
,	O	O
and	O	O
by	O	O
mutations	O	O
in	O	O
the	O	O
UBE3A	O	O
gene	O	O
.	O	O

UBE3A	O	O
encodes	O	O
a	O	O
ubiquitin	O	O
-	O	O
protein	O	O
ligase	O	O
and	O	O
shows	O	O
brain	O	O
-	O	O
specific	O	O
imprinting	O	O
.	O	O

Here	O	O
we	O	O
describe	O	O
UBE3A	O	O
coding	O	O
-	O	O
region	O	O
mutations	O	O
detected	O	O
by	O	O
SSCP	O	O
analysis	O	O
in	O	O
13	O	O
AS	B-Disease	D017204
individuals	O	O
or	O	O
families	O	O
.	O	O

Two	O	O
identical	O	O
de	O	O
novo	O	O
5	O	O
-	O	O
bp	O	O
duplications	O	O
in	O	O
exon	O	O
16	O	O
were	O	O
found	O	O
.	O	O

Among	O	O
the	O	O
other	O	O
11	O	O
unique	O	O
mutations	O	O
,	O	O
8	O	O
were	O	O
small	O	O
deletions	O	O
or	O	O
insertions	O	O
predicted	O	O
to	O	O
cause	O	O
frameshifts	O	O
,	O	O
1	O	O
was	O	O
a	O	O
mutation	O	O
to	O	O
a	O	O
stop	O	O
codon	O	O
,	O	O
1	O	O
was	O	O
a	O	O
missense	O	O
mutation	O	O
,	O	O
and	O	O
1	O	O
was	O	O
predicted	O	O
to	O	O
cause	O	O
insertion	O	O
of	O	O
an	O	O
isoleucine	O	O
in	O	O
the	O	O
hect	O	O
domain	O	O
of	O	O
the	O	O
UBE3A	O	O
protein	O	O
,	O	O
which	O	O
functions	O	O
in	O	O
E2	O	O
binding	O	O
and	O	O
ubiquitin	O	O
transfer	O	O
.	O	O

Eight	O	O
of	O	O
the	O	O
cases	O	O
were	O	O
familial	O	O
,	O	O
and	O	O
five	O	O
were	O	O
sporadic	O	O
.	O	O

In	O	O
two	O	O
familial	O	O
cases	O	O
and	O	O
one	O	O
sporadic	O	O
case	O	O
,	O	O
mosaicism	O	O
for	O	O
UBE3A	O	O
mutations	O	O
was	O	O
detected	O	O
in	O	O
the	O	O
mother	O	O
of	O	O
three	O	O
AS	B-Disease	D017204
sons	O	O
,	O	O
in	O	O
the	O	O
maternal	O	O
grandfather	O	O
of	O	O
two	O	O
AS	B-Disease	D017204
first	O	O
cousins	O	O
,	O	O
and	O	O
in	O	O
the	O	O
mother	O	O
of	O	O
an	O	O
AS	B-Disease	D017204
daughter	O	O
.	O	O

The	O	O
frequencies	O	O
with	O	O
which	O	O
we	O	O
detected	O	O
mutations	O	O
were	O	O
5	O	O
(	O	O
14	O	O
%	O	O
)	O	O
of	O	O
35	O	O
in	O	O
sporadic	O	O
cases	O	O
and	O	O
8	O	O
(	O	O
80	O	O
%	O	O
)	O	O
of	O	O
10	O	O
in	O	O
familial	O	O
cases	O	O
.	O	O

.	O	O

Autosomal	B-Disease	OMIM:125700
dominant	I-Disease	OMIM:125700
neurohypophyseal	I-Disease	OMIM:125700
diabetes	I-Disease	OMIM:125700
insipidus	I-Disease	OMIM:125700
associated	O	O
with	O	O
a	O	O
missense	O	O
mutation	O	O
encoding	O	O
Gly23	O	O
-	O	O
-	O	O
>	O	O
Val	O	O
in	O	O
neurophysin	O	O
II	O	O
.	O	O

Autosomal	B-Disease	OMIM:125700
dominant	I-Disease	OMIM:125700
neurohypophyseal	I-Disease	OMIM:125700
diabetes	I-Disease	OMIM:125700
insipidus	I-Disease	OMIM:125700
(	O	O
ADNDI	B-Disease	OMIM:125700
)	O	O
is	O	O
an	O	O
inherited	B-Disease	D030342
disease	I-Disease	D030342
caused	O	O
by	O	O
progressive	O	O
degeneration	O	O
of	O	O
the	O	O
magnocellular	O	O
neurons	O	O
of	O	O
the	O	O
hypothalamus	O	O
leading	O	O
to	O	O
decreased	O	O
ability	O	O
to	O	O
produce	O	O
the	O	O
hormone	O	O
arginine	O	O
vasopressin	O	O
(	O	O
AVP	O	O
)	O	O
.	O	O

Affected	O	O
individuals	O	O
are	O	O
not	O	O
symptomatic	O	O
at	O	O
birth	O	O
,	O	O
but	O	O
usually	O	O
develop	O	O
diabetes	B-Disease	D003919
insipidus	I-Disease	D003919
at	O	O
1	O	O
-	O	O
6	O	O
yr	O	O
of	O	O
age	O	O
.	O	O

The	O	O
genetic	O	O
locus	O	O
of	O	O
the	O	O
disease	O	O
is	O	O
the	O	O
AVP	O	O
-	O	O
neurophysin	O	O
II	O	O
(	O	O
NPII	O	O
)	O	O
gene	O	O
,	O	O
and	O	O
mutations	O	O
that	O	O
cause	O	O
ADNDI	B-Disease	OMIM:125700
have	O	O
been	O	O
found	O	O
in	O	O
both	O	O
the	O	O
signal	O	O
peptide	O	O
of	O	O
the	O	O
prepro	O	O
-	O	O
AVP	O	O
-	O	O
NPII	O	O
precursor	O	O
and	O	O
within	O	O
NPII	O	O
itself	O	O
.	O	O

An	O	O
affected	O	O
girl	O	O
who	O	O
presented	O	O
at	O	O
9	O	O
months	O	O
of	O	O
age	O	O
and	O	O
her	O	O
similarly	O	O
affected	O	O
younger	O	O
brother	O	O
and	O	O
father	O	O
were	O	O
all	O	O
found	O	O
to	O	O
have	O	O
a	O	O
novel	O	O
missense	O	O
mutation	O	O
(	O	O
G1758	O	O
-	O	O
-	O	O
>	O	O
T	O	O
)	O	O
encoding	O	O
the	O	O
amino	O	O
acid	O	O
substitution	O	O
Gly23	O	O
-	O	O
-	O	O
>	O	O
Val	O	O
within	O	O
NPII	O	O
.	O	O

The	O	O
mutation	O	O
was	O	O
confirmed	O	O
by	O	O
restriction	O	O
endonuclease	O	O
analysis	O	O
.	O	O

A	O	O
T1	O	O
-	O	O
weighted	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
of	O	O
the	O	O
fathers	O	O
pituitary	O	O
gland	O	O
demonstrates	O	O
an	O	O
attenuated	O	O
posterior	O	O
pituitary	O	O
bright	O	O
spot	O	O
.	O	O

This	O	O
mutation	O	O
may	O	O
be	O	O
valuable	O	O
for	O	O
developing	O	O
models	O	O
of	O	O
dominantly	B-Disease	D020271
inherited	I-Disease	D020271
neurodegeneration	I-Disease	D020271
,	O	O
as	O	O
the	O	O
early	O	O
age	O	O
of	O	O
onset	O	O
of	O	O
symptoms	O	O
suggests	O	O
that	O	O
this	O	O
mutation	O	O
may	O	O
be	O	O
particularly	O	O
deleterious	O	O
to	O	O
the	O	O
magnocellular	O	O
neuron	O	O
.	O	O

.	O	O

Reversal	O	O
of	O	O
severe	O	O
hypertrophic	B-Disease	D002312
cardiomyopathy	I-Disease	D002312
and	O	O
excellent	O	O
neuropsychologic	O	O
outcome	O	O
in	O	O
very	B-Disease	C536353
-	I-Disease	C536353
long	I-Disease	C536353
-	I-Disease	C536353
chain	I-Disease	C536353
acyl	I-Disease	C536353
-	I-Disease	C536353
coenzyme	I-Disease	C536353
A	I-Disease	C536353
dehydrogenase	I-Disease	C536353
deficiency	I-Disease	C536353
.	O	O

Very	B-Disease	C536353
-	I-Disease	C536353
long	I-Disease	C536353
-	I-Disease	C536353
chain	I-Disease	C536353
acyl	I-Disease	C536353
-	I-Disease	C536353
coenzyme	I-Disease	C536353
A	I-Disease	C536353
dehydrogenase	I-Disease	C536353
(	I-Disease	C536353
VLCAD	I-Disease	C536353
)	I-Disease	C536353
deficiency	I-Disease	C536353
is	O	O
a	O	O
disorder	O	O
of	O	O
fatty	O	O
acid	O	O
beta	O	O
oxidation	O	O
that	O	O
reportedly	O	O
has	O	O
high	O	O
rates	O	O
of	O	O
morbidity	O	O
and	O	O
mortality	O	O
.	O	O

We	O	O
describe	O	O
the	O	O
outcome	O	O
of	O	O
a	O	O
5	O	O
-	O	O
year	O	O
-	O	O
old	O	O
girl	O	O
with	O	O
VLCAD	B-Disease	C536353
deficiency	I-Disease	C536353
who	O	O
was	O	O
first	O	O
seen	O	O
at	O	O
5	O	O
months	O	O
of	O	O
age	O	O
with	O	O
severe	O	O
hypertrophic	B-Disease	D002312
cardiomyopathy	I-Disease	D002312
,	O	O
hepatomegaly	B-Disease	D006529
,	O	O
encephalopathy	B-Disease	D001927
,	O	O
and	O	O
hypotonia	B-Disease	D009123
.	O	O

Biochemical	O	O
studies	O	O
indicated	O	O
VLCAD	B-Disease	C536353
deficiency	I-Disease	C536353
caused	O	O
by	O	O
a	O	O
stable	O	O
yet	O	O
inactive	O	O
enzyme	O	O
.	O	O

Molecular	O	O
genetic	O	O
analysis	O	O
of	O	O
her	O	O
VLCAD	O	O
gene	O	O
revealed	O	O
a	O	O
T1372C	O	O
(	O	O
F458L	O	O
)	O	O
missense	O	O
mutation	O	O
and	O	O
a	O	O
1668	O	O
ACAG	O	O
1669	O	O
splice	O	O
site	O	O
mutation	O	O
.	O	O

After	O	O
initial	O	O
treatment	O	O
with	O	O
intravenous	O	O
glucose	O	O
and	O	O
carnitine	O	O
,	O	O
the	O	O
patient	O	O
has	O	O
thrived	O	O
on	O	O
a	O	O
low	O	O
-	O	O
fat	O	O
diet	O	O
supplemented	O	O
with	O	O
medium	O	O
-	O	O
chain	O	O
triglyceride	O	O
oil	O	O
and	O	O
carnitine	O	O
and	O	O
avoidance	O	O
of	O	O
fasting	O	O
.	O	O

Her	O	O
ventricular	O	O
hypertrophy	O	O
resolved	O	O
significantly	O	O
over	O	O
1	O	O
year	O	O
,	O	O
and	O	O
cognitively	O	O
,	O	O
she	O	O
is	O	O
in	O	O
the	O	O
superior	O	O
range	O	O
for	O	O
age	O	O
.	O	O

Clinical	O	O
recognition	O	O
of	O	O
VLCAD	B-Disease	C536353
deficiency	I-Disease	C536353
is	O	O
important	O	O
because	O	O
it	O	O
is	O	O
one	O	O
of	O	O
the	O	O
few	O	O
directly	O	O
treatable	O	O
causes	O	O
of	O	O
cardiomyopathy	B-Disease	D009202
in	O	O
children	O	O
.	O	O

.	O	O

Mutations	O	O
of	O	O
the	O	O
ATM	O	O
gene	O	O
detected	O	O
in	O	O
Japanese	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
patients	O	O
:	O	O
possible	O	O
preponderance	O	O
of	O	O
the	O	O
two	O	O
founder	O	O
mutations	O	O
4612del165	O	O
and	O	O
7883del5	O	O
.	O	O

The	O	O
ATM	O	O
(	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
,	O	O
mutated	O	O
)	O	O
gene	O	O
on	O	O
human	O	O
chromosome	O	O
11q22	O	O
.	O	O

3	O	O
has	O	O
recently	O	O
been	O	O
identified	O	O
as	O	O
the	O	O
gene	O	O
responsible	O	O
for	O	O
the	O	O
human	O	O
recessive	B-Disease	D030342
disease	I-Disease	D030342
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
(	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
)	O	O
.	O	O

In	O	O
order	O	O
to	O	O
define	O	O
the	O	O
types	O	O
of	O	O
disease	O	O
-	O	O
causing	O	O
ATM	O	O
mutations	O	O
in	O	O
Japanese	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
patients	O	O
as	O	O
well	O	O
as	O	O
to	O	O
look	O	O
for	O	O
possible	O	O
mutational	O	O
hotspots	O	O
,	O	O
reverse	O	O
-	O	O
transcribed	O	O
RNA	O	O
derived	O	O
from	O	O
ten	O	O
patients	O	O
belonging	O	O
to	O	O
eight	O	O
unrelated	O	O
Japanese	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
families	O	O
was	O	O
analyzed	O	O
for	O	O
mutations	O	O
by	O	O
the	O	O
restriction	O	O
endonuclease	O	O
fingerprinting	O	O
method	O	O
.	O	O

As	O	O
has	O	O
been	O	O
reported	O	O
by	O	O
others	O	O
,	O	O
mutations	O	O
that	O	O
lead	O	O
to	O	O
exon	O	O
skipping	O	O
or	O	O
premature	O	O
protein	O	O
truncation	O	O
were	O	O
also	O	O
predominant	O	O
in	O	O
our	O	O
mutants	O	O
.	O	O

Six	O	O
different	O	O
mutations	O	O
were	O	O
identified	O	O
on	O	O
12	O	O
of	O	O
the	O	O
16	O	O
alleles	O	O
examined	O	O
.	O	O

Four	O	O
were	O	O
deletions	O	O
involving	O	O
a	O	O
loss	O	O
of	O	O
a	O	O
single	O	O
exon	O	O
exon	O	O
7	O	O
,	O	O
exon	O	O
16	O	O
,	O	O
exon	O	O
33	O	O
or	O	O
exon	O	O
35	O	O
.	O	O

The	O	O
others	O	O
were	O	O
minute	O	O
deletions	O	O
,	O	O
4649delA	O	O
in	O	O
exon	O	O
33	O	O
and	O	O
7883del5	O	O
in	O	O
exon	O	O
55	O	O
.	O	O

The	O	O
mutations	O	O
4612del165	O	O
and	O	O
7883del5	O	O
were	O	O
found	O	O
in	O	O
more	O	O
than	O	O
two	O	O
unrelated	O	O
families	O	O
;	O	O
44	O	O
%	O	O
(	O	O
7	O	O
of	O	O
16	O	O
)	O	O
of	O	O
the	O	O
mutant	O	O
alleles	O	O
had	O	O
one	O	O
of	O	O
the	O	O
two	O	O
mutations	O	O
.	O	O

The	O	O
4612del165	O	O
mutations	O	O
in	O	O
three	O	O
different	O	O
families	O	O
were	O	O
all	O	O
ascribed	O	O
to	O	O
the	O	O
same	O	O
T	O	O
-	O	O
-	O	O
>	O	O
A	O	O
substitution	O	O
at	O	O
the	O	O
splice	O	O
donor	O	O
site	O	O
in	O	O
intron	O	O
33	O	O
.	O	O

Microsatellite	O	O
genotyping	O	O
around	O	O
the	O	O
ATM	O	O
locus	O	O
also	O	O
indicated	O	O
that	O	O
a	O	O
common	O	O
haplotype	O	O
was	O	O
shared	O	O
by	O	O
the	O	O
mutant	O	O
alleles	O	O
in	O	O
both	O	O
mutations	O	O
.	O	O

This	O	O
suggests	O	O
that	O	O
these	O	O
two	O	O
founder	O	O
mutations	O	O
may	O	O
be	O	O
predominant	O	O
among	O	O
Japanese	O	O
ATM	O	O
mutant	O	O
alleles	O	O
.	O	O

Down	O	O
-	O	O
regulation	O	O
of	O	O
transmembrane	O	O
carbonic	O	O
anhydrases	O	O
in	O	O
renal	B-Disease	D002292
cell	I-Disease	D002292
carcinoma	I-Disease	D002292
cell	O	O
lines	O	O
by	O	O
wild	O	O
-	O	O
type	O	O
von	B-Disease	D006623
Hippel	I-Disease	D006623
-	I-Disease	D006623
Lindau	I-Disease	D006623
transgenes	O	O
.	O	O

To	O	O
discover	O	O
genes	O	O
involved	O	O
in	O	O
von	B-Disease	D006623
Hippel	I-Disease	D006623
-	I-Disease	D006623
Lindau	I-Disease	D006623
(	O	O
VHL	B-Disease	D006623
)	O	O
-	O	O
mediated	O	O
carcinogenesis	O	O
,	O	O
we	O	O
used	O	O
renal	B-Disease	D002292
cell	I-Disease	D002292
carcinoma	I-Disease	D002292
cell	O	O
lines	O	O
stably	O	O
transfected	O	O
with	O	O
wild	O	O
-	O	O
type	O	O
VHL	B-Disease	D006623
-	O	O
expressing	O	O
transgenes	O	O
.	O	O

Large	O	O
-	O	O
scale	O	O
RNA	O	O
differential	O	O
display	O	O
technology	O	O
applied	O	O
to	O	O
these	O	O
cell	O	O
lines	O	O
identified	O	O
several	O	O
differentially	O	O
expressed	O	O
genes	O	O
,	O	O
including	O	O
an	O	O
alpha	O	O
carbonic	O	O
anhydrase	O	O
gene	O	O
,	O	O
termed	O	O
CA12	O	O
.	O	O

The	O	O
deduced	O	O
protein	O	O
sequence	O	O
was	O	O
classified	O	O
as	O	O
a	O	O
one	O	O
-	O	O
pass	O	O
transmembrane	O	O
CA	O	O
possessing	O	O
an	O	O
apparently	O	O
intact	O	O
catalytic	O	O
domain	O	O
in	O	O
the	O	O
extracellular	O	O
CA	O	O
module	O	O
.	O	O

Reintroduced	O	O
wild	O	O
-	O	O
type	O	O
VHL	B-Disease	D006623
strongly	O	O
inhibited	O	O
the	O	O
overexpression	O	O
of	O	O
the	O	O
CA12	O	O
gene	O	O
in	O	O
the	O	O
parental	O	O
renal	B-Disease	D002292
cell	I-Disease	D002292
carcinoma	I-Disease	D002292
cell	O	O
lines	O	O
.	O	O

Similar	O	O
results	O	O
were	O	O
obtained	O	O
with	O	O
CA9	O	O
,	O	O
encoding	O	O
another	O	O
transmembrane	O	O
CA	O	O
with	O	O
an	O	O
intact	O	O
catalytic	O	O
domain	O	O
.	O	O

Although	O	O
both	O	O
domains	O	O
of	O	O
the	O	O
VHL	B-Disease	D006623
protein	O	O
contribute	O	O
to	O	O
regulation	O	O
of	O	O
CA12	O	O
expression	O	O
,	O	O
the	O	O
elongin	O	O
binding	O	O
domain	O	O
alone	O	O
could	O	O
effectively	O	O
regulate	O	O
CA9	O	O
expression	O	O
.	O	O

We	O	O
mapped	O	O
CA12	O	O
and	O	O
CA9	O	O
loci	O	O
to	O	O
chromosome	O	O
bands	O	O
15q22	O	O
and	O	O
17q21	O	O
.	O	O

2	O	O
respectively	O	O
,	O	O
regions	O	O
prone	O	O
to	O	O
amplification	O	O
in	O	O
some	O	O
human	O	O
cancers	B-Disease	D009369
.	O	O

Additional	O	O
experiments	O	O
are	O	O
needed	O	O
to	O	O
define	O	O
the	O	O
role	O	O
of	O	O
CA	O	O
IX	O	O
and	O	O
CA	O	O
XII	O	O
enzymes	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
pH	O	O
in	O	O
the	O	O
extracellular	O	O
microenvironment	O	O
and	O	O
its	O	O
potential	O	O
impact	O	O
on	O	O
cancer	B-Disease	D009369
cell	O	O
growth	O	O
.	O	O

A	O	O
novel	O	O
common	O	O
missense	O	O
mutation	O	O
G301C	O	O
in	O	O
the	O	O
N	O	O
-	O	O
acetylgalactosamine	O	O
-	O	O
6	O	O
-	O	O
sulfate	O	O
sulfatase	O	O
gene	O	O
in	O	O
mucopolysaccharidosis	B-Disease	OMIM:253000
IVA	I-Disease	OMIM:253000
.	O	O

Mucopolysaccharidosis	B-Disease	OMIM:253000
IVA	I-Disease	OMIM:253000
(	O	O
MPS	B-Disease	OMIM:253000
IVA	I-Disease	OMIM:253000
)	O	O
is	O	O
an	O	O
autosomal	B-Disease	D016464
recessive	I-Disease	D016464
lysosomal	I-Disease	D016464
storage	I-Disease	D016464
disorder	I-Disease	D016464
caused	O	O
by	O	O
a	O	O
genetic	B-Disease	D030342
defect	I-Disease	D030342
in	O	O
N	O	O
-	O	O
acetylgalactosamine	O	O
-	O	O
6	O	O
-	O	O
sulfate	O	O
sulfatase	O	O
(	O	O
GALNS	O	O
)	O	O
.	O	O

In	O	O
previous	O	O
studies	O	O
,	O	O
we	O	O
have	O	O
found	O	O
two	O	O
common	O	O
mutations	O	O
in	O	O
Caucasians	O	O
and	O	O
Japanese	O	O
,	O	O
respectively	O	O
.	O	O

To	O	O
characterize	O	O
the	O	O
mutational	O	O
spectrum	O	O
in	O	O
various	O	O
ethnic	O	O
groups	O	O
,	O	O
mutations	O	O
in	O	O
the	O	O
GALNS	O	O
gene	O	O
in	O	O
Colombian	O	O
MPS	B-Disease	OMIM:253000
IVA	I-Disease	OMIM:253000
patients	O	O
were	O	O
investigated	O	O
,	O	O
and	O	O
genetic	O	O
backgrounds	O	O
were	O	O
extensively	O	O
analyzed	O	O
to	O	O
identify	O	O
racial	O	O
origin	O	O
,	O	O
based	O	O
on	O	O
mitochondrial	O	O
DNA	O	O
(	O	O
mtDNA	O	O
)	O	O
lineages	O	O
.	O	O

Three	O	O
novel	O	O
missense	O	O
mutations	O	O
never	O	O
identified	O	O
previously	O	O
in	O	O
other	O	O
populations	O	O
and	O	O
found	O	O
in	O	O
16	O	O
out	O	O
of	O	O
19	O	O
Colombian	O	O
MPS	B-Disease	OMIM:253000
IVA	I-Disease	OMIM:253000
unrelated	O	O
alleles	O	O
account	O	O
for	O	O
84	O	O
.	O	O

2	O	O
%	O	O
of	O	O
the	O	O
alleles	O	O
in	O	O
this	O	O
study	O	O
.	O	O

The	O	O
G301C	O	O
and	O	O
S162F	O	O
mutations	O	O
account	O	O
for	O	O
68	O	O
.	O	O

4	O	O
%	O	O
and	O	O
10	O	O
.	O	O

5	O	O
%	O	O
of	O	O
mutations	O	O
,	O	O
respectively	O	O
,	O	O
whereas	O	O
the	O	O
remaining	O	O
F69V	O	O
is	O	O
limited	O	O
to	O	O
a	O	O
single	O	O
allele	O	O
.	O	O

The	O	O
skewed	O	O
prevalence	O	O
of	O	O
G301C	O	O
in	O	O
only	O	O
Colombian	O	O
patients	O	O
and	O	O
haplotype	O	O
analysis	O	O
by	O	O
restriction	O	O
fragment	O	O
length	O	O
polymorphisms	O	O
in	O	O
the	O	O
GALNS	O	O
gene	O	O
suggest	O	O
that	O	O
G301C	O	O
originated	O	O
from	O	O
a	O	O
common	O	O
ancestor	O	O
.	O	O

Investigation	O	O
of	O	O
the	O	O
genetic	O	O
background	O	O
by	O	O
means	O	O
of	O	O
mtDNA	O	O
lineages	O	O
indicate	O	O
that	O	O
all	O	O
our	O	O
patients	O	O
are	O	O
probably	O	O
of	O	O
native	O	O
American	O	O
descent	O	O
W474C	O	O
amino	O	O
acid	O	O
substitution	O	O
affects	O	O
early	O	O
processing	O	O
of	O	O
the	O	O
alpha	O	O
-	O	O
subunit	O	O
of	O	O
beta	O	O
-	O	O
hexosaminidase	O	O
A	O	O
and	O	O
is	O	O
associated	O	O
with	O	O
subacute	O	O
G	B-Disease	D020143
(	I-Disease	D020143
M2	I-Disease	D020143
)	I-Disease	D020143
gangliosidosis	I-Disease	D020143
.	O	O

Mutations	O	O
in	O	O
the	O	O
HEXA	O	O
gene	O	O
,	O	O
encoding	O	O
the	O	O
alpha	O	O
-	O	O
subunit	O	O
of	O	O
beta	O	O
-	O	O
hexosaminidase	O	O
A	O	O
(	O	O
Hex	O	O
A	O	O
)	O	O
,	O	O
that	O	O
abolish	O	O
Hex	O	O
A	O	O
enzyme	O	O
activity	O	O
cause	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
(	O	O
TSD	B-Disease	D013661
)	O	O
,	O	O
the	O	O
fatal	O	O
infantile	B-Disease	D020143
form	I-Disease	D020143
of	I-Disease	D020143
G	I-Disease	D020143
(	I-Disease	D020143
M2	I-Disease	D020143
)	I-Disease	D020143
gangliosidosis	I-Disease	D020143
,	I-Disease	D020143
Type	I-Disease	D020143
1	I-Disease	D020143
.	O	O

Less	O	O
severe	O	O
,	O	O
subacute	O	O
(	O	O
juvenile	O	O
-	O	O
onset	O	O
)	O	O
and	O	O
chronic	O	O
(	O	O
adult	O	O
-	O	O
onset	O	O
)	O	O
variants	O	O
are	O	O
characterized	O	O
by	O	O
a	O	O
broad	O	O
spectrum	O	O
of	O	O
clinical	O	O
manifestations	O	O
and	O	O
are	O	O
associated	O	O
with	O	O
residual	O	O
levels	O	O
of	O	O
Hex	O	O
A	O	O
enzyme	O	O
activity	O	O
.	O	O

We	O	O
identified	O	O
a	O	O
1422	O	O
G	O	O
-	O	O
-	O	O
>	O	O
C	O	O
(	O	O
amino	O	O
acid	O	O
W474C	O	O
)	O	O
substitution	O	O
in	O	O
the	O	O
first	O	O
position	O	O
of	O	O
exon	O	O
13	O	O
of	O	O
HEXA	O	O
of	O	O
a	O	O
non	O	O
-	O	O
Jewish	O	O
proband	O	O
who	O	O
manifested	O	O
a	O	O
subacute	O	O
variant	O	O
of	O	O
G	B-Disease	D020143
(	I-Disease	D020143
M2	I-Disease	D020143
)	I-Disease	D020143
gangliosidosis	I-Disease	D020143
.	O	O

On	O	O
the	O	O
second	O	O
maternally	O	O
inherited	O	O
allele	O	O
,	O	O
we	O	O
identified	O	O
the	O	O
common	O	O
infantile	O	O
disease	O	O
-	O	O
causing	O	O
4	O	O
-	O	O
bp	O	O
insertion	O	O
,	O	O
+	O	O
TATC	O	O
1278	O	O
,	O	O
in	O	O
exon	O	O
11	O	O
.	O	O

Pulse	O	O
-	O	O
chase	O	O
analysis	O	O
using	O	O
proband	O	O
fibroblasts	O	O
revealed	O	O
that	O	O
the	O	O
W474C	O	O
-	O	O
containing	O	O
alpha	O	O
-	O	O
subunit	O	O
precursor	O	O
was	O	O
normally	O	O
synthesized	O	O
,	O	O
but	O	O
not	O	O
phosphorylated	O	O
or	O	O
secreted	O	O
,	O	O
and	O	O
the	O	O
mature	O	O
lysosomal	O	O
alpha	O	O
-	O	O
subunit	O	O
was	O	O
not	O	O
detected	O	O
.	O	O

When	O	O
the	O	O
W474C	O	O
-	O	O
containing	O	O
alpha	O	O
-	O	O
subunit	O	O
was	O	O
transiently	O	O
co	O	O
-	O	O
expressed	O	O
with	O	O
the	O	O
beta	O	O
-	O	O
subunit	O	O
to	O	O
produce	O	O
Hex	O	O
A	O	O
(	O	O
alphabeta	O	O
)	O	O
in	O	O
COS	O	O
-	O	O
7	O	O
cells	O	O
,	O	O
the	O	O
mature	O	O
alpha	O	O
-	O	O
subunit	O	O
was	O	O
present	O	O
,	O	O
but	O	O
its	O	O
level	O	O
was	O	O
much	O	O
lower	O	O
than	O	O
that	O	O
from	O	O
normal	O	O
alpha	O	O
-	O	O
subunit	O	O
transfections	O	O
,	O	O
although	O	O
higher	O	O
than	O	O
in	O	O
those	O	O
cells	O	O
transfected	O	O
with	O	O
an	O	O
alpha	O	O
-	O	O
subunit	O	O
associated	O	O
with	O	O
infantile	O	O
TSD	B-Disease	D013661
.	O	O

Furthermore	O	O
,	O	O
the	O	O
precursor	O	O
level	O	O
of	O	O
the	O	O
W474C	O	O
alpha	O	O
-	O	O
subunit	O	O
was	O	O
found	O	O
to	O	O
accumulate	O	O
in	O	O
comparison	O	O
to	O	O
the	O	O
normal	O	O
alpha	O	O
-	O	O
subunit	O	O
precursor	O	O
levels	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
the	O	O
1422	O	O
G	O	O
-	O	O
-	O	O
>	O	O
C	O	O
mutation	O	O
is	O	O
the	O	O
cause	O	O
of	O	O
Hex	B-Disease	D013661
A	I-Disease	D013661
enzyme	I-Disease	D013661
deficiency	I-Disease	D013661
in	O	O
the	O	O
proband	O	O
.	O	O

The	O	O
resulting	O	O
W474C	O	O
substitution	O	O
clearly	O	O
interferes	O	O
with	O	O
alpha	O	O
-	O	O
subunit	O	O
processing	O	O
,	O	O
but	O	O
because	O	O
the	O	O
base	O	O
substitution	O	O
falls	O	O
at	O	O
the	O	O
first	O	O
position	O	O
of	O	O
exon	O	O
13	O	O
,	O	O
aberrant	O	O
splicing	O	O
may	O	O
also	O	O
contribute	O	O
to	O	O
Hex	B-Disease	D013661
A	I-Disease	D013661
deficiency	I-Disease	D013661
in	O	O
this	O	O
proband	O	O
.	O	O

.	O	O

Myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
protein	O	O
kinase	O	O
is	O	O
involved	O	O
in	O	O
the	O	O
modulation	O	O
of	O	O
the	O	O
Ca2	O	O
+	O	O
homeostasis	O	O
in	O	O
skeletal	O	O
muscle	O	O
cells	O	O
.	O	O

Myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
,	O	O
the	O	O
most	O	O
prevalent	O	O
muscular	B-Disease	D009135
disorder	I-Disease	D009135
in	O	O
adults	O	O
,	O	O
is	O	O
caused	O	O
by	O	O
(	O	O
CTG	O	O
)	O	O
n	O	O
-	O	O
repeat	O	O
expansion	O	O
in	O	O
a	O	O
gene	O	O
encoding	O	O
a	O	O
protein	O	O
kinase	O	O
(	O	O
DM	B-Disease	D009223
protein	O	O
kinase	O	O
;	O	O
DMPK	O	O
)	O	O
and	O	O
involves	O	O
changes	O	O
in	O	O
cytoarchitecture	O	O
and	O	O
ion	O	O
homeostasis	O	O
.	O	O

To	O	O
obtain	O	O
clues	O	O
to	O	O
the	O	O
normal	O	O
biological	O	O
role	O	O
of	O	O
DMPK	O	O
in	O	O
cellular	O	O
ion	O	O
homeostasis	O	O
,	O	O
we	O	O
have	O	O
compared	O	O
the	O	O
resting	O	O
[	O	O
Ca2	O	O
+	O	O
]	O	O
i	O	O
,	O	O
the	O	O
amplitude	O	O
and	O	O
shape	O	O
of	O	O
depolarization	O	O
-	O	O
induced	O	O
Ca2	O	O
+	O	O
transients	O	O
,	O	O
and	O	O
the	O	O
content	O	O
of	O	O
ATP	O	O
-	O	O
driven	O	O
ion	O	O
pumps	O	O
in	O	O
cultured	O	O
skeletal	O	O
muscle	O	O
cells	O	O
of	O	O
wild	O	O
-	O	O
type	O	O
and	O	O
DMPK	O	O
[	O	O
-	O	O
/	O	O
-	O	O
]	O	O
knockout	O	O
mice	O	O
.	O	O

In	O	O
vitro	O	O
-	O	O
differentiated	O	O
DMPK	O	O
[	O	O
-	O	O
/	O	O
-	O	O
]	O	O
myotubes	O	O
exhibit	O	O
a	O	O
higher	O	O
resting	O	O
[	O	O
Ca2	O	O
+	O	O
]	O	O
i	O	O
than	O	O
do	O	O
wild	O	O
-	O	O
type	O	O
myotubes	O	O
because	O	O
of	O	O
an	O	O
altered	O	O
open	O	O
probability	O	O
of	O	O
voltage	O	O
-	O	O
dependent	O	O
l	O	O
-	O	O
type	O	O
Ca2	O	O
+	O	O
and	O	O
Na	O	O
+	O	O
channels	O	O
.	O	O

The	O	O
mutant	O	O
myotubes	O	O
exhibit	O	O
smaller	O	O
and	O	O
slower	O	O
Ca2	O	O
+	O	O
responses	O	O
upon	O	O
triggering	O	O
by	O	O
acetylcholine	O	O
or	O	O
high	O	O
external	O	O
K	O	O
+	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
observed	O	O
that	O	O
these	O	O
Ca2	O	O
+	O	O
transients	O	O
partially	O	O
result	O	O
from	O	O
an	O	O
influx	O	O
of	O	O
extracellular	O	O
Ca2	O	O
+	O	O
through	O	O
the	O	O
l	O	O
-	O	O
type	O	O
Ca2	O	O
+	O	O
channel	O	O
.	O	O

Neither	O	O
the	O	O
content	O	O
nor	O	O
the	O	O
activity	O	O
of	O	O
Na	O	O
+	O	O
/	O	O
K	O	O
+	O	O
ATPase	O	O
and	O	O
sarcoplasmic	O	O
reticulum	O	O
Ca2	O	O
+	O	O
-	O	O
ATPase	O	O
are	O	O
affected	O	O
by	O	O
DMPK	O	O
absence	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
our	O	O
data	O	O
suggest	O	O
that	O	O
DMPK	O	O
is	O	O
involved	O	O
in	O	O
modulating	O	O
the	O	O
initial	O	O
events	O	O
of	O	O
excitation	O	O
-	O	O
contraction	O	O
coupling	O	O
in	O	O
skeletal	O	O
muscle	O	O
.	O	O

.	O	O

Insertional	O	O
mutation	O	O
by	O	O
transposable	O	O
element	O	O
,	O	O
L1	O	O
,	O	O
in	O	O
the	O	O
DMD	B-Disease	D020388
gene	O	O
results	O	O
in	O	O
X	B-Disease	D002311
-	I-Disease	D002311
linked	I-Disease	D002311
dilated	I-Disease	D002311
cardiomyopathy	I-Disease	D002311
.	O	O

X	B-Disease	D002311
-	I-Disease	D002311
linked	I-Disease	D002311
dilated	I-Disease	D002311
cardiomyopathy	I-Disease	D002311
(	O	O
XLDCM	B-Disease	D002311
)	O	O
is	O	O
a	O	O
clinical	O	O
phenotype	O	O
of	O	O
dystrophinopathy	B-Disease	D009136
which	O	O
is	O	O
characterized	O	O
by	O	O
preferential	O	O
myocardial	B-Disease	D009202
involvement	I-Disease	D009202
without	O	O
any	O	O
overt	O	O
clinical	O	O
signs	O	O
of	O	O
skeletal	B-Disease	D009135
myopathy	I-Disease	D009135
.	O	O

To	O	O
date	O	O
,	O	O
several	O	O
mutations	O	O
in	O	O
the	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
gene	O	O
,	O	O
DMD	B-Disease	D020388
,	O	O
have	O	O
been	O	O
identified	O	O
in	O	O
patients	O	O
with	O	O
XLDCM	B-Disease	D002311
,	O	O
but	O	O
a	O	O
pathogenic	O	O
correlation	O	O
of	O	O
these	O	O
cardiospecific	O	O
mutations	O	O
in	O	O
DMD	B-Disease	D020388
with	O	O
the	O	O
XLDCM	B-Disease	D002311
phenotype	O	O
has	O	O
remained	O	O
to	O	O
be	O	O
elucidated	O	O
.	O	O

We	O	O
report	O	O
here	O	O
the	O	O
identification	O	O
of	O	O
a	O	O
unique	O	O
de	O	O
novo	O	O
L1	O	O
insertion	O	O
in	O	O
the	O	O
muscle	O	O
exon	O	O
1	O	O
in	O	O
DMD	B-Disease	D020388
in	O	O
three	O	O
XLDCM	B-Disease	D002311
patients	O	O
from	O	O
two	O	O
unrelated	O	O
Japanese	O	O
families	O	O
.	O	O

The	O	O
insertion	O	O
was	O	O
a	O	O
5	O	O
-	O	O
truncated	O	O
form	O	O
of	O	O
human	O	O
L1	O	O
inversely	O	O
integrated	O	O
in	O	O
the	O	O
5	O	O
-	O	O
untranslated	O	O
region	O	O
in	O	O
the	O	O
muscle	O	O
exon	O	O
1	O	O
,	O	O
which	O	O
affected	O	O
the	O	O
transcription	O	O
or	O	O
the	O	O
stability	O	O
of	O	O
the	O	O
muscle	O	O
form	O	O
of	O	O
dystrophin	O	O
transcripts	O	O
but	O	O
not	O	O
that	O	O
of	O	O
the	O	O
brain	O	O
or	O	O
Purkinje	O	O
cell	O	O
form	O	O
,	O	O
probably	O	O
due	O	O
to	O	O
its	O	O
unique	O	O
site	O	O
of	O	O
integration	O	O
.	O	O

We	O	O
speculate	O	O
that	O	O
this	O	O
insertion	O	O
of	O	O
an	O	O
L1	O	O
sequence	O	O
in	O	O
DMD	B-Disease	D020388
is	O	O
responsible	O	O
for	O	O
some	O	O
of	O	O
the	O	O
population	O	O
of	O	O
Japanese	O	O
patients	O	O
with	O	O
XLDCM	B-Disease	D002311
.	O	O

.	O	O

Genetic	O	O
heterogeneity	O	O
of	O	O
Saethre	B-Disease	OMIM:101400
-	I-Disease	OMIM:101400
Chotzen	I-Disease	OMIM:101400
syndrome	I-Disease	OMIM:101400
,	O	O
due	O	O
to	O	O
TWIST	O	O
and	O	O
FGFR	O	O
mutations	O	O
.	O	O

Thirty	O	O
-	O	O
two	O	O
unrelated	O	O
patients	O	O
with	O	O
features	O	O
of	O	O
Saethre	B-Disease	OMIM:101400
-	I-Disease	OMIM:101400
Chotzen	I-Disease	OMIM:101400
syndrome	I-Disease	OMIM:101400
,	O	O
a	O	O
common	O	O
autosomal	B-Disease	D030342
dominant	I-Disease	D030342
condition	I-Disease	D030342
of	O	O
craniosynostosis	B-Disease	D003398
and	O	O
limb	B-Disease	D017880
anomalies	I-Disease	D017880
,	O	O
were	O	O
screened	O	O
for	O	O
mutations	O	O
in	O	O
TWIST	O	O
,	O	O
FGFR2	O	O
,	O	O
and	O	O
FGFR3	O	O
.	O	O

Nine	O	O
novel	O	O
and	O	O
three	O	O
recurrent	O	O
TWIST	O	O
mutations	O	O
were	O	O
found	O	O
in	O	O
12	O	O
families	O	O
.	O	O

Seven	O	O
families	O	O
were	O	O
found	O	O
to	O	O
have	O	O
the	O	O
FGFR3	O	O
P250R	O	O
mutation	O	O
,	O	O
and	O	O
one	O	O
individual	O	O
was	O	O
found	O	O
to	O	O
have	O	O
an	O	O
FGFR2	O	O
VV269	O	O
-	O	O
270	O	O
deletion	O	O
.	O	O

To	O	O
date	O	O
,	O	O
our	O	O
detection	O	O
rate	O	O
for	O	O
TWIST	O	O
or	O	O
FGFR	O	O
mutations	O	O
is	O	O
68	O	O
%	O	O
in	O	O
our	O	O
Saethre	B-Disease	OMIM:101400
-	I-Disease	OMIM:101400
Chotzen	I-Disease	OMIM:101400
syndrome	I-Disease	OMIM:101400
patients	O	O
,	O	O
including	O	O
our	O	O
five	O	O
patients	O	O
elsewhere	O	O
reported	O	O
with	O	O
TWIST	O	O
mutations	O	O
.	O	O

More	O	O
than	O	O
35	O	O
different	O	O
TWIST	O	O
mutations	O	O
are	O	O
now	O	O
known	O	O
in	O	O
the	O	O
literature	O	O
.	O	O

The	O	O
most	O	O
common	O	O
phenotypic	O	O
features	O	O
,	O	O
present	O	O
in	O	O
more	O	O
than	O	O
a	O	O
third	O	O
of	O	O
our	O	O
patients	O	O
with	O	O
TWIST	O	O
mutations	O	O
,	O	O
are	O	O
coronal	B-Disease	D003398
synostosis	I-Disease	D003398
,	O	O
brachycephaly	B-Disease	D003398
,	O	O
low	B-Disease	D019465
frontal	I-Disease	D019465
hairline	I-Disease	D019465
,	O	O
facial	B-Disease	D005146
asymmetry	I-Disease	D005146
,	O	O
ptosis	B-Disease	D001763
,	O	O
hypertelorism	B-Disease	D006972
,	O	O
broad	B-Disease	D005532
great	I-Disease	D005532
toes	I-Disease	D005532
,	O	O
and	O	O
clinodactyly	B-Disease	C536852
.	O	O

Significant	O	O
intra	O	O
-	O	O
and	O	O
interfamilial	O	O
phenotypic	O	O
variability	O	O
is	O	O
present	O	O
for	O	O
either	O	O
TWIST	O	O
mutations	O	O
or	O	O
FGFR	O	O
mutations	O	O
.	O	O

The	O	O
overlap	O	O
in	O	O
clinical	O	O
features	O	O
and	O	O
the	O	O
presence	O	O
,	O	O
in	O	O
the	O	O
same	O	O
genes	O	O
,	O	O
of	O	O
mutations	O	O
for	O	O
more	O	O
than	O	O
one	O	O
craniosynostotic	B-Disease	D003398
condition	I-Disease	D003398
-	O	O
such	O	O
as	O	O
Saethre	B-Disease	OMIM:101400
-	I-Disease	OMIM:101400
Chotzen	I-Disease	OMIM:101400
,	I-Disease	OMIM:101400
Crouzon	I-Disease	OMIM:101400
,	I-Disease	OMIM:101400
and	I-Disease	OMIM:101400
Pfeiffer	I-Disease	OMIM:101400
syndromes	I-Disease	OMIM:101400
-	O	O
support	O	O
the	O	O
hypothesis	O	O
that	O	O
TWIST	O	O
and	O	O
FGFRs	O	O
are	O	O
components	O	O
of	O	O
the	O	O
same	O	O
molecular	O	O
pathway	O	O
involved	O	O
in	O	O
the	O	O
modulation	O	O
of	O	O
craniofacial	O	O
and	O	O
limb	O	O
development	O	O
in	O	O
humans	O	O
.	O	O

.	O	O

Frequent	O	O
inactivation	O	O
of	O	O
PTEN	O	O
/	O	O
MMAC1	O	O
in	O	O
primary	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
.	O	O

Sporadic	B-Disease	D011471
prostate	I-Disease	D011471
carcinoma	I-Disease	D011471
is	O	O
the	O	O
most	O	O
common	O	O
male	B-Disease	D005834
cancer	I-Disease	D005834
in	O	O
the	O	O
Western	O	O
world	O	O
,	O	O
yet	O	O
many	O	O
of	O	O
the	O	O
major	O	O
genetic	O	O
events	O	O
involved	O	O
in	O	O
the	O	O
progression	O	O
of	O	O
this	O	O
often	O	O
fatal	O	O
cancer	B-Disease	D009369
remain	O	O
to	O	O
be	O	O
elucidated	O	O
.	O	O

Numerous	O	O
cytogenetic	O	O
and	O	O
allelotype	O	O
studies	O	O
have	O	O
reported	O	O
frequent	O	O
loss	O	O
of	O	O
heterozygosity	O	O
on	O	O
chromosomal	O	O
arm	O	O
10q	O	O
in	O	O
sporadic	B-Disease	D011471
prostate	I-Disease	D011471
cancer	I-Disease	D011471
.	O	O

Deletion	O	O
mapping	O	O
studies	O	O
have	O	O
unambiguously	O	O
identified	O	O
a	O	O
region	O	O
of	O	O
chromosome	O	O
10q23	O	O
to	O	O
be	O	O
the	O	O
minimal	O	O
area	O	O
of	O	O
loss	O	O
.	O	O

A	O	O
new	O	O
tumor	B-Disease	D009369
suppressor	O	O
gene	O	O
,	O	O
PTEN	O	O
/	O	O
MMAC1	O	O
,	O	O
was	O	O
isolated	O	O
recently	O	O
at	O	O
this	O	O
region	O	O
of	O	O
chromosome	O	O
10q23	O	O
and	O	O
found	O	O
to	O	O
be	O	O
inactivated	O	O
by	O	O
mutation	O	O
in	O	O
three	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
cell	O	O
lines	O	O
.	O	O

We	O	O
screened	O	O
80	O	O
prostate	B-Disease	D011471
tumors	I-Disease	D011471
by	O	O
microsatellite	O	O
analysis	O	O
and	O	O
found	O	O
chromosome	O	O
10q23	O	O
to	O	O
be	O	O
deleted	O	O
in	O	O
23	O	O
cases	O	O
.	O	O

We	O	O
then	O	O
proceeded	O	O
with	O	O
sequence	O	O
analysis	O	O
of	O	O
the	O	O
entire	O	O
PTEN	O	O
/	O	O
MMAC1	O	O
coding	O	O
region	O	O
and	O	O
tested	O	O
for	O	O
homozygous	O	O
deletion	O	O
with	O	O
new	O	O
intragenic	O	O
markers	O	O
in	O	O
these	O	O
23	O	O
cases	O	O
with	O	O
10q23	O	O
loss	O	O
of	O	O
heterozygosity	O	O
.	O	O

The	O	O
identification	O	O
of	O	O
the	O	O
second	O	O
mutational	O	O
event	O	O
in	O	O
10	O	O
(	O	O
43	O	O
%	O	O
)	O	O
tumors	B-Disease	D009369
establishes	O	O
PTEN	O	O
/	O	O
MMAC1	O	O
as	O	O
a	O	O
main	O	O
inactivation	O	O
target	O	O
of	O	O
10q	O	O
loss	O	O
in	O	O
sporadic	B-Disease	D011471
prostate	I-Disease	D011471
cancer	I-Disease	D011471
.	O	O

.	O	O

Molecular	O	O
heterogeneity	O	O
in	O	O
mucopolysaccharidosis	B-Disease	OMIM:253000
IVA	I-Disease	OMIM:253000
in	O	O
Australia	O	O
and	O	O
Northern	O	O
Ireland	O	O
:	O	O
nine	O	O
novel	O	O
mutations	O	O
including	O	O
T312S	O	O
,	O	O
a	O	O
common	O	O
allele	O	O
that	O	O
confers	O	O
a	O	O
mild	O	O
phenotype	O	O
.	O	O

Mucopolysaccharidosis	B-Disease	OMIM:253000
IVA	I-Disease	OMIM:253000
(	O	O
MPS	B-Disease	OMIM:253000
IVA	I-Disease	OMIM:253000
)	O	O
is	O	O
an	O	O
autosomal	B-Disease	D016464
recessive	I-Disease	D016464
lysosomal	I-Disease	D016464
storage	I-Disease	D016464
disorder	I-Disease	D016464
caused	O	O
by	O	O
a	O	O
genetic	B-Disease	D030342
defect	I-Disease	D030342
in	O	O
N	O	O
-	O	O
acetylgalactosamine	O	O
-	O	O
6	O	O
-	O	O
sulfate	O	O
sulfatase	O	O
(	O	O
GALNS	O	O
)	O	O
.	O	O

Previous	O	O
studies	O	O
of	O	O
patients	O	O
from	O	O
a	O	O
British	O	O
-	O	O
Irish	O	O
population	O	O
showed	O	O
that	O	O
the	O	O
I113F	O	O
mutation	O	O
is	O	O
the	O	O
most	O	O
common	O	O
single	O	O
mutation	O	O
among	O	O
MPS	B-Disease	OMIM:253000
IVA	I-Disease	OMIM:253000
patients	O	O
and	O	O
produces	O	O
a	O	O
severe	O	O
clinical	O	O
phenotype	O	O
.	O	O

We	O	O
studied	O	O
mutations	O	O
in	O	O
the	O	O
GALNS	O	O
gene	O	O
from	O	O
23	O	O
additional	O	O
MPS	B-Disease	OMIM:253000
IVA	I-Disease	OMIM:253000
patients	O	O
(	O	O
15	O	O
from	O	O
Australia	O	O
,	O	O
8	O	O
from	O	O
Northern	O	O
Ireland	O	O
)	O	O
,	O	O
with	O	O
various	O	O
clinical	O	O
phenotypes	O	O
(	O	O
severe	O	O
,	O	O
16	O	O
cases	O	O
;	O	O
intermediate	O	O
,	O	O
4	O	O
cases	O	O
;	O	O
mild	O	O
,	O	O
3	O	O
cases	O	O
)	O	O
.	O	O

We	O	O
found	O	O
two	O	O
common	O	O
mutations	O	O
that	O	O
together	O	O
accounted	O	O
for	O	O
32	O	O
%	O	O
of	O	O
the	O	O
44	O	O
unrelated	O	O
alleles	O	O
in	O	O
these	O	O
patients	O	O
.	O	O

One	O	O
is	O	O
the	O	O
T312S	O	O
mutation	O	O
,	O	O
a	O	O
novel	O	O
mutation	O	O
found	O	O
exclusively	O	O
in	O	O
milder	O	O
patients	O	O
.	O	O

The	O	O
other	O	O
is	O	O
the	O	O
previously	O	O
described	O	O
I113F	O	O
that	O	O
produces	O	O
a	O	O
severe	O	O
phenotype	O	O
.	O	O

The	O	O
I113F	O	O
and	O	O
T312S	O	O
mutations	O	O
accounted	O	O
for	O	O
8	O	O
(	O	O
18	O	O
%	O	O
)	O	O
and	O	O
6	O	O
(	O	O
14	O	O
%	O	O
)	O	O
of	O	O
44	O	O
unrelated	O	O
alleles	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
relatively	O	O
high	O	O
residual	O	O
GALNS	O	O
activity	O	O
seen	O	O
when	O	O
the	O	O
T312S	O	O
mutant	O	O
cDNA	O	O
is	O	O
overexpressed	O	O
in	O	O
mutant	O	O
cells	O	O
provides	O	O
an	O	O
explanation	O	O
for	O	O
the	O	O
mild	O	O
phenotype	O	O
in	O	O
patients	O	O
with	O	O
this	O	O
mutation	O	O
.	O	O

The	O	O
distribution	O	O
and	O	O
relative	O	O
frequencies	O	O
of	O	O
the	O	O
I113F	O	O
and	O	O
T312S	O	O
mutations	O	O
in	O	O
Australia	O	O
corresponded	O	O
to	O	O
those	O	O
observed	O	O
in	O	O
Northern	O	O
Ireland	O	O
and	O	O
are	O	O
unique	O	O
to	O	O
these	O	O
two	O	O
populations	O	O
,	O	O
suggesting	O	O
that	O	O
both	O	O
mutations	O	O
were	O	O
probably	O	O
introduced	O	O
to	O	O
Australia	O	O
by	O	O
Irish	O	O
migrants	O	O
during	O	O
the	O	O
19th	O	O
century	O	O
.	O	O

Haplotype	O	O
analysis	O	O
using	O	O
6	O	O
RFLPs	O	O
provides	O	O
additional	O	O
data	O	O
that	O	O
the	O	O
I113F	O	O
mutation	O	O
originated	O	O
from	O	O
a	O	O
common	O	O
ancestor	O	O
.	O	O

The	O	O
other	O	O
9	O	O
novel	O	O
mutations	O	O
identified	O	O
in	O	O
these	O	O
23	O	O
patients	O	O
were	O	O
each	O	O
limited	O	O
to	O	O
a	O	O
single	O	O
family	O	O
.	O	O

These	O	O
data	O	O
provide	O	O
further	O	O
evidence	O	O
for	O	O
extensive	O	O
allelic	O	O
heterogeneity	O	O
in	O	O
MPS	B-Disease	OMIM:253000
IVA	I-Disease	OMIM:253000
in	O	O
British	O	O
-	O	O
Irish	O	O
patients	O	O
and	O	O
provide	O	O
evidence	O	O
for	O	O
their	O	O
transmission	O	O
to	O	O
Australia	O	O
by	O	O
British	O	O
-	O	O
Irish	O	O
migrants	O	O
.	O	O

.	O	O

Further	O	O
evidence	O	O
for	O	O
a	O	O
major	O	O
ancient	O	O
mutation	O	O
underlying	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
from	O	O
linkage	O	O
disequilibrium	O	O
studies	O	O
in	O	O
the	O	O
Japanese	O	O
population	O	O
.	O	O

The	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
mutation	O	O
is	O	O
an	O	O
unstable	O	O
(	O	O
CTG	O	O
)	O	O
n	O	O
repeat	O	O
,	O	O
present	O	O
at	O	O
a	O	O
copy	O	O
number	O	O
of	O	O
5	O	O
-	O	O
37	O	O
repeats	O	O
on	O	O
normal	O	O
chromosomes	O	O
but	O	O
amplified	O	O
to	O	O
50	O	O
-	O	O
3000	O	O
copies	O	O
on	O	O
DM	B-Disease	D009223
chromosomes	O	O
.	O	O

Previous	O	O
findings	O	O
in	O	O
Caucasian	O	O
populations	O	O
of	O	O
a	O	O
DM	B-Disease	D009223
founder	O	O
chromosome	O	O
raise	O	O
a	O	O
question	O	O
about	O	O
the	O	O
molecular	O	O
events	O	O
involved	O	O
in	O	O
the	O	O
expansion	O	O
mutation	O	O
.	O	O

To	O	O
investigate	O	O
whether	O	O
a	O	O
founder	O	O
chromosome	O	O
for	O	O
the	O	O
DM	B-Disease	D009223
mutation	O	O
exists	O	O
in	O	O
the	O	O
Japanese	O	O
population	O	O
,	O	O
we	O	O
genotyped	O	O
families	O	O
using	O	O
polymorphic	O	O
markers	O	O
near	O	O
the	O	O
(	O	O
CTG	O	O
)	O	O
n	O	O
repeat	O	O
region	O	O
and	O	O
constructed	O	O
haplotypes	O	O
.	O	O

Six	O	O
different	O	O
haplotypes	O	O
were	O	O
found	O	O
and	O	O
DM	B-Disease	D009223
alleles	O	O
were	O	O
always	O	O
haplotype	O	O
A	O	O
.	O	O

To	O	O
find	O	O
an	O	O
origin	O	O
of	O	O
the	O	O
(	O	O
CTG	O	O
)	O	O
n	O	O
repeat	O	O
mutation	O	O
and	O	O
to	O	O
investigate	O	O
the	O	O
mechanism	O	O
of	O	O
the	O	O
expansion	O	O
mutation	O	O
in	O	O
the	O	O
Japanese	O	O
population	O	O
we	O	O
have	O	O
studied	O	O
90	O	O
Japanese	O	O
DM	B-Disease	D009223
families	O	O
comprising	O	O
190	O	O
affected	O	O
and	O	O
130	O	O
unaffected	O	O
members	O	O
.	O	O

The	O	O
results	O	O
suggest	O	O
that	O	O
a	O	O
few	O	O
common	O	O
ancestral	O	O
mutations	O	O
in	O	O
both	O	O
Caucasian	O	O
and	O	O
Japanese	O	O
populations	O	O
have	O	O
originated	O	O
by	O	O
expansion	O	O
of	O	O
an	O	O
ancestral	O	O
n	O	O
=	O	O
5	O	O
repeat	O	O
to	O	O
n	O	O
=	O	O
19	O	O
-	O	O
37	O	O
copies	O	O
.	O	O

These	O	O
data	O	O
support	O	O
multistep	O	O
models	O	O
of	O	O
triplet	O	O
repeat	O	O
expansion	O	O
that	O	O
have	O	O
been	O	O
proposed	O	O
for	O	O
both	O	O
DM	B-Disease	D009223
and	O	O
Friedreichs	B-Disease	D005621
ataxia	I-Disease	D005621
.	O	O

.	O	O

Prevalence	O	O
of	O	O
p16	O	O
and	O	O
CDK4	O	O
germline	O	O
mutations	O	O
in	O	O
48	O	O
melanoma	B-Disease	D008545
-	O	O
prone	O	O
families	O	O
in	O	O
France	O	O
.	O	O

The	O	O
French	O	O
Familial	B-Disease	D008545
Melanoma	I-Disease	D008545
Study	O	O
Group	O	O
.	O	O

Germline	O	O
mutations	O	O
in	O	O
the	O	O
p16	O	O
and	O	O
CDK4	O	O
genes	O	O
have	O	O
been	O	O
reported	O	O
in	O	O
a	O	O
subset	O	O
of	O	O
melanoma	B-Disease	D008545
pedigrees	O	O
,	O	O
but	O	O
their	O	O
prevalence	O	O
is	O	O
not	O	O
well	O	O
known	O	O
.	O	O

We	O	O
searched	O	O
for	O	O
such	O	O
germline	O	O
mutations	O	O
in	O	O
48	O	O
French	O	O
melanoma	B-Disease	D008545
-	O	O
prone	O	O
families	O	O
selected	O	O
according	O	O
to	O	O
two	O	O
major	O	O
criteria	O	O
families	O	O
with	O	O
at	O	O
least	O	O
three	O	O
affected	O	O
members	O	O
(	O	O
n	O	O
=	O	O
20	O	O
)	O	O
or	O	O
families	O	O
with	O	O
two	O	O
affected	O	O
members	O	O
,	O	O
one	O	O
of	O	O
them	O	O
affected	O	O
before	O	O
the	O	O
age	O	O
of	O	O
50	O	O
(	O	O
n	O	O
=	O	O
28	O	O
)	O	O
,	O	O
and	O	O
one	O	O
additional	O	O
minor	O	O
criterion	O	O
.	O	O

Sixteen	O	O
different	O	O
p16	O	O
germline	O	O
mutations	O	O
were	O	O
found	O	O
in	O	O
21	O	O
families	O	O
,	O	O
while	O	O
one	O	O
germline	O	O
mutation	O	O
,	O	O
Arg24His	O	O
,	O	O
was	O	O
detected	O	O
in	O	O
the	O	O
CDK4	O	O
gene	O	O
.	O	O

The	O	O
frequency	O	O
of	O	O
p16	O	O
gene	O	O
mutation	O	O
in	O	O
our	O	O
sample	O	O
(	O	O
44	O	O
%	O	O
)	O	O
is	O	O
among	O	O
the	O	O
highest	O	O
rates	O	O
yet	O	O
reported	O	O
and	O	O
the	O	O
CDK4	O	O
mutation	O	O
is	O	O
the	O	O
second	O	O
mutation	O	O
detected	O	O
in	O	O
this	O	O
gene	O	O
worldwide	O	O
.	O	O

In	O	O
summary	O	O
,	O	O
our	O	O
results	O	O
show	O	O
frequent	O	O
involvement	O	O
of	O	O
the	O	O
p16	O	O
gene	O	O
in	O	O
familial	B-Disease	D008545
melanoma	I-Disease	D008545
and	O	O
confirm	O	O
the	O	O
role	O	O
of	O	O
the	O	O
CDK4	O	O
gene	O	O
as	O	O
a	O	O
melanoma	B-Disease	D008545
-	O	O
predisposing	O	O
gene	O	O
.	O	O

.	O	O

Systematic	O	O
analysis	O	O
of	O	O
coproporphyrinogen	O	O
oxidase	O	O
gene	B-Disease	D030342
defects	I-Disease	D030342
in	O	O
hereditary	B-Disease	D046349
coproporphyria	I-Disease	D046349
and	O	O
mutation	O	O
update	O	O
.	O	O

Hereditary	B-Disease	D046349
coproporphyria	I-Disease	D046349
(	O	O
HC	B-Disease	D046349
)	O	O
is	O	O
an	O	O
acute	O	O
hepatic	B-Disease	D017094
porphyria	I-Disease	D017094
with	O	O
autosomal	O	O
dominant	O	O
inheritance	O	O
caused	O	O
by	O	O
deficient	B-Disease	D046349
activity	I-Disease	D046349
of	I-Disease	D046349
coproporphyrinogen	I-Disease	D046349
III	I-Disease	D046349
oxidase	I-Disease	D046349
(	O	O
CPO	O	O
)	O	O
.	O	O

Clinical	O	O
manifestations	O	O
of	O	O
the	O	O
disease	O	O
are	O	O
characterized	O	O
by	O	O
acute	O	O
attacks	O	O
of	O	O
neurological	B-Disease	D009422
dysfunction	I-Disease	D009422
often	O	O
precipitated	O	O
by	O	O
drugs	O	O
,	O	O
fasting	O	O
,	O	O
cyclical	O	O
hormonal	O	O
changes	O	O
,	O	O
or	O	O
infectious	B-Disease	D003141
diseases	I-Disease	D003141
.	O	O

Skin	O	O
photosensitivity	O	O
may	O	O
also	O	O
be	O	O
present	O	O
.	O	O

The	O	O
seven	O	O
exons	O	O
,	O	O
the	O	O
exon	O	O
/	O	O
intron	O	O
boundaries	O	O
and	O	O
part	O	O
of	O	O
3	O	O
noncoding	O	O
sequence	O	O
of	O	O
the	O	O
CPO	O	O
gene	O	O
were	O	O
systematically	O	O
analyzed	O	O
by	O	O
an	O	O
exon	O	O
-	O	O
by	O	O
-	O	O
exon	O	O
denaturing	O	O
gradient	O	O
gel	O	O
electrophoresis	O	O
(	O	O
DGGE	O	O
)	O	O
strategy	O	O
followed	O	O
by	O	O
direct	O	O
sequencing	O	O
in	O	O
seven	O	O
unrelated	O	O
heterozygous	O	O
HC	B-Disease	D046349
patients	O	O
from	O	O
France	O	O
,	O	O
Holland	O	O
,	O	O
and	O	O
Czech	O	O
Republic	O	O
.	O	O

Seven	O	O
novel	O	O
mutations	O	O
and	O	O
two	O	O
new	O	O
polymorphisms	O	O
were	O	O
detected	O	O
.	O	O

Among	O	O
these	O	O
mutations	O	O
two	O	O
are	O	O
missense	O	O
(	O	O
G197W	O	O
,	O	O
W427R	O	O
)	O	O
,	O	O
two	O	O
are	O	O
nonsense	O	O
(	O	O
Q306X	O	O
,	O	O
Q385X	O	O
)	O	O
,	O	O
two	O	O
are	O	O
small	O	O
deletions	O	O
(	O	O
662de14bp	O	O
;	O	O
1168del3bp	O	O
removing	O	O
a	O	O
glycine	O	O
at	O	O
position	O	O
390	O	O
)	O	O
,	O	O
and	O	O
one	O	O
is	O	O
a	O	O
splicing	O	O
mutation	O	O
(	O	O
IVS1	O	O
-	O	O
15c	O	O
-	O	O
-	O	O
>	O	O
g	O	O
)	O	O
which	O	O
creates	O	O
a	O	O
new	O	O
acceptor	O	O
splice	O	O
site	O	O
.	O	O

The	O	O
pathological	O	O
significance	O	O
of	O	O
the	O	O
point	O	O
mutations	O	O
G197W	O	O
,	O	O
W427R	O	O
,	O	O
and	O	O
the	O	O
in	O	O
-	O	O
frame	O	O
deletion	O	O
390delGly	O	O
were	O	O
assessed	O	O
by	O	O
their	O	O
respective	O	O
expression	O	O
in	O	O
a	O	O
prokaryotic	O	O
system	O	O
using	O	O
site	O	O
-	O	O
directed	O	O
mutagenesis	O	O
.	O	O

These	O	O
mutations	O	O
resulted	O	O
in	O	O
the	O	O
absence	O	O
or	O	O
a	O	O
dramatic	O	O
decrease	O	O
of	O	O
CPO	O	O
activity	O	O
.	O	O

The	O	O
two	O	O
polymorphisms	O	O
were	O	O
localized	O	O
in	O	O
noncoding	O	O
part	O	O
of	O	O
the	O	O
gene	O	O
1	O	O
)	O	O
a	O	O
C	O	O
/	O	O
G	O	O
polymorphism	O	O
in	O	O
the	O	O
promotor	O	O
region	O	O
,	O	O
142	O	O
bp	O	O
upstream	O	O
from	O	O
the	O	O
transcriptional	O	O
initiation	O	O
site	O	O
(	O	O
-	O	O
142C	O	O
/	O	O
G	O	O
)	O	O
,	O	O
and	O	O
2	O	O
)	O	O
a	O	O
6	O	O
bp	O	O
deletion	O	O
polymorphism	O	O
in	O	O
the	O	O
3	O	O
noncoding	O	O
part	O	O
of	O	O
the	O	O
CPO	O	O
gene	O	O
,	O	O
574	O	O
bp	O	O
downstream	O	O
of	O	O
the	O	O
last	O	O
base	O	O
of	O	O
the	O	O
normal	O	O
termination	O	O
codon	O	O
(	O	O
+	O	O
574	O	O
delATTCTT	O	O
)	O	O
.	O	O

Five	O	O
intragenic	O	O
dimorphisms	O	O
are	O	O
now	O	O
well	O	O
characterized	O	O
and	O	O
the	O	O
high	O	O
degree	O	O
of	O	O
allelic	O	O
heterogeneity	O	O
in	O	O
HC	B-Disease	D046349
is	O	O
demonstrated	O	O
with	O	O
seven	O	O
new	O	O
different	O	O
mutations	O	O
making	O	O
a	O	O
total	O	O
of	O	O
nineteen	O	O
CPO	O	O
gene	B-Disease	D030342
defects	I-Disease	D030342
reported	O	O
so	O	O
far	O	O
.	O	O

.	O	O

The	O	O
haptoglobin	O	O
-	O	O
gene	O	O
deletion	O	O
responsible	O	O
for	O	O
anhaptoglobinemia	B-Disease	D000740
.	O	O

We	O	O
have	O	O
found	O	O
an	O	O
allelic	O	O
deletion	O	O
of	O	O
the	O	O
haptoglobin	O	O
(	O	O
Hp	O	O
)	O	O
gene	O	O
from	O	O
an	O	O
individual	O	O
with	O	O
anhaptoglobinemia	B-Disease	D000740
.	O	O

The	O	O
Hp	O	O
gene	O	O
cluster	O	O
consists	O	O
of	O	O
coding	O	O
regions	O	O
of	O	O
the	O	O
alpha	O	O
chain	O	O
and	O	O
beta	O	O
chain	O	O
of	O	O
the	O	O
haptoglobin	O	O
gene	O	O
(	O	O
Hp	O	O
)	O	O
and	O	O
of	O	O
the	O	O
alpha	O	O
chain	O	O
and	O	O
beta	O	O
chain	O	O
of	O	O
the	O	O
haptoglobin	O	O
-	O	O
related	O	O
gene	O	O
(	O	O
Hpr	O	O
)	O	O
,	O	O
in	O	O
tandem	O	O
from	O	O
the	O	O
5	O	O
side	O	O
.	O	O

Southern	O	O
blot	O	O
and	O	O
PCR	O	O
analyses	O	O
have	O	O
indicated	O	O
that	O	O
the	O	O
individual	O	O
with	O	O
anhaptoglobinemia	B-Disease	D000740
was	O	O
homozygous	O	O
for	O	O
the	O	O
gene	O	O
deletion	O	O
and	O	O
that	O	O
the	O	O
gene	O	O
deletion	O	O
was	O	O
included	O	O
at	O	O
least	O	O
from	O	O
the	O	O
promoter	O	O
region	O	O
of	O	O
Hp	O	O
to	O	O
Hpr	O	O
alpha	O	O
but	O	O
not	O	O
to	O	O
Hpr	O	O
beta	O	O
(	O	O
Hpdel	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
found	O	O
seven	O	O
individuals	O	O
with	O	O
hypohaptoglobinemia	B-Disease	D000740
in	O	O
three	O	O
families	O	O
,	O	O
and	O	O
the	O	O
genotypes	O	O
of	O	O
six	O	O
of	O	O
the	O	O
seven	O	O
individuals	O	O
were	O	O
found	O	O
to	O	O
be	O	O
Hp2	O	O
/	O	O
Hpdel	O	O
.	O	O

The	O	O
phenotypes	O	O
and	O	O
genotypes	O	O
in	O	O
one	O	O
of	O	O
these	O	O
three	O	O
families	O	O
showed	O	O
the	O	O
father	O	O
to	O	O
be	O	O
hypohaptoglobinemic	B-Disease	D000740
(	O	O
Hp2	O	O
)	O	O
and	O	O
Hp2	O	O
/	O	O
Hpdel	O	O
,	O	O
the	O	O
mother	O	O
to	O	O
be	O	O
Hp2	O	O
-	O	O
1	O	O
and	O	O
Hp1	O	O
/	O	O
Hp2	O	O
,	O	O
one	O	O
of	O	O
the	O	O
two	O	O
children	O	O
to	O	O
be	O	O
hypohaptoglobinemic	B-Disease	D000740
(	O	O
Hp2	O	O
)	O	O
and	O	O
Hp2	O	O
/	O	O
Hpdel	O	O
,	O	O
and	O	O
the	O	O
other	O	O
child	O	O
to	O	O
be	O	O
Hp1	O	O
and	O	O
Hp1	O	O
/	O	O
Hpdel	O	O
,	O	O
showing	O	O
an	O	O
anomalous	O	O
inheritance	O	O
of	O	O
Hp	O	O
phenotypes	O	O
in	O	O
the	O	O
child	O	O
with	O	O
Hp1	O	O
.	O	O

The	O	O
Hp2	O	O
/	O	O
Hpdel	O	O
individuals	O	O
had	O	O
an	O	O
extremely	O	O
low	O	O
level	O	O
of	O	O
Hp	O	O
(	O	O
mean	O	O
+	O	O
/	O	O
-	O	O
SD	O	O
=	O	O
0	O	O
.	O	O

049	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

043	O	O
mg	O	O
/	O	O
ml	O	O
;	O	O
n	O	O
=	O	O
6	O	O
)	O	O
,	O	O
compared	O	O
with	O	O
the	O	O
level	O	O
(	O	O
1	O	O
.	O	O

64	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

07	O	O
mg	O	O
/	O	O
ml	O	O
)	O	O
obtained	O	O
from	O	O
52	O	O
healthy	O	O
volunteers	O	O
having	O	O
phenotype	O	O
Hp2	O	O
,	O	O
whereas	O	O
the	O	O
serum	O	O
Hp	O	O
level	O	O
of	O	O
an	O	O
individual	O	O
with	O	O
Hp1	O	O
/	O	O
Hpdel	O	O
was	O	O
0	O	O
.	O	O

50	O	O
mg	O	O
/	O	O
ml	O	O
,	O	O
which	O	O
was	O	O
approximately	O	O
half	O	O
the	O	O
level	O	O
of	O	O
Hp	O	O
in	O	O
control	O	O
sera	O	O
from	O	O
the	O	O
Hp1	O	O
phenotype	O	O
(	O	O
1	O	O
.	O	O

26	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

33	O	O
mg	O	O
/	O	O
ml	O	O
;	O	O
n	O	O
=	O	O
9	O	O
)	O	O
,	O	O
showing	O	O
a	O	O
gene	O	O
-	O	O
dosage	O	O
effect	O	O
.	O	O

The	O	O
other	O	O
allele	O	O
(	O	O
Hp2	O	O
)	O	O
of	O	O
individuals	O	O
with	O	O
Hp2	O	O
/	O	O
Hpdel	O	O
was	O	O
found	O	O
to	O	O
have	O	O
,	O	O
in	O	O
all	O	O
exons	O	O
,	O	O
no	O	O
mutation	O	O
,	O	O
by	O	O
DNA	O	O
sequencing	O	O
.	O	O

On	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
present	O	O
study	O	O
,	O	O
the	O	O
mechanism	O	O
of	O	O
anhaptoglobinemia	B-Disease	D000740
and	O	O
the	O	O
mechanism	O	O
of	O	O
anomalous	O	O
inheritance	O	O
of	O	O
Hp	O	O
phenotypes	O	O
were	O	O
well	O	O
explained	O	O
.	O	O

However	O	O
,	O	O
the	O	O
mechanism	O	O
of	O	O
hypohaptoglobinemia	B-Disease	D000740
remains	O	O
unknown	O	O
Genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
in	O	O
attenuated	B-Disease	C538265
adenomatous	I-Disease	C538265
polyposis	I-Disease	C538265
coli	I-Disease	C538265
.	O	O

Germ	O	O
-	O	O
line	O	O
mutations	O	O
of	O	O
the	O	O
tumor	B-Disease	D009369
suppressor	O	O
APC	B-Disease	D011125
are	O	O
implicated	O	O
in	O	O
attenuated	B-Disease	C538265
adenomatous	I-Disease	C538265
polyposis	I-Disease	C538265
coli	I-Disease	C538265
(	O	O
AAPC	B-Disease	C538265
)	O	O
,	O	O
a	O	O
variant	O	O
of	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
(	O	O
FAP	B-Disease	D011125
)	O	O
.	O	O

AAPC	B-Disease	C538265
is	O	O
recognized	O	O
by	O	O
the	O	O
occurrence	O	O
of	O	O
<	O	O
100	O	O
colonic	B-Disease	D018256
adenomas	I-Disease	D018256
and	O	O
a	O	O
later	O	O
onset	O	O
of	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
(	O	O
age	O	O
>	O	O
40	O	O
years	O	O
)	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
assess	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
in	O	O
AAPC	B-Disease	C538265
families	O	O
.	O	O

By	O	O
protein	O	O
-	O	O
truncation	O	O
test	O	O
(	O	O
PTT	O	O
)	O	O
assay	O	O
,	O	O
the	O	O
entire	O	O
coding	O	O
region	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
was	O	O
screened	O	O
in	O	O
affected	O	O
individuals	O	O
from	O	O
11	O	O
AAPC	B-Disease	C538265
kindreds	O	O
,	O	O
and	O	O
their	O	O
phenotypic	O	O
differences	O	O
were	O	O
examined	O	O
.	O	O

Five	O	O
novel	O	O
germ	O	O
-	O	O
line	O	O
APC	B-Disease	D011125
mutations	O	O
were	O	O
identified	O	O
in	O	O
seven	O	O
kindreds	O	O
.	O	O

Mutations	O	O
were	O	O
located	O	O
in	O	O
three	O	O
different	O	O
regions	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
(	O	O
1	O	O
)	O	O
at	O	O
the	O	O
5	O	O
end	O	O
spanning	O	O
exons	O	O
4	O	O
and	O	O
5	O	O
,	O	O
(	O	O
2	O	O
)	O	O
within	O	O
exon	O	O
9	O	O
,	O	O
and	O	O
(	O	O
3	O	O
)	O	O
at	O	O
the	O	O
3	O	O
distal	O	O
end	O	O
of	O	O
the	O	O
gene	O	O
.	O	O

Variability	O	O
in	O	O
the	O	O
number	O	O
of	O	O
colorectal	B-Disease	D018256
adenomas	I-Disease	D018256
was	O	O
most	O	O
apparent	O	O
in	O	O
individuals	O	O
with	O	O
mutations	O	O
in	O	O
region	O	O
1	O	O
,	O	O
and	O	O
upper	O	O
-	O	O
gastrointestinal	O	O
manifestations	O	O
were	O	O
more	O	O
severe	O	O
in	O	O
them	O	O
.	O	O

In	O	O
individuals	O	O
with	O	O
mutations	O	O
in	O	O
either	O	O
region	O	O
2	O	O
or	O	O
region	O	O
3	O	O
,	O	O
the	O	O
average	O	O
number	O	O
of	O	O
adenomas	B-Disease	D000236
tended	O	O
to	O	O
be	O	O
lower	O	O
than	O	O
those	O	O
in	O	O
individuals	O	O
with	O	O
mutations	O	O
in	O	O
region	O	O
1	O	O
,	O	O
although	O	O
age	O	O
at	O	O
diagnosis	O	O
was	O	O
similar	O	O
.	O	O

In	O	O
all	O	O
AAPC	B-Disease	C538265
kindreds	O	O
,	O	O
a	O	O
predominance	O	O
of	O	O
right	O	O
-	O	O
sided	O	O
colorectal	B-Disease	D018256
adenomas	I-Disease	D018256
and	O	O
rectal	B-Disease	D011127
polyp	I-Disease	D011127
sparing	O	O
was	O	O
observed	O	O
.	O	O

No	O	O
desmoid	B-Disease	D018222
tumors	I-Disease	D018222
were	O	O
found	O	O
in	O	O
these	O	O
kindreds	O	O
.	O	O

Our	O	O
data	O	O
suggest	O	O
that	O	O
,	O	O
in	O	O
AAPC	B-Disease	C538265
families	O	O
,	O	O
the	O	O
location	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
mutation	O	O
may	O	O
partially	O	O
predict	O	O
specific	O	O
phenotypic	O	O
expression	O	O
.	O	O

This	O	O
should	O	O
help	O	O
in	O	O
the	O	O
design	O	O
of	O	O
tailored	O	O
clinical	O	O
-	O	O
management	O	O
protocols	O	O
in	O	O
this	O	O
subset	O	O
of	O	O
FAP	B-Disease	D011125
patients	O	O
.	O	O

.	O	O

The	O	O
APC	B-Disease	D011125
variants	O	O
I1307K	O	O
and	O	O
E1317Q	O	O
are	O	O
associated	O	O
with	O	O
colorectal	B-Disease	D015179
tumors	I-Disease	D015179
,	O	O
but	O	O
not	O	O
always	O	O
with	O	O
a	O	O
family	O	O
history	O	O
.	O	O

Classical	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
(	O	O
FAP	B-Disease	D011125
)	O	O
is	O	O
a	O	O
high	O	O
-	O	O
penetrance	O	O
autosomal	B-Disease	D030342
dominant	I-Disease	D030342
disease	I-Disease	D030342
that	O	O
predisposes	O	O
to	O	O
hundreds	O	O
or	O	O
thousands	O	O
of	O	O
colorectal	B-Disease	D018256
adenomas	I-Disease	D018256
and	I-Disease	D018256
carcinoma	I-Disease	D018256
and	O	O
that	O	O
results	O	O
from	O	O
truncating	O	O
mutations	O	O
in	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
.	O	O

A	O	O
variant	O	O
of	O	O
FAP	B-Disease	D011125
is	O	O
attenuated	B-Disease	C538265
adenomatous	I-Disease	C538265
polyposis	I-Disease	C538265
coli	I-Disease	C538265
,	O	O
which	O	O
results	O	O
from	O	O
germ	O	O
-	O	O
line	O	O
mutations	O	O
in	O	O
the	O	O
5	O	O
and	O	O
3	O	O
regions	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
.	O	O

Attenuated	B-Disease	C538265
adenomatous	I-Disease	C538265
polyposis	I-Disease	C538265
coli	I-Disease	C538265
patients	O	O
have	O	O
"	O	O
multiple	O	O
"	O	O
colorectal	B-Disease	D000236
adenomas	I-Disease	D000236
(	O	O
typically	O	O
fewer	O	O
than	O	O
100	O	O
)	O	O
without	O	O
the	O	O
florid	O	O
phenotype	O	O
of	O	O
classical	O	O
FAP	B-Disease	D011125
.	O	O

Another	O	O
group	O	O
of	O	O
patients	O	O
with	O	O
multiple	O	O
adenomas	B-Disease	D000236
has	O	O
no	O	O
mutations	O	O
in	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
,	O	O
and	O	O
their	O	O
phenotype	O	O
probably	O	O
results	O	O
from	O	O
variation	O	O
at	O	O
a	O	O
locus	O	O
,	O	O
or	O	O
loci	O	O
,	O	O
elsewhere	O	O
in	O	O
the	O	O
genome	O	O
.	O	O

Recently	O	O
,	O	O
however	O	O
,	O	O
a	O	O
missense	O	O
variant	O	O
of	O	O
APC	B-Disease	D011125
(	O	O
I1307K	O	O
)	O	O
was	O	O
described	O	O
that	O	O
confers	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
colorectal	B-Disease	D015179
tumors	I-Disease	D015179
,	O	O
including	O	O
multiple	O	O
adenomas	B-Disease	D000236
,	O	O
in	O	O
Ashkenazim	O	O
.	O	O

We	O	O
have	O	O
studied	O	O
a	O	O
set	O	O
of	O	O
164	O	O
patients	O	O
with	O	O
multiple	O	O
colorectal	B-Disease	D000236
adenomas	I-Disease	D000236
and	O	O
/	O	O
or	O	O
carcinoma	O	O
and	O	O
analyzed	O	O
codons	O	O
1263	O	O
-	O	O
1377	O	O
(	O	O
exon	O	O
15G	O	O
)	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
for	O	O
germ	O	O
-	O	O
line	O	O
variants	O	O
.	O	O

Three	O	O
patients	O	O
with	O	O
the	O	O
I1307K	O	O
allele	O	O
were	O	O
detected	O	O
,	O	O
each	O	O
of	O	O
Ashkenazi	O	O
descent	O	O
.	O	O

Four	O	O
patients	O	O
had	O	O
a	O	O
germ	O	O
-	O	O
line	O	O
E1317Q	O	O
missense	O	O
variant	O	O
of	O	O
APC	B-Disease	D011125
that	O	O
was	O	O
not	O	O
present	O	O
in	O	O
controls	O	O
;	O	O
one	O	O
of	O	O
these	O	O
individuals	O	O
had	O	O
an	O	O
unusually	O	O
large	O	O
number	O	O
of	O	O
metaplastic	B-Disease	D003111
polyps	I-Disease	D003111
of	I-Disease	D003111
the	I-Disease	D003111
colorectum	I-Disease	D003111
.	O	O

There	O	O
is	O	O
increasing	O	O
evidence	O	O
that	O	O
there	O	O
exist	O	O
germ	O	O
-	O	O
line	O	O
variants	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
that	O	O
predispose	O	O
to	O	O
the	O	O
development	O	O
of	O	O
multiple	O	O
colorectal	B-Disease	D018256
adenomas	I-Disease	D018256
and	I-Disease	D018256
carcinoma	I-Disease	D018256
,	O	O
but	O	O
without	O	O
the	O	O
florid	O	O
phenotype	O	O
of	O	O
classical	O	O
FAP	B-Disease	D011125
,	O	O
and	O	O
possibly	O	O
with	O	O
importance	O	O
for	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
risk	O	O
in	O	O
the	O	O
general	O	O
population	O	O
.	O	O

.	O	O

The	O	O
hemochromatosis	B-Disease	D006432
845	O	O
G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
and	O	O
187	O	O
C	O	O
-	O	O
-	O	O
>	O	O
G	O	O
mutations	O	O
:	O	O
prevalence	O	O
in	O	O
non	O	O
-	O	O
Caucasian	O	O
populations	O	O
.	O	O

Hemochromatosis	B-Disease	D006432
,	O	O
the	O	O
inherited	B-Disease	D019189
disorder	I-Disease	D019189
of	I-Disease	D019189
iron	I-Disease	D019189
metabolism	I-Disease	D019189
,	O	O
leads	O	O
,	O	O
if	O	O
untreated	O	O
,	O	O
to	O	O
progressive	O	O
iron	B-Disease	D019190
overload	I-Disease	D019190
and	O	O
premature	B-Disease	D003643
death	I-Disease	D003643
.	O	O

The	O	O
hemochromatosis	B-Disease	D006432
gene	O	O
,	O	O
HFE	O	O
,	O	O
recently	O	O
has	O	O
been	O	O
identified	O	O
,	O	O
and	O	O
characterization	O	O
of	O	O
this	O	O
gene	O	O
has	O	O
shown	O	O
that	O	O
it	O	O
contains	O	O
two	O	O
mutations	O	O
that	O	O
result	O	O
in	O	O
amino	O	O
acid	O	O
substitutions	O	O
-	O	O
cDNA	O	O
nucleotides	O	O
845	O	O
G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
(	O	O
C282Y	O	O
)	O	O
and	O	O
187	O	O
C	O	O
-	O	O
-	O	O
>	O	O
G	O	O
(	O	O
H63D	O	O
)	O	O
.	O	O

Although	O	O
hemochromatosis	B-Disease	D006432
is	O	O
common	O	O
in	O	O
Caucasians	O	O
,	O	O
affecting	O	O
>	O	O
=	O	O
1	O	O
/	O	O
300	O	O
individuals	O	O
of	O	O
northern	O	O
European	O	O
origin	O	O
,	O	O
it	O	O
has	O	O
not	O	O
been	O	O
recognized	O	O
in	O	O
other	O	O
populations	O	O
.	O	O

The	O	O
present	O	O
study	O	O
used	O	O
PCR	O	O
and	O	O
restriction	O	O
-	O	O
enzyme	O	O
digestion	O	O
to	O	O
analyze	O	O
the	O	O
frequency	O	O
of	O	O
the	O	O
845	O	O
G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
and	O	O
187	O	O
C	O	O
-	O	O
-	O	O
>	O	O
G	O	O
mutations	O	O
in	O	O
HLA	O	O
-	O	O
typed	O	O
samples	O	O
from	O	O
non	O	O
-	O	O
Caucasian	O	O
populations	O	O
,	O	O
comprising	O	O
Australian	O	O
Aboriginal	O	O
,	O	O
Chinese	O	O
,	O	O
and	O	O
Pacific	O	O
Islanders	O	O
.	O	O

Results	O	O
showed	O	O
that	O	O
the	O	O
845	O	O
G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
mutation	O	O
was	O	O
present	O	O
in	O	O
these	O	O
populations	O	O
(	O	O
allele	O	O
frequency	O	O
0	O	O
.	O	O

32	O	O
%	O	O
)	O	O
,	O	O
and	O	O
,	O	O
furthermore	O	O
,	O	O
it	O	O
was	O	O
always	O	O
seen	O	O
in	O	O
conjunction	O	O
with	O	O
HLA	O	O
haplotypes	O	O
common	O	O
in	O	O
Caucasians	O	O
,	O	O
suggesting	O	O
that	O	O
845	O	O
G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
may	O	O
have	O	O
been	O	O
introduced	O	O
into	O	O
these	O	O
populations	O	O
by	O	O
Caucasian	O	O
admixture	O	O
.	O	O

187	O	O
C	O	O
-	O	O
-	O	O
>	O	O
G	O	O
was	O	O
present	O	O
at	O	O
an	O	O
allele	O	O
frequency	O	O
of	O	O
2	O	O
.	O	O

68	O	O
%	O	O
in	O	O
the	O	O
two	O	O
populations	O	O
analyzed	O	O
(	O	O
Australian	O	O
Aboriginal	O	O
and	O	O
Chinese	O	O
)	O	O
.	O	O

In	O	O
the	O	O
Australian	O	O
Aboriginal	O	O
samples	O	O
,	O	O
187	O	O
C	O	O
-	O	O
-	O	O
>	O	O
G	O	O
was	O	O
found	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
HLA	O	O
haplotypes	O	O
common	O	O
in	O	O
Caucasians	O	O
,	O	O
suggesting	O	O
that	O	O
it	O	O
was	O	O
introduced	O	O
by	O	O
recent	O	O
admixture	O	O
.	O	O

In	O	O
the	O	O
Chinese	O	O
samples	O	O
analyzed	O	O
,	O	O
187	O	O
C	O	O
-	O	O
-	O	O
>	O	O
G	O	O
was	O	O
present	O	O
in	O	O
association	O	O
with	O	O
a	O	O
wide	O	O
variety	O	O
of	O	O
HLA	O	O
haplotypes	O	O
,	O	O
showing	O	O
this	O	O
mutation	O	O
to	O	O
be	O	O
widespread	O	O
and	O	O
likely	O	O
to	O	O
predate	O	O
the	O	O
more	O	O
genetically	O	O
restricted	O	O
845	O	O
G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
mutation	O	O
.	O	O

BRCA1	O	O
required	O	O
for	O	O
transcription	O	O
-	O	O
coupled	O	O
repair	O	O
of	O	O
oxidative	O	O
DNA	O	O
damage	O	O
.	O	O

The	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
susceptibility	O	O
gene	O	O
BRCA1	O	O
encodes	O	O
a	O	O
zinc	O	O
finger	O	O
protein	O	O
of	O	O
unknown	O	O
function	O	O
.	O	O

Association	O	O
of	O	O
the	O	O
BRCA1	O	O
protein	O	O
with	O	O
the	O	O
DNA	O	O
repair	O	O
protein	O	O
Rad51	O	O
and	O	O
changes	O	O
in	O	O
the	O	O
phosphorylation	O	O
and	O	O
cellular	O	O
localization	O	O
of	O	O
the	O	O
protein	O	O
after	O	O
exposure	O	O
to	O	O
DNA	O	O
-	O	O
damaging	O	O
agents	O	O
are	O	O
consistent	O	O
with	O	O
a	O	O
role	O	O
for	O	O
BRCA1	O	O
in	O	O
DNA	O	O
repair	O	O
.	O	O

Here	O	O
,	O	O
it	O	O
is	O	O
shown	O	O
that	O	O
mouse	O	O
embryonic	O	O
stem	O	O
cells	O	O
deficient	B-Disease	OMIM:604370
in	I-Disease	OMIM:604370
BRCA1	I-Disease	OMIM:604370
are	O	O
defective	O	O
in	O	O
the	O	O
ability	O	O
to	O	O
carry	O	O
out	O	O
transcription	O	O
-	O	O
coupled	O	O
repair	O	O
of	O	O
oxidative	O	O
DNA	O	O
damage	O	O
,	O	O
and	O	O
are	O	O
hypersensitive	O	O
to	O	O
ionizing	O	O
radiation	O	O
and	O	O
hydrogen	O	O
peroxide	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
BRCA1	O	O
participates	O	O
,	O	O
directly	O	O
or	O	O
indirectly	O	O
,	O	O
in	O	O
transcription	O	O
-	O	O
coupled	O	O
repair	O	O
of	O	O
oxidative	O	O
DNA	O	O
damage	O	O
.	O	O

.	O	O

A	O	O
mouse	O	O
model	O	O
of	O	O
severe	O	O
von	B-Disease	D014842
Willebrand	I-Disease	D014842
disease	I-Disease	D014842
:	O	O
defects	O	O
in	O	O
hemostasis	O	O
and	O	O
thrombosis	B-Disease	D013927
.	O	O

von	B-Disease	C531844
Willebrand	I-Disease	C531844
factor	I-Disease	C531844
(	I-Disease	C531844
vWf	I-Disease	C531844
)	I-Disease	C531844
deficiency	I-Disease	C531844
causes	O	O
severe	O	O
von	B-Disease	D014842
Willebrand	I-Disease	D014842
disease	I-Disease	D014842
in	O	O
humans	O	O
.	O	O

We	O	O
generated	O	O
a	O	O
mouse	O	O
model	O	O
for	O	O
this	O	O
disease	O	O
by	O	O
using	O	O
gene	O	O
targeting	O	O
.	O	O

vWf	B-Disease	C531844
-	I-Disease	C531844
deficient	I-Disease	C531844
mice	O	O
appeared	O	O
normal	O	O
at	O	O
birth	O	O
;	O	O
they	O	O
were	O	O
viable	O	O
and	O	O
fertile	O	O
.	O	O

Neither	O	O
vWf	O	O
nor	O	O
vWf	O	O
propolypeptide	O	O
(	O	O
von	B-Disease	D014842
Willebrand	I-Disease	D014842
antigen	O	O
II	O	O
)	O	O
were	O	O
detectable	O	O
in	O	O
plasma	O	O
,	O	O
platelets	O	O
,	O	O
or	O	O
endothelial	O	O
cells	O	O
of	O	O
the	O	O
homozygous	O	O
mutant	O	O
mice	O	O
.	O	O

The	O	O
mutant	O	O
mice	O	O
exhibited	O	O
defects	O	O
in	O	O
hemostasis	O	O
with	O	O
a	O	O
highly	O	O
prolonged	O	O
bleeding	O	O
time	O	O
and	O	O
spontaneous	O	O
bleeding	O	O
events	O	O
in	O	O
approximately	O	O
10	O	O
%	O	O
of	O	O
neonates	O	O
.	O	O

As	O	O
in	O	O
the	O	O
human	O	O
disease	O	O
,	O	O
the	O	O
factor	O	O
VIII	O	O
level	O	O
in	O	O
these	O	O
mice	O	O
was	O	O
reduced	O	O
strongly	O	O
as	O	O
a	O	O
result	O	O
of	O	O
the	O	O
lack	O	O
of	O	O
protection	O	O
provided	O	O
by	O	O
vWf	O	O
.	O	O

Defective	O	O
thrombosis	B-Disease	D013927
in	O	O
mutant	O	O
mice	O	O
was	O	O
also	O	O
evident	O	O
in	O	O
an	O	O
in	O	O
vivo	O	O
model	O	O
of	O	O
vascular	B-Disease	D057772
injury	I-Disease	D057772
.	O	O

In	O	O
this	O	O
model	O	O
,	O	O
the	O	O
exteriorized	O	O
mesentery	O	O
was	O	O
superfused	O	O
with	O	O
ferric	O	O
chloride	O	O
and	O	O
the	O	O
accumulation	O	O
of	O	O
fluorescently	O	O
labeled	O	O
platelets	O	O
was	O	O
observed	O	O
by	O	O
intravital	O	O
microscopy	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
these	O	O
mice	O	O
very	O	O
closely	O	O
mimic	O	O
severe	O	O
human	O	O
von	B-Disease	D014842
Willebrand	I-Disease	D014842
disease	I-Disease	D014842
and	O	O
will	O	O
be	O	O
very	O	O
useful	O	O
for	O	O
investigating	O	O
the	O	O
role	O	O
of	O	O
vWf	O	O
in	O	O
normal	O	O
physiology	O	O
and	O	O
in	O	O
disease	O	O
models	O	O
.	O	O

.	O	O

The	O	O
von	B-Disease	D006623
Hippel	I-Disease	D006623
-	I-Disease	D006623
Lindau	I-Disease	D006623
tumor	I-Disease	D006623
suppressor	O	O
gene	O	O
is	O	O
required	O	O
for	O	O
cell	O	O
cycle	O	O
exit	O	O
upon	O	O
serum	O	O
withdrawal	O	O
.	O	O

The	O	O
inactivation	O	O
of	O	O
the	O	O
von	B-Disease	D006623
Hippel	I-Disease	D006623
-	I-Disease	D006623
Lindau	I-Disease	D006623
(	I-Disease	D006623
VHL	I-Disease	D006623
)	I-Disease	D006623
tumor	I-Disease	D006623
suppressor	O	O
gene	O	O
predisposes	O	O
affected	O	O
individuals	O	O
to	O	O
the	O	O
human	O	O
VHL	B-Disease	D006623
cancer	I-Disease	D006623
syndrome	I-Disease	D006623
and	O	O
is	O	O
associated	O	O
with	O	O
sporadic	B-Disease	D002292
renal	I-Disease	D002292
cell	I-Disease	D002292
carcinomas	I-Disease	D002292
(	O	O
RCC	B-Disease	D002292
)	O	O
and	O	O
brain	B-Disease	D018325
hemangioblastomas	I-Disease	D018325
.	O	O

VHL	B-Disease	D006623
-	O	O
negative	O	O
786	O	O
-	O	O
0	O	O
RCC	B-Disease	D002292
cells	O	O
are	O	O
tumorigenic	O	O
in	O	O
nude	O	O
mice	O	O
which	O	O
is	O	O
suppressed	O	O
by	O	O
the	O	O
reintroduction	O	O
of	O	O
VHL	B-Disease	D006623
.	O	O

Remarkably	O	O
,	O	O
this	O	O
occurs	O	O
without	O	O
affecting	O	O
the	O	O
growth	O	O
rate	O	O
and	O	O
cell	O	O
cycle	O	O
profile	O	O
of	O	O
these	O	O
cells	O	O
in	O	O
culture	O	O
.	O	O

The	O	O
786	O	O
-	O	O
0	O	O
cell	O	O
line	O	O
,	O	O
like	O	O
many	O	O
cancer	B-Disease	D009369
cells	O	O
,	O	O
fails	O	O
to	O	O
exit	O	O
the	O	O
cell	O	O
cycle	O	O
upon	O	O
serum	O	O
withdrawal	O	O
.	O	O

Here	O	O
,	O	O
it	O	O
is	O	O
shown	O	O
that	O	O
reintroduction	O	O
of	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
VHL	B-Disease	D006623
gene	O	O
restores	O	O
the	O	O
ability	O	O
of	O	O
VHL	B-Disease	D006623
-	O	O
negative	O	O
RCC	B-Disease	D002292
cancer	B-Disease	D009369
cells	O	O
to	O	O
exit	O	O
the	O	O
cell	O	O
cycle	O	O
and	O	O
enter	O	O
G0	O	O
/	O	O
quiescence	O	O
in	O	O
low	O	O
serum	O	O
.	O	O

Both	O	O
VHL	B-Disease	D006623
-	O	O
positive	O	O
and	O	O
VHL	B-Disease	D006623
-	O	O
negative	O	O
RCC	B-Disease	D002292
cells	O	O
exit	O	O
the	O	O
cell	O	O
cycle	O	O
by	O	O
contact	O	O
inhibition	O	O
.	O	O

The	O	O
cyclin	O	O
-	O	O
dependent	O	O
kinase	O	O
inhibitor	O	O
,	O	O
p27	O	O
,	O	O
accumulates	O	O
upon	O	O
serum	O	O
withdrawal	O	O
,	O	O
only	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
VHL	B-Disease	D006623
,	O	O
as	O	O
a	O	O
result	O	O
of	O	O
the	O	O
stabilization	O	O
of	O	O
the	O	O
protein	O	O
.	O	O

We	O	O
propose	O	O
that	O	O
the	O	O
loss	O	O
of	O	O
wild	O	O
-	O	O
type	O	O
VHL	B-Disease	D006623
gene	O	O
results	O	O
in	O	O
a	O	O
specific	O	O
cellular	O	O
defect	O	O
in	O	O
serum	O	O
-	O	O
dependent	O	O
growth	O	O
control	O	O
,	O	O
which	O	O
may	O	O
initiate	O	O
tumor	B-Disease	D009369
formation	O	O
.	O	O

This	O	O
is	O	O
corrected	O	O
by	O	O
the	O	O
reintroduction	O	O
of	O	O
wild	O	O
-	O	O
type	O	O
VHL	B-Disease	D006623
,	O	O
implicating	O	O
VHL	B-Disease	D006623
as	O	O
the	O	O
first	O	O
tumor	B-Disease	D009369
suppressor	O	O
involved	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
cell	O	O
cycle	O	O
exit	O	O
,	O	O
which	O	O
is	O	O
consistent	O	O
with	O	O
its	O	O
gatekeeper	O	O
function	O	O
in	O	O
the	O	O
kidney	O	O
.	O	O

.	O	O

Nonsense	O	O
mutation	O	O
in	O	O
exon	O	O
4	O	O
of	O	O
human	O	O
complement	O	O
C9	O	O
gene	O	O
is	O	O
the	O	O
major	O	O
cause	O	O
of	O	O
Japanese	O	O
complement	B-Disease	OMIM:613825
C9	I-Disease	OMIM:613825
deficiency	I-Disease	OMIM:613825
.	O	O

Deficiency	B-Disease	OMIM:613825
of	I-Disease	OMIM:613825
the	I-Disease	OMIM:613825
ninth	I-Disease	OMIM:613825
component	I-Disease	OMIM:613825
of	I-Disease	OMIM:613825
human	I-Disease	OMIM:613825
complement	I-Disease	OMIM:613825
(	O	O
C9	O	O
)	O	O
is	O	O
the	O	O
most	O	O
common	O	O
complement	B-Disease	 D007153
deficiency	I-Disease	 D007153
in	O	O
Japan	O	O
but	O	O
is	O	O
rare	O	O
in	O	O
other	O	O
countries	O	O
.	O	O

We	O	O
studied	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
C9	B-Disease	OMIM:613825
deficiency	I-Disease	OMIM:613825
in	O	O
four	O	O
Japanese	O	O
C9	B-Disease	OMIM:613825
-	I-Disease	OMIM:613825
deficient	I-Disease	OMIM:613825
patients	O	O
who	O	O
had	O	O
suffered	O	O
from	O	O
meningococcal	B-Disease	D008585
meningitis	I-Disease	D008585
.	O	O

Direct	O	O
sequencing	O	O
of	O	O
amplified	O	O
C9	O	O
cDNA	O	O
and	O	O
DNA	O	O
revealed	O	O
a	O	O
nonsense	O	O
substitution	O	O
(	O	O
CGA	O	O
-	O	O
-	O	O
>	O	O
TGA	O	O
)	O	O
at	O	O
codon	O	O
95	O	O
in	O	O
exon	O	O
4	O	O
in	O	O
the	O	O
four	O	O
C9	B-Disease	OMIM:613825
-	I-Disease	OMIM:613825
deficient	I-Disease	OMIM:613825
individuals	O	O
.	O	O

An	O	O
allele	O	O
-	O	O
specific	O	O
polymerase	O	O
chain	O	O
reaction	O	O
system	O	O
designed	O	O
to	O	O
detect	O	O
exclusively	O	O
only	O	O
one	O	O
of	O	O
the	O	O
normal	O	O
and	O	O
mutant	O	O
alleles	O	O
indicated	O	O
that	O	O
all	O	O
the	O	O
four	O	O
patients	O	O
were	O	O
homozygous	O	O
for	O	O
the	O	O
mutation	O	O
in	O	O
exon	O	O
4	O	O
and	O	O
that	O	O
the	O	O
parents	O	O
of	O	O
patient	O	O
2	O	O
were	O	O
heterozygous	O	O
.	O	O

The	O	O
common	O	O
mutation	O	O
at	O	O
codon	O	O
95	O	O
in	O	O
exon	O	O
4	O	O
might	O	O
be	O	O
responsible	O	O
for	O	O
most	O	O
Japanese	O	O
C9	B-Disease	OMIM:613825
deficiency	I-Disease	OMIM:613825
.	O	O

.	O	O

Human	B-Disease	OMIM:609814
complement	I-Disease	OMIM:609814
factor	I-Disease	OMIM:609814
H	I-Disease	OMIM:609814
deficiency	I-Disease	OMIM:609814
associated	O	O
with	O	O
hemolytic	B-Disease	D006463
uremic	I-Disease	D006463
syndrome	I-Disease	D006463
.	O	O

This	O	O
study	O	O
reports	O	O
on	O	O
six	O	O
cases	O	O
of	O	O
deficiency	B-Disease	OMIM:609814
in	I-Disease	OMIM:609814
the	I-Disease	OMIM:609814
human	I-Disease	OMIM:609814
complement	I-Disease	OMIM:609814
regulatory	I-Disease	OMIM:609814
protein	I-Disease	OMIM:609814
Factor	I-Disease	OMIM:609814
H	I-Disease	OMIM:609814
(	O	O
FH	O	O
)	O	O
in	O	O
the	O	O
context	O	O
of	O	O
an	O	O
acute	B-Disease	D007674
renal	I-Disease	D007674
disease	I-Disease	D007674
.	O	O

Five	O	O
of	O	O
the	O	O
cases	O	O
were	O	O
observed	O	O
in	O	O
children	O	O
presenting	O	O
with	O	O
idiopathic	O	O
hemolytic	B-Disease	D006463
uremic	I-Disease	D006463
syndrome	I-Disease	D006463
(	O	O
HUS	B-Disease	D006463
)	O	O
.	O	O

Two	O	O
of	O	O
the	O	O
children	O	O
exhibited	O	O
a	O	O
homozygous	O	O
deficiency	O	O
characterized	O	O
by	O	O
the	O	O
absence	O	O
of	O	O
the	O	O
150	O	O
-	O	O
kD	O	O
form	O	O
of	O	O
Factor	O	O
H	O	O
and	O	O
the	O	O
presence	O	O
,	O	O
upon	O	O
immunoblotting	O	O
,	O	O
of	O	O
the	O	O
42	O	O
-	O	O
kD	O	O
Factor	O	O
H	O	O
-	O	O
like	O	O
protein	O	O
1	O	O
(	O	O
FHL	O	O
-	O	O
1	O	O
)	O	O
and	O	O
other	O	O
FH	O	O
-	O	O
related	O	O
protein	O	O
(	O	O
FHR	O	O
)	O	O
bands	O	O
.	O	O

Southern	O	O
blot	O	O
and	O	O
PCR	O	O
analysis	O	O
of	O	O
DNA	O	O
of	O	O
one	O	O
patient	O	O
with	O	O
homozygous	O	O
deficiency	O	O
ruled	O	O
out	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
large	O	O
deletion	O	O
of	O	O
the	O	O
FH	O	O
gene	O	O
as	O	O
the	O	O
underlying	O	O
defect	O	O
for	O	O
the	O	O
deficiency	O	O
.	O	O

The	O	O
other	O	O
four	O	O
children	O	O
presented	O	O
with	O	O
heterozygous	O	O
deficiency	O	O
and	O	O
exhibited	O	O
a	O	O
normal	O	O
immunoblotting	O	O
pattern	O	O
of	O	O
proteins	O	O
of	O	O
the	O	O
FH	O	O
family	O	O
.	O	O

Factor	B-Disease	OMIM:609814
H	I-Disease	OMIM:609814
deficiency	I-Disease	OMIM:609814
is	O	O
the	O	O
only	O	O
complement	B-Disease	D007153
deficiency	I-Disease	D007153
associated	O	O
with	O	O
HUS	B-Disease	D006463
.	O	O

These	O	O
observations	O	O
suggest	O	O
a	O	O
role	O	O
for	O	O
FH	O	O
and	O	O
/	O	O
or	O	O
FH	O	O
receptors	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
idiopathic	O	O
HUS	B-Disease	D006463
.	O	O

.	O	O

Cell	O	O
cycle	O	O
-	O	O
dependent	O	O
colocalization	O	O
of	O	O
BARD1	O	O
and	O	O
BRCA1	O	O
proteins	O	O
in	O	O
discrete	O	O
nuclear	O	O
domains	O	O
.	O	O

Germ	O	O
-	O	O
line	O	O
mutations	O	O
of	O	O
the	O	O
BRCA1	O	O
gene	O	O
predispose	O	O
women	O	O
to	O	O
early	O	O
-	O	O
onset	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
by	O	O
compromising	O	O
the	O	O
genes	O	O
presumptive	O	O
function	O	O
as	O	O
a	O	O
tumor	B-Disease	D009369
suppressor	O	O
.	O	O

Although	O	O
the	O	O
biochemical	O	O
properties	O	O
of	O	O
BRCA1	O	O
polypeptides	O	O
are	O	O
not	O	O
understood	O	O
,	O	O
their	O	O
expression	O	O
pattern	O	O
and	O	O
subcellular	O	O
localization	O	O
suggest	O	O
a	O	O
role	O	O
in	O	O
cell	O	O
-	O	O
cycle	O	O
regulation	O	O
.	O	O

When	O	O
resting	O	O
cells	O	O
are	O	O
induced	O	O
to	O	O
proliferate	O	O
,	O	O
the	O	O
steady	O	O
-	O	O
state	O	O
levels	O	O
of	O	O
BRCA1	O	O
increase	O	O
in	O	O
late	O	O
G1	O	O
and	O	O
reach	O	O
a	O	O
maximum	O	O
during	O	O
S	O	O
phase	O	O
.	O	O

Moreover	O	O
,	O	O
in	O	O
S	O	O
phase	O	O
cells	O	O
,	O	O
BRCA1	O	O
polypeptides	O	O
are	O	O
hyperphosphorylated	O	O
and	O	O
accumulate	O	O
into	O	O
discrete	O	O
subnuclear	O	O
foci	O	O
termed	O	O
"	O	O
BRCA1	O	O
nuclear	O	O
dots	O	O
.	O	O

"	O	O
BRCA1	O	O
associates	O	O
in	O	O
vivo	O	O
with	O	O
a	O	O
structurally	O	O
related	O	O
protein	O	O
termed	O	O
BARD1	O	O
.	O	O

Here	O	O
we	O	O
show	O	O
that	O	O
the	O	O
steady	O	O
-	O	O
state	O	O
levels	O	O
of	O	O
BARD1	O	O
,	O	O
unlike	O	O
those	O	O
of	O	O
BRCA1	O	O
,	O	O
remain	O	O
relatively	O	O
constant	O	O
during	O	O
cell	O	O
cycle	O	O
progression	O	O
.	O	O

However	O	O
,	O	O
immunostaining	O	O
revealed	O	O
that	O	O
BARD1	O	O
resides	O	O
within	O	O
BRCA1	O	O
nuclear	O	O
dots	O	O
during	O	O
S	O	O
phase	O	O
of	O	O
the	O	O
cell	O	O
cycle	O	O
,	O	O
but	O	O
not	O	O
during	O	O
the	O	O
G1	O	O
phase	O	O
.	O	O

Nevertheless	O	O
,	O	O
BARD1	O	O
polypeptides	O	O
are	O	O
found	O	O
exclusively	O	O
in	O	O
the	O	O
nuclear	O	O
fractions	O	O
of	O	O
both	O	O
G1	O	O
-	O	O
and	O	O
S	O	O
-	O	O
phase	O	O
cells	O	O
.	O	O

Therefore	O	O
,	O	O
progression	O	O
to	O	O
S	O	O
phase	O	O
is	O	O
accompanied	O	O
by	O	O
the	O	O
aggregation	O	O
of	O	O
nuclear	O	O
BARD1	O	O
polypeptides	O	O
into	O	O
BRCA1	O	O
nuclear	O	O
dots	O	O
.	O	O

This	O	O
cell	O	O
cycle	O	O
-	O	O
dependent	O	O
colocalization	O	O
of	O	O
BARD1	O	O
and	O	O
BRCA1	O	O
indicates	O	O
a	O	O
role	O	O
for	O	O
BARD1	O	O
in	O	O
BRCA1	O	O
-	O	O
mediated	O	O
tumor	B-Disease	D009369
suppression	O	O
.	O	O

Genetic	O	O
basis	O	O
and	O	O
molecular	O	O
mechanism	O	O
for	O	O
idiopathic	B-Disease	C537182
ventricular	I-Disease	C537182
fibrillation	I-Disease	C537182
.	O	O

Ventricular	B-Disease	D014693
fibrillation	I-Disease	D014693
causes	O	O
more	O	O
than	O	O
300	O	O
,	O	O
000	O	O
sudden	O	O
deaths	O	O
each	O	O
year	O	O
in	O	O
the	O	O
USA	O	O
alone	O	O
.	O	O

In	O	O
approximately	O	O
5	O	O
-	O	O
12	O	O
%	O	O
of	O	O
these	O	O
cases	O	O
,	O	O
there	O	O
are	O	O
no	O	O
demonstrable	O	O
cardiac	O	O
or	O	O
non	O	O
-	O	O
cardiac	O	O
causes	O	O
to	O	O
account	O	O
for	O	O
the	O	O
episode	O	O
,	O	O
which	O	O
is	O	O
therefore	O	O
classified	O	O
as	O	O
idiopathic	B-Disease	C537182
ventricular	I-Disease	C537182
fibrillation	I-Disease	C537182
(	O	O
IVF	B-Disease	C537182
)	O	O
.	O	O

A	O	O
distinct	O	O
group	O	O
of	O	O
IVF	B-Disease	C537182
patients	O	O
has	O	O
been	O	O
found	O	O
to	O	O
present	O	O
with	O	O
a	O	O
characteristic	O	O
electrocardiographic	O	O
pattern	O	O
.	O	O

Because	O	O
of	O	O
the	O	O
small	O	O
size	O	O
of	O	O
most	O	O
pedigrees	O	O
and	O	O
the	O	O
high	O	O
incidence	O	O
of	O	O
sudden	B-Disease	D003645
death	I-Disease	D003645
,	O	O
however	O	O
,	O	O
molecular	O	O
genetic	O	O
studies	O	O
of	O	O
IVF	B-Disease	C537182
have	O	O
not	O	O
yet	O	O
been	O	O
done	O	O
.	O	O

Because	O	O
IVF	B-Disease	C537182
causes	O	O
cardiac	O	O
rhythm	O	O
disturbance	O	O
,	O	O
we	O	O
investigated	O	O
whether	O	O
malfunction	O	O
of	O	O
ion	O	O
channels	O	O
could	O	O
cause	O	O
the	O	O
disorder	O	O
by	O	O
studying	O	O
mutations	O	O
in	O	O
the	O	O
cardiac	O	O
sodium	O	O
channel	O	O
gene	O	O
SCN5A	O	O
.	O	O

We	O	O
have	O	O
now	O	O
identified	O	O
a	O	O
missense	O	O
mutation	O	O
,	O	O
a	O	O
splice	O	O
-	O	O
donor	O	O
mutation	O	O
,	O	O
and	O	O
a	O	O
frameshift	O	O
mutation	O	O
in	O	O
the	O	O
coding	O	O
region	O	O
of	O	O
SCN5A	O	O
in	O	O
three	O	O
IVF	B-Disease	C537182
families	O	O
.	O	O

We	O	O
show	O	O
that	O	O
sodium	O	O
channels	O	O
with	O	O
the	O	O
missense	O	O
mutation	O	O
recover	O	O
from	O	O
inactivation	O	O
more	O	O
rapidly	O	O
than	O	O
normal	O	O
and	O	O
that	O	O
the	O	O
frameshift	O	O
mutation	O	O
causes	O	O
the	O	O
sodium	O	O
channel	O	O
to	O	O
be	O	O
non	O	O
-	O	O
functional	O	O
.	O	O

Our	O	O
results	O	O
indicate	O	O
that	O	O
mutations	O	O
in	O	O
cardiac	O	O
ion	O	O
-	O	O
channel	O	O
genes	O	O
contribute	O	O
to	O	O
the	O	O
risk	O	O
of	O	O
developing	O	O
IVF	B-Disease	C537182
.	O	O

.	O	O

Prevalence	O	O
of	O	O
the	O	O
I1307K	O	O
APC	B-Disease	D011125
gene	O	O
variant	O	O
in	O	O
Israeli	O	O
Jews	O	O
of	O	O
differing	O	O
ethnic	O	O
origin	O	O
and	O	O
risk	O	O
for	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
.	O	O

BACKGROUND	O	O
&	O	O
AIMS	O	O
Israeli	O	O
Jews	O	O
of	O	O
European	O	O
birth	O	O
,	O	O
i	O	O
.	O	O

e	O	O
.	O	O

,	O	O
Ashkenazim	O	O
,	O	O
have	O	O
the	O	O
highest	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
incidence	O	O
of	O	O
any	O	O
Israeli	O	O
ethnic	O	O
group	O	O
.	O	O

The	O	O
I1307K	O	O
APC	B-Disease	D011125
gene	O	O
variant	O	O
was	O	O
found	O	O
in	O	O
6	O	O
.	O	O

1	O	O
%	O	O
of	O	O
American	O	O
Jews	O	O
,	O	O
28	O	O
%	O	O
of	O	O
their	O	O
familial	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
cases	O	O
,	O	O
but	O	O
not	O	O
in	O	O
non	O	O
-	O	O
Jews	O	O
.	O	O

We	O	O
assessed	O	O
the	O	O
I1307K	O	O
prevalence	O	O
in	O	O
Israeli	O	O
Jews	O	O
of	O	O
differing	O	O
ethnic	O	O
origin	O	O
and	O	O
risk	O	O
for	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
.	O	O

METHODS	O	O
DNA	O	O
samples	O	O
from	O	O
500	O	O
unrelated	O	O
Jews	O	O
of	O	O
European	O	O
or	O	O
non	O	O
-	O	O
European	O	O
origin	O	O
,	O	O
with	O	O
or	O	O
without	O	O
a	O	O
personal	O	O
and	O	O
/	O	O
or	O	O
family	O	O
history	O	O
of	O	O
neoplasia	B-Disease	D009369
,	O	O
were	O	O
examined	O	O
for	O	O
the	O	O
I1307K	O	O
variant	O	O
by	O	O
the	O	O
allele	O	O
-	O	O
specific	O	O
oligonucleotide	O	O
(	O	O
ASO	O	O
)	O	O
method	O	O
.	O	O

RESULTS	O	O
In	O	O
persons	O	O
at	O	O
average	O	O
risk	O	O
for	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
,	O	O
I1307K	O	O
was	O	O
found	O	O
in	O	O
5	O	O
.	O	O

0	O	O
%	O	O
of	O	O
120	O	O
European	O	O
and	O	O
1	O	O
.	O	O

6	O	O
%	O	O
of	O	O
188	O	O
non	O	O
-	O	O
European	O	O
Jews	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

08	O	O
)	O	O
.	O	O

It	O	O
occurred	O	O
in	O	O
15	O	O
.	O	O

4	O	O
%	O	O
of	O	O
52	O	O
Ashkenazi	O	O
Israelis	O	O
with	O	O
familial	O	O
cancer	B-Disease	D009369
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

02	O	O
)	O	O
and	O	O
was	O	O
not	O	O
detected	O	O
in	O	O
51	O	O
non	O	O
-	O	O
European	O	O
Jews	O	O
at	O	O
increased	O	O
cancer	B-Disease	D009369
risk	O	O
.	O	O

Colorectal	B-Disease	D015179
neoplasia	I-Disease	D015179
occurred	O	O
personally	O	O
or	O	O
in	O	O
the	O	O
families	O	O
of	O	O
13	O	O
of	O	O
20	O	O
Ashkenazi	O	O
I1307K	O	O
carriers	O	O
,	O	O
8	O	O
of	O	O
whom	O	O
also	O	O
had	O	O
a	O	O
personal	O	O
or	O	O
family	O	O
history	O	O
of	O	O
noncolonic	O	O
neoplasia	B-Disease	D009369
.	O	O

CONCLUSIONS	O	O
The	O	O
I1307K	O	O
APC	B-Disease	D011125
variant	O	O
may	O	O
represent	O	O
a	O	O
susceptibility	O	O
gene	O	O
for	O	O
colorectal	B-Disease	D009369
,	I-Disease	D009369
or	I-Disease	D009369
other	I-Disease	D009369
,	I-Disease	D009369
cancers	I-Disease	D009369
in	O	O
Ashkenazi	O	O
Jews	O	O
,	O	O
and	O	O
partially	O	O
explains	O	O
the	O	O
higher	O	O
incidence	O	O
of	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
in	O	O
European	O	O
Israelis	O	O
.	O	O

Susceptibility	O	O
to	O	O
ankylosing	B-Disease	D013167
spondylitis	I-Disease	D013167
in	O	O
twins	O	O
:	O	O
the	O	O
role	O	O
of	O	O
genes	O	O
,	O	O
HLA	O	O
,	O	O
and	O	O
the	O	O
environment	O	O
.	O	O

OBJECTIVE	O	O
To	O	O
determine	O	O
the	O	O
relative	O	O
effects	O	O
of	O	O
genetic	O	O
and	O	O
environmental	O	O
factors	O	O
in	O	O
susceptibility	O	O
to	O	O
ankylosing	B-Disease	D013167
spondylitis	I-Disease	D013167
(	O	O
AS	B-Disease	D013167
)	O	O
.	O	O

METHODS	O	O
Twins	O	O
with	O	O
AS	B-Disease	D013167
were	O	O
identified	O	O
from	O	O
the	O	O
Royal	O	O
National	O	O
Hospital	O	O
for	O	O
Rheumatic	B-Disease	D012216
Diseases	I-Disease	D012216
database	O	O
.	O	O

Clinical	O	O
and	O	O
radiographic	O	O
examinations	O	O
were	O	O
performed	O	O
to	O	O
establish	O	O
diagnoses	O	O
,	O	O
and	O	O
disease	O	O
severity	O	O
was	O	O
assessed	O	O
using	O	O
a	O	O
combination	O	O
of	O	O
validated	O	O
scoring	O	O
systems	O	O
.	O	O

HLA	O	O
typing	O	O
for	O	O
HLA	O	O
-	O	O
B27	O	O
,	O	O
HLA	O	O
-	O	O
B60	O	O
,	O	O
and	O	O
HLA	O	O
-	O	O
DR1	O	O
was	O	O
performed	O	O
by	O	O
polymerase	O	O
chain	O	O
reaction	O	O
with	O	O
sequence	O	O
-	O	O
specific	O	O
primers	O	O
,	O	O
and	O	O
zygosity	O	O
was	O	O
assessed	O	O
using	O	O
microsatellite	O	O
markers	O	O
.	O	O

Genetic	O	O
and	O	O
environmental	O	O
variance	O	O
components	O	O
were	O	O
assessed	O	O
with	O	O
the	O	O
program	O	O
Mx	O	O
,	O	O
using	O	O
data	O	O
from	O	O
this	O	O
and	O	O
previous	O	O
studies	O	O
of	O	O
twins	O	O
with	O	O
AS	B-Disease	D013167
.	O	O

RESULTS	O	O
Six	O	O
of	O	O
8	O	O
monozygotic	O	O
(	O	O
MZ	O	O
)	O	O
twin	O	O
pairs	O	O
were	O	O
disease	O	O
concordant	O	O
,	O	O
compared	O	O
with	O	O
4	O	O
of	O	O
15	O	O
B27	O	O
-	O	O
positive	O	O
dizygotic	O	O
(	O	O
DZ	O	O
)	O	O
twin	O	O
pairs	O	O
(	O	O
27	O	O
%	O	O
)	O	O
and	O	O
4	O	O
of	O	O
32	O	O
DZ	O	O
twin	O	O
pairs	O	O
overall	O	O
(	O	O
12	O	O
.	O	O

5	O	O
%	O	O
)	O	O
.	O	O

Nonsignificant	O	O
increases	O	O
in	O	O
similarity	O	O
with	O	O
regard	O	O
to	O	O
age	O	O
at	O	O
disease	O	O
onset	O	O
and	O	O
all	O	O
of	O	O
the	O	O
disease	O	O
severity	O	O
scores	O	O
assessed	O	O
were	O	O
noted	O	O
in	O	O
disease	O	O
-	O	O
concordant	O	O
MZ	O	O
twins	O	O
compared	O	O
with	O	O
concordant	O	O
DZ	O	O
twins	O	O
.	O	O

HLA	O	O
-	O	O
B27	O	O
and	O	O
B60	O	O
were	O	O
associated	O	O
with	O	O
the	O	O
disease	O	O
in	O	O
probands	O	O
,	O	O
and	O	O
the	O	O
rate	O	O
of	O	O
disease	O	O
concordance	O	O
was	O	O
significantly	O	O
increased	O	O
among	O	O
DZ	O	O
twin	O	O
pairs	O	O
in	O	O
which	O	O
the	O	O
co	O	O
-	O	O
twin	O	O
was	O	O
positive	O	O
for	O	O
both	O	O
B27	O	O
and	O	O
DR1	O	O
.	O	O

Additive	O	O
genetic	O	O
effects	O	O
were	O	O
estimated	O	O
to	O	O
contribute	O	O
97	O	O
%	O	O
of	O	O
the	O	O
population	O	O
variance	O	O
.	O	O

CONCLUSION	O	O
Susceptibility	O	O
to	O	O
AS	B-Disease	D013167
is	O	O
largely	O	O
genetically	O	O
determined	O	O
,	O	O
and	O	O
the	O	O
environmental	O	O
trigger	O	O
for	O	O
the	O	O
disease	O	O
is	O	O
probably	O	O
ubiquitous	O	O
.	O	O

HLA	O	O
-	O	O
B27	O	O
accounts	O	O
for	O	O
a	O	O
minority	O	O
of	O	O
the	O	O
overall	O	O
genetic	O	O
susceptibility	O	O
to	O	O
AS	B-Disease	D013167
.	O	O

The	O	O
APCI1307K	O	O
allele	O	O
and	O	O
cancer	B-Disease	D009369
risk	O	O
in	O	O
a	O	O
community	O	O
-	O	O
based	O	O
study	O	O
of	O	O
Ashkenazi	O	O
Jews	O	O
.	O	O

Mutations	O	O
in	O	O
APC	B-Disease	D011125
are	O	O
classically	O	O
associated	O	O
with	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
(	O	O
FAP	B-Disease	D011125
)	O	O
,	O	O
a	O	O
highly	O	O
penetrant	O	O
autosomal	B-Disease	D030342
dominant	I-Disease	D030342
disorder	I-Disease	D030342
characterized	O	O
by	O	O
multiple	O	O
intestinal	O	O
polyps	B-Disease	D011127
and	O	O
,	O	O
without	O	O
surgical	O	O
intervention	O	O
,	O	O
the	O	O
development	O	O
of	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
(	O	O
CRC	B-Disease	D015179
)	O	O
.	O	O

APC	B-Disease	D011125
is	O	O
a	O	O
tumour	O	O
-	O	O
suppressor	O	O
gene	O	O
,	O	O
and	O	O
somatic	O	O
loss	O	O
occurs	O	O
in	O	O
tumours	B-Disease	D009369
.	O	O

The	O	O
germline	O	O
T	O	O
-	O	O
to	O	O
-	O	O
A	O	O
transversion	O	O
responsible	O	O
for	O	O
the	O	O
APC	B-Disease	D011125
I1307K	O	O
allele	O	O
converts	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
sequence	O	O
to	O	O
a	O	O
homopolymer	O	O
tract	O	O
(	O	O
A8	O	O
)	O	O
that	O	O
is	O	O
genetically	O	O
unstable	O	O
and	O	O
prone	O	O
to	O	O
somatic	O	O
mutation	O	O
.	O	O

The	O	O
I1307K	O	O
allele	O	O
was	O	O
found	O	O
in	O	O
6	O	O
.	O	O

1	O	O
%	O	O
of	O	O
unselected	O	O
Ashkenazi	O	O
Jews	O	O
and	O	O
higher	O	O
proportions	O	O
of	O	O
Ashkenazim	O	O
with	O	O
family	O	O
or	O	O
personal	O	O
histories	O	O
of	O	O
CRC	B-Disease	D015179
(	O	O
ref	O	O
.	O	O

2	O	O
)	O	O
.	O	O

To	O	O
evaluate	O	O
the	O	O
role	O	O
of	O	O
I1307K	O	O
in	O	O
cancer	B-Disease	D009369
,	O	O
we	O	O
genotyped	O	O
5	O	O
,	O	O
081	O	O
Ashkenazi	O	O
volunteers	O	O
in	O	O
a	O	O
community	O	O
survey	O	O
.	O	O

Risk	O	O
of	O	O
developing	O	O
colorectal	B-Disease	D001943
,	I-Disease	D001943
breast	I-Disease	D001943
and	I-Disease	D001943
other	I-Disease	D001943
cancers	I-Disease	D001943
were	O	O
compared	O	O
between	O	O
genotyped	O	O
I1307K	O	O
carriers	O	O
and	O	O
non	O	O
-	O	O
carriers	O	O
and	O	O
their	O	O
first	O	O
-	O	O
degree	O	O
relatives	O	O
.	O	O

The	O	O
hemochromatosis	B-Disease	D006432
gene	O	O
product	O	O
complexes	O	O
with	O	O
the	O	O
transferrin	O	O
receptor	O	O
and	O	O
lowers	O	O
its	O	O
affinity	O	O
for	O	O
ligand	O	O
binding	O	O
.	O	O

We	O	O
recently	O	O
reported	O	O
the	O	O
positional	O	O
cloning	O	O
of	O	O
a	O	O
candidate	O	O
gene	O	O
for	O	O
hereditary	B-Disease	D006432
hemochromatosis	I-Disease	D006432
called	O	O
HFE	O	O
.	O	O

The	O	O
gene	O	O
product	O	O
,	O	O
a	O	O
member	O	O
of	O	O
the	O	O
major	O	O
histocompatibility	O	O
complex	O	O
class	O	O
I	O	O
-	O	O
like	O	O
family	O	O
,	O	O
was	O	O
found	O	O
to	O	O
have	O	O
a	O	O
mutation	O	O
,	O	O
Cys	O	O
-	O	O
282	O	O
-	O	O
-	O	O
>	O	O
Tyr	O	O
(	O	O
C282Y	O	O
)	O	O
,	O	O
in	O	O
85	O	O
%	O	O
of	O	O
patient	O	O
chromosomes	O	O
.	O	O

This	O	O
mutation	O	O
eliminates	O	O
the	O	O
ability	O	O
of	O	O
HFE	O	O
to	O	O
associate	O	O
with	O	O
beta2	O	O
-	O	O
microglobulin	O	O
(	O	O
beta2m	O	O
)	O	O
and	O	O
prevents	O	O
cell	O	O
-	O	O
surface	O	O
expression	O	O
.	O	O

A	O	O
second	O	O
mutation	O	O
that	O	O
has	O	O
no	O	O
effect	O	O
on	O	O
beta2m	O	O
association	O	O
,	O	O
H63D	O	O
,	O	O
was	O	O
found	O	O
in	O	O
eight	O	O
out	O	O
of	O	O
nine	O	O
patients	O	O
heterozygous	O	O
for	O	O
the	O	O
C282Y	O	O
mutant	O	O
.	O	O

In	O	O
this	O	O
report	O	O
,	O	O
we	O	O
demonstrate	O	O
in	O	O
cultured	O	O
293	O	O
cells	O	O
overexpressing	O	O
wild	O	O
-	O	O
type	O	O
or	O	O
mutant	O	O
HFE	O	O
proteins	O	O
that	O	O
both	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
and	O	O
H63D	O	O
HFE	O	O
proteins	O	O
form	O	O
stable	O	O
complexes	O	O
with	O	O
the	O	O
transferrin	O	O
receptor	O	O
(	O	O
TfR	O	O
)	O	O
.	O	O

The	O	O
C282Y	O	O
mutation	O	O
nearly	O	O
completely	O	O
prevents	O	O
the	O	O
association	O	O
of	O	O
the	O	O
mutant	O	O
HFE	O	O
protein	O	O
with	O	O
the	O	O
TfR	O	O
.	O	O

Studies	O	O
on	O	O
cell	O	O
-	O	O
associated	O	O
transferrin	O	O
at	O	O
37	O	O
degrees	O	O
C	O	O
suggest	O	O
that	O	O
the	O	O
overexpressed	O	O
wild	O	O
-	O	O
type	O	O
HFE	O	O
protein	O	O
decreases	O	O
the	O	O
affinity	O	O
of	O	O
the	O	O
TfR	O	O
for	O	O
transferrin	O	O
.	O	O

The	O	O
overexpressed	O	O
H63D	O	O
protein	O	O
does	O	O
not	O	O
have	O	O
this	O	O
effect	O	O
,	O	O
providing	O	O
the	O	O
first	O	O
direct	O	O
evidence	O	O
for	O	O
a	O	O
functional	O	O
consequence	O	O
of	O	O
the	O	O
H63D	O	O
mutation	O	O
.	O	O

Addition	O	O
of	O	O
soluble	O	O
wild	O	O
-	O	O
type	O	O
HFE	O	O
/	O	O
beta2m	O	O
heterodimers	O	O
to	O	O
cultured	O	O
cells	O	O
also	O	O
decreased	O	O
the	O	O
apparent	O	O
affinity	O	O
of	O	O
the	O	O
TfR	O	O
for	O	O
its	O	O
ligand	O	O
under	O	O
steady	O	O
-	O	O
state	O	O
conditions	O	O
,	O	O
both	O	O
in	O	O
293	O	O
cells	O	O
and	O	O
in	O	O
HeLa	O	O
cells	O	O
.	O	O

Furthermore	O	O
,	O	O
at	O	O
4	O	O
degrees	O	O
C	O	O
,	O	O
the	O	O
added	O	O
soluble	O	O
complex	O	O
of	O	O
HFE	O	O
/	O	O
beta2m	O	O
inhibited	O	O
binding	O	O
of	O	O
transferrin	O	O
to	O	O
HeLa	O	O
cell	O	O
TfR	O	O
in	O	O
a	O	O
concentration	O	O
-	O	O
dependent	O	O
manner	O	O
.	O	O

Scatchard	O	O
plots	O	O
of	O	O
these	O	O
data	O	O
indicate	O	O
that	O	O
the	O	O
added	O	O
heterodimer	O	O
substantially	O	O
reduced	O	O
the	O	O
affinity	O	O
of	O	O
TfR	O	O
for	O	O
transferrin	O	O
.	O	O

These	O	O
results	O	O
establish	O	O
a	O	O
molecular	O	O
link	O	O
between	O	O
HFE	O	O
and	O	O
a	O	O
key	O	O
protein	O	O
involved	O	O
in	O	O
iron	O	O
transport	O	O
,	O	O
the	O	O
TfR	O	O
,	O	O
and	O	O
raise	O	O
the	O	O
possibility	O	O
that	O	O
alterations	O	O
in	O	O
this	O	O
regulatory	O	O
mechanism	O	O
may	O	O
play	O	O
a	O	O
role	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
hereditary	B-Disease	D006432
hemochromatosis	I-Disease	D006432
.	O	O

.	O	O

Cycloheximide	O	O
facilitates	O	O
the	O	O
identification	O	O
of	O	O
aberrant	O	O
transcripts	O	O
resulting	O	O
from	O	O
a	O	O
novel	O	O
splice	O	O
-	O	O
site	O	O
mutation	O	O
in	O	O
COL17A1	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
generalized	O	O
atrophic	B-Disease	D016109
benign	I-Disease	D016109
epidermolysis	I-Disease	D016109
bullosa	I-Disease	D016109
.	O	O

Patients	O	O
with	O	O
generalized	O	O
atrophic	B-Disease	D016109
benign	I-Disease	D016109
epidermolysis	I-Disease	D016109
bullosa	I-Disease	D016109
often	O	O
show	O	O
decreased	O	O
expression	O	O
of	O	O
type	O	O
XVII	O	O
collagen	O	O
,	O	O
a	O	O
transmembrane	O	O
hemidesmosomal	O	O
protein	O	O
encoded	O	O
by	O	O
COL17A1	O	O
.	O	O

This	O	O
report	O	O
documents	O	O
a	O	O
novel	O	O
splice	O	O
-	O	O
site	O	O
mutation	O	O
in	O	O
COL17A1	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
generalized	O	O
atrophic	B-Disease	D016109
benign	I-Disease	D016109
epidermolysis	I-Disease	D016109
bullosa	I-Disease	D016109
,	O	O
and	O	O
applies	O	O
a	O	O
new	O	O
methodology	O	O
to	O	O
define	O	O
and	O	O
characterize	O	O
the	O	O
resulting	O	O
mRNA	O	O
splice	O	O
variants	O	O
.	O	O

Mutational	O	O
analysis	O	O
of	O	O
COL17A1	O	O
identified	O	O
a	O	O
maternally	O	O
inherited	O	O
G	O	O
-	O	O
to	O	O
-	O	O
T	O	O
transversion	O	O
at	O	O
the	O	O
-	O	O
1	O	O
position	O	O
of	O	O
exon	O	O
32	O	O
.	O	O

This	O	O
acceptor	O	O
splice	O	O
-	O	O
site	O	O
mutation	O	O
led	O	O
to	O	O
the	O	O
formation	O	O
of	O	O
aberrant	O	O
transcripts	O	O
present	O	O
at	O	O
extremely	O	O
low	O	O
levels	O	O
.	O	O

Based	O	O
on	O	O
our	O	O
recent	O	O
finding	O	O
that	O	O
cycloheximide	O	O
stabilized	O	O
mutant	O	O
COL17A1	O	O
transcripts	O	O
in	O	O
keratinocytes	O	O
homozygous	O	O
for	O	O
a	O	O
frameshift	O	O
mutation	O	O
,	O	O
the	O	O
effects	O	O
of	O	O
the	O	O
splice	O	O
-	O	O
site	O	O
mutation	O	O
on	O	O
splicing	O	O
of	O	O
COL17A1	O	O
transcripts	O	O
were	O	O
determined	O	O
using	O	O
reverse	O	O
transcriptase	O	O
polymerase	O	O
chain	O	O
reaction	O	O
of	O	O
total	O	O
RNA	O	O
from	O	O
keratinocytes	O	O
incubated	O	O
for	O	O
2	O	O
.	O	O

5	O	O
h	O	O
in	O	O
the	O	O
presence	O	O
or	O	O
absence	O	O
of	O	O
10	O	O
microg	O	O
cycloheximide	O	O
per	O	O
ml	O	O
.	O	O

Using	O	O
this	O	O
approach	O	O
,	O	O
an	O	O
abnormally	O	O
spliced	O	O
transcript	O	O
was	O	O
identified	O	O
that	O	O
contains	O	O
an	O	O
extra	O	O
264	O	O
bases	O	O
upstream	O	O
from	O	O
exon	O	O
32	O	O
,	O	O
resulting	O	O
in	O	O
a	O	O
premature	O	O
termination	O	O
codon	O	O
27	O	O
bp	O	O
downstream	O	O
from	O	O
the	O	O
cryptic	O	O
splice	O	O
site	O	O
.	O	O

Three	O	O
other	O	O
splice	O	O
variants	O	O
,	O	O
including	O	O
one	O	O
derived	O	O
from	O	O
the	O	O
skipping	O	O
of	O	O
exon	O	O
32	O	O
,	O	O
were	O	O
also	O	O
identified	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
the	O	O
usefulness	O	O
of	O	O
cycloheximide	O	O
treatment	O	O
in	O	O
evaluating	O	O
the	O	O
abnormal	O	O
processing	O	O
of	O	O
mRNA	O	O
due	O	O
to	O	O
splice	O	O
-	O	O
site	O	O
mutations	O	O
,	O	O
because	O	O
(	O	O
i	O	O
)	O	O
aberrant	O	O
splicing	O	O
often	O	O
generates	O	O
a	O	O
premature	O	O
termination	O	O
codon	O	O
,	O	O
(	O	O
ii	O	O
)	O	O
transcripts	O	O
with	O	O
premature	O	O
termination	O	O
codons	O	O
can	O	O
occur	O	O
at	O	O
low	O	O
or	O	O
undetectable	O	O
levels	O	O
due	O	O
to	O	O
nonsense	O	O
-	O	O
mediated	O	O
mRNA	O	O
decay	O	O
,	O	O
and	O	O
(	O	O
iii	O	O
)	O	O
the	O	O
levels	O	O
of	O	O
these	O	O
transcripts	O	O
can	O	O
be	O	O
increased	O	O
by	O	O
cycloheximide	O	O
.	O	O

The	O	O
DMPK	O	O
gene	O	O
of	O	O
severely	O	O
affected	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
patients	O	O
is	O	O
hypermethylated	O	O
proximal	O	O
to	O	O
the	O	O
largely	O	O
expanded	O	O
CTG	O	O
repeat	O	O
.	O	O

Using	O	O
methylation	O	O
-	O	O
sensitive	O	O
restriction	O	O
enzymes	O	O
,	O	O
we	O	O
characterized	O	O
the	O	O
methylation	O	O
pattern	O	O
on	O	O
the	O	O
5	O	O
side	O	O
of	O	O
the	O	O
CTG	O	O
repeat	O	O
in	O	O
the	O	O
DMPK	O	O
gene	O	O
of	O	O
normal	O	O
individuals	O	O
and	O	O
of	O	O
patients	O	O
affected	O	O
with	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
,	O	O
showing	O	O
expansions	O	O
of	O	O
the	O	O
repetitive	O	O
sequence	O	O
.	O	O

The	O	O
gene	O	O
segment	O	O
analyzed	O	O
corresponds	O	O
to	O	O
the	O	O
genomic	O	O
SacI	O	O
-	O	O
HindIII	O	O
fragment	O	O
carrying	O	O
exons	O	O
11	O	O
-	O	O
15	O	O
.	O	O

There	O	O
is	O	O
constitutive	O	O
methylation	O	O
in	O	O
intron	O	O
12	O	O
at	O	O
restriction	O	O
sites	O	O
of	O	O
SacII	O	O
and	O	O
HhaI	O	O
,	O	O
localized	O	O
1	O	O
,	O	O
159	O	O
-	O	O
1	O	O
,	O	O
232	O	O
bp	O	O
upstream	O	O
of	O	O
the	O	O
CTG	O	O
repeat	O	O
,	O	O
whereas	O	O
most	O	O
,	O	O
if	O	O
not	O	O
all	O	O
,	O	O
of	O	O
the	O	O
other	O	O
sites	O	O
of	O	O
SacII	O	O
,	O	O
HhaI	O	O
,	O	O
and	O	O
HpaII	O	O
in	O	O
this	O	O
region	O	O
are	O	O
unmethylated	O	O
,	O	O
in	O	O
normal	O	O
individuals	O	O
and	O	O
most	O	O
of	O	O
the	O	O
patients	O	O
.	O	O

In	O	O
a	O	O
number	O	O
of	O	O
young	O	O
and	O	O
severely	O	O
affected	O	O
patients	O	O
,	O	O
however	O	O
,	O	O
complete	O	O
methylation	O	O
of	O	O
these	O	O
restriction	O	O
sites	O	O
was	O	O
found	O	O
in	O	O
the	O	O
mutated	O	O
allele	O	O
.	O	O

In	O	O
most	O	O
of	O	O
these	O	O
patients	O	O
,	O	O
the	O	O
onset	O	O
of	O	O
the	O	O
disease	O	O
was	O	O
congenital	O	O
.	O	O

Preliminary	O	O
in	O	O
vivo	O	O
footprinting	O	O
data	O	O
gave	O	O
evidence	O	O
for	O	O
protein	O	O
-	O	O
DNA	O	O
contact	O	O
in	O	O
normal	O	O
genes	O	O
at	O	O
an	O	O
Sp1	O	O
consensus	O	O
binding	O	O
site	O	O
upstream	O	O
of	O	O
the	O	O
CTG	O	O
repeat	O	O
and	O	O
for	O	O
a	O	O
significant	O	O
reduction	O	O
of	O	O
this	O	O
interaction	O	O
in	O	O
cells	O	O
with	O	O
a	O	O
hypermethylated	O	O
DMPK	O	O
gene	O	O
.	O	O

.	O	O

Progression	O	O
of	O	O
somatic	O	O
CTG	O	O
repeat	O	O
length	O	O
heterogeneity	O	O
in	O	O
the	O	O
blood	O	O
cells	O	O
of	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
patients	O	O
.	O	O

The	O	O
genetic	O	O
basis	O	O
of	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
is	O	O
the	O	O
expansion	O	O
of	O	O
an	O	O
unstable	O	O
CTG	O	O
repeat	O	O
in	O	O
the	O	O
34	O	O
UTR	O	O
of	O	O
the	O	O
DM	B-Disease	D009223
protein	O	O
kinase	O	O
gene	O	O
on	O	O
chromosome	O	O
19	O	O
.	O	O

One	O	O
of	O	O
the	O	O
principal	O	O
features	O	O
of	O	O
the	O	O
DM	B-Disease	D009223
mutation	O	O
is	O	O
an	O	O
extraordinarily	O	O
high	O	O
level	O	O
of	O	O
somatic	O	O
mosaicism	O	O
,	O	O
due	O	O
to	O	O
an	O	O
extremely	O	O
high	O	O
degree	O	O
of	O	O
somatic	O	O
instability	O	O
both	O	O
within	O	O
and	O	O
between	O	O
different	O	O
tissues	O	O
.	O	O

This	O	O
instability	O	O
appears	O	O
to	O	O
be	O	O
biased	O	O
towards	O	O
further	O	O
expansion	O	O
and	O	O
continuous	O	O
throughout	O	O
the	O	O
life	O	O
of	O	O
an	O	O
individual	O	O
,	O	O
features	O	O
that	O	O
could	O	O
be	O	O
associated	O	O
with	O	O
the	O	O
progressive	O	O
nature	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

Although	O	O
increasing	O	O
measured	O	O
allele	O	O
size	O	O
between	O	O
patients	O	O
clearly	O	O
correlates	O	O
with	O	O
an	O	O
increased	O	O
severity	O	O
of	O	O
symptoms	O	O
and	O	O
an	O	O
earlier	O	O
age	O	O
of	O	O
onset	O	O
,	O	O
this	O	O
correlation	O	O
is	O	O
not	O	O
precise	O	O
and	O	O
measured	O	O
allele	O	O
length	O	O
cannot	O	O
be	O	O
used	O	O
as	O	O
an	O	O
accurate	O	O
predictor	O	O
of	O	O
age	O	O
of	O	O
onset	O	O
.	O	O

In	O	O
order	O	O
to	O	O
further	O	O
characterize	O	O
the	O	O
dynamics	O	O
of	O	O
DM	B-Disease	D009223
CTG	O	O
repeat	O	O
somatic	O	O
instability	O	O
,	O	O
we	O	O
have	O	O
studied	O	O
repeat	O	O
length	O	O
changes	O	O
over	O	O
time	O	O
in	O	O
111	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
patients	O	O
with	O	O
varying	O	O
clinical	O	O
severity	O	O
and	O	O
CTG	O	O
repeat	O	O
size	O	O
over	O	O
time	O	O
intervals	O	O
of	O	O
1	O	O
-	O	O
7	O	O
years	O	O
.	O	O

We	O	O
have	O	O
found	O	O
a	O	O
direct	O	O
progression	O	O
of	O	O
the	O	O
size	O	O
heterogeneity	O	O
over	O	O
time	O	O
related	O	O
to	O	O
initial	O	O
CTG	O	O
repeat	O	O
size	O	O
and	O	O
the	O	O
time	O	O
interval	O	O
and	O	O
always	O	O
biased	O	O
towards	O	O
further	O	O
expansion	O	O
.	O	O

Attempts	O	O
to	O	O
mathematically	O	O
model	O	O
the	O	O
dynamics	O	O
have	O	O
proved	O	O
only	O	O
partially	O	O
successful	O	O
suggesting	O	O
that	O	O
individual	O	O
specific	O	O
genetic	O	O
and	O	O
/	O	O
or	O	O
environmental	O	O
factors	O	O
also	O	O
play	O	O
a	O	O
role	O	O
in	O	O
somatic	O	O
mosaicism	O	O
.	O	O

.	O	O

Inherited	B-Disease	D011125
colorectal	I-Disease	D011125
polyposis	I-Disease	D011125
and	O	O
cancer	B-Disease	D009369
risk	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
I1307K	O	O
polymorphism	O	O
.	O	O

Germ	O	O
-	O	O
line	O	O
and	O	O
somatic	O	O
truncating	O	O
mutations	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
are	O	O
thought	O	O
to	O	O
initiate	O	O
colorectal	B-Disease	D015179
tumor	I-Disease	D015179
formation	O	O
in	O	O
familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
syndrome	I-Disease	D011125
and	O	O
sporadic	O	O
colorectal	O	O
carcinogenesis	O	O
,	O	O
respectively	O	O
.	O	O

Recently	O	O
,	O	O
an	O	O
isoleucine	O	O
-	O	O
-	O	O
>	O	O
lysine	O	O
polymorphism	O	O
at	O	O
codon	O	O
1307	O	O
(	O	O
I1307K	O	O
)	O	O
of	O	O
the	O	O
APC	B-Disease	D011125
gene	O	O
has	O	O
been	O	O
identified	O	O
in	O	O
6	O	O
%	O	O
-	O	O
7	O	O
%	O	O
of	O	O
the	O	O
Ashkenazi	O	O
Jewish	O	O
population	O	O
.	O	O

To	O	O
assess	O	O
the	O	O
risk	O	O
of	O	O
this	O	O
common	O	O
APC	B-Disease	D011125
allelic	O	O
variant	O	O
in	O	O
colorectal	O	O
carcinogenesis	O	O
,	O	O
we	O	O
have	O	O
analyzed	O	O
a	O	O
large	O	O
cohort	O	O
of	O	O
unselected	O	O
Ashkenazi	O	O
Jewish	O	O
subjects	O	O
with	O	O
adenomatous	B-Disease	D018256
polyps	I-Disease	D018256
and	O	O
.	O	O

or	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
,	I-Disease	D015179
for	O	O
the	O	O
APC	B-Disease	D011125
I1307K	O	O
polymorphism	O	O
.	O	O

The	O	O
APC	B-Disease	D011125
I1307K	O	O
allele	O	O
was	O	O
identified	O	O
in	O	O
48	O	O
(	O	O
10	O	O
.	O	O

1	O	O
%	O	O
)	O	O
of	O	O
476	O	O
patients	O	O
.	O	O

Compared	O	O
with	O	O
the	O	O
frequency	O	O
in	O	O
two	O	O
separate	O	O
population	O	O
control	O	O
groups	O	O
,	O	O
the	O	O
APC	B-Disease	D011125
I1307K	O	O
allele	O	O
is	O	O
associated	O	O
with	O	O
an	O	O
estimated	O	O
relative	O	O
risk	O	O
of	O	O
1	O	O
.	O	O

5	O	O
-	O	O
1	O	O
.	O	O

7	O	O
for	O	O
colorectal	B-Disease	D015179
neoplasia	I-Disease	D015179
(	O	O
both	O	O
P	O	O
=	O	O
.	O	O

01	O	O
)	O	O
.	O	O

Furthermore	O	O
,	O	O
compared	O	O
with	O	O
noncarriers	O	O
,	O	O
APC	B-Disease	D011125
I1307K	O	O
carriers	O	O
had	O	O
increased	O	O
numbers	O	O
of	O	O
adenomas	B-Disease	D000236
and	O	O
colorectal	B-Disease	D015179
cancers	I-Disease	D015179
per	O	O
patient	O	O
(	O	O
P	O	O
=	O	O
.	O	O

03	O	O
)	O	O
,	O	O
as	O	O
well	O	O
as	O	O
a	O	O
younger	O	O
age	O	O
at	O	O
diagnosis	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
the	O	O
APC	B-Disease	D011125
I1307K	O	O
variant	O	O
leads	O	O
to	O	O
increased	O	O
adenoma	B-Disease	D000236
formation	O	O
and	O	O
directly	O	O
contributes	O	O
to	O	O
3	O	O
%	O	O
-	O	O
4	O	O
%	O	O
of	O	O
all	O	O
Ashkenazi	O	O
Jewish	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
.	O	O

The	O	O
estimated	O	O
relative	O	O
risk	O	O
for	O	O
carriers	O	O
may	O	O
justify	O	O
specific	O	O
clinical	O	O
screening	O	O
for	O	O
the	O	O
360	O	O
,	O	O
000	O	O
Americans	O	O
expected	O	O
to	O	O
harbor	O	O
this	O	O
allele	O	O
,	O	O
and	O	O
genetic	O	O
testing	O	O
in	O	O
the	O	O
setting	O	O
of	O	O
long	O	O
-	O	O
term	O	O
-	O	O
outcome	O	O
studies	O	O
may	O	O
impact	O	O
significantly	O	O
on	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
prevention	O	O
in	O	O
this	O	O
population	O	O
.	O	O

Human	O	O
MLH1	O	O
deficiency	O	O
predisposes	O	O
to	O	O
hematological	B-Disease	D019337
malignancy	I-Disease	D019337
and	O	O
neurofibromatosis	B-Disease	D009456
type	I-Disease	D009456
1	I-Disease	D009456
.	O	O

Heterozygous	O	O
germ	O	O
-	O	O
line	O	O
mutations	O	O
in	O	O
the	O	O
DNA	O	O
mismatch	O	O
repair	O	O
genes	O	O
lead	O	O
to	O	O
hereditary	B-Disease	D003123
nonpolyposis	I-Disease	D003123
colorectal	I-Disease	D003123
cancer	I-Disease	D003123
.	O	O

The	O	O
disease	O	O
susceptibility	O	O
of	O	O
individuals	O	O
who	O	O
constitutionally	O	O
lack	O	O
both	O	O
wild	O	O
-	O	O
type	O	O
alleles	O	O
is	O	O
unknown	O	O
.	O	O

We	O	O
have	O	O
identified	O	O
three	O	O
offspring	O	O
in	O	O
a	O	O
hereditary	B-Disease	D003123
nonpolyposis	I-Disease	D003123
colorectal	I-Disease	D003123
cancer	I-Disease	D003123
family	O	O
who	O	O
developed	O	O
hematological	B-Disease	D019337
malignancy	I-Disease	D019337
at	O	O
a	O	O
very	O	O
early	O	O
age	O	O
,	O	O
and	O	O
at	O	O
least	O	O
two	O	O
of	O	O
them	O	O
displayed	O	O
signs	O	O
of	O	O
neurofibromatosis	B-Disease	D009456
type	I-Disease	D009456
1	I-Disease	D009456
(	O	O
NF1	B-Disease	D009456
)	O	O
.	O	O

DNA	O	O
sequence	O	O
analysis	O	O
and	O	O
allele	O	O
-	O	O
specific	O	O
amplification	O	O
in	O	O
two	O	O
siblings	O	O
revealed	O	O
a	O	O
homozygous	O	O
MLH1	O	O
mutation	O	O
(	O	O
C676T	O	O
-	O	O
-	O	O
>	O	O
Arg226Stop	O	O
)	O	O
.	O	O

Thus	O	O
,	O	O
a	O	O
homozygous	O	O
germ	O	O
-	O	O
line	O	O
MLH1	O	O
mutation	O	O
and	O	O
consequent	O	O
mismatch	O	O
repair	O	O
deficiency	O	O
results	O	O
in	O	O
a	O	O
mutator	O	O
phenotype	O	O
characterized	O	O
by	O	O
leukemia	B-Disease	D007938
and	O	O
/	O	O
or	O	O
lymphoma	B-Disease	D008223
associated	O	O
with	O	O
neurofibromatosis	B-Disease	D009456
type	I-Disease	D009456
1	I-Disease	D009456
.	O	O

.	O	O

Are	O	O
Dp71	O	O
and	O	O
Dp140	O	O
brain	O	O
dystrophin	O	O
isoforms	O	O
related	O	O
to	O	O
cognitive	B-Disease	D003072
impairment	I-Disease	D003072
in	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
?	O	O
Molecular	O	O
study	O	O
and	O	O
neuropsychological	O	O
analysis	O	O
were	O	O
performed	O	O
concurrently	O	O
on	O	O
49	O	O
patients	O	O
with	O	O
Duchenne	B-Disease	D020388
muscular	I-Disease	D020388
dystrophy	I-Disease	D020388
(	O	O
DMD	B-Disease	D020388
)	O	O
in	O	O
order	O	O
to	O	O
find	O	O
a	O	O
molecular	O	O
explanation	O	O
for	O	O
the	O	O
cognitive	B-Disease	D003072
impairment	I-Disease	D003072
observed	O	O
in	O	O
most	O	O
DMD	B-Disease	D020388
patients	O	O
.	O	O

Complete	O	O
analysis	O	O
of	O	O
the	O	O
dystrophin	O	O
gene	O	O
was	O	O
performed	O	O
to	O	O
define	O	O
the	O	O
localization	O	O
of	O	O
deletions	O	O
and	O	O
duplications	O	O
in	O	O
relation	O	O
to	O	O
the	O	O
different	O	O
DMD	B-Disease	D020388
promoters	O	O
.	O	O

Qualitative	O	O
analysis	O	O
of	O	O
the	O	O
Dp71	O	O
transcript	O	O
and	O	O
testing	O	O
for	O	O
the	O	O
specific	O	O
first	O	O
exon	O	O
of	O	O
Dp140	O	O
were	O	O
also	O	O
carried	O	O
out	O	O
.	O	O

Neuropsychological	O	O
analysis	O	O
assessed	O	O
verbal	O	O
and	O	O
visuospatial	O	O
intelligence	O	O
,	O	O
verbal	O	O
memory	O	O
,	O	O
and	O	O
reading	O	O
skills	O	O
.	O	O

Comparison	O	O
of	O	O
molecular	O	O
and	O	O
psychometric	O	O
findings	O	O
demonstrated	O	O
that	O	O
deletions	O	O
and	O	O
duplications	O	O
that	O	O
were	O	O
localized	O	O
in	O	O
the	O	O
distal	O	O
part	O	O
of	O	O
the	O	O
gene	O	O
seemed	O	O
to	O	O
be	O	O
preferentially	O	O
associated	O	O
with	O	O
cognitive	B-Disease	D003072
impairment	I-Disease	D003072
.	O	O

Two	O	O
altered	O	O
Dp71	O	O
transcripts	O	O
and	O	O
two	O	O
deleted	O	O
Dp140	O	O
DNA	O	O
sequences	O	O
were	O	O
found	O	O
in	O	O
four	O	O
patients	O	O
with	O	O
severe	O	O
cerebral	B-Disease	D001927
dysfunction	I-Disease	D001927
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
some	O	O
sequences	O	O
located	O	O
in	O	O
the	O	O
distal	O	O
part	O	O
of	O	O
the	O	O
gene	O	O
and	O	O
,	O	O
in	O	O
particular	O	O
,	O	O
some	O	O
DMD	B-Disease	D020388
isoforms	O	O
expressed	O	O
in	O	O
the	O	O
brain	O	O
may	O	O
be	O	O
related	O	O
to	O	O
the	O	O
cognitive	B-Disease	D003072
impairment	I-Disease	D003072
associated	O	O
with	O	O
DMD	B-Disease	D020388
.	O	O

.	O	O

A	O	O
genome	O	O
-	O	O
wide	O	O
search	O	O
for	O	O
chromosomal	O	O
loci	O	O
linked	O	O
to	O	O
mental	O	O
health	O	O
wellness	O	O
in	O	O
relatives	O	O
at	O	O
high	O	O
risk	O	O
for	O	O
bipolar	B-Disease	D001714
affective	I-Disease	D001714
disorder	I-Disease	D001714
among	O	O
the	O	O
Old	O	O
Order	O	O
Amish	O	O
.	O	O

Bipolar	B-Disease	D001714
affective	I-Disease	D001714
disorder	I-Disease	D001714
(	O	O
BPAD	B-Disease	D001714
;	O	O
manic	B-Disease	D001714
-	I-Disease	D001714
depressive	I-Disease	D001714
illness	I-Disease	D001714
)	O	O
is	O	O
characterized	O	O
by	O	O
episodes	O	O
of	O	O
mania	B-Disease	D001714
and	O	O
/	O	O
or	O	O
hypomania	B-Disease	D019964
interspersed	O	O
with	O	O
periods	O	O
of	O	O
depression	B-Disease	D003866
.	O	O

Compelling	O	O
evidence	O	O
supports	O	O
a	O	O
significant	O	O
genetic	O	O
component	O	O
in	O	O
the	O	O
susceptibility	O	O
to	O	O
develop	O	O
BPAD	B-Disease	D001714
.	O	O

To	O	O
date	O	O
,	O	O
however	O	O
,	O	O
linkage	O	O
studies	O	O
have	O	O
attempted	O	O
only	O	O
to	O	O
identify	O	O
chromosomal	O	O
loci	O	O
that	O	O
cause	O	O
or	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
developing	O	O
BPAD	B-Disease	D001714
.	O	O

To	O	O
determine	O	O
whether	O	O
there	O	O
could	O	O
be	O	O
protective	O	O
alleles	O	O
that	O	O
prevent	O	O
or	O	O
reduce	O	O
the	O	O
risk	O	O
of	O	O
developing	O	O
BPAD	B-Disease	D001714
,	O	O
similar	O	O
to	O	O
what	O	O
is	O	O
observed	O	O
in	O	O
other	O	O
genetic	B-Disease	D030342
disorders	I-Disease	D030342
,	O	O
we	O	O
used	O	O
mental	O	O
health	O	O
wellness	O	O
(	O	O
absence	O	O
of	O	O
any	O	O
psychiatric	B-Disease	D001523
disorder	I-Disease	D001523
)	O	O
as	O	O
the	O	O
phenotype	O	O
in	O	O
our	O	O
genome	O	O
-	O	O
wide	O	O
linkage	O	O
scan	O	O
of	O	O
several	O	O
large	O	O
multigeneration	O	O
Old	O	O
Order	O	O
Amish	O	O
pedigrees	O	O
exhibiting	O	O
an	O	O
extremely	O	O
high	O	O
incidence	O	O
of	O	O
BPAD	B-Disease	D001714
.	O	O

We	O	O
have	O	O
found	O	O
strong	O	O
evidence	O	O
for	O	O
a	O	O
locus	O	O
on	O	O
chromosome	O	O
4p	O	O
at	O	O
D4S2949	O	O
(	O	O
maximum	O	O
GENEHUNTER	O	O
-	O	O
PLUS	O	O
nonparametric	O	O
linkage	O	O
score	O	O
=	O	O
4	O	O
.	O	O

05	O	O
,	O	O
P	O	O
=	O	O
5	O	O
.	O	O

22	O	O
x	O	O
10	O	O
(	O	O
-	O	O
4	O	O
)	O	O
;	O	O
SIBPAL	O	O
Pempirical	O	O
value	O	O
<	O	O
3	O	O
x	O	O
10	O	O
(	O	O
-	O	O
5	O	O
)	O	O
)	O	O
and	O	O
suggestive	O	O
evidence	O	O
for	O	O
a	O	O
locus	O	O
on	O	O
chromosome	O	O
4q	O	O
at	O	O
D4S397	O	O
(	O	O
maximum	O	O
GENEHUNTER	O	O
-	O	O
PLUS	O	O
nonparametric	O	O
linkage	O	O
score	O	O
=	O	O
3	O	O
.	O	O

29	O	O
,	O	O
P	O	O
=	O	O
2	O	O
.	O	O

57	O	O
x	O	O
10	O	O
(	O	O
-	O	O
3	O	O
)	O	O
;	O	O
SIBPAL	O	O
Pempirical	O	O
value	O	O
<	O	O
1	O	O
x	O	O
10	O	O
(	O	O
-	O	O
3	O	O
)	O	O
)	O	O
that	O	O
are	O	O
linked	O	O
to	O	O
mental	O	O
health	O	O
wellness	O	O
.	O	O

These	O	O
findings	O	O
are	O	O
consistent	O	O
with	O	O
the	O	O
hypothesis	O	O
that	O	O
certain	O	O
alleles	O	O
could	O	O
prevent	O	O
or	O	O
modify	O	O
the	O	O
clinical	O	O
manifestations	O	O
of	O	O
BPAD	B-Disease	D001714
and	O	O
perhaps	O	O
other	O	O
related	O	O
affective	B-Disease	D019964
disorders	I-Disease	D019964
.	O	O

Hereditary	B-Disease	OMIM:609536
deficiency	I-Disease	OMIM:609536
of	I-Disease	OMIM:609536
the	I-Disease	OMIM:609536
fifth	I-Disease	OMIM:609536
component	I-Disease	OMIM:609536
of	I-Disease	OMIM:609536
complement	I-Disease	OMIM:609536
in	O	O
man	O	O
.	O	O

I	O	O
.	O	O

Clinical	O	O
,	O	O
immunochemical	O	O
,	O	O
and	O	O
family	O	O
studies	O	O
.	O	O

The	O	O
first	O	O
recognized	O	O
human	O	O
kindred	O	O
with	O	O
hereditary	B-Disease	OMIM:609536
deficiency	I-Disease	OMIM:609536
of	I-Disease	OMIM:609536
the	I-Disease	OMIM:609536
fifth	I-Disease	OMIM:609536
component	I-Disease	OMIM:609536
of	I-Disease	OMIM:609536
complement	I-Disease	OMIM:609536
(	O	O
C5	O	O
)	O	O
is	O	O
described	O	O
.	O	O

The	O	O
proband	O	O
,	O	O
a	O	O
20	O	O
-	O	O
year	O	O
-	O	O
old	O	O
black	O	O
female	O	O
with	O	O
systemic	B-Disease	D008180
lupus	I-Disease	D008180
erythematosus	I-Disease	D008180
since	O	O
age	O	O
11	O	O
,	O	O
lacked	O	O
serum	O	O
hemolytic	O	O
complement	O	O
activity	O	O
,	O	O
even	O	O
during	O	O
remission	O	O
.	O	O

C5	O	O
was	O	O
undetectable	O	O
in	O	O
her	O	O
serum	O	O
by	O	O
both	O	O
immunodiffusion	O	O
and	O	O
hemolytic	O	O
assays	O	O
.	O	O

Other	O	O
complement	O	O
components	O	O
were	O	O
normal	O	O
during	O	O
remission	O	O
of	O	O
lupus	O	O
,	O	O
but	O	O
C1	O	O
,	O	O
C4	O	O
,	O	O
C2	O	O
,	O	O
and	O	O
C3	O	O
levels	O	O
fell	O	O
during	O	O
exacerbations	O	O
.	O	O

A	O	O
younger	O	O
half	O	O
-	O	O
sister	O	O
,	O	O
who	O	O
had	O	O
no	O	O
underlying	O	O
disease	O	O
,	O	O
was	O	O
also	O	O
found	O	O
to	O	O
lack	O	O
immunochemically	O	O
detectable	O	O
C5	O	O
.	O	O

By	O	O
hemolytic	O	O
assay	O	O
,	O	O
she	O	O
exhibited	O	O
1	O	O
-	O	O
2	O	O
%	O	O
of	O	O
the	O	O
normal	O	O
serum	O	O
C5	O	O
level	O	O
and	O	O
normal	O	O
concentrations	O	O
of	O	O
other	O	O
complement	O	O
components	O	O
.	O	O

C5	O	O
levels	O	O
of	O	O
other	O	O
family	O	O
members	O	O
were	O	O
either	O	O
normal	O	O
or	O	O
approximately	O	O
half	O	O
-	O	O
normal	O	O
,	O	O
consistent	O	O
with	O	O
autosomal	O	O
codominant	O	O
inheritance	O	O
of	O	O
the	O	O
gene	O	O
determining	O	O
C5	B-Disease	OMIM:609536
deficiency	I-Disease	OMIM:609536
.	O	O

Normal	O	O
hemolytic	O	O
titers	O	O
were	O	O
restored	O	O
to	O	O
both	O	O
homozygous	O	O
C5	B-Disease	OMIM:609536
-	I-Disease	OMIM:609536
deficient	I-Disease	OMIM:609536
(	O	O
C5D	B-Disease	OMIM:609536
)	O	O
sera	O	O
by	O	O
addition	O	O
of	O	O
highly	O	O
purified	O	O
human	O	O
C5	O	O
.	O	O

In	O	O
specific	O	O
C5	O	O
titrations	O	O
,	O	O
however	O	O
,	O	O
it	O	O
was	O	O
noted	O	O
that	O	O
when	O	O
limited	O	O
amounts	O	O
of	O	O
C5	O	O
were	O	O
assayed	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
low	O	O
dilutions	O	O
of	O	O
either	O	O
C5D	B-Disease	OMIM:609536
serum	O	O
,	O	O
curving	O	O
rather	O	O
than	O	O
linear	O	O
dose	O	O
-	O	O
response	O	O
plots	O	O
were	O	O
consistently	O	O
obtained	O	O
,	O	O
suggesting	O	O
some	O	O
inhibitory	O	O
effect	O	O
.	O	O

Further	O	O
studies	O	O
suggested	O	O
that	O	O
low	O	O
dilutions	O	O
of	O	O
C5D	B-Disease	OMIM:609536
serum	O	O
contain	O	O
a	O	O
factor	O	O
(	O	O
or	O	O
factors	O	O
)	O	O
interfering	O	O
at	O	O
some	O	O
step	O	O
in	O	O
the	O	O
hemolytic	O	O
assay	O	O
of	O	O
C5	O	O
,	O	O
rather	O	O
than	O	O
a	O	O
true	O	O
C5	O	O
inhibitor	O	O
or	O	O
inactivator	O	O
.	O	O

Of	O	O
clinical	O	O
interest	O	O
are	O	O
(	O	O
a	O	O
)	O	O
the	O	O
documentation	O	O
of	O	O
membranous	O	O
glomerulonephritis	B-Disease	D005921
,	O	O
vasculitis	B-Disease	D014657
,	O	O
and	O	O
arthritis	B-Disease	D001168
in	O	O
an	O	O
individual	O	O
lacking	O	O
C5	O	O
(	O	O
and	O	O
its	O	O
biologic	O	O
functions	O	O
)	O	O
,	O	O
and	O	O
(	O	O
b	O	O
)	O	O
a	O	O
remarkable	O	O
propensity	O	O
to	O	O
bacterial	B-Disease	D001424
infections	I-Disease	D001424
in	O	O
the	O	O
proband	O	O
,	O	O
even	O	O
during	O	O
periods	O	O
of	O	O
low	O	O
-	O	O
dose	O	O
or	O	O
alternate	O	O
-	O	O
day	O	O
corticosteroid	O	O
therapy	O	O
.	O	O

Other	O	O
observations	O	O
indicate	O	O
that	O	O
the	O	O
C5D	B-Disease	OMIM:609536
state	O	O
is	O	O
compatible	O	O
with	O	O
normal	O	O
coagulation	O	O
function	O	O
and	O	O
the	O	O
capacity	O	O
to	O	O
mount	O	O
a	O	O
neutrophilic	O	O
leukocytosis	O	O
during	O	O
pyogenic	B-Disease	D007239
infection	I-Disease	D007239
.	O	O

.	O	O

Detection	O	O
of	O	O
heterozygous	O	O
carriers	O	O
of	O	O
the	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
(	O	O
ATM	O	O
)	O	O
gene	O	O
by	O	O
G2	O	O
phase	O	O
chromosomal	O	O
radiosensitivity	O	O
of	O	O
peripheral	O	O
blood	O	O
lymphocytes	O	O
.	O	O

In	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
(	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
)	O	O
patients	O	O
,	O	O
mutations	O	O
in	O	O
a	O	O
single	O	O
gene	O	O
,	O	O
ATM	O	O
,	O	O
result	O	O
in	O	O
an	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
syndrome	I-Disease	D030342
that	O	O
embraces	O	O
a	O	O
variety	O	O
of	O	O
clinical	O	O
features	O	O
and	O	O
manifests	O	O
extreme	O	O
radiosensitivity	O	O
and	O	O
a	O	O
strong	O	O
pre	O	O
-	O	O
disposition	O	O
to	O	O
malignancy	B-Disease	D009369
.	O	O

Heterozygotes	O	O
for	O	O
the	O	O
ATM	O	O
gene	O	O
have	O	O
no	O	O
clinical	O	O
expression	O	O
of	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
but	O	O
may	O	O
be	O	O
cancer	B-Disease	D009369
prone	O	O
with	O	O
a	O	O
moderate	O	O
increase	O	O
in	O	O
in	O	O
vitro	O	O
radiosensitivity	O	O
.	O	O

We	O	O
performed	O	O
a	O	O
blind	O	O
chromosomal	O	O
analysis	O	O
on	O	O
G2	O	O
-	O	O
phase	O	O
lymphocytes	O	O
from	O	O
7	O	O
unrelated	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
patients	O	O
,	O	O
13	O	O
obligate	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
heterozygotes	O	O
(	O	O
parents	O	O
of	O	O
the	O	O
patients	O	O
)	O	O
,	O	O
and	O	O
14	O	O
normal	O	O
controls	O	O
following	O	O
X	O	O
-	O	O
irradiation	O	O
with	O	O
1	O	O
Gy	O	O
in	O	O
order	O	O
to	O	O
evaluate	O	O
this	O	O
cytogenetic	O	O
method	O	O
as	O	O
a	O	O
tool	O	O
for	O	O
detection	O	O
of	O	O
ATM	O	O
carriers	O	O
.	O	O

Both	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
homozygotes	O	O
and	O	O
heterozygotes	O	O
showed	O	O
significantly	O	O
increased	O	O
levels	O	O
of	O	O
radiation	O	O
-	O	O
induced	O	O
chromatid	O	O
damage	O	O
relative	O	O
to	O	O
that	O	O
of	O	O
normal	O	O
controls	O	O
.	O	O

These	O	O
results	O	O
show	O	O
that	O	O
the	O	O
G2	O	O
-	O	O
phase	O	O
chromosomal	O	O
radiosensitivity	O	O
assay	O	O
can	O	O
be	O	O
used	O	O
for	O	O
the	O	O
detection	O	O
of	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
heterozygotes	O	O
.	O	O

In	O	O
combination	O	O
with	O	O
molecular	O	O
genetic	O	O
analyses	O	O
,	O	O
this	O	O
test	O	O
may	O	O
be	O	O
of	O	O
value	O	O
in	O	O
studies	O	O
of	O	O
familial	B-Disease	D009369
and	I-Disease	D009369
sporadic	I-Disease	D009369
cancers	I-Disease	D009369
aimed	O	O
at	O	O
determination	O	O
of	O	O
the	O	O
potential	O	O
involvement	O	O
of	O	O
ATM	O	O
mutations	O	O
in	O	O
tumor	B-Disease	D009369
risk	O	O
or	O	O
development	O	O
.	O	O

.	O	O

The	O	O
molecular	O	O
basis	O	O
of	O	O
C6	B-Disease	OMIM:612446
deficiency	I-Disease	OMIM:612446
in	O	O
the	O	O
western	O	O
Cape	O	O
,	O	O
South	O	O
Africa	O	O
.	O	O

Deficiency	B-Disease	OMIM:612446
of	I-Disease	OMIM:612446
the	I-Disease	OMIM:612446
sixth	I-Disease	OMIM:612446
component	I-Disease	OMIM:612446
of	I-Disease	OMIM:612446
human	I-Disease	OMIM:612446
complement	I-Disease	OMIM:612446
(	O	O
C6	O	O
)	O	O
has	O	O
been	O	O
reported	O	O
in	O	O
a	O	O
number	O	O
of	O	O
families	O	O
from	O	O
the	O	O
western	O	O
Cape	O	O
,	O	O
South	O	O
Africa	O	O
.	O	O

Meningococcal	B-Disease	D008589
disease	I-Disease	D008589
is	O	O
endemic	O	O
in	O	O
the	O	O
Cape	O	O
and	O	O
almost	O	O
all	O	O
pedigrees	O	O
of	O	O
total	O	O
C6	B-Disease	OMIM:612446
deficiency	I-Disease	OMIM:612446
(	O	O
C6Q0	O	O
)	O	O
have	O	O
been	O	O
ascertained	O	O
because	O	O
of	O	O
recurrent	O	O
disease	O	O
.	O	O

We	O	O
have	O	O
sequenced	O	O
the	O	O
expressed	O	O
exons	O	O
of	O	O
the	O	O
C6	O	O
gene	O	O
from	O	O
selected	O	O
cases	O	O
and	O	O
have	O	O
found	O	O
three	O	O
molecular	O	O
defects	O	O
leading	O	O
to	O	O
total	O	O
deficiency	O	O
879delG	O	O
,	O	O
which	O	O
is	O	O
the	O	O
common	O	O
defect	O	O
in	O	O
the	O	O
Cape	O	O
and	O	O
hitherto	O	O
unreported	O	O
,	O	O
and	O	O
1195delC	O	O
and	O	O
1936delG	O	O
,	O	O
which	O	O
have	O	O
been	O	O
previously	O	O
reported	O	O
in	O	O
African	O	O
-	O	O
Americans	O	O
.	O	O

We	O	O
also	O	O
show	O	O
that	O	O
the	O	O
879delG	O	O
and	O	O
1195delC	O	O
defects	O	O
are	O	O
associated	O	O
with	O	O
characteristic	O	O
C6	O	O
/	O	O
C7	O	O
region	O	O
DNA	O	O
marker	O	O
haplotypes	O	O
,	O	O
although	O	O
small	O	O
variations	O	O
were	O	O
observed	O	O
.	O	O

The	O	O
1936delG	O	O
defect	O	O
was	O	O
observed	O	O
only	O	O
once	O	O
in	O	O
the	O	O
Cape	O	O
,	O	O
but	O	O
its	O	O
associated	O	O
haplotype	O	O
could	O	O
be	O	O
deduced	O	O
.	O	O

The	O	O
data	O	O
from	O	O
the	O	O
haplotypes	O	O
indicate	O	O
that	O	O
these	O	O
three	O	O
molecular	O	O
defects	O	O
account	O	O
for	O	O
the	O	O
defects	O	O
in	O	O
all	O	O
the	O	O
38	O	O
unrelated	O	O
C6Q0	O	O
individuals	O	O
we	O	O
have	O	O
studied	O	O
from	O	O
the	O	O
Cape	O	O
.	O	O

We	O	O
have	O	O
also	O	O
observed	O	O
the	O	O
879delG	O	O
defect	O	O
in	O	O
two	O	O
Dutch	O	O
C6	B-Disease	OMIM:612446
-	I-Disease	OMIM:612446
deficient	I-Disease	OMIM:612446
kindreds	O	O
,	O	O
but	O	O
the	O	O
879delG	O	O
defect	O	O
in	O	O
the	O	O
Cape	O	O
probably	O	O
did	O	O
not	O	O
come	O	O
from	O	O
The	O	O
Netherlands	O	O
.	O	O

.	O	O

The	O	O
R496H	O	O
mutation	O	O
of	O	O
arylsulfatase	O	O
A	O	O
does	O	O
not	O	O
cause	O	O
metachromatic	B-Disease	D007966
leukodystrophy	I-Disease	D007966
.	O	O

Deficiency	B-Disease	D007966
of	I-Disease	D007966
arylsulfatase	I-Disease	D007966
A	I-Disease	D007966
(	O	O
ARSA	O	O
)	O	O
enzyme	O	O
activity	O	O
causes	O	O
metachromatic	B-Disease	D007966
leukodystrophy	I-Disease	D007966
(	O	O
MLD	B-Disease	D007966
)	O	O
.	O	O

A	O	O
number	O	O
of	O	O
ARSA	O	O
gene	O	O
mutations	O	O
responsible	O	O
for	O	O
MLD	B-Disease	D007966
have	O	O
been	O	O
identified	O	O
.	O	O

Recently	O	O
,	O	O
the	O	O
R496H	O	O
mutation	O	O
of	O	O
ARSA	O	O
was	O	O
proposed	O	O
to	O	O
be	O	O
a	O	O
cause	O	O
of	O	O
MLD	B-Disease	D007966
(	O	O
Draghia	O	O
et	O	O
al	O	O
.	O	O

,	O	O
1997	O	O
)	O	O
.	O	O

We	O	O
have	O	O
investigated	O	O
the	O	O
R496H	O	O
mutation	O	O
and	O	O
found	O	O
this	O	O
mutation	O	O
at	O	O
a	O	O
relatively	O	O
high	O	O
frequency	O	O
in	O	O
an	O	O
African	O	O
American	O	O
population	O	O
(	O	O
f	O	O
=	O	O
0	O	O
.	O	O

09	O	O
,	O	O
n	O	O
=	O	O
61	O	O
subjects	O	O
)	O	O
.	O	O

The	O	O
ARSA	O	O
enzyme	O	O
activity	O	O
in	O	O
subjects	O	O
with	O	O
and	O	O
without	O	O
the	O	O
R496H	O	O
mutation	O	O
was	O	O
determined	O	O
and	O	O
found	O	O
to	O	O
be	O	O
normal	O	O
.	O	O

It	O	O
is	O	O
therefore	O	O
concluded	O	O
that	O	O
the	O	O
R496H	O	O
mutation	O	O
of	O	O
ARSA	O	O
does	O	O
not	O	O
negatively	O	O
influence	O	O
the	O	O
activity	O	O
of	O	O
ARSA	O	O
and	O	O
is	O	O
not	O	O
a	O	O
cause	O	O
of	O	O
MLD	B-Disease	D007966
Piebaldism	B-Disease	D016116
with	O	O
deafness	B-Disease	D003638
:	O	O
molecular	O	O
evidence	O	O
for	O	O
an	O	O
expanded	O	O
syndrome	O	O
.	O	O

In	O	O
a	O	O
South	O	O
African	O	O
girl	O	O
of	O	O
Xhosa	O	O
stock	O	O
with	O	O
severe	O	O
piebaldism	B-Disease	D016116
and	O	O
profound	O	O
congenital	O	O
sensorineural	B-Disease	D006319
deafness	I-Disease	D006319
we	O	O
identified	O	O
a	O	O
novel	O	O
missense	O	O
substitution	O	O
at	O	O
a	O	O
highly	O	O
conserved	O	O
residue	O	O
in	O	O
the	O	O
intracellular	O	O
kinase	O	O
domain	O	O
of	O	O
the	O	O
KIT	O	O
proto	O	O
-	O	O
oncogene	O	O
,	O	O
R796G	O	O
.	O	O

Though	O	O
auditory	B-Disease	D001304
anomalies	I-Disease	D001304
have	O	O
been	O	O
observed	O	O
in	O	O
mice	O	O
with	O	O
dominant	O	O
white	O	O
spotting	O	O
(	O	O
W	O	O
)	O	O
due	O	O
to	O	O
KIT	O	O
mutations	O	O
,	O	O
deafness	B-Disease	D003638
is	O	O
not	O	O
typical	O	O
in	O	O
human	O	O
piebaldism	B-Disease	D016116
.	O	O

Thus	O	O
,	O	O
the	O	O
occurrence	O	O
of	O	O
sensorineural	B-Disease	D006319
deafness	I-Disease	D006319
in	O	O
this	O	O
patient	O	O
extends	O	O
considerably	O	O
the	O	O
phenotypic	O	O
range	O	O
of	O	O
piebaldism	B-Disease	D016116
due	O	O
to	O	O
KIT	O	O
gene	O	O
mutation	O	O
in	O	O
humans	O	O
and	O	O
tightens	O	O
the	O	O
clinical	O	O
similarity	O	O
between	O	O
piebaldism	B-Disease	D016116
and	O	O
the	O	O
various	O	O
forms	O	O
of	O	O
Waardenburg	B-Disease	D014849
syndrome	I-Disease	D014849
.	O	O

.	O	O

Genetic	O	O
heterogeneity	O	O
and	O	O
penetrance	O	O
analysis	O	O
of	O	O
the	O	O
BRCA1	O	O
and	O	O
BRCA2	O	O
genes	O	O
in	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
families	O	O
.	O	O

The	O	O
Breast	B-Disease	D001943
Cancer	I-Disease	D001943
Linkage	O	O
Consortium	O	O
.	O	O

The	O	O
contribution	O	O
of	O	O
BRCA1	O	O
and	O	O
BRCA2	O	O
to	O	O
inherited	B-Disease	D001943
breast	I-Disease	D001943
cancer	I-Disease	D001943
was	O	O
assessed	O	O
by	O	O
linkage	O	O
and	O	O
mutation	O	O
analysis	O	O
in	O	O
237	O	O
families	O	O
,	O	O
each	O	O
with	O	O
at	O	O
least	O	O
four	O	O
cases	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
,	O	O
collected	O	O
by	O	O
the	O	O
Breast	B-Disease	D001943
Cancer	I-Disease	D001943
Linkage	O	O
Consortium	O	O
.	O	O

Families	O	O
were	O	O
included	O	O
without	O	O
regard	O	O
to	O	O
the	O	O
occurrence	O	O
of	O	O
ovarian	B-Disease	D010051
or	I-Disease	D010051
other	I-Disease	D010051
cancers	I-Disease	D010051
.	O	O

Overall	O	O
,	O	O
disease	O	O
was	O	O
linked	O	O
to	O	O
BRCA1	O	O
in	O	O
an	O	O
estimated	O	O
52	O	O
%	O	O
of	O	O
families	O	O
,	O	O
to	O	O
BRCA2	O	O
in	O	O
32	O	O
%	O	O
of	O	O
families	O	O
,	O	O
and	O	O
to	O	O
neither	O	O
gene	O	O
in	O	O
16	O	O
%	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
6	O	O
%	O	O
-	O	O
28	O	O
%	O	O
)	O	O
,	O	O
suggesting	O	O
other	O	O
predisposition	O	O
genes	O	O
.	O	O

The	O	O
majority	O	O
(	O	O
81	O	O
%	O	O
)	O	O
of	O	O
the	O	O
breast	B-Disease	D061325
-	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
families	O	O
were	O	O
due	O	O
to	O	O
BRCA1	O	O
,	O	O
with	O	O
most	O	O
others	O	O
(	O	O
14	O	O
%	O	O
)	O	O
due	O	O
to	O	O
BRCA2	O	O
.	O	O

Conversely	O	O
,	O	O
the	O	O
majority	O	O
of	O	O
families	O	O
with	O	O
male	B-Disease	D018567
and	I-Disease	D018567
female	I-Disease	D018567
breast	I-Disease	D018567
cancer	I-Disease	D018567
were	O	O
due	O	O
to	O	O
BRCA2	O	O
(	O	O
76	O	O
%	O	O
)	O	O
.	O	O

The	O	O
largest	O	O
proportion	O	O
(	O	O
67	O	O
%	O	O
)	O	O
of	O	O
families	O	O
due	O	O
to	O	O
other	O	O
genes	O	O
was	O	O
found	O	O
in	O	O
families	O	O
with	O	O
four	O	O
or	O	O
five	O	O
cases	O	O
of	O	O
female	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
only	O	O
.	O	O

These	O	O
estimates	O	O
were	O	O
not	O	O
substantially	O	O
affected	O	O
either	O	O
by	O	O
changing	O	O
the	O	O
assumed	O	O
penetrance	O	O
model	O	O
for	O	O
BRCA1	O	O
or	O	O
by	O	O
including	O	O
or	O	O
excluding	O	O
BRCA1	O	O
mutation	O	O
data	O	O
.	O	O

Among	O	O
those	O	O
families	O	O
with	O	O
disease	O	O
due	O	O
to	O	O
BRCA1	O	O
that	O	O
were	O	O
tested	O	O
by	O	O
one	O	O
of	O	O
the	O	O
standard	O	O
screening	O	O
methods	O	O
,	O	O
mutations	O	O
were	O	O
detected	O	O
in	O	O
the	O	O
coding	O	O
sequence	O	O
or	O	O
splice	O	O
sites	O	O
in	O	O
an	O	O
estimated	O	O
63	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
51	O	O
%	O	O
-	O	O
77	O	O
%	O	O
)	O	O
.	O	O

The	O	O
estimated	O	O
sensitivity	O	O
was	O	O
identical	O	O
for	O	O
direct	O	O
sequencing	O	O
and	O	O
other	O	O
techniques	O	O
.	O	O

The	O	O
penetrance	O	O
of	O	O
BRCA2	O	O
was	O	O
estimated	O	O
by	O	O
maximizing	O	O
the	O	O
LOD	O	O
score	O	O
in	O	O
BRCA2	O	O
-	O	O
mutation	O	O
families	O	O
,	O	O
over	O	O
all	O	O
possible	O	O
penetrance	O	O
functions	O	O
.	O	O

The	O	O
estimated	O	O
cumulative	O	O
risk	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
reached	O	O
28	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
9	O	O
%	O	O
-	O	O
44	O	O
%	O	O
)	O	O
by	O	O
age	O	O
50	O	O
years	O	O
and	O	O
84	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
43	O	O
%	O	O
-	O	O
95	O	O
%	O	O
)	O	O
by	O	O
age	O	O
70	O	O
years	O	O
.	O	O

The	O	O
corresponding	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
risks	O	O
were	O	O
0	O	O
.	O	O

4	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
0	O	O
%	O	O
-	O	O
1	O	O
%	O	O
)	O	O
by	O	O
age	O	O
50	O	O
years	O	O
and	O	O
27	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
0	O	O
%	O	O
-	O	O
47	O	O
%	O	O
)	O	O
by	O	O
age	O	O
70	O	O
years	O	O
.	O	O

The	O	O
lifetime	O	O
risk	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
appears	O	O
similar	O	O
to	O	O
the	O	O
risk	O	O
in	O	O
BRCA1	O	O
carriers	O	O
,	O	O
but	O	O
there	O	O
was	O	O
some	O	O
suggestion	O	O
of	O	O
a	O	O
lower	O	O
risk	O	O
in	O	O
BRCA2	O	O
carriers	O	O
<	O	O
50	O	O
years	O	O
of	O	O
age	O	O
.	O	O

Severe	O	O
early	O	O
-	O	O
onset	O	O
obesity	B-Disease	D009765
,	O	O
adrenal	B-Disease	D000309
insufficiency	I-Disease	D000309
and	O	O
red	O	O
hair	O	O
pigmentation	O	O
caused	O	O
by	O	O
POMC	O	O
mutations	O	O
in	O	O
humans	O	O
.	O	O

Sequential	O	O
cleavage	O	O
of	O	O
the	O	O
precursor	O	O
protein	O	O
pre	O	O
-	O	O
pro	O	O
-	O	O
opiomelanocortin	O	O
(	O	O
POMC	O	O
)	O	O
generates	O	O
the	O	O
melanocortin	O	O
peptides	O	O
adrenocorticotrophin	O	O
(	O	O
ACTH	O	O
)	O	O
,	O	O
melanocyte	O	O
-	O	O
stimulating	O	O
hormones	O	O
(	O	O
MSH	O	O
)	O	O
alpha	O	O
,	O	O
beta	O	O
and	O	O
gamma	O	O
as	O	O
well	O	O
as	O	O
the	O	O
opioid	O	O
-	O	O
receptor	O	O
ligand	O	O
beta	O	O
-	O	O
endorphin	O	O
.	O	O

While	O	O
a	O	O
few	O	O
cases	O	O
of	O	O
isolated	O	O
ACTH	B-Disease	OMIM:201400
deficiency	I-Disease	OMIM:201400
have	O	O
been	O	O
reported	O	O
(	O	O
OMIM	O	O
201400	O	O
)	O	O
,	O	O
an	O	O
inherited	O	O
POMC	O	O
defect	O	O
has	O	O
not	O	O
been	O	O
described	O	O
so	O	O
far	O	O
.	O	O

Recent	O	O
studies	O	O
in	O	O
animal	O	O
models	O	O
elucidated	O	O
a	O	O
central	O	O
role	O	O
of	O	O
alpha	O	O
-	O	O
MSH	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
food	O	O
intake	O	O
by	O	O
activation	O	O
of	O	O
the	O	O
brain	O	O
melanocortin	O	O
-	O	O
4	O	O
-	O	O
receptor	O	O
(	O	O
MC4	O	O
-	O	O
R	O	O
;	O	O
refs	O	O
3	O	O
-	O	O
5	O	O
)	O	O
and	O	O
the	O	O
linkage	O	O
of	O	O
human	O	O
obesity	B-Disease	D009765
to	O	O
chromosome	O	O
2	O	O
in	O	O
close	O	O
proximity	O	O
to	O	O
the	O	O
POMC	O	O
locus	O	O
,	O	O
led	O	O
to	O	O
the	O	O
proposal	O	O
of	O	O
an	O	O
association	O	O
of	O	O
POMC	O	O
with	O	O
human	O	O
obesity	B-Disease	D009765
.	O	O

The	O	O
dual	O	O
role	O	O
of	O	O
alpha	O	O
-	O	O
MSH	O	O
in	O	O
regulating	O	O
food	O	O
intake	O	O
and	O	O
influencing	O	O
hair	O	O
pigmentation	O	O
predicts	O	O
that	O	O
the	O	O
phenotype	O	O
associated	O	O
with	O	O
a	O	O
defect	O	O
in	O	O
POMC	O	O
function	O	O
would	O	O
include	O	O
obesity	B-Disease	D009765
,	O	O
alteration	O	O
in	O	O
pigmentation	O	O
and	O	O
ACTH	B-Disease	OMIM:201400
deficiency	I-Disease	OMIM:201400
.	O	O

The	O	O
observation	O	O
of	O	O
these	O	O
symptoms	O	O
in	O	O
two	O	O
probands	O	O
prompted	O	O
us	O	O
to	O	O
search	O	O
for	O	O
mutations	O	O
within	O	O
their	O	O
POMC	O	O
genes	O	O
.	O	O

Patient	O	O
1	O	O
was	O	O
found	O	O
to	O	O
be	O	O
a	O	O
compound	O	O
heterozygote	O	O
for	O	O
two	O	O
mutations	O	O
in	O	O
exon	O	O
3	O	O
(	O	O
G7013T	O	O
,	O	O
C7133delta	O	O
)	O	O
which	O	O
interfere	O	O
with	O	O
appropriate	O	O
synthesis	O	O
of	O	O
ACTH	O	O
and	O	O
alpha	O	O
-	O	O
MSH	O	O
.	O	O

Patient	O	O
2	O	O
was	O	O
homozygous	O	O
for	O	O
a	O	O
mutation	O	O
in	O	O
exon	O	O
2	O	O
(	O	O
C3804A	O	O
)	O	O
which	O	O
abolishes	O	O
POMC	O	O
translation	O	O
.	O	O

These	O	O
findings	O	O
represent	O	O
the	O	O
first	O	O
examples	O	O
of	O	O
a	O	O
genetic	B-Disease	D030342
defect	I-Disease	D030342
within	O	O
the	O	O
POMC	O	O
gene	O	O
and	O	O
define	O	O
a	O	O
new	O	O
monogenic	B-Disease	D004700
endocrine	I-Disease	D004700
disorder	I-Disease	D004700
resulting	O	O
in	O	O
early	O	O
-	O	O
onset	O	O
obesity	B-Disease	D009765
,	O	O
adrenal	B-Disease	D000309
insufficiency	I-Disease	D000309
and	O	O
red	O	O
hair	O	O
pigmentation	O	O
.	O	O

.	O	O

The	O	O
tumor	B-Disease	D009369
suppressor	O	O
gene	O	O
Smad4	O	O
/	O	O
Dpc4	O	O
is	O	O
required	O	O
for	O	O
gastrulation	O	O
and	O	O
later	O	O
for	O	O
anterior	O	O
development	O	O
of	O	O
the	O	O
mouse	O	O
embryo	O	O
.	O	O

Mutations	O	O
in	O	O
the	O	O
SMAD4	O	O
/	O	O
DPC4	O	O
tumor	B-Disease	D009369
suppressor	O	O
gene	O	O
,	O	O
a	O	O
key	O	O
signal	O	O
transducer	O	O
in	O	O
most	O	O
TGFbeta	O	O
-	O	O
related	O	O
pathways	O	O
,	O	O
are	O	O
involved	O	O
in	O	O
50	O	O
%	O	O
of	O	O
pancreatic	B-Disease	D010190
cancers	I-Disease	D010190
.	O	O

Homozygous	O	O
Smad4	O	O
mutant	O	O
mice	O	O
die	O	O
before	O	O
day	O	O
7	O	O
.	O	O

5	O	O
of	O	O
embryogenesis	O	O
.	O	O

Mutant	O	O
embryos	O	O
have	O	O
reduced	O	O
size	O	O
,	O	O
fail	O	O
to	O	O
gastrulate	O	O
or	O	O
express	O	O
a	O	O
mesodermal	O	O
marker	O	O
,	O	O
and	O	O
show	O	O
abnormal	O	O
visceral	O	O
endoderm	O	O
development	O	O
.	O	O

Growth	B-Disease	D005317
retardation	I-Disease	D005317
of	O	O
the	O	O
Smad4	O	O
-	O	O
deficient	O	O
embryos	O	O
results	O	O
from	O	O
reduced	O	O
cell	O	O
proliferation	O	O
rather	O	O
than	O	O
increased	O	O
apoptosis	O	O
.	O	O

Aggregation	O	O
of	O	O
mutant	O	O
Smad4	O	O
ES	O	O
cells	O	O
with	O	O
wild	O	O
-	O	O
type	O	O
tetraploid	O	O
morulae	O	O
rescues	O	O
the	O	O
gastrulation	B-Disease	D004194
defect	I-Disease	D004194
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
Smad4	O	O
is	O	O
initially	O	O
required	O	O
for	O	O
the	O	O
differentiation	O	O
of	O	O
the	O	O
visceral	O	O
endoderm	O	O
and	O	O
that	O	O
the	O	O
gastrulation	B-Disease	D004194
defect	I-Disease	D004194
in	O	O
the	O	O
epiblast	O	O
is	O	O
secondary	O	O
and	O	O
non	O	O
-	O	O
cell	O	O
autonomous	O	O
.	O	O

Rescued	O	O
embryos	O	O
show	O	O
severe	O	O
anterior	O	O
truncations	O	O
,	O	O
indicating	O	O
a	O	O
second	O	O
important	O	O
role	O	O
for	O	O
Smad4	O	O
in	O	O
anterior	O	O
patterning	O	O
during	O	O
embryogenesis	O	O
.	O	O

Coincidence	O	O
of	O	O
two	O	O
novel	O	O
arylsulfatase	O	O
A	O	O
alleles	O	O
and	O	O
mutation	O	O
459	O	O
+	O	O
1G	O	O
>	O	O
A	O	O
within	O	O
a	O	O
family	O	O
with	O	O
metachromatic	B-Disease	D007966
leukodystrophy	I-Disease	D007966
:	O	O
molecular	O	O
basis	O	O
of	O	O
phenotypic	O	O
heterogeneity	O	O
.	O	O

In	O	O
a	O	O
family	O	O
with	O	O
three	O	O
siblings	O	O
,	O	O
one	O	O
developed	O	O
classical	O	O
late	O	O
infantile	O	O
metachromatic	B-Disease	D007966
leukodystrophy	I-Disease	D007966
(	O	O
MLD	B-Disease	D007966
)	O	O
,	O	O
fatal	O	O
at	O	O
age	O	O
5	O	O
years	O	O
,	O	O
with	O	O
deficient	O	O
arylsulfatase	O	O
A	O	O
(	O	O
ARSA	O	O
)	O	O
activity	O	O
and	O	O
increased	O	O
galactosylsulfatide	O	O
(	O	O
GS	O	O
)	O	O
excretion	O	O
.	O	O

The	O	O
two	O	O
other	O	O
siblings	O	O
,	O	O
apparently	O	O
healthy	O	O
at	O	O
12	O	O
(	O	O
1	O	O
/	O	O
2	O	O
)	O	O
and	O	O
15	O	O
years	O	O
,	O	O
respectively	O	O
,	O	O
and	O	O
their	O	O
father	O	O
,	O	O
apparently	O	O
healthy	O	O
as	O	O
well	O	O
,	O	O
presented	O	O
ARSA	O	O
and	O	O
GS	O	O
values	O	O
within	O	O
the	O	O
range	O	O
of	O	O
MLD	B-Disease	D007966
patients	O	O
.	O	O

Mutation	O	O
screening	O	O
and	O	O
sequence	O	O
analysis	O	O
disclosed	O	O
the	O	O
involvement	O	O
of	O	O
three	O	O
different	O	O
ARSA	O	O
mutations	O	O
being	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
intrafamilial	O	O
phenotypic	O	O
heterogeneity	O	O
.	O	O

The	O	O
late	O	O
infantile	O	O
patient	O	O
inherited	O	O
from	O	O
his	O	O
mother	O	O
the	O	O
frequent	O	O
0	O	O
-	O	O
type	O	O
mutation	O	O
459	O	O
+	O	O
1G	O	O
>	O	O
A	O	O
,	O	O
and	O	O
from	O	O
his	O	O
father	O	O
a	O	O
novel	O	O
,	O	O
single	O	O
basepair	O	O
microdeletion	O	O
of	O	O
guanine	O	O
at	O	O
nucleotide	O	O
7	O	O
in	O	O
exon	O	O
1	O	O
(	O	O
7delG	O	O
)	O	O
.	O	O

The	O	O
two	O	O
clinically	O	O
unaffected	O	O
siblings	O	O
carried	O	O
the	O	O
maternal	O	O
mutation	O	O
459	O	O
+	O	O
1G	O	O
>	O	O
A	O	O
and	O	O
,	O	O
on	O	O
their	O	O
paternal	O	O
allele	O	O
,	O	O
a	O	O
novel	O	O
cytosine	O	O
to	O	O
thymidine	O	O
transition	O	O
at	O	O
nucleotide	O	O
2435	O	O
in	O	O
exon	O	O
8	O	O
,	O	O
resulting	O	O
in	O	O
substitution	O	O
of	O	O
alanine	O	O
464	O	O
by	O	O
valine	O	O
(	O	O
A464V	O	O
)	O	O
.	O	O

The	O	O
fathers	O	O
genotype	O	O
thus	O	O
was	O	O
7delG	O	O
/	O	O
A464V	O	O
.	O	O

Mutation	O	O
A464V	O	O
was	O	O
not	O	O
found	O	O
in	O	O
18	O	O
unrelated	O	O
MLD	B-Disease	D007966
patients	O	O
and	O	O
50	O	O
controls	O	O
.	O	O

A464V	O	O
,	O	O
although	O	O
clearly	O	O
modifying	O	O
ARSA	O	O
and	O	O
GS	O	O
levels	O	O
,	O	O
apparently	O	O
bears	O	O
little	O	O
significance	O	O
for	O	O
clinical	O	O
manifestation	O	O
of	O	O
MLD	B-Disease	D007966
,	O	O
mimicking	O	O
the	O	O
frequent	O	O
ARSA	O	O
pseudodeficiency	O	O
allele	O	O
.	O	O

Our	O	O
results	O	O
demonstrate	O	O
that	O	O
in	O	O
certain	O	O
genetic	O	O
conditions	O	O
MLD	B-Disease	D007966
-	O	O
like	O	O
ARSA	O	O
and	O	O
GS	O	O
values	O	O
need	O	O
not	O	O
be	O	O
paralleled	O	O
by	O	O
clinical	O	O
disease	O	O
,	O	O
a	O	O
finding	O	O
with	O	O
serious	O	O
diagnostic	O	O
and	O	O
prognostic	O	O
implications	O	O
.	O	O

Moreover	O	O
,	O	O
further	O	O
ARSA	O	O
alleles	O	O
functionally	O	O
similar	O	O
to	O	O
A464V	O	O
might	O	O
exist	O	O
which	O	O
,	O	O
together	O	O
with	O	O
0	O	O
-	O	O
type	O	O
mutations	O	O
,	O	O
may	O	O
cause	O	O
pathological	O	O
ARSA	O	O
and	O	O
GS	O	O
levels	O	O
,	O	O
but	O	O
not	O	O
clinical	O	O
outbreak	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

.	O	O

Low	O	O
levels	O	O
of	O	O
beta	O	O
hexosaminidase	O	O
A	O	O
in	O	O
healthy	O	O
individuals	O	O
with	O	O
apparent	O	O
deficiency	O	O
of	O	O
this	O	O
enzyme	O	O
.	O	O

Appreciable	O	O
beta	O	O
hexosaminidase	O	O
A	O	O
(	O	O
hex	O	O
A	O	O
)	O	O
activity	O	O
has	O	O
been	O	O
detected	O	O
in	O	O
cultured	O	O
skin	O	O
fibroblasts	O	O
and	O	O
melanoma	B-Disease	D008545
tissue	O	O
from	O	O
healthy	O	O
individuals	O	O
previously	O	O
reported	O	O
as	O	O
having	O	O
deficiency	B-Disease	D013661
of	I-Disease	D013661
hex	I-Disease	D013661
A	I-Disease	D013661
activity	O	O
indistinguishable	O	O
from	O	O
that	O	O
of	O	O
patients	O	O
with	O	O
Tay	B-Disease	D013661
-	I-Disease	D013661
Sachs	I-Disease	D013661
disease	I-Disease	D013661
(	O	O
TSD	B-Disease	D013661
)	O	O
.	O	O

Identification	O	O
and	O	O
quantitation	O	O
of	O	O
hex	O	O
A	O	O
,	O	O
amounting	O	O
to	O	O
3	O	O
.	O	O

5	O	O
%	O	O
-	O	O
6	O	O
.	O	O

9	O	O
%	O	O
of	O	O
total	O	O
beta	O	O
hexosaminidase	O	O
activity	O	O
,	O	O
has	O	O
been	O	O
obtained	O	O
by	O	O
cellulose	O	O
acetate	O	O
gel	O	O
electrophoresis	O	O
,	O	O
DEAE	O	O
-	O	O
cellulose	O	O
ion	O	O
-	O	O
exchange	O	O
chromatography	O	O
,	O	O
radial	O	O
immunodiffusion	O	O
,	O	O
and	O	O
radioimmunoassay	O	O
.	O	O

Previous	O	O
family	O	O
studies	O	O
suggested	O	O
that	O	O
these	O	O
individuals	O	O
may	O	O
be	O	O
compound	O	O
heterozygotes	O	O
for	O	O
the	O	O
common	O	O
mutant	O	O
TSD	B-Disease	D013661
gene	O	O
and	O	O
a	O	O
rare	O	O
(	O	O
allelic	O	O
)	O	O
mutant	O	O
gene	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
postulated	O	O
rate	O	O
mutant	O	O
gene	O	O
appears	O	O
to	O	O
code	O	O
for	O	O
the	O	O
expression	O	O
of	O	O
low	O	O
amounts	O	O
of	O	O
hex	O	O
A	O	O
.	O	O

Heterozygotes	O	O
for	O	O
the	O	O
rare	O	O
mutant	O	O
may	O	O
be	O	O
indistinguishable	O	O
from	O	O
heterozygotes	O	O
for	O	O
the	O	O
common	O	O
TSD	B-Disease	D013661
mutant	O	O
.	O	O

However	O	O
,	O	O
direct	O	O
visualization	O	O
and	O	O
quantitation	O	O
of	O	O
hex	O	O
A	O	O
by	O	O
the	O	O
methods	O	O
described	O	O
may	O	O
prevent	O	O
false	O	O
-	O	O
positive	O	O
prenatal	O	O
diagnosis	O	O
of	O	O
TSD	B-Disease	D013661
in	O	O
fetuses	O	O
having	O	O
the	O	O
incomplete	O	O
hex	B-Disease	D013661
A	I-Disease	D013661
deficiency	I-Disease	D013661
of	O	O
the	O	O
type	O	O
described	O	O
in	O	O
the	O	O
four	O	O
healthy	O	O
individuals	O	O
A	O	O
mouse	O	O
model	O	O
for	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
imprinting	O	O
-	O	O
centre	O	O
mutations	O	O
.	O	O

Imprinting	O	O
in	O	O
the	O	O
15q11	O	O
-	O	O
q13	O	O
region	O	O
involves	O	O
an	O	O
imprinting	O	O
centre	O	O
(	O	O
IC	O	O
)	O	O
,	O	O
mapping	O	O
in	O	O
part	O	O
to	O	O
the	O	O
promoter	O	O
and	O	O
first	O	O
exon	O	O
of	O	O
SNRPN	O	O
.	O	O

Deletion	O	O
of	O	O
this	O	O
IC	O	O
abolishes	O	O
local	O	O
paternally	O	O
derived	O	O
gene	O	O
expression	O	O
and	O	O
results	O	O
in	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
(	O	O
PWS	B-Disease	D011218
)	O	O
.	O	O

We	O	O
have	O	O
created	O	O
two	O	O
deletion	O	O
mutations	O	O
in	O	O
mice	O	O
to	O	O
understand	O	O
PWS	B-Disease	D011218
and	O	O
the	O	O
mechanism	O	O
of	O	O
this	O	O
IC	O	O
.	O	O

Mice	O	O
harbouring	O	O
an	O	O
intragenic	O	O
deletion	O	O
in	O	O
Snrpn	O	O
are	O	O
phenotypically	O	O
normal	O	O
,	O	O
suggesting	O	O
that	O	O
mutations	O	O
of	O	O
SNRPN	O	O
are	O	O
not	O	O
sufficient	O	O
to	O	O
induce	O	O
PWS	B-Disease	D011218
.	O	O

Mice	O	O
with	O	O
a	O	O
larger	O	O
deletion	O	O
involving	O	O
both	O	O
Snrpn	O	O
and	O	O
the	O	O
putative	O	O
PWS	B-Disease	D011218
-	O	O
IC	O	O
lack	O	O
expression	O	O
of	O	O
the	O	O
imprinted	O	O
genes	O	O
Zfp127	O	O
(	O	O
mouse	O	O
homologue	O	O
of	O	O
ZNF127	O	O
)	O	O
,	O	O
Ndn	O	O
and	O	O
Ipw	O	O
,	O	O
and	O	O
manifest	O	O
several	O	O
phenotypes	O	O
common	O	O
to	O	O
PWS	B-Disease	D011218
infants	O	O
.	O	O

These	O	O
data	O	O
demonstrate	O	O
that	O	O
both	O	O
the	O	O
position	O	O
of	O	O
the	O	O
IC	O	O
and	O	O
its	O	O
role	O	O
in	O	O
the	O	O
coordinate	O	O
expression	O	O
of	O	O
genes	O	O
is	O	O
conserved	O	O
between	O	O
mouse	O	O
and	O	O
human	O	O
,	O	O
and	O	O
indicate	O	O
that	O	O
the	O	O
mouse	O	O
is	O	O
a	O	O
suitable	O	O
model	O	O
system	O	O
in	O	O
which	O	O
to	O	O
investigate	O	O
the	O	O
molecular	O	O
mechanisms	O	O
of	O	O
imprinting	O	O
in	O	O
this	O	O
region	O	O
of	O	O
the	O	O
genome	O	O
.	O	O

.	O	O

A	O	O
deletion	O	O
mutation	O	O
in	O	O
COL17A1	O	O
in	O	O
five	O	O
Austrian	O	O
families	O	O
with	O	O
generalized	O	O
atrophic	B-Disease	D016109
benign	I-Disease	D016109
epidermolysis	I-Disease	D016109
bullosa	I-Disease	D016109
represents	O	O
propagation	O	O
of	O	O
an	O	O
ancestral	O	O
allele	O	O
.	O	O

Patients	O	O
with	O	O
generalized	O	O
atrophic	B-Disease	D016109
benign	I-Disease	D016109
epidermolysis	I-Disease	D016109
bullosa	I-Disease	D016109
,	O	O
a	O	O
usually	O	O
nonlethal	O	O
form	O	O
of	O	O
junctional	B-Disease	D016109
epidermolysis	I-Disease	D016109
bullosa	I-Disease	D016109
,	O	O
have	O	O
generalized	O	O
blistering	B-Disease	D001768
,	O	O
nail	B-Disease	C538333
dystrophy	I-Disease	C538333
,	O	O
patchy	B-Disease	C531609
alopecia	I-Disease	C531609
,	O	O
and	O	O
dental	B-Disease	D014071
abnormalities	I-Disease	D014071
.	O	O

Skin	B-Disease	C536183
fragility	I-Disease	C536183
in	O	O
most	O	O
cases	O	O
is	O	O
due	O	O
to	O	O
mutations	O	O
in	O	O
the	O	O
gene	O	O
encoding	O	O
type	O	O
XVII	O	O
collagen	O	O
(	O	O
COL17A1	O	O
)	O	O
.	O	O

Recently	O	O
,	O	O
we	O	O
reported	O	O
five	O	O
Austrian	O	O
families	O	O
with	O	O
generalized	O	O
atrophic	B-Disease	D016109
benign	I-Disease	D016109
epidermolysis	I-Disease	D016109
bullosa	I-Disease	D016109
who	O	O
share	O	O
the	O	O
same	O	O
COL17A1	O	O
mutation	O	O
.	O	O

Affected	O	O
individuals	O	O
in	O	O
three	O	O
families	O	O
are	O	O
homozygous	O	O
for	O	O
4003delTC	O	O
,	O	O
whereas	O	O
those	O	O
in	O	O
two	O	O
others	O	O
are	O	O
compound	O	O
heterozygotes	O	O
.	O	O

To	O	O
determine	O	O
if	O	O
the	O	O
occurrence	O	O
of	O	O
4003delTC	O	O
in	O	O
these	O	O
unrelated	O	O
families	O	O
signifies	O	O
propagation	O	O
of	O	O
an	O	O
ancestral	O	O
allele	O	O
or	O	O
a	O	O
mutational	O	O
hot	O	O
spot	O	O
,	O	O
haplotypes	O	O
were	O	O
determined	O	O
for	O	O
polymorphisms	O	O
both	O	O
within	O	O
and	O	O
flanking	O	O
COL17A1	O	O
.	O	O

Five	O	O
intragenic	O	O
polymorphisms	O	O
were	O	O
chosen	O	O
based	O	O
on	O	O
their	O	O
informativeness	O	O
.	O	O

One	O	O
of	O	O
these	O	O
,	O	O
not	O	O
previously	O	O
reported	O	O
,	O	O
was	O	O
2988	O	O
A	O	O
or	O	O
C	O	O
that	O	O
introduces	O	O
a	O	O
new	O	O
restriction	O	O
site	O	O
for	O	O
Eco0109	O	O
I	O	O
.	O	O

All	O	O
the	O	O
4003delTC	O	O
alleles	O	O
showed	O	O
the	O	O
same	O	O
haplotype	O	O
for	O	O
these	O	O
five	O	O
polymorphic	O	O
markers	O	O
.	O	O

Fourteen	O	O
microsatellite	O	O
polymorphisms	O	O
were	O	O
selected	O	O
based	O	O
on	O	O
their	O	O
high	O	O
heterozygosity	O	O
and	O	O
their	O	O
location	O	O
within	O	O
10q23	O	O
-	O	O
q25	O	O
near	O	O
COL17A1	O	O
.	O	O

Three	O	O
families	O	O
shared	O	O
microsatellite	O	O
polymorphisms	O	O
covering	O	O
at	O	O
most	O	O
19	O	O
cM	O	O
,	O	O
whereas	O	O
the	O	O
others	O	O
shared	O	O
smaller	O	O
regions	O	O
consistent	O	O
with	O	O
cross	O	O
-	O	O
over	O	O
events	O	O
during	O	O
passage	O	O
of	O	O
this	O	O
mutation	O	O
through	O	O
several	O	O
generations	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
4003delTC	O	O
occurs	O	O
on	O	O
a	O	O
single	O	O
ancestral	O	O
allele	O	O
.	O	O

.	O	O

Identification	O	O
of	O	O
a	O	O
novel	O	O
mutation	O	O
of	O	O
the	O	O
CPO	O	O
gene	O	O
in	O	O
a	O	O
Japanese	O	O
hereditary	B-Disease	D046349
coproporphyria	I-Disease	D046349
family	O	O
.	O	O

Hereditary	B-Disease	D046349
coproporphyria	I-Disease	D046349
(	O	O
HCP	B-Disease	D046349
)	O	O
is	O	O
an	O	O
autosomal	B-Disease	D030342
dominant	I-Disease	D030342
disease	I-Disease	D030342
characterized	O	O
by	O	O
a	O	O
deficiency	B-Disease	D046349
of	I-Disease	D046349
coproporphyrinogen	I-Disease	D046349
oxidase	I-Disease	D046349
(	O	O
CPO	O	O
)	O	O
caused	O	O
by	O	O
a	O	O
mutation	O	O
in	O	O
the	O	O
CPO	O	O
gene	O	O
.	O	O

Only	O	O
11	O	O
mutations	O	O
of	O	O
the	O	O
gene	O	O
have	O	O
been	O	O
reported	O	O
in	O	O
HCP	B-Disease	D046349
patients	O	O
.	O	O

We	O	O
report	O	O
another	O	O
mutation	O	O
in	O	O
a	O	O
Japanese	O	O
family	O	O
.	O	O

Polymerase	O	O
chain	O	O
reaction	O	O
-	O	O
single	O	O
strand	O	O
conformational	O	O
polymorphism	O	O
and	O	O
direct	O	O
sequence	O	O
analyses	O	O
demonstrated	O	O
a	O	O
C	O	O
to	O	O
T	O	O
substitution	O	O
in	O	O
exon	O	O
1	O	O
of	O	O
the	O	O
CPO	O	O
gene	O	O
at	O	O
nucleotide	O	O
position	O	O
85	O	O
,	O	O
which	O	O
lies	O	O
in	O	O
the	O	O
putative	O	O
presequence	O	O
for	O	O
targeting	O	O
to	O	O
mitochondria	O	O
.	O	O

This	O	O
mutation	O	O
changes	O	O
the	O	O
codon	O	O
for	O	O
glutamine	O	O
to	O	O
a	O	O
termination	O	O
codon	O	O
at	O	O
amino	O	O
acid	O	O
position	O	O
29	O	O
.	O	O

MaeI	O	O
restriction	O	O
analysis	O	O
showed	O	O
two	O	O
other	O	O
carriers	O	O
in	O	O
the	O	O
family	O	O
.	O	O

The	O	O
C	O	O
-	O	O
T	O	O
mutation	O	O
is	O	O
located	O	O
within	O	O
a	O	O
recently	O	O
proposed	O	O
putative	O	O
alternative	O	O
translation	O	O
initiation	O	O
codon	O	O
(	O	O
TIC	O	O
-	O	O
1	O	O
)	O	O
,	O	O
supporting	O	O
that	O	O
TIC	O	O
-	O	O
1	O	O
is	O	O
the	O	O
real	O	O
TIC	O	O
rather	O	O
than	O	O
TIC	O	O
-	O	O
2	O	O
.	O	O

.	O	O

The	O	O
chromosomal	O	O
order	O	O
of	O	O
genes	O	O
controlling	O	O
the	O	O
major	O	O
histocompatibility	O	O
complex	O	O
,	O	O
properdin	O	O
factor	O	O
B	O	O
,	O	O
and	O	O
deficiency	B-Disease	OMIM:217000
of	I-Disease	OMIM:217000
the	I-Disease	OMIM:217000
second	I-Disease	OMIM:217000
component	I-Disease	OMIM:217000
of	I-Disease	OMIM:217000
complement	I-Disease	OMIM:217000
.	O	O

The	O	O
relationship	O	O
of	O	O
the	O	O
genes	O	O
coding	O	O
for	O	O
HLA	O	O
to	O	O
those	O	O
coding	O	O
for	O	O
properdin	O	O
Factor	O	O
B	O	O
allotypes	O	O
and	O	O
for	O	O
deficiency	B-Disease	OMIM:217000
of	I-Disease	OMIM:217000
the	I-Disease	OMIM:217000
second	I-Disease	OMIM:217000
component	I-Disease	OMIM:217000
of	I-Disease	OMIM:217000
complement	I-Disease	OMIM:217000
(	O	O
C2	O	O
)	O	O
was	O	O
studied	O	O
in	O	O
families	O	O
of	O	O
patients	O	O
with	O	O
connective	O	O
tissue	O	O
disorders	O	O
.	O	O

Patients	O	O
were	O	O
selected	O	O
because	O	O
they	O	O
were	O	O
heterozygous	O	O
or	O	O
homozygous	O	O
for	O	O
C2	B-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
.	O	O

12	O	O
families	O	O
with	O	O
15	O	O
matings	O	O
informative	O	O
for	O	O
C2	B-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
were	O	O
found	O	O
.	O	O

Of	O	O
57	O	O
informative	O	O
meioses	O	O
,	O	O
two	O	O
crossovers	O	O
were	O	O
noted	O	O
between	O	O
the	O	O
C2	B-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
gene	O	O
and	O	O
the	O	O
HLA	O	O
-	O	O
B	O	O
gene	O	O
,	O	O
with	O	O
a	O	O
recombinant	O	O
fraction	O	O
of	O	O
0	O	O
.	O	O

035	O	O
.	O	O

A	O	O
lod	O	O
score	O	O
of	O	O
13	O	O
was	O	O
calculated	O	O
for	O	O
linkage	O	O
between	O	O
C2	B-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
and	O	O
HLA	O	O
-	O	O
B	O	O
at	O	O
a	O	O
maximum	O	O
likelihood	O	O
value	O	O
of	O	O
the	O	O
recombinant	O	O
fraction	O	O
of	O	O
0	O	O
.	O	O

04	O	O
.	O	O

18	O	O
families	O	O
with	O	O
21	O	O
informative	O	O
matings	O	O
for	O	O
both	O	O
properdin	O	O
Factor	O	O
B	O	O
allotype	O	O
and	O	O
HLA	O	O
-	O	O
B	O	O
were	O	O
found	O	O
.	O	O

Of	O	O
72	O	O
informative	O	O
meioses	O	O
,	O	O
three	O	O
recombinants	O	O
were	O	O
found	O	O
,	O	O
giving	O	O
a	O	O
recombinant	O	O
fraction	O	O
of	O	O
0	O	O
.	O	O

042	O	O
.	O	O

A	O	O
lod	O	O
score	O	O
of	O	O
16	O	O
between	O	O
HLA	O	O
-	O	O
B	O	O
and	O	O
Factor	O	O
B	O	O
allotypes	O	O
was	O	O
calculated	O	O
at	O	O
a	O	O
maximum	O	O
likelihood	O	O
value	O	O
of	O	O
the	O	O
recombinant	O	O
fraction	O	O
of	O	O
0	O	O
.	O	O

04	O	O
.	O	O

A	O	O
crossover	O	O
was	O	O
shown	O	O
to	O	O
have	O	O
occurred	O	O
between	O	O
genes	O	O
for	O	O
Factor	O	O
B	O	O
and	O	O
HLA	O	O
-	O	O
D	O	O
,	O	O
in	O	O
which	O	O
HLA	O	O
-	O	O
D	O	O
segregared	O	O
with	O	O
HLA	O	O
-	O	O
A	O	O
and	O	O
B	O	O
.	O	O

These	O	O
studies	O	O
suggest	O	O
that	O	O
the	O	O
genes	O	O
for	O	O
Factor	O	O
B	O	O
and	O	O
C2	B-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
are	O	O
located	O	O
outside	O	O
those	O	O
for	O	O
HLA	O	O
,	O	O
that	O	O
the	O	O
order	O	O
of	O	O
genese	O	O
is	O	O
HLA	O	O
-	O	O
A	O	O
,	O	O
-	O	O
B	O	O
,	O	O
-	O	O
D	O	O
,	O	O
Factor	O	O
B	O	O
allotype	O	O
,	O	O
C2	B-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
,	O	O
that	O	O
the	O	O
genes	O	O
coding	O	O
for	O	O
C2	B-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
and	O	O
Factor	O	O
B	O	O
allotypes	O	O
are	O	O
approximately	O	O
3	O	O
-	O	O
-	O	O
5	O	O
centimorgans	O	O
from	O	O
the	O	O
HLA	O	O
-	O	O
A	O	O
and	O	O
HLA	O	O
-	O	O
B	O	O
loci	O	O
,	O	O
and	O	O
that	O	O
the	O	O
apparent	O	O
lack	O	O
of	O	O
recombinants	O	O
between	O	O
the	O	O
Factor	O	O
B	O	O
gene	O	O
and	O	O
C2	B-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
gene	O	O
suggests	O	O
that	O	O
these	O	O
two	O	O
genes	O	O
lie	O	O
in	O	O
close	O	O
proximity	O	O
to	O	O
one	O	O
another	O	O
.	O	O

A	O	O
novel	O	O
missense	O	O
mutation	O	O
in	O	O
patients	O	O
from	O	O
a	O	O
retinoblastoma	B-Disease	D012175
pedigree	O	O
showing	O	O
only	O	O
mild	O	O
expression	O	O
of	O	O
the	O	O
tumor	B-Disease	D009369
phenotype	O	O
.	O	O

We	O	O
have	O	O
used	O	O
single	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
analysis	O	O
to	O	O
study	O	O
the	O	O
27	O	O
exons	O	O
of	O	O
the	O	O
RB1	O	O
gene	O	O
in	O	O
individuals	O	O
from	O	O
a	O	O
family	O	O
showing	O	O
mild	O	O
expression	O	O
of	O	O
the	O	O
retinoblastoma	B-Disease	D012175
phenotype	O	O
.	O	O

In	O	O
this	O	O
family	O	O
affected	O	O
individuals	O	O
developed	O	O
unilateral	B-Disease	D009369
tumors	I-Disease	D009369
and	O	O
,	O	O
as	O	O
a	O	O
result	O	O
of	O	O
linkage	O	O
analysis	O	O
,	O	O
unaffected	O	O
mutation	O	O
carriers	O	O
were	O	O
also	O	O
identified	O	O
within	O	O
the	O	O
pedigree	O	O
.	O	O

A	O	O
single	O	O
band	O	O
shift	O	O
using	O	O
SSCP	O	O
was	O	O
identified	O	O
in	O	O
exon	O	O
21	O	O
which	O	O
resulted	O	O
in	O	O
a	O	O
missense	O	O
mutation	O	O
converting	O	O
a	O	O
cys	O	O
-	O	O
-	O	O
>	O	O
arg	O	O
at	O	O
nucleotide	O	O
position	O	O
28	O	O
in	O	O
the	O	O
exon	O	O
.	O	O

The	O	O
mutation	O	O
destroyed	O	O
an	O	O
NdeI	O	O
restriction	O	O
enzyme	O	O
site	O	O
.	O	O

Analysis	O	O
of	O	O
all	O	O
family	O	O
members	O	O
demonstrated	O	O
that	O	O
the	O	O
missense	O	O
mutation	O	O
co	O	O
-	O	O
segregated	O	O
with	O	O
patients	O	O
with	O	O
tumors	B-Disease	D009369
or	O	O
who	O	O
,	O	O
as	O	O
a	O	O
result	O	O
of	O	O
linkage	O	O
analysis	O	O
had	O	O
been	O	O
predicted	O	O
to	O	O
carry	O	O
the	O	O
predisposing	O	O
mutation	O	O
.	O	O

These	O	O
observations	O	O
point	O	O
to	O	O
another	O	O
region	O	O
of	O	O
the	O	O
RB1	O	O
gene	O	O
where	O	O
mutations	O	O
only	O	O
modify	O	O
the	O	O
function	O	O
of	O	O
the	O	O
gene	O	O
and	O	O
raise	O	O
important	O	O
questions	O	O
for	O	O
genetic	O	O
counseling	O	O
in	O	O
families	O	O
with	O	O
these	O	O
distinctive	O	O
phenotypes	O	O
.	O	O

.	O	O

Complement	B-Disease	OMIM:610102
C7	I-Disease	OMIM:610102
deficiency	I-Disease	OMIM:610102
:	O	O
seven	O	O
further	O	O
molecular	O	O
defects	O	O
and	O	O
their	O	O
associated	O	O
marker	O	O
haplotypes	O	O
.	O	O

Seven	O	O
further	O	O
molecular	O	O
bases	O	O
of	O	O
C7	B-Disease	OMIM:610102
deficiency	I-Disease	OMIM:610102
are	O	O
described	O	O
.	O	O

All	O	O
these	O	O
new	O	O
molecular	O	O
defects	O	O
involve	O	O
single	O	O
-	O	O
nucleotide	O	O
events	O	O
,	O	O
deletions	O	O
and	O	O
substitutions	O	O
,	O	O
some	O	O
of	O	O
which	O	O
alter	O	O
splice	O	O
sites	O	O
,	O	O
and	O	O
others	O	O
codons	O	O
.	O	O

They	O	O
are	O	O
distributed	O	O
along	O	O
the	O	O
C7	O	O
gene	O	O
,	O	O
but	O	O
predominantly	O	O
towards	O	O
the	O	O
3	O	O
end	O	O
.	O	O

All	O	O
were	O	O
found	O	O
in	O	O
compound	O	O
heterozygous	O	O
individuals	O	O
.	O	O

The	O	O
C6	O	O
/	O	O
C7	O	O
marker	O	O
haplotypes	O	O
associated	O	O
with	O	O
most	O	O
C7	B-Disease	OMIM:610102
defects	I-Disease	OMIM:610102
are	O	O
tabulated	O	O
.	O	O

.	O	O

Identification	O	O
of	O	O
constitutional	O	O
WT1	O	O
mutations	O	O
,	O	O
in	O	O
patients	O	O
with	O	O
isolated	O	O
diffuse	B-Disease	C537346
mesangial	I-Disease	C537346
sclerosis	I-Disease	C537346
,	O	O
and	O	O
analysis	O	O
of	O	O
genotype	O	O
/	O	O
phenotype	O	O
correlations	O	O
by	O	O
use	O	O
of	O	O
a	O	O
computerized	O	O
mutation	O	O
database	O	O
.	O	O

Constitutional	O	O
mutations	O	O
of	O	O
the	O	O
WT1	O	O
gene	O	O
,	O	O
encoding	O	O
a	O	O
zinc	O	O
-	O	O
finger	O	O
transcription	O	O
factor	O	O
involved	O	O
in	O	O
renal	O	O
and	O	O
gonadal	O	O
development	O	O
,	O	O
are	O	O
found	O	O
in	O	O
most	O	O
patients	O	O
with	O	O
Denys	B-Disease	D030321
-	I-Disease	D030321
Drash	I-Disease	D030321
syndrome	I-Disease	D030321
(	O	O
DDS	B-Disease	D030321
)	O	O
,	O	O
or	O	O
diffuse	B-Disease	C537346
mesangial	I-Disease	C537346
sclerosis	I-Disease	C537346
(	O	O
DMS	B-Disease	C537346
)	O	O
associated	O	O
with	O	O
pseudohermaphroditism	B-Disease	D012734
and	O	O
/	O	O
or	O	O
Wilms	B-Disease	D009396
tumor	I-Disease	D009396
(	O	O
WT	B-Disease	D009396
)	O	O
.	O	O

Most	O	O
mutations	O	O
in	O	O
DDS	B-Disease	D030321
patients	O	O
lie	O	O
in	O	O
exon	O	O
8	O	O
or	O	O
exon	O	O
9	O	O
,	O	O
encoding	O	O
zinc	O	O
finger	O	O
2	O	O
or	O	O
zinc	O	O
finger	O	O
3	O	O
,	O	O
respectively	O	O
,	O	O
with	O	O
a	O	O
hot	O	O
spot	O	O
(	O	O
R394W	O	O
)	O	O
in	O	O
exon	O	O
9	O	O
.	O	O

We	O	O
analyzed	O	O
a	O	O
series	O	O
of	O	O
24	O	O
patients	O	O
,	O	O
10	O	O
with	O	O
isolated	B-Disease	C537346
DMS	I-Disease	C537346
(	O	O
IDMS	B-Disease	C537346
)	O	O
,	O	O
10	O	O
with	O	O
DDS	B-Disease	D030321
,	O	O
and	O	O
4	O	O
with	O	O
urogenital	B-Disease	D014564
abnormalities	I-Disease	D014564
and	O	O
/	O	O
or	O	O
WT	B-Disease	D009396
.	O	O

We	O	O
report	O	O
WT1	O	O
heterozygous	O	O
mutations	O	O
in	O	O
16	O	O
patients	O	O
,	O	O
4	O	O
of	O	O
whom	O	O
presented	O	O
with	O	O
IDMS	B-Disease	C537346
.	O	O

One	O	O
male	O	O
and	O	O
two	O	O
female	O	O
IDMS	B-Disease	C537346
patients	O	O
with	O	O
WT1	O	O
mutations	O	O
underwent	O	O
normal	O	O
puberty	O	O
.	O	O

Two	O	O
mutations	O	O
associated	O	O
with	O	O
IDMS	B-Disease	C537346
are	O	O
different	O	O
from	O	O
those	O	O
described	O	O
in	O	O
DDS	B-Disease	D030321
patients	O	O
.	O	O

No	O	O
WT1	O	O
mutations	O	O
were	O	O
detected	O	O
in	O	O
the	O	O
six	O	O
other	O	O
IDMS	B-Disease	C537346
patients	O	O
,	O	O
suggesting	O	O
genetic	O	O
heterogeneity	O	O
of	O	O
this	O	O
disease	O	O
.	O	O

We	O	O
analyzed	O	O
genotype	O	O
/	O	O
phenotype	O	O
correlations	O	O
,	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
constitution	O	O
of	O	O
a	O	O
WT1	O	O
mutation	O	O
database	O	O
of	O	O
84	O	O
germ	O	O
-	O	O
line	O	O
mutations	O	O
,	O	O
to	O	O
compare	O	O
the	O	O
distribution	O	O
and	O	O
type	O	O
of	O	O
mutations	O	O
,	O	O
according	O	O
to	O	O
the	O	O
different	O	O
symptoms	O	O
.	O	O

This	O	O
demonstrated	O	O
(	O	O
1	O	O
)	O	O
the	O	O
association	O	O
between	O	O
mutations	O	O
in	O	O
exons	O	O
8	O	O
and	O	O
9	O	O
and	O	O
DMS	B-Disease	C537346
;	O	O
(	O	O
2	O	O
)	O	O
among	O	O
patients	O	O
with	O	O
DMS	B-Disease	C537346
,	O	O
a	O	O
higher	O	O
frequency	O	O
of	O	O
exon	O	O
8	O	O
mutations	O	O
among	O	O
46	O	O
,	O	O
XY	O	O
patients	O	O
with	O	O
female	O	O
phenotype	O	O
than	O	O
among	O	O
46	O	O
,	O	O
XY	O	O
patients	O	O
with	O	O
sexual	O	O
ambiguity	O	O
or	O	O
male	O	O
phenotype	O	O
;	O	O
and	O	O
(	O	O
3	O	O
)	O	O
statistically	O	O
significant	O	O
evidence	O	O
that	O	O
mutations	O	O
in	O	O
exons	O	O
8	O	O
and	O	O
9	O	O
preferentially	O	O
affect	O	O
amino	O	O
acids	O	O
with	O	O
different	O	O
functions	O	O
.	O	O

.	O	O

Paternal	O	O
transmission	O	O
of	O	O
congenital	B-Disease	D009223
myotonic	I-Disease	D009223
dystrophy	I-Disease	D009223
.	O	O

We	O	O
report	O	O
a	O	O
rare	O	O
case	O	O
of	O	O
paternally	O	O
transmitted	O	O
congenital	B-Disease	D009223
myotonic	I-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
.	O	O

The	O	O
proband	O	O
is	O	O
a	O	O
23	O	O
year	O	O
old	O	O
,	O	O
mentally	B-Disease	D008607
retarded	I-Disease	D008607
male	O	O
who	O	O
suffers	O	O
severe	O	O
muscular	B-Disease	D018908
weakness	I-Disease	D018908
.	O	O

He	O	O
presented	O	O
with	O	O
respiratory	O	O
and	O	O
feeding	O	O
difficulties	O	O
at	O	O
birth	O	O
.	O	O

His	O	O
two	O	O
sibs	O	O
suffer	O	O
from	O	O
childhood	O	O
onset	O	O
DM	B-Disease	D009223
.	O	O

Their	O	O
late	O	O
father	O	O
had	O	O
the	O	O
adult	O	O
type	O	O
of	O	O
DM	B-Disease	D009223
,	O	O
with	O	O
onset	O	O
around	O	O
30	O	O
years	O	O
.	O	O

Only	O	O
six	O	O
other	O	O
cases	O	O
of	O	O
paternal	O	O
transmission	O	O
of	O	O
congenital	B-Disease	D009223
DM	I-Disease	D009223
have	O	O
been	O	O
reported	O	O
recently	O	O
.	O	O

We	O	O
review	O	O
the	O	O
sex	O	O
related	O	O
effects	O	O
on	O	O
transmission	O	O
of	O	O
congenital	B-Disease	D009223
DM	I-Disease	D009223
.	O	O

Decreased	O	O
fertility	O	O
of	O	O
males	O	O
with	O	O
adult	O	O
onset	O	O
DM	B-Disease	D009223
and	O	O
contraction	O	O
of	O	O
the	O	O
repeat	O	O
upon	O	O
male	O	O
transmission	O	O
contribute	O	O
to	O	O
the	O	O
almost	O	O
absent	O	O
occurrence	O	O
of	O	O
paternal	O	O
transmission	O	O
of	O	O
congenital	B-Disease	D009223
DM	I-Disease	D009223
.	O	O

Also	O	O
the	O	O
fathers	O	O
of	O	O
the	O	O
reported	O	O
congenitally	O	O
affected	O	O
children	O	O
showed	O	O
,	O	O
on	O	O
average	O	O
,	O	O
shorter	O	O
CTG	O	O
repeat	O	O
lengths	O	O
and	O	O
hence	O	O
less	O	O
severe	O	O
clinical	O	O
symptoms	O	O
than	O	O
the	O	O
mothers	O	O
of	O	O
children	O	O
with	O	O
congenital	B-Disease	D009223
DM	I-Disease	D009223
.	O	O

We	O	O
conclude	O	O
that	O	O
paternal	O	O
transmission	O	O
of	O	O
congenital	B-Disease	D009223
DM	I-Disease	D009223
is	O	O
rare	O	O
and	O	O
preferentially	O	O
occurs	O	O
with	O	O
onset	O	O
of	O	O
DM	B-Disease	D009223
past	O	O
30	O	O
years	O	O
in	O	O
the	O	O
father	O	O
.	O	O

.	O	O

Genomic	O	O
organization	O	O
of	O	O
the	O	O
UBE3A	O	O
/	O	O
E6	O	O
-	O	O
AP	O	O
gene	O	O
and	O	O
related	O	O
pseudogenes	O	O
.	O	O

The	O	O
UBE3A	O	O
gene	O	O
encodes	O	O
the	O	O
E6	O	O
-	O	O
AP	O	O
ubiquitin	O	O
-	O	O
protein	O	O
ligase	O	O
and	O	O
has	O	O
recently	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
mutated	O	O
in	O	O
Angelman	B-Disease	D017204
syndrome	I-Disease	D017204
patients	O	O
who	O	O
lack	O	O
15q11	O	O
-	O	O
q13	O	O
deletions	O	O
or	O	O
chromosome	O	O
15	O	O
paternal	O	O
uniparental	B-Disease	D024182
disomy	I-Disease	D024182
.	O	O

Previous	O	O
UBE3A	O	O
cDNA	O	O
analysis	O	O
has	O	O
shown	O	O
a	O	O
coding	O	O
region	O	O
of	O	O
approximately	O	O
2	O	O
.	O	O

6	O	O
kb	O	O
and	O	O
a	O	O
3	O	O
-	O	O
untranslated	O	O
region	O	O
(	O	O
UTR	O	O
)	O	O
of	O	O
<	O	O
50	O	O
bp	O	O
,	O	O
whereas	O	O
Northern	O	O
analysis	O	O
has	O	O
indicated	O	O
mRNA	O	O
sizes	O	O
of	O	O
5	O	O
-	O	O
8	O	O
kb	O	O
.	O	O

We	O	O
have	O	O
analyzed	O	O
additional	O	O
cDNA	O	O
clones	O	O
and	O	O
provide	O	O
evidence	O	O
for	O	O
an	O	O
additional	O	O
0	O	O
.	O	O

5	O	O
kb	O	O
of	O	O
5	O	O
-	O	O
UTR	O	O
and	O	O
>	O	O
2	O	O
kb	O	O
of	O	O
3	O	O
-	O	O
UTR	O	O
.	O	O

We	O	O
have	O	O
established	O	O
the	O	O
genomic	O	O
organization	O	O
of	O	O
UBE3A	O	O
and	O	O
the	O	O
sequence	O	O
of	O	O
intron	O	O
-	O	O
exon	O	O
borders	O	O
.	O	O

We	O	O
have	O	O
also	O	O
mapped	O	O
two	O	O
highly	O	O
homologous	O	O
processed	O	O
pseudogenes	O	O
,	O	O
UBE3AP1	O	O
and	O	O
UBE3AP2	O	O
,	O	O
to	O	O
chromosomes	O	O
2	O	O
and	O	O
21	O	O
,	O	O
respectively	O	O
,	O	O
and	O	O
determined	O	O
their	O	O
genomic	O	O
organization	O	O
.	O	O

These	O	O
results	O	O
will	O	O
form	O	O
the	O	O
basis	O	O
for	O	O
studies	O	O
of	O	O
mutation	O	O
and	O	O
imprinting	O	O
of	O	O
UBE3A	O	O
.	O	O

Distribution	O	O
of	O	O
emerin	O	O
and	O	O
lamins	O	O
in	O	O
the	O	O
heart	O	O
and	O	O
implications	O	O
for	O	O
Emery	B-Disease	D020389
-	I-Disease	D020389
Dreifuss	I-Disease	D020389
muscular	I-Disease	D020389
dystrophy	I-Disease	D020389
.	O	O

Emerin	O	O
is	O	O
a	O	O
nuclear	O	O
membrane	O	O
protein	O	O
which	O	O
is	O	O
missing	O	O
or	O	O
defective	O	O
in	O	O
Emery	B-Disease	D020389
-	I-Disease	D020389
Dreifuss	I-Disease	D020389
muscular	I-Disease	D020389
dystrophy	I-Disease	D020389
(	O	O
EDMD	B-Disease	D020389
)	O	O
.	O	O

It	O	O
is	O	O
one	O	O
member	O	O
of	O	O
a	O	O
family	O	O
of	O	O
lamina	O	O
-	O	O
associated	O	O
proteins	O	O
which	O	O
includes	O	O
LAP1	O	O
,	O	O
LAP2	O	O
and	O	O
lamin	O	O
B	O	O
receptor	O	O
(	O	O
LBR	O	O
)	O	O
.	O	O

A	O	O
panel	O	O
of	O	O
16	O	O
monoclonal	O	O
antibodies	O	O
(	O	O
mAbs	O	O
)	O	O
has	O	O
been	O	O
mapped	O	O
to	O	O
six	O	O
specific	O	O
sites	O	O
throughout	O	O
the	O	O
emerin	O	O
molecule	O	O
using	O	O
phage	O	O
-	O	O
displayed	O	O
peptide	O	O
libraries	O	O
and	O	O
has	O	O
been	O	O
used	O	O
to	O	O
localize	O	O
emerin	O	O
in	O	O
human	O	O
and	O	O
rabbit	O	O
heart	O	O
.	O	O

Several	O	O
mAbs	O	O
against	O	O
different	O	O
emerin	O	O
epitopes	O	O
did	O	O
not	O	O
recognize	O	O
intercalated	O	O
discs	O	O
in	O	O
the	O	O
heart	O	O
,	O	O
though	O	O
they	O	O
recognized	O	O
cardiomyocyte	O	O
nuclei	O	O
strongly	O	O
,	O	O
both	O	O
at	O	O
the	O	O
rim	O	O
and	O	O
in	O	O
intranuclear	O	O
spots	O	O
or	O	O
channels	O	O
.	O	O

A	O	O
polyclonal	O	O
rabbit	O	O
antiserum	O	O
against	O	O
emerin	O	O
did	O	O
recognize	O	O
both	O	O
nuclear	O	O
membrane	O	O
and	O	O
intercalated	O	O
discs	O	O
but	O	O
,	O	O
after	O	O
affinity	O	O
purification	O	O
against	O	O
a	O	O
pure	O	O
-	O	O
emerin	O	O
band	O	O
on	O	O
a	O	O
western	O	O
blot	O	O
,	O	O
it	O	O
stained	O	O
only	O	O
the	O	O
nuclear	O	O
membrane	O	O
.	O	O

These	O	O
results	O	O
would	O	O
not	O	O
be	O	O
expected	O	O
if	O	O
immunostaining	O	O
at	O	O
intercalated	O	O
discs	O	O
were	O	O
due	O	O
to	O	O
a	O	O
product	O	O
of	O	O
the	O	O
emerin	O	O
gene	O	O
and	O	O
,	O	O
therefore	O	O
,	O	O
cast	O	O
some	O	O
doubt	O	O
upon	O	O
the	O	O
hypothesis	O	O
that	O	O
cardiac	B-Disease	D006330
defects	I-Disease	D006330
in	O	O
EDMD	B-Disease	D020389
are	O	O
caused	O	O
by	O	O
absence	O	O
of	O	O
emerin	O	O
from	O	O
intercalated	O	O
discs	O	O
.	O	O

Although	O	O
emerin	O	O
was	O	O
abundant	O	O
in	O	O
the	O	O
membranes	O	O
of	O	O
cardiomyocyte	O	O
nuclei	O	O
,	O	O
it	O	O
was	O	O
absent	O	O
from	O	O
many	O	O
non	O	O
-	O	O
myocyte	O	O
cells	O	O
in	O	O
the	O	O
heart	O	O
.	O	O

This	O	O
distribution	O	O
of	O	O
emerin	O	O
was	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
lamin	O	O
A	O	O
,	O	O
a	O	O
candidate	O	O
gene	O	O
for	O	O
an	O	O
autosomal	O	O
form	O	O
of	O	O
EDMD	B-Disease	D020389
.	O	O

In	O	O
contrast	O	O
,	O	O
lamin	O	O
B1	O	O
was	O	O
absent	O	O
from	O	O
cardiomyocyte	O	O
nuclei	O	O
,	O	O
showing	O	O
that	O	O
lamin	O	O
B1	O	O
is	O	O
not	O	O
essential	O	O
for	O	O
localization	O	O
of	O	O
emerin	O	O
to	O	O
the	O	O
nuclear	O	O
lamina	O	O
.	O	O

Lamin	O	O
B1	O	O
is	O	O
also	O	O
almost	O	O
completely	O	O
absent	O	O
from	O	O
skeletal	O	O
muscle	O	O
nuclei	O	O
.	O	O

In	O	O
EDMD	B-Disease	D020389
,	O	O
the	O	O
additional	O	O
absence	O	O
of	O	O
lamin	O	O
B1	O	O
from	O	O
heart	O	O
and	O	O
skeletal	O	O
muscle	O	O
nuclei	O	O
which	O	O
already	O	O
lack	O	O
emerin	O	O
may	O	O
offer	O	O
an	O	O
alternative	O	O
explanation	O	O
of	O	O
why	O	O
these	O	O
tissues	O	O
are	O	O
particularly	O	O
affected	O	O
.	O	O

.	O	O

